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ABSTRACT 
Determining the Effectiveness of Fibrin Sealants in Reducing  
Complications in Patients Undergoing Lateral Neck Dissection (DEFeND): 
a randomised external pilot trial  
By 
Mandeep S. Bajwa 
Background 
Complications after major surgery are a significant cause of morbidity and mortality. Neck Dissection (ND) 
is one of the most commonly performed major operations in Head and Neck Surgery (HNS). Significant 
surgical complications occur in approximately 10 – 40% of all patients. 
A systematic review and meta-analysis of randomised controlled trials (RCT) suggests that Fibrin Sealants 
(FS) may have potential clinical advantages in HNS through the reduction of complications, volume of 
wound drainage and retention time of the drains. So far, all RCTs have been single centre explanatory studies 
that lack external validity and are of variable quality. The paucity of high-quality pragmatic trials means that 
a surgical trial to determine the effectiveness of FS in reducing the rate and severity of complications in 
patients undergoing lateral neck dissection is warranted. The DEFeND randomised external pilot trial 
(REPT) will address critical questions on how well key components of the proposed study design work 
together as well as the feasibility of a definitive trial. 
Currently a Core Outcome Set (COS) for HNS does not exist and there is a paucity of patient centred outcome 
measures specific to HNS. A scoping review of surgical COS is proposed to guide the direction of future 
HNS outcomes research.  
Methods 
The trial design that is being piloted is that of a two arm, parallel group, superiority trial with block random-
isation in a 1:1 allocation ratio. The interventional arm will constitute the application of FS (ARTISS, Baxter 
Healthcare Ltd) to the surgical wound following completion of ND in addition to standard of care (SoC). 
The control arm will constitute SoC alone. Patients will be recruited from two sites, Aintree University 
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Hospital (AUH) and Queen Victoria Hospital (QVH). Eligible patients will include patients who require a 
lateral neck dissection with a minimum of three cervical nodal levels. Patients who require bilateral neck 
procedures or undergoing immediate reconstruction with free or regional flaps will be excluded. The out-
comes being assessed are recruitment rate; screened to randomisation rate; fidelity of blinding process using 
blinding indices; number of missing or incomplete data entries; number of protocol deviations; number of 
losses to follow-up.  
A scoping review of surgical COS registered with the COMET database will be undertaken. Only COS in 
which patients or their carers are stakeholders will be included. The suitability of outcome measures pro-
posed for the definitive DEFeND trial will also be discussed.  
Results 
Overall, the trial recruited ahead of time and target. Out of 101 eligible patients 48 (47.5%) were randomised 
successfully at a rate of 5.3 patients per month. Five patients were withdrawn from the trial before surgery 
due to a change in treatment plan that meant they were no longer eligible. Blinding of patients, Research 
Nurses and outcome assessors was effective as determined by blinding indices. Missing outcome data was 
low and there were no differences between treatment arm and site. Two significant protocol deviations were 
reported relating to the allocation reveal at a specific time point during surgery. Both occurred early in the 
trial and were not repeated after corrective and preventative actions. Two (4%) patients were lost to follow-
up.  
The scoping review yielded 207 outcomes from 19 surgically relevant COS published between 2014 – 2020. 
Outcomes were classified (humanistic (71), complications (57), measurements (39), resource use (22), mor-
tality (18)). Humanistic and complication outcomes were the most frequently utilised in surgical COS.   
Conclusion 
The DEFeND REPT has demonstrated that many components of the trial design work well together and a 
definitive pragmatic trial is feasible. Refinements in trial design and conduct are discussed and have the 
potential to improve the performance of the trial even further. The process has also revealed an important 
deficiency in patient centred outcomes that needs to be addressed before a definitive trial can be commenced. 
The validity and reliability of the Clavien-Dindo classification of surgical complications is discussed. De-
veloping a COS for HNS trials is an important first step in identifying and developing patient centred 
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outcomes. Consideration should be given to using patient reported outcome measures (PROM) for subjective 
core outcomes. This study has shown that PROMs are both acceptable and feasible in HNS trials.  
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Chapter 1.  INTRODUCTION 
1.1 Overview 
This Introduction will cover key background information relating to the DEFeND randomised 
external pilot trial. A thorough explanation of what a Neck Dissection (ND) involves and the 
common complications that patient’s experience will be provided.  A complete discussion of 
the mechanism of action of Fibrin Sealants (FS) as well as a summary of existing evidence will 
also be discussed. Following on from this, the rationale for a randomized external pilot trial 
(REPT) prior to a definitive trial will be discussed. 
1.2 Neck Dissection 
Head and neck cancers (HNC) encompass a heterogeneous group of cancers that are collec-
tively ranked the 8th most common cancer in the UK with approximately 12,000 new cases 
every year; this equates to 3% of all new cancer cases. In 1993 the incidence of HNC was 15 
per 100,000 population and in 2017 the incidence increased to 20 per 100,000 population.(1)  
The reason for this increase is likely to be multifactorial. Since the incidence of HNC increases 
with age, an ageing population is likely to be the most significant factor.(1, 2) HNC predomi-
nantly affects males, however the proportion of females is increasing. This may be explained 
by the fact that females have a longer life expectancy and therefore represent a greater pro-
portion of cases in older age groups.(2) Oropharyngeal cancers (OPC) have seen the sharpest 
rise in incidence with a 100% increase between 2002 and 2011. In part, this is due to a rise in 
Human Papilloma Virus (HPV) induced tumours which are attributable to changes in sexual 
behaviour that have occurred over time. However, OPC has seen a proportionate rise in HPV 
negative cases too. Smoking and alcohol consumption are the main aetiological factors for 
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HPV negative cases. Interestingly adult smoking rates have declined in the UK however alcohol 
consumption has increased. This change in societal behaviour may explain why the orophar-
ynx, which is exposed to alcohol during the act of swallowing, has seen a sharp rise in cases 
but the larynx which is protected from alcohol but exposed to smoking is more stable.(3) 
The management of HNC may involve surgery, radiotherapy, chemotherapy or a combination 
of these treatments. The management of the neck forms a key part of the decision-making 
process when considering surgery. Metastatic spread to regional lymph nodes is one of the 
most important prognostic indicators in patients with HNC.(4) In patients with Squamous Cell 
Carcinoma (SCC), It has been reported that the presence of cervical lymph node metastases 
drops overall survival by 50%, this is even worse if there is evidence of extracapsular spread.(5, 
6) The importance of regional lymph node metastases was recognised as early as 1905 when 
Crile first described the ‘en-bloc’ dissection of the neck.(7)  
 
ND is a surgical procedure that involves removal of lymph nodes (lymphadenectomy) and sur-
rounding tissues from within the neck. The reasons for performing a ND can be for staging 
and/or therapeutic purposes. In patients without clinical evidence of lymph node metastases 
ND may be performed to stage the neck and identify possible occult disease. The purpose of 
staging the neck is to enable decisions regarding adjuvant treatment such as Radiotherapy 
(RT) or concurrent Chemoradiotherapy (CRT) as well as providing prognostic information. In 
the presence of clinical and/or radiological lymph node metastases ND has a therapeutic role. 
ND can also be performed in the salvage setting if the patient has had primary RT/CRT. Figure 
1 shows the various neck levels with their anatomical relationships. The levels demonstrated 
can be utilised for description of areas dissected during a lateral ND. 
Historically, Neck Dissections (ND) were radical by today’s standards and consequently carried 
high levels of morbidity without necessarily conferring a survival advantage. With advance-
ments in surgery, anaesthesia and adjuvant treatments these operations are now selective and 
aim to preserve as much function as possible.(8) Currently, Neck dissection is the second most 
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commonly performed head and neck surgical procedure after resection of the primary tumor 
with approximately 2000 neck dissections being performed annually in England.(9)The rising 
incidence of HNC and the fact that ND is one of the most commonly performed major opera-
tions in HNS makes research into the improvement of patient outcomes following neck dissec-
tion a priority.  
 
 
Figure 1 Neck levels 
1.2.1 Overview of surgical technique and relevance to morbidity 
The choice of incision is dependent upon surgeon preference, maximising access to the 
planned levels of dissection and the location of existing neck skin creases to hide the scar. In 
general, most incisions will start at the mastoid tip, travel down along the Sternocleidomastoid 
(SCM) muscle before curving anteriorly towards the midline. Figure 2 demonstrates three 
commonly used incisions that can be modified to access the lateral neck. The vascular supply 
of the cervical skin is derived from the external carotid artery superiorly and the subclavian 
artery inferiorly. Incisions which involve trifurcations (Figure 2 righthand image) or run parallel 
to carotid artery are best avoided in patients that have had previous radiotherapy as there is a 
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Figure 2 Commonly used neck incisions 
After making the skin incision, skin flaps are raised in a subplatysmal plane to widely expose 
the anatomy to be dissected. The lymph nodes are contained within fibrofatty tissue that lies 
between layers of deep cervical fascia. Figure 3 shows this fibrofatty tissue being dissected 
off the underlying muscle while taking care to preserve neurovascular structures (if oncologi-
cally safe do so). Important structures include the contents of the carotid sheath (Internal Jug-
ular Vein (IJV), Carotid Artery (CA), Vagus Nerve), Marginal Mandibular branch of Facial Nerve, 
Spinal Accessory Nerve, Hypoglossal Nerve, Phrenic Nerve and Thoracic Duct.  
 
 
Figure 3 Tissue containing lymph nodes being dissected off underlying muscle in level IB. (Image 
taken from Atlas of Head & Neck Surgery(11)) 
 
Care must be taken when dissecting around these structures to ensure they are preserved. 
Iatrogenic injury to either the IJV or CA can result in profuse bleeding that needs to be ad-
dressed immediately. Because the CA is a substantial thick-walled vessel, vascular injury is 
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almost unheard of apart from cases where the vessel has been significantly damaged by pre-
vious irradiation, exposed due to wound breakdown or surgical site infection (SSI) or is closely 
associated with tumour. Iatrogenic injury to the IJV that requires repair is more common and 
reported to occur in 2.4% of neck dissections.(11) Once the surgeon has proximal and distal 
control of the vessel, repair is relatively straightforward. However, if injury occurs at the superior 
and inferior limits of the neck repair can be very difficult and will often result in significant blood 
loss. In addition to bleeding, IJV injury can result in an air embolus. Once Injury to the IJV has 
occurred it is important to apply pressure immediately, inform the anaesthetist and place the 
patient in the Trendelenburg (head down) position.(10) It is often necessary to ligate branches 
of the IJV and External CA. Care must be taken to ensure that the vessels are ligated securely 
to prevent post-operative bleeding.   
 
The Thoracic Duct is a lymphatic structure that originates from the cisterna chyli at the level of 
the second lumbar vertebra. It ascends cranially to eventually reach the root of the left neck. 
Where it terminates into the venous circulation. It enters the IJV in 46% of cases, the confluence 
of the IJV with the Subclavian Vein in 32% and the Subclavian Vein in 18%.(12) Care must be 
taken when dissecting this area of the neck to avoid iatrogenic injury to the thoracic duct. Injury 
will result in a chyle leak which, if recognised intra-operatively, can be repaired. Often injury is 
not recognised until the patient commences diet post-operatively.  
 
Neural injury can have a significant impact on the patient’s post-operative recovery and long 
term quality of life. In the immediate post-operative period, injury to the Vagus Nerve can result 
in dysphagia and aspiration. If it occurs below the Nodose Ganglion it may result in Vocal Chord 
paralysis.(13) Injury to the Phrenic Nerve can cause paralysis of the hemidiaphragm and result 
in basal atelectasis of the lung and subsequent chest sepsis. Injury to the Hypoglossal Nerve 
can cause paralysis of the ipsilateral side of the Tongue. This can have a significant impact on 
the patients ability to swallow resulting in aspiration and feeding tube dependence.(10, 13)  
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Injury to the Spinal Accessory Nerve can cause shoulder dysfunction and pain. Injury to the 
Marginal Mandibular branch of the facial nerve can cause lower lip asymmetry and impaired 
function. Whilst these complications may not have a significant impact in the immediate post-
operative period they are widely recognised to reduce the patients longer term quality of life.(14, 
15) 
   
An important part of the dissection involves removing the deep cervical chain of lymph nodes. 
These lymph nodes lie near the IJV. Figure 4 demonstrates the fibrofatty tissue containing 
these lymph nodes being dissected off the SCM and IJV. Once the neck dissection specimen 
has been removed the resulting wound has a large surface area with undermined skin flaps 
and muscle, exposed blood vessels and areas of surgical ‘dead space’. Dead space can be 
defined as the space between the dissected structures where blood and fluid can collect. The 
collection of blood or other fluids within this space can result in complications e.g. haematoma 
or seroma formation which can result in delayed wound healing, SSI and may compromise the 
patient’s airway.  
 
 
Figure 4 Demonstration of surgical dead space created by dissecting levels II and III off the In-
ternal Jugular Vein. (Image taken from Atlas of Head & Neck Surgery(11)) 
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1.2.2 Neck dissection complications 
Complications after major surgery are a significant cause of morbidity and mortality in patients. 
As previously mentioned, ND is one of the most frequently performed major operations in the 
NHS and carries a complication rate of up to 30%.(16) Recently published qualitative research 
to develop a core information set for patients undergoing HNS demonstrated that “the likelihood 
of wound problems” and “details of major or common complications” were a priority for both 
patients and healthcare professionals during the consent process.(17) 
Complications following surgery may be thought of as specific to the procedure and resulting 
wound (e.g. surgical site infection) or more generalised and related to the patient undergoing 
surgery in the broader context (e.g. venous thromboembolism due to reduced mobility). Im-
paired wound healing has a direct impact on procedure specific complications as well as an 
indirect impact on generalised/systemic complications. The risks of impaired wound healing 
can be classified into local and patient factors. (18) Local factors are those that directly influ-
ence the nature of the surgical wound, whereas patient factors are related to the health of an 
individual and their ability to heal.(18) Local factors that lead to impaired wound healing include 
problems with tissue oxygenation and perfusion, infection and foreign body reaction. For ex-
ample, patients who have previously undergone RT to the neck may have impaired wound 
healing due to microvascular damage and local tissue hypoxia.(19) Patient factors that lead to 
impaired wound healing include problems such as immunosuppression, poor nutrition, smok-
ing, alcohol, diabetes and obesity. It is important to mention that all types of complications and 
their associated risk factors tend to be interrelated at some level e.g. a patient with a surgical 
site infection may develop sepsis that can result in a myriad of downstream effects on other 
organ systems (e.g. type 2 myocardial infarction or acute renal failure). 
The severity of complications may be classified according to the widely used Clavien-Dindo 
classification.(20, 21) The authors first described the classification in 1992 and later revised it 
in 2004.(22, 23) The rationale behind classification development was to allow a comparison in 
outcomes between different surgical procedures and institutions. The revised version was 
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validated in a cohort of 6336 patients undergoing elective general surgery in the author’s insti-
tution.(23) Despite being validated in general surgical procedures, the classification is used 
across multiple surgical specialties.(24-26) The revised classification is presented in Table 1.  
  
Table 1 Clavien-Dindo Classification of surgical complications.(24) 
Grade of Complication Definition 
Grade I Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic and radiological inter-
vention. Acceptable therapeutic regimens are drugs such as antiemetics, 
analgesia, diuretics, electrolytes, and physiotherapy. This grade also in-
cludes wound infections opened at the bedside. 
Grade II Requiring pharmacological treatment with drugs other than those al-
lowed for grade I complications. Blood transfusions and total parenteral 
nutrition are also included. 
Grade III Requiring surgical, endoscopic or radiological intervention. 
Grade III-a Intervention NOT under general anaesthesia 
Grade III-b Intervention under general anaesthesia 
Grade IV Life-threatening complication requiring HDU/ICU management 
Grade IV-a Single organ dysfunction (including dialysis) 
Grade IV-b Multi-organ dysfunction 
Grade V Death 
HDU High Dependency Unit, ICU Intensive Care Unit.  
Given that an ageing population is one of the key reasons behind the rise in HNC incidence in 
the UK,(2) it is important to understand and identify which patients are at risk of complications 
following surgery. The prevalence of comorbidities, disability, geriatric syndromes and social 
issues makes treatment planning and the prevention of complications in this population more 
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challenging. Watt et al recently published a systematic review and meta-analysis on identifying 
older adults at risk of harm following elective surgery. The study found that the geriatric syn-
dromes of frailty and cognitive impairment were associated with the development of postoper-
ative complications whereas chronological age was not.(27) This may be because there is a 
great deal of diversity amongst patients of the same chronological age and the severity of these 
geriatric syndromes is a better marker of a patient’s physiological reserve and their ability to 
avoid complications. This is supported by evidence from the HNC literature which has demon-
strated that frailty is associated with increased complications, mortality, length of stay and re-
admission rates.(28, 29) The evolving demographic of HNC patients with a shift towards a 
population with a greater prevalence of geriatric syndromes means that research into strategies 
that prevent complications is a priority.  
Several small retrospective case series on complications following ND have been published in 
the Italian, Brazilian and Indian literature.(13, 30, 31) It is questionable how relevant this data 
is to clinicians working within the NHS setting. In a series of 119 patients Pellini et al reported 
an overall complication rate of approximately 20%. Haematoma was the most frequent compli-
cation occurring in 12% of patients (5% were considered ‘massive’ and 7% ‘small’). Wound 
dehiscence occurred in 6%, seroma in 1.6% and chyle leak in 0.8%. This study found that 
previous treatment to the neck including CRT, RT and previous surgery (especially radical ND 
or modified radical ND) were risk factors for major wound complications.(30)  
In a series of 708 NDs Dedivitis et al reported only 0.14% patients suffered with a haema-
toma/haemorrhage, 0.28% patients developed a wound infection, 0.42% developed a chyle 
leak, 6% developed superficial dehiscence/epidermolysis and 1.6% developed a deep dehis-
cence.(13)  
In a series of 82 patients Malgonde reported an overall complication rate of 20%. Seroma oc-
curred in 3.65% of patients, wound dehiscence occurred in 2.43%, wound dehiscence with 
haematoma occurred in 1.21%, chyle leak occurred in 2.43%, surgical site infection occurred 
in 1.21% and fistula in 1.21%.(31) It is evident from these retrospective case series that the 
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rate and type of complications reported is highly variable, not least because there are inherent 
differences in the inclusion criteria dependent on the case mix at each institution.  
Complication rates that are more relevant to the NHS setting may be gleaned from the supple-
mentary data provided by two UK based multicentre surgical RCTs. The “nationwide random-
ized trial evaluating elective ND for early-stage oral cancer” (SEND study) included 250 ran-
domised patients recruited from 25 UK hospitals.(32) This trial compared elective ND to a 
‘watch and wait’ approach in patients with small oral cavity tumours, no clinically evident neck 
disease and no prior treatment. Therefore, it would be reasonable to expect complication rates 
in the elective ND arm to be on the lower end of the spectrum in this study. Wound problems 
specific to ND occurred in 4% of patients. Haemorrhage/haematoma occurred in 13.9% of pa-
tients however, this figure includes haemorrhage that occurred from resection of the index tu-
mour.(32)  
The PET-CT surveillance versus neck dissection in advanced head and neck cancer (PET-
NECK) trial randomised 564 patients recruited from 37 UK hospitals.(16) This trial compared 
PET-CT surveillance to ND in patients who had received primary CRT with advanced N2 or N3 
disease. Therefore, it would be reasonable to expect complication rates to be on the higher 
end of the spectrum in this study. In the planned ND arm, surgical complications occurred in 
29% of patients. The neck haematoma rate was 1.4% and the seroma rate was 0.3%. Infection 
was reported in 16% of patients however this was not limited to SSI (i.e., chest infections were 
included). (16, 33) 
Kerawala published a literature review on the prevention of complications after ND. The effects 
of ‘patient factors’ such as poor nutritional intake, smoking and alcohol can be minimized by 
preoperative optimisation strategies e.g., early placement of feeding tubes to improve nutrition, 
smoking cessation and alcohol detox. The effects of ‘local factors’ can be minimized by asep-
sis, prudent use of antibiotics, meticulous surgical technique and the use of surgical drains.(10) 
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1.3 Surgical Drains in Neck Dissection 
ND results in a wound with exposed great vessels and a relatively large area of dead space in 
which fluid may collect. Collections of fluid such as inflammatory exudate (seroma) or blood 
(haematoma) may impair wound healing and increase the risk of SSI.(34) If significant haem-
orrhage occurs post-operatively there is the additional concern of airway compromise. Airway 
compromise may present as bleeding directly into the airway or an expanding haematoma that 
compresses the adjacent structures and potentially narrows the upper airway.  For these rea-
sons surgical drains are widely used in ND. Indeed, all respondents in surveys of the Canadian 
Society of Otolaryngology and American Head and Neck Society used drains in ND.(35, 36) 
However, there is good counterevidence that drains are detrimental in thyroid surgery. In a 
systematic review of RCTs comparing thyroid surgery with drains and without, Woods et al 
reported that drainless surgery did not significantly increase the rate of re-operation for hae-
matoma or wound collections requiring intervention. However, surgery with drains increased 
the rate of SSI, pain and length of stay (LoS). Importantly, patients undergoing lateral ND were 
excluded from this review.(37) Whilst there is no evidence to support drainless (lateral) ND, the 
review by Woods et al does suggest that drains placed in the neck are a nidus for infection. 
From a patient perspective, there are anecdotal reports from patients in the Aintree Head & 
Neck Cancer Research Forum state that drains are uncomfortable and an impediment to mo-
bilisation. In addition to promoting better wound healing, timely removal of drains may reduce 
LoS which connotes health economic benefits to healthcare providers. On this basis a strong 
argument can be made to reduce the retention time of drains in ND 
Surgical drains can be classified as passive (e.g., Penrose or Corrugated drains) or active (e.g., 
high- or low-pressure suction drains). The previously cited surveys of North American surgeons 
suggest that the majority use active drains.(35, 36) A prospective study comparing active and 
passive drains in ND found that passive drains were associated with a significantly higher rate 
of wound dehiscence associated with discharge of fluid.(38) The author’s attributed this 
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observation to a failure of passive drains to adhere skin flaps to the underlying wound and 
permit the collection of fluid.  
The threshold for drain removal is based on a balance of risk between retaining drains long 
enough to prevent fluid collections and removing them before they instigate SSI. The threshold 
may be defined by volume, appearance of fluid (i.e., once the fluid becomes more se-
rous/clear), time or a combination of these factors. The majority of surgeons in North America 
use volume as the main indicator for drain removal with 30ml in a 24-hour period being the 
most popular threshold.(35, 36) The threshold of 30ml/24hrs is also common amongst different 
surgical specialties working in different anatomical areas but there is a surprising lack of objec-
tive evidence supporting it.(39, 40) some authors have compared 30ml/24hrs to 50ml/24hrs 
and found that the higher threshold promotes earlier drain removal without a significant in-
crease in complications.(41, 42) Tamplen et al conducted a small randomized study and found 
that a cut-off of 100ml/24hrs was safe.(43) Equally, some authors have found that measuring 
drain output more frequently facilitates the achievement of the criteria for earlier removal.(44)  
In summary, surgeons generally favour active drains over passive drains because they encour-
age adherence of the wound surfaces through negative pressure, thereby preventing fluid col-
lections. Timely removal of drains is considered beneficial because they are a nidus for infec-
tion and associated with potential health economic benefits.  
1.4 Fibrin Sealants 
1.4.1 Introduction 
FS are commercially available and US Food and Drug Administration (FDA) approved products 
that are derived from human blood and mimic the final stages of the coagulation pathway.(45) 
They have been extensively investigated in recent years, within several areas of surgery, as 
adjuncts to haemostasis.(46) The two key components of FS are Fibrinogen and Thrombin 
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which are mixed together and applied to the raw surfaces of the surgical wound prior to closure. 
Thrombin cleaves fibrinogen to form a fibrin clot that may seal small bleeding vessels. If the FS 
is applied more widely to the surgical field, it can also adhere the raw wound surfaces together 
thereby reducing surgical dead space.  The ability to seal small vessels and reduce dead space 
has the potential to expedite healing after surgery, reduce complications and facilitate earlier 
drain removal. (47) 
Baxter Healthcare LTD is a major global supplier of FS and along with Johnson & Johnson 
Services, Inc holds the majority market share, with Baxter leading in terms of revenue.(48) FS 
produced by these companies are commonly packaged as double chamber syringes, one 
chamber containing Thrombin and the other Fibrinogen as shown in Figure 5.(49, 50) The two 
active ingredients are mixed in the joining piece located at the tip of the syringe when the double 
plunger is depressed. There are several ways to apply FS to a wound surface including droplets 
via a cannula if targeting a small area (Figure 5A), or a spray driven by pressurised medical 
grade air or carbon dioxide (Figure 5B) if wide wound coverage is required.(51) As ND pro-
duces a wound with a relatively large surface area, the sprayable form is most relevant to this 
body of work. 
 
 
    A    B 
Figure 5 A: components of a fibrin sealant syringe and cannula for targeted application. B: fi-
brin sealant syringe being driven by medical grade air to produce a fine spray for wide wound 
coverage. (images taken from https://globaladvancedsurgery.baxter.com 
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1.4.2 History and licensing 
The first use of Fibrin to promote wound healing was reported by Bergel in 1909.(52) However, 
the combination of thrombin with fibrinogen to produce a FS was first reported by Cronkite in 
the Journal of the American Medical Association in 1944 where it was described as a material 
that could adhere skin grafts to the wounds of soldiers with burns.(53) Due to low fibrinogen 
concentrations, the resulting FS was considered to have low adhesive strength. Also, at that 
time many patients became infected with viral hepatitis that was transmitted through the human 
fibrinogen. Due to the limited efficacy and the risk of transmitted infection the wound healing 
benefits did not outweigh the risk and further development of FS was halted in the US.(54) In 
the 1970s the introduction of industrial plasma fractionation methods allowed the production of 
more concentrated fibrinogen which improved the rheological properties of FS.(54)   
The first commercially available FS that was made from human fibrinogen and thrombin was 
available in Europe in 1972.(55) In 1972 a German group described the successful application 
of FS to repair the nerves of rabbits.(56) They subsequently published their experience of using 
FS in human subjects in 1973.(57) However, due to the history of transmitted infections, FDA 
approval was delayed until 1998.(54) This approval was granted on the basis of a growing body 
of evidence supporting efficacy and safety as well as improved techniques for virus inactivation 
such as nanofiltration and heat pasteurization.(54) Tisseel (Baxter Healthcare LTD) was the 
first FS to be approved by the FDA.(58)  
Following an updated guidance by the MHRA in 2014 there are currently four sprayable FS 
that are authorised in the UK: Evicel (Johnson & Johnson Inc), Tisseel (‘Lyo’ and ‘Ready to 
use’ have identical composition) and ARTISS (Baxter Healthcare LTD).(59) Table 2 describes 
their ‘on-label’ indications taken from their respective Summary of Product Characteristics 
(SmPC) documentation.(60-62)  
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Table 2 'On-label' indications for sprayable FS available in the UK (contents of table taken ver-
batim from respective Summaries of Product Characteristics). 
Sprayable Fibrin Sealant ‘On-Label’ Indication for Use 
Evicel(60) Supportive treatment in surgery where standard surgical 
techniques are insufficient, for improvement of haemostasis 
Also indicated as suture support for haemostasis in vascular 
surgery and for suture line sealing in dura mater closure. 
Tisseel (Lyo/Ready to 
use)(61) 
Supportive treatment where standard surgical techniques are 
insufficient 
• For improvement of haemostatsis 
• As a tissue glue to promote adhesion/sealing, or as 
suture support: 
o In gastrointestinal anastomoses 
o In neurosurgery where contact with cerebro-
spinal fluid or dura mater may occur 
• For mesh fixation in hernia repair, as an alternative 
or adjunct to sutures or staples.  
ARTISS (62) Adhere/seal subcutaneous tissue in plastic, reconstructive 
and burns surgery, as a replacement or an adjunct to sutures 
or staples.  
In addition, ARTISS is indicated as an adjunct to haemostasis 
on subcutaneous tissue surfaces 
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1.4.3 Mechanism of action 
Following surgical injury that results in bleeding, the body attempts to achieve haemostasis 
through the coagulation pathway (Figure 6). Primary haemostasis is the aggregation of plate-
lets forming a plug at the site of blood vessel injury. Secondary haemostasis is achieved 
through the intrinsic and extrinsic pathways which converge to form the common pathway 
which activates fibrinogen into fibrin. The resulting fibrin strands cross-link to form a mesh 




Figure 6 Coagulation pathway 
 
FS mimics the final stages of physiological coagulation. Fibrinogen is split into fibrin monomers 
and fibrinopeptides. The fibrin monomers aggregate to form the FS polymer or clot which is 
initially unstable (refer to Figure 6 Coagulation pathway). In the presence of calcium ions, 
thrombin catalyses the generation of Factor XIIIa from Factor XIII. Factor XIIIa has the effect 
of stabilising the FS polymer by cross-linking the fibrin fibres.(60-62) 
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The fibrin and thrombin components of FS can be manipulated depending on the desired hae-
mostatic or adhesive effect. The adhesive strength of FS can be increased by increasing the 
fibrinogen concentration. Increasing the thrombin concentration increases the rate of polymer-
isation. If the desired effect is immediate haemostasis, a high thrombin concentration FS is 
desirable. If the desired effect is adhesion of skin flaps lower thrombin concentration allows 
necessary time for manipulation and positioning of tissues.(63)  
 
Fibrinolytic activity induced by plasmin, a naturally occurring fibrinolytic enzyme, is increased 
as wound healing progresses. Aprotinin is an antifibrinolytic agent that prevents premature 
proteolytic degradation of the FS polymer. Ultimately FS is metabolised by the processes of 
fibrinolysis and phagocytosis in the same way as endogenous fibrin.(61)  
 
A description of the key constituents of each of the sprayable FS authorised for use in the UK 
is provided in Table 3. The concentration of Fibrinogen is similar across all products but the 
Thrombin concentration varies. Evicel contains the highest concentration of thrombin but does 
not contain an antifibrinolytic agent, therefore polymerisation will occur quickly but the FS pol-
ymer will also be metabolised quickly. Tisseel contains a high concentration of thrombin, there-
fore polymerisation will occur quickly and the presence of Aprotinin will inhibit early degradation 
of the FS polymer. ARTISS contains a low concentration of thrombin, therefore polymerisation 
will take longer and the presence of Aprotinin will inhibit early degradation of the FS polymer. 
These concentrations suggest that Evicel and Tisseel are primarily haemostatic agents and 
ARTISS is primarily an adhesive agent.(60-62)  
 
Table 3 Key constituents of sprayable fibrin sealants. *Concentration of Calcium Chloride not 
provided in Summary of Product Characteristics. **Kallidinogenase Inactivator Unit. 
Fibrin Sealant Sealer Protein Solution Thrombin Solution 
Evicel(60) 55 – 85 mg/ml Human Fibrin-
ogen 
800 – 1,200 IU Human 
Thrombin 
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 Calcium Chloride* 
Tisseel(61) 91mg/ml Human Fibrinogen 
3000 KIU**/ml Aprotinin 
500 IU/ml Human Thrombin 
40 µmol/ml Calcium Chloride 
Dihydrate 
ARTISS (62) 91mg/ml Human Fibrinogen 
3000 KIU**/ml Aprotinin 
4 IU/ml Human Thrombin 
40 µmol/ml Calcium Chloride 
Dihydrate 
 
1.4.4 Role of Fibrin Sealants in patients with bleeding disorders 
Up to this point, FS has been considered as an adjunct to haemostasis and wound healing in 
patients that have normal physiology. It is also important to understand the role of FS when 
these processes have been disrupted by disease or medication. Patients who have a tendency 
to bleed pose a challenge to surgeons across all specialties necessitating involvement of Hae-
matologists and perioperative optimisation. Table 4 describes some of the more common 
bleeding disorders encountered within surgical practice according to whether the condition is 
inherited or acquired.(64) 
Table 4 Description of common bleeding disorders.(62) 
Bleeding Disorder Description 
Inherited Bleeding 
Disorders 
Haemophilia A Inherited disorder due to deficiency in factor VIII 
Haemophilia B Inherited disorder due to deficiency of factor IX 
von Willebrand’s 
disease 
Most common inherited bleeding disorder. Deffi-
ciency in von Willebrand factor resulting in a fail-
ure of platelet adhesion and deficiency in factor 
VIII 
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Acquired Bleeding 
Disorders 
Thrombocytopenia Low platelet count due to reduced production 




Warfarin is a vitamin K antagonist which pre-
dominantly affects the extrinsic pathway. It inhib-
its the production of dependent clotting factors 
Thrombin, VII, IX, X.(65) 
Heparin binds to and increases activity of An-
tithrombin III which in turn inactivates several 
factors, but most importantly Thrombin and fac-
tor X. It predominantly affects the intrinsic path-
way.(65) 
Novel Oral Anticoagulants (NOAC) work by di-
rectly inactivating either Thrombin (e.g. 
Dabigatran) or factor Xa (e.g. Rivaroxaban, 
Apixaban, Edoxaban).(65)  
Liver Disease Liver produces most clotting factors. Patients 





Complication of an underlying disorder that 
causes widespread endothelial damage. This 
results in systemic activation of the clotting cas-
cade and rapid depletion of factors and platelets 
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Effective use of FS has been reported by Martinowitz et al in patients with haemophilia A, B 
and von Willebrand’s disease undergoing oral surgery, trauma and orthopaedic surgery and 
urology. The use of FS in these patients was reported to lead to a reduction in perioperative 
bleeding and coagulation factor supplementation.(66)  
Milic et al reported that FS reduced the number of haematomas in patients who were antico-
agulated with either heparin or warfarin after pacemaker insertion.(67) This evidence is sup-
ported by Bodner et al who reported FS reduced bleeding after oral surgery in anticoagulated 
patients.(68) There are currently no studies that report on the effectiveness of FS in patients 
on NOAC treatment or who suffer from thrombocytopenia.  
No detailed explanation of how and why FS is effective in patients with bleeding disorders has 
been provided by the authors of these articles. As Table 4 demonstrates, most conditions (apart 
from DIC) are associated with deficiencies of clotting factors upstream of the conversion of 
fibrinogen to fibrin in the coagulation pathway. One may cautiously postulate that FS provides 
an exogenous source of fibrinogen and thrombin that is sufficient to overcome the patient’s 
deficiency and facilitate haemostasis. 
Referring back to section 1.4.3, FS requires endogenous factor XIII to stabilize the final fibrin 
polymer. According to the SmPC of the sprayable FS products, none contain exogenous factor 
XIII. (60-62) No studies assessing the effectiveness of FS in patients with factor XIII deficiency 
(a very rare condition that affects 1 in 1 – 3 million people worldwide(69)) have been performed 
at the time of writing. Again, one may cautiously postulate that FS without additional exogenous 
factor XIII may have impaired effectiveness in these patients. Dickneite et al have reported 
improved rheological properties of FS when factor XIII is added in an animal model.(70) Beri-
plast P produced by CSL Behring, Germany is a commercially available FS which contains 
factor XIII, however, it is not licensed for spray application in the UK.(71)    
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1.5 Evidence for Fibrin Sealants in Surgical Literature 
Edwards et al conducted an extensive and detailed systematic review of Randomised Con-
trolled Trials (RCTs) and observational studies on the use of FS across all non-emergency 
surgery.(46) The primary outcome measures of interest were prevention of seroma and hae-
matoma development. Across all surgical specialties the meta-analysis did not identify a sig-
nificant benefit for FS over standard of care (SoC) in the prevention of seroma (OR 0.84, 95% 
CI 0.68 to 1.04; p = 0.13; I2 = 12.7%). However, there was a statistically significant effect for 
FS compared with SoC in the prevention of haematoma (OR 0.62, 95% CI 0.44 to 0.86; p = 
0.01; I2 = 0%). This was primarily driven by the results for hernia surgery (OR 0.22 95% CI 0.06 
to 0.74; p = 0.01; I2 = 0%). There was a trend for haematoma prevention in the other surgical 
specialties, but it was not statistically significant. A post hoc analysis that combined both 
seroma and haematoma prevention showed a statistically significant benefit for FS versus SoC 
(OR 0.77, 95% CI 0.64 to 0.92; p = 0.01; I2 = 6.7%).(46) 
 
Regarding secondary outcomes, there was no statistically significant difference between FS 
and SoC in the prevention of post-operative haemorrhage (OR 0.64, 95% CI 0.40 to 1.02; p = 
0.08; I2 = 0%) or the prevention of SSI (OR 0.76, 95% CI 0.54 to 1.06; p = 0.12; I2 = 0%). 
However, FS did significantly reduce the rate of reoperation (OR 0.65, 95% CI 0.48 to 0.87; p 
= 0.00; I2 = 0%). Fibrin sealants were also shown to reduce the length of hospital stay for people 
undergoing Upper GI, Cardiothoracic and Breast surgery. The duration of post-operative drain-
age was also slightly reduced by FS for Breast surgery (fixed-effects model: MD –0.50 days, 
95% CI –0.68 to –0.33 days; p < 0.01; I2 = 90.6%; random-effects model: MD –1.06 days, 95% 
CI –1.69 to –0.42 days; p = 0.01) and Cardiothoracic surgery (fixed-effects model: MD –0.46 
days, 95% CI –0.53 to –0.39 days; p < 0.01; I2 = 91.0%; random-effects model: MD –2.10 days, 
95% CI –3.65 to –0.56 days; p = 0.01).(46) 
 
Interestingly Edwards et al provide the results of their meta-analysis using both fixed- and ran-
dom-effects models.(46) Under the fixed-effect model we assume that the “true” effect size for 
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all studies is the same and the observed differences are due to sampling error. Under this 
model, greater weight is given to larger studies as they provide better information about the 
“true” effect size. Whereas the random-effects model estimates the mean of the different effect 
sizes. Under this model, all effect sizes are represented and not given less weight because 
they are from smaller studies i.e. the overall estimate is not inordinately influenced by any 
single study. The fixed-effect model is advisable if two conditions are met: firstly, all included 
studies are clinically and methodologically homogeneous; secondly, the aim is to calculate the 
common effect size for a specific population and not to generalise to other populations. How-
ever, when accumulating data from studies that have been performed by different researchers 
operating independently, it is unlikely that the studies will be homogeneous. There is a likeli-
hood that any one of several elements (e.g. the patient sample, the nature of the intervention 
or the method of intervention delivery) might be different, therefore, a common “true” effect size 
cannot be assumed.  Furthermore, if the aim of the analysis is to generalise the results beyond 
the included studies, as is the case with Edwards et al, a random-effects model is more appro-
priate. A caveat to using random-effects models is that they should only be employed when 
analysing a large number of studies (e.g. >5) On this basis, meta-analyses of FS trials across 
different surgical specialties, institutions and patient samples should use the random-effects 
model.(72) 
 
In summary, whilst the review by Edwards et al is extensive and detailed, it includes a very 
broad range of surgical procedures performed for different conditions within the same analyses. 
The results of this systematic review suggest that the efficacy of FS may vary across different 
surgical procedures and anatomical sites.(46) In order to understand the role of FS in ND it is 
important to review more specific evidence. However, prior to this body of work no systematic 
review on the role of FS in ND had been performed. Therefore, it is relevant to review the 
evidence of FS in other lymphadenectomy procedures that may have, at least a degree of 
applicability to lymphadenectomy in the neck. 
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1.5.1 Evidence for Fibrin Sealants in lymphadenectomy procedures 
Lymphadenectomy procedures are commonly performed in the neck, the axilla or the groin. 
Despite being in different anatomical locations the procedures share some similarities. These 
similarities include: the removal of lymphatic tissue around important neurovascular structures; 
The creation of dead space that often requires a surgical drain; they are performed as part of 
the management of malignant disease that drains into that specific lymph node basin. It is 
therefore interesting to note that the morbidity of these procedures is very different. This may 
be related to the different types of malignancy being treated and the demographic/risk profile 
of patients. However, the difference between procedures still exists in patients being treated 
for malignant melanoma (MM). Depending on the site of the index tumour, MM can drain to the 
neck, axilla or groin. This may necessitate lymphadenectomy in any of the three sites while 
sharing a broadly similar pathology and patient population. In a review of 236 consecutive lym-
phadenectomy procedures for MM, Akkooi et al reported much higher rates of wound infection 
and seroma in inguinal lymph node dissection (ILND) compared to axillary or neck dissec-
tion.(73) Furthermore, seroma formation was more common after axillary dissection compared 
to the neck. Rates of postoperative bleeding and nerve injury were similar across all sites. This 
suggests that the surgical site itself may influence the incidence and type of complications 
patients encounter.(73) The aetiology for these occurrences are not well documented but the 
following factors may have a role: the ability to obtain dependent drainage being easier in the 
neck and axilla; the ability to mobilise early being easier after neck and axillary surgery; the 
ability to establish collateral drainage of lymph being easier in the neck than in the limbs; the 
patient’s ability to maintain a clean and dry surgical site. Given these proposed differences, 
one may infer that the efficacy of FS may also be different according to the surgical site.   
Weldrick et al conducted a systematic review of RCTs on the use of FS in ILND.(74) Only six 
studies met the eligibility criteria. All studies were reported to have some risk of bias (RoB) but 
often there was not enough detail to make an accurate RoB assessment. The meta-analysis 
was performed using a random effects model and no statistical heterogeneity between studies 
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was reported. Overall, FS did not have a positive impact on any of the outcomes assessed 
when compared to an unexposed control arm. The results of the meta-analysis are summa-
rised. FS did not prevent wound Infection (RR 0.94 95% CI 0.68 – 1.32; p = 0.74); seroma (RR 
1.00 95% CI 0.65 – 1.55; p = 0.99); seroma requiring drainage (RR 0.79 95% CI 0.42 – 1.47; 
p = 0.45); wound necrosis (RR 0.96 95% CI 0.27 – 3.47; p = 0.95); wound dehiscence (RR 
1.09 95% CI 0.59 – 2.04; p = 0.78); haematoma (RR 0.71 95% CI 0.12 – 4.14; p = 0.70). There 
was a tendency towards FS reducing the number of drainage days, but this difference was not 
statistically significant (Weighted Mean Difference -2.64 days 95% CI -6.18 – 0.90; p = 0.14). 
Overall complications were reported in 2/6 trials. At least one post-op complication was seen 
in 55/88 (62.5%) patients in the FS arm and 57/89 (64%) in the unexposed control arm (RR 
0.97 95% CI 0.77 – 1.21; p = 0.75).(74) Although this systematic review did not identify any 
significant benefit of FS, it is important to remember that the number of included studies was 
small. Therefore, it is difficult to make generalisations about the use of FS in ILND beyond the 
included studies and no firm conclusions can be made.   
Sajid et al conducted a Cochrane Review on the role of FS in breast and axillary surgery.(75) 
18 studies met the eligibility criteria. The authors concluded that the overall quality of evidence 
was inadequate and biased. When considering mastectomy alone OR combined mastectomy 
and axillary surgery, FS failed to reduce the incidence of seroma, mean volume of seroma, 
SSI, post-operative complications or length of stay. However, when only the trials that assessed 
the role of FS in combined mastectomy and axillary surgery were analysed (using the random-
effects model) the results were marginally better. FS did not improve the incidence of seroma, 
mean volume of seroma, SSI or post-operative complications. However, it did influence total 
volume of drained seroma (Standardised Mean Difference -0.54 95% CI -1.06 – -0.02; p = 0.04; 
I2 = 75.78%); number of drainage days (Standardised Mean Difference -0.68 95% CI -0.98 – -
0.39; p <0.0001; I2 = 85.77%); length of stay (Standardised Mean Difference -0.93 95% CI -
1.23 – -0.62; p <0.0001; I2 = 39.51%).(75)  
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There are several points to note when interpreting the review by Sajid et al.(75) Firstly, due to 
the methodological and statistical heterogeneity between studies the random-effects model 
was appropriately used. However, the sub-group analysis of mastectomy and axillary surgery 
trials needs to be interpreted with caution due to the small number of trials (7 in total) and the 
potential impact on the utility of the applied random-effects model.(75) Secondly, the use of 
Standardised Mean Difference rather than Weighted or Raw Mean Difference makes interpre-
tation of the results more complex. Standardised Mean difference is a summary statistic used 
in meta-analysis when the studies assess the same outcome but do so in different ways (e.g. 
using different scales). This often makes interpretation of the intervention difficult because it is 
reported in units of standard deviation rather than in units of a scale.(76) It is therefore difficult 
to know whether the differences observed in the sub-group analyses discussed are clinically 
meaningful. Nevertheless, as with the review by Weldrick et al(74), the quality of evidence is 
poor and making firm conclusions about the role of FS in ILND and breast and axillary surgery 
is problematic.   
An important but unreported observation in the Sajid review pertains to the types of FS used in 
the included studies. Tisseel was used as the interventional product in 6 studies, Tissucol in 5, 
Quixil in 1, Hemaseel in 1, Greemplast in 1, Autologous FS in 1 and the type of FS was unre-
ported in 3.(75) The vast majority of these are high Thrombin concentration products(49, 63, 
77) and therefore primarily designed for haemostasis rather than adhesion. The Thrombin con-
centration is unknown for 5 of these studies including Greemplast and Autologous FS making 
the generalisability of these particular studies extremely limited.  
Benevento et al published an RCT on the role of the low thrombin concentration FS, ARTISS 
in axillary surgery.(78) This trial was published in 2014, after the review by Sajid et al. Although 
a small single-centre study with only 60 patients recruited, the results demonstrated a signifi-
cant (both clinically and statistically) benefit of using ARTISS. The authors reported significantly 
less drainage volume, drainage time and length of stay.(78) Of course, the outcome of this 
isolated trial is not generalisable or conclusive but it does support the premise that low 
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Thrombin concentration FS may deliver clinically significant benefit where high Thrombin con-
centration FS has not. Lymphadenectomy procedures are routinely performed as ‘open’ surgi-
cal procedures where the surgeon has direct access to the wound. Sound surgical technique 
entails achieving good haemostasis via ligatures, clips or diathermy prior to wound closure. 
There should be minimal need to rely on FS for haemostasis however, due to the surgical dead 
space, there are potential benefits from adhesion. A low Thrombin concentration FS allows 
time for the surgeon to reposition the skin flaps and commence wound closure before the com-
pletion of polymerization.(51) The identifiable products included in the review by Sajid et al take 
a matter of seconds to commence polymerization (before tissue approximation would be com-
pleted), therefore limiting their efficacy as adhesive agents.(61, 75) 
ARTISS has been approved for use in the UK and USA since 2009 and is the only FS marketed 
as having a low thrombin concentration for the purposes of adhesion (see section 1.4.3).(51) 
Very few RCTs have been conducted utilising ARTISS however results are largely encourag-
ing. In a “split-face”single-centre RCT (where one side of the patient’s face received the inter-
vention and the other did not), Hester et al reported significantly reduced drainage volume after 
rhytidectomy on the side of the face that received Artis.(79) Pilone et al conducted a small 
single-centre RCT in post-bariatric patients undergoing abdominoplasty and found that ARTISS 
significantly reduced length of stay, seroma formation and complications.(80) In a multi-centre 
phase III RCT of patients with burns, Foster et al reported that using ARTISS to adhere skin 
grafts resulted in fewer seromas and haematomas.(81)  
In summary, evidence gleaned from systematic reviews of RCTs suggests that FS does not 
provide significant benefit in patients undergoing lymphadenectomy procedures.(74, 75) How-
ever, the quality of trials as well as the statistical and methodological heterogeneity are issues 
that make any conclusions difficult. Furthermore, the type of FS used in the included trials are 
primarily haemostatic products. In the few trials that have used low thrombin concentration FS 
for adhesion, results have been encouraging but by no means conclusive.(78-81) Based on 
the findings of studies like Akkooi et al, it is clear that the different lymphadenectomy 
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procedures have a different complication profile.(73) Therefore to further understand the role 
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Chapter 2.  PRE-TRIAL SYSTEMATIC REVIEW OF FIBRIN 
SEALANTS IN HEAD AND NECK SURGERY 
 
The conduct and outcomes of this systematic review were published prior to the doctoral re-
search period.(82) However, the results and implications are of critical relevance to the justifi-
cation and design of the DEFeND trial, justifying their inclusion.  
2.1 Introduction 
There have been three previously published systematic reviews on the use of tissue adhesives 
(not necessarily FS) in soft-tissue surgery of the head and neck region looking specifically at 
rhytidectomy and tonsillectomy.(83-85) The most recent systematic review on the use of tissue 
adhesives in rhytidectomy by Killion et al showed that their application significantly reduced the 
rate of haematoma formation and reduced the volume of surgical drainage. Sproat et al(85) 
published their systematic review on the use of tissue adhesives in tonsillectomy wounds in 
2016 and found that they did not significantly reduce the rate of post-operative pain or bleeding. 
The authors commented on the fact that most studies were of low quality and were underpow-
ered to detect statistical significance even when pooled in the meta-analysis.(85)  
 
Prior to this work there have been no systematic reviews on the use of FS that encompass the 
entirety of soft-tissue head and neck surgery or even look specifically at thyroid surgery, parotid 
surgery or neck dissection. With a comprehensive understanding of the available evidence, 
decisions regarding the necessity of further research in this field can be made. To this end a 
systematic review of RCTs was conducted to answer the following questions regarding the 
application of FS in patients undergoing soft-tissue surgery of the head and neck region that 
would commonly require a surgical drain compared to a non-exposed control group:  
1) Is there evidence that FS reduces the volume of wound drainage? 
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Is there evidence that FS reduces the time of surgical drain retention? 
2) Is there evidence that FS reduces the time to discharge or time to being declared sur-
gically fit for discharge? 
3) Is there evidence that FS reduces the rate of clinically significant adverse events (AEs) 
defined as Clavien-Dindo(23) grade II or worse, or the rate of haematoma/seroma for-
mation? 
4) Is there evidence that FS reduces post-operative pain? 
5) Is there evidence that FS allows a quicker return to normal function as documented by 
patient reported outcome measures? 
6) Is FS considered to be an acceptable intervention by patients? 
7) Is FS a cost-effective intervention? 
2.2 Methods 
A review protocol was established and prospectively registered on the ‘PROSPERO: Interna-
tional Prospective Register of Systematic Reviews’ website.(86) This study was written in ac-
cordance with the ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ 
(PRISMA) guidelines.(87)  
 
All published RCTs comparing FS to non-exposed controls, published during any year and 
written in any language including adult patients of any gender or ethnicity having soft-tissue 
surgery of the head and neck anatomical region that would commonly require the placement 
of a surgical drain were included. RCTs that included patients having FS applied to bone, car-
tilage, dental, ocular, middle ear or intra-cranial tissues were excluded except if the FS was 
used to close the soft tissue dead space created to access underlying structures.  
 
The following databases were searched: EMBASE (1974 to July 2016); MEDLINE (1946 to 
October 2016); PubMed (start of records to November 2016); Cochrane Library and Central 
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Register of Controlled Trials (October 2016); ClinicalTrials.gov (October 2016); World Health 
Organisation International Clinical Trials Registry Platform (October 2016). The website “Re-
search Gate” was also searched for unpublished work, conference presentations or posters 
(October 2016). The search strategy using MeSH terms was as follows: (“head and neck neo-
plasms” or “otorhinolaryngologic diseases” or “otorhinolaryngologic surgical procedures” or 
“oral surgical procedures” or “dermatologic surgical procedures” or “cervicoplasty” or “rhino-
plasty” or “lymph node excision” or “salivary gland” or “stomatognathic diseases” or “cranio-
cerebral trauma” or “neck injuries”) and (“controlled clinical trials” or “systematic review” or 
“meta-analysis” or “randomised controlled trial as topic”) and (“fibrin tissue adhesive”). The 
search was limited to humans. 
 
The study selection process was carried out by uploading the search results from all databases 
to “EPPI-Reviewer 4: software for systematic reviews” (Social Science Research Unit, Univer-
sity of London). This software also facilitated the removal of duplicate studies. Two reviewers 
(Bajwa; PhD candidate and Schache; primary supervisor) selected studies by screening the 
title and abstract and then repeating the process using full-text versions of studies that cleared 
the first stage of screening. Studies were excluded if it transpired that they were based on 
excluded surgical procedures (as previously mentioned), did not specifically use FS or were 
not the correct study design. All resultant studies that cleared the second round of screening 
were included in the systematic review and meta-analysis. There were no conflicts of opinion 
between the two authors applying the inclusion and exclusion criteria.  
 
Data was collected in keeping with the guidance published in the “Cochrane Handbook for 
Systematic Reviews of Interventions” version 5.1.0. The quality assessment was carried out 
using the Cochrane Collaboration’s tool for assessing risk of bias which can be found in the 
handbook.(88) This was also performed independently by two reviewers assessing: random 
sequence generation, allocation concealment, blinding of participants and personnel, blinding 
of outcome assessment, incomplete outcome data, selective reporting and other sources of 
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bias. Each source of bias was reported as low risk, uncertain or high risk. Clearly blinding of 
the surgeon poses challenges in the study design so in terms of performance bias, un-blinding 
the surgeon at the point of wound closure was the minimum acceptable standard.  
 
The primary outcomes of interest in this review were ‘volume of drainage’ and ‘time of drain 
retention.’ Secondary outcomes were ‘time to hospital discharge’ or ‘being declared surgically 
fit for discharge,’ ‘wound complications or adverse events,’ ‘post-operative pain,’ ‘time to return 
to normal function using patient reported outcome measures,’ ‘patient acceptability to FS’ and 
‘cost analysis.’ Data was collected using a spreadsheet with predetermined column headings 
for each data entry and was trialled on the first two studies. Where important information was 
lacking formal requests were made to the corresponding authors. In order to standardise the 
severity of complications the Clavien-Dindo classification was used.(23) Only complications of 
grade II (see Table 1) or worse were considered significant. 
2.2.1 Statistical analysis 
Data was analysed using RevMan version 5.3.5 software (Cochrane Collaboration). For each 
trial the difference in means and 95% confidence interval were calculated for continuous out-
comes and the risk ratio and 95% confidence interval calculated for dichotomous outcomes. 
Individual trial effects were combined using a random effects inverse variance weighted 
method for continuous outcomes and Mantel-Haenszel method for dichotomous outcomes. 
The degree of heterogeneity was assessed using the I2 statistic and sensitivity analyses as-
suming a fixed treatment effect undertaken for comparison. If authors chose to present their 
continuous data as median and interquartile range (IQR) then it was assumed the data was 
skewed. The authors were approached for the actual mean and standard deviation (SD). If 
there was no response and the degree of skewness was minimal then it was considered ap-
propriate to estimate the mean and SD for the purposes of meta-analysis, accepting the limi-
tations of this approach.(89) The mean and SD was also estimated if the authors did not re-
spond and presented their data as median with minimum and maximum values.(90) If adequate 
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data permitted, the following subgroup analyses had been planned to compare the surgical 
procedure performed (e.g. thyroidectomy); the type and volume of fibrin adhesive used; use of 
harmonic scalpel or similar thermo-coagulation device for haemostasis; type of post-operative 
drainage (e.g. active versus passive, open versus closed); the maximum volume of drain output 
over 24 hours that was considered safe to remove the drain. 
2.3 Results 
A total of 421 articles were identified after duplicates were removed from the various searches. 
Of these 11 studies were included in the final review and meta-analysis. A total of 522 patients 
were randomised across these 11 studies, including 180 patients in rhytidectomy trials that 
were ‘split-patient’ controlled trials (i.e. rhytidectomies were bilateral procedures and patients 
were randomised according to whether the right or left side received FS). Figure 7 provides 
details of the screening processes in the form of a PRISMA diagram. 
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Figure 7 PRISMA diagram describing the screening process 
 
 
Details of the included articles are provided in Table 5. Two trials looked at the use of FS in 
thyroidectomy (hemi- and total),(91, 92) 2 at total thyroidectomy with some form of neck dis-
section (Kim et al(93) included patients having central neck dissection whereas Vidal-Perez et 
al(94) included patients having central and lateral neck dissections), 1 at lateral neck dissec-
tion,(95) 1 at parotidectomy(96) and 5 at rhytidectomy.(79, 97-100) Only 6 of the included stud-
ies(79, 91, 93-95, 97) reported a sample size calculation and only 3 of these reached the 
planned sample size. Inclusion and exclusion criteria were broadly similar among all studies 
with all trials only including healthy adult patients and excluding patients who had previous 
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surgery to the area, were anticoagulated or had a bleeding/clotting disorder. Of note, only the 
trials by Hester et al used a low thrombin concentration FS (ARTISS) that is primarily designed 
to aid adhesion. All the other trials used high thrombin concentration FS that is primarily de-
signed to aid haemostasis.  
 
Table 5 Summary of included trials. Pts = Patients, FS = Fibrin Sealant. 
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2006 Parotidectomy Canada - 60 10 Incomplete 
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follow-up 
No Tisseel FS No FS 
Marchac 
et al(99) 
2005 Rhytidecomy France - 30 0 - - Tisseel FS No FS 
Oliver et 
al(100) 












Spain 60 60 0 - - Tissucol FS No FS 
 
Details of the risk of bias assessment are provided in Table 6. The overall quality of trials 
varied and many did not report complete methodological information to carry out a full assess-
ment of risk of bias. In cases of incomplete information, authors were approached by email 
however only one responded. Key findings were that while random sequence generation was 
mostly adequately performed, such attempts at reducing selection bias were incomplete due 
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to the lack of adequate reporting of allocation concealment. None of the 5 trials in which pa-
tients dropped out after randomisation performed an ‘Intention-to-treat’ analysis. They were 
considered at high risk of attrition bias if the number of dropouts were unequal between the two 
groups of patients.(79, 91, 95-97) Four trials pre-registered their protocol on ClinicalTrials.gov 
so that a comparison between the planned outcomes and reported outcomes could be made 
and assessment of reporting bias possible.(79, 91, 93, 97) Several trials were industry funded 
but only the trials by Hester et al included authors who were employed by or were stockholders 
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Table 6 Risk of bias assessment of included trials. Green = low risk of bias, yellow = uncertainty, 
red = high risk of bias. A brief description of why the study was cat-egorised to a particular risk 
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2.3.1 Primary outcomes 
With regards to wound drainage all trials used a closed suction drain of varying calibre apart 
from Lee et al. who did not use any drains for rhytidectomy but rather applied a pressure band-
age for 3 days.(98) Figure 8 shows the forest plot for all trials that provided enough data to 
perform meta-analysis on ‘mean total drainage volume’. Similar surgical procedures are 
grouped together to enable sub-group analysis. Hornig et al(91) presented their data as median 
and IQR, the skewness was thought to be minimal and therefore the mean and SD was esti-
mated.(89) Vidal-Perez et al presented their data as median with minimum and maximum val-
ues and the mean and SD was estimated.(90) The meta-analysis showed substantial statistical 
heterogeneity in all the sub-groups (thyroidectomy I2 = 79%; surgery involving neck dissection 
I2 = 94%) apart from in rhytidectomy (I2 = 0%). There was a clear tendency for reduced ‘mean 
total drainage volume’ with FS in the overall analysis with a mean difference of 26.86ml (95% 
CI -43.41 to -10.31, p < 0.00001). Although this was statistically significant, the result needs to 
be interpreted with caution due to the substantial statistical and clinical heterogeneity of the 
studies (I2 = 97%). The individual sub-group analysis concurs with the overall analysis, however 
for surgery involving neck dissection, the difference was not quite statistically significant (p = 
0.08). The sub-group analysis of rhytidectomy shows a clear statistically significant benefit of 
FS reducing drainage volume with no statistical heterogeneity. The study by Maharaj et al was 
not included in the meta-analysis because they did not provide the standard deviation of the 
mean nor provide enough information to estimate it. The trial did however find that the mean 
total drainage volume in superficial and total parotidectomies was 41.3ml in the FS arm com-
pared to control that was 65.3ml. This was a statistically significant difference (p = 0.02).(96)  
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Figure 8 The effect of fibrin sealant on 'mean total drainage volume' (ml). Sub-group analysis of similar surgical procedures has been performed. 
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The meta-analysis on the retention time of drains (days) is shown in Figure 9A. This analysis 
includes 4 studies that looked at different surgical procedures and had different protocols for 
drain removal. Hornig et al removed the drain once it produced <10ml/8hrs; Huang et al 
<10ml/24hrs; Kim et al <20ml/24hrs; Vidal-Perez et al <20ml/24hrs. The overall analysis shows 
a tendency for FS to reduce the mean retention time of drains by 1.24 days (I2 = 99%, 95%CI 
-3.32 to 0.85, p = 0.25) however there is substantial statistical heterogeneity and the difference 
is not statistically significant. This heterogeneity is primarily because the study by Vidal-Perez 
et al(94) very strongly favours the use of FS compared to the other studies. Studies involving 
rhytidectomy were not included because all drains were removed at approximately 24 hours. 
Maharaj et al(96) found that, for patients having parotidectomy, the FS group retained the drain 
for 25.6 hours and the control 30.4 hours; this study was excluded from meta-analysis because 
it did not provide the SD or p value other than to say it was not significant.  
2.3.2 Secondary outcomes 
The meta-analysis on ‘hospital length of stay’ in days is shown in Figure 9B. Overall, there 
was a tendency for FS to reduce hospital stay by 2.09 days (I2 = 97%, 95% CI -5.18 to 0.99, p 
= 0.18) however this was not statistically significant and there was substantial statistical heter-
ogeneity. Again, Maharaj et al was not included in the analysis because of missing information; 
they found that the mean time to discharge for patient having parotidectomy was 1.4 days in 
the FS group and 1.6 days in the control group, again this was not statistically significant (p 
value not provid
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The meta-analysis of AEs (Clavien-Dindo grade II or worse) is shown in Figure 10A. This 
includes all surgical complications that required treatment within 30 days of the procedure and 
included haematoma/seroma formation that required invasive treatment, nerve palsies that re-
quired intervention, wound infections and ICU admission. There were no deaths reported in 
any study and there were no adverse reactions to FS (e.g. aprotinin sensitivity or surgical em-
physema) reported. The meta-analysis shows that there was no statistical heterogeneity be-
tween trials (I2 = 0%) and suggested that FS may be protective against developing a significant 
AE with a risk ratio of 0.69 but the 95% CI (0.35 to 1.38) includes values of risk ratio that could 
indicate harmful effect of either FS or standard care and so this result is inconclusive. Figure 
10B shows the forest plot of a further analysis on the rate of haematoma/seroma requiring an 
intervention (e.g. aspiration or return to theatre). Again, there was no statistical heterogeneity 
(I2 = 0%) and FS showed a tendency to reduce the risk of developing a haematoma or seroma 
with a risk ratio of 0.49 (95% CI 0.22 – 1.07). The effect of FS in reducing the rate of haematoma 
or seroma was not statistically significant (p = 0.07). 
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Figure 10 The effect of fibrin sealant on reducing complications. A) Shows the forest plot of all 
post-operative adverse events (Clavien-Dindo grade II or worse). B) Shows the forest plot of hae-
matoma or seroma formation that required invasive treatment 
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Post-operative pain was reported in 3 studies that found no significant difference between FS 
and control.(94, 95, 97) All studies reported pain using visual analogue scales (VAS); only 
Vidal-Perez et al presented the data as a mean with SD, however they failed to specify at what 
point in the patient’s pathway the VAS was measured. The other 2 studies presented the VAS 
in a bar graph format with no additional information. Unfortunately, due to the poor reporting of 
post-operative pain meta-analysis was not possible, however individually, no study found a 
statistically significant difference between the FS group and control. No trials assessed if FS 
improved the recovery of function using patient reported outcome measures. In terms of FS 
being acceptable to patients, only the trial by Huang et al reporting difficulties in recruit-
ment.(95) Finally, Vidal-Perez et al was the only study to attempt a cost analysis. They found 
that the cost per patient in their institution was 377.72 Euro for the FS group and 1133.16 Euro 
for the control group. This was a significant difference (p < 0.05) and was primarily driven by 
the increased ‘hospital length of stay’ in the control group.   
2.4 Discussion 
This systematic review identified 11 RCTs that assessed the effect of FS on patients having 
soft-tissue surgery to the head and neck anatomical region. These studies were very hetero-
geneous in their quality, design and reporting making meta-analysis difficult to interpret and 
provide conclusive answers to the questions set out in the introduction. Whilst benefit from the 
inclusion of FS was a consistently apparent finding in all trials, this did not always translate into 
a difference in clinical outcome. Each operative sub-group is discussed in turn. 
2.4.1 Thyroidectomy (Hemi- and Total) 
There was substantial statistical heterogeneity in the sub-group analysis of thyroidectomy stud-
ies (I2 = 79%) in terms of ‘mean total drainage volume’. This heterogeneity may have been 
because the differences in cut-off volume for drain removal (10ml/8hr for Hornig et al and 
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10ml/24hr for Uwiera et al) and the mean and SD was estimated for the study by Hornig et 
al.(89, 91) The ‘mean total drainage volume’ for thyroidectomy was significantly reduced by 
36.36ml in the FS arm compared to control (95% CI -72.82 to 0.10, p = 0.05) however this is 
tempered by the high statistical heterogeneity. Hornig et al(91) and Uwiera et al(92) reported a 
“mean total drainage volume” ranging from approximately 70 – 120ml, this is contradictory to 
the meta-analysis by Woods et al(37) who demonstrated that not using drains was safe and 
may even be beneficial i.e. one would expect 70 – 120ml in the anterior neck to be clinically 
obvious and needing aspiration/evacuation. It is unclear if this disparity is simply due to the 
stimulating effect of a closed suction drain in the wound. As Woods et al(37) have shown that 
drains are not routinely required in thyroid surgery it is difficult to argue the case for using FS. 
The current meta-analysis shows that FS has potential benefits in reducing drainage volume 
but this has not translated into a significant difference in clinical outcome (both in the pooled 
and individual study analysis). The findings of this study offer little to change the practice of 
surgeons who already perform drainless surgery other than to say FS is safe to use. More 
evidence is required on the use of FS in patients who are at higher risk of complications (e.g. 
patients on anticoagulation).  
2.4.2 Surgery involving neck dissection (central or lateral) 
Overall FS had a tendency towards being beneficial in ‘surgery that involved a neck dissection’ 
in terms of reducing the ‘mean total drainage volume’ by 33.21ml (I2 = 94%, 95% CI -70.01 to 
3.59, p = 0.08). It is difficult to draw any conclusions regarding the clinical impact of this reduc-
tion in drainage volume because the result was not statistically significant and there was sub-
stantial statistical heterogeneity. This heterogeneity can be explained by the fact that the 3 
studies included in this analysis incorporated different surgical procedures. Huang et al(95) just 
looked at lateral neck dissection, Kim et al(93) just looked at total thyroidectomy with central 
neck dissection and Vidal-Perez et al(94) looked at total thyroidectomy with central and lateral 
neck dissection. The degree of heterogeneity is compounded by the fact that Vidal-Perez et 
al(94) showed a significantly greater benefit of using FS compared to the other studies. Similar 
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effects of this study on the heterogeneity of meta-analysis can be seen in ‘retention time of 
drains’ and ‘hospital length of stay’ (Figure 9). It is possible that the estimation of mean and 
SD along with the subtle variation in drain removal protocol may have had a small part to play. 
Another explanation could be that FS is of greater benefit to patients who have a lateral neck 
dissection. Of all the procedures included in this review, lateral neck dissection is the most 
extensive and creates the greatest potential dead space. The surgery commonly involves large 
muscle belly exposure with dissection around large calibre vessels and carries with it, risks of 
major complication due in part to the proximity to the airway. Huang et al(95) did not show such 
a marked benefit from using FS, however their study was vastly underpowered due to problems 
with recruitment. The premise that FS is of greater benefit in patients having lateral neck dis-
section is supported by three non-randomised studies that both showed a clear benefit of using 
tissue adhesives (FS or autologous platelet and plasma adhesives). This is both in terms of 
total wound drainage and retention time of drains.(101-103) 
2.4.3 Rhytidectomy & Parotidectomy 
The evidence for the use of FS in parotidectomy and rhytidectomy seems more clear-cut. The 
meta-analysis shows that FS has a definite benefit in reducing wound drainage in rhytidectomy 
trials by approximately 13ml (p < 0.00001); this benefit also translates to a reduced rate of 
haematoma/seroma formation. The findings of this study agree with the findings of Killion et 
al(84), despite some differences in inclusion criteria of studies and statistical method, and sup-
port the use of FS in rhytidectomy.  
 
Unfortunately the trial by Maharaj et al(96) on the use of FS in parotidectomies only provided 
enough data to include it in the meta-analysis on AEs and haematoma/seroma formation. If we 
analyse their results in isolation, they do support the use of FS in terms of reducing ‘mean total 
drainage volume’ and ‘haematoma/seroma’ formation. This is supported by the findings of 
Conboy and Brown who performed 21 parotidectomies using FS without a drain in a day sur-
gery setting and reported no wound complications and found a health economic benefit.(104) 
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There is a need to substantiate these findings with a well-designed RCT comparing FS with no 
drain to standard of care with a drain. Having a third arm of this trial where patients are deprived 
of both FS and a drain is possible but may be controversial in terms of patient safety unless 
additional measures are taken e.g. pressure bandages are applied. 
 
The types of FS used in each of the included studies is reported in Table 5. As already dis-
cussed, different FS preparations contain variable amounts of Thrombin, with a consequent 
impact on handling properties and balance between adhesion and haemostasis With reference 
to (sections 1.4.3 and 1.5.1). Only the two studies by Hester et al used a low Thrombin con-
centration FS. Both studies were strongly positive in terms of FS reducing mean total drainage 
volume after rhytidectomy. All remaining studies used high Thrombin concentration FS. The 
studies by Uwiera et al(92), Vidal-Perez et al(94) and Oliver et al(100) suggest that high Throm-
bin concentration FS can also reduce mean total drainage volume. This implies that whilst low 
Thrombin concentration FS may be effective at reducing drainage volume through closure of 
dead space, high Thrombin concentration FS may be effective at reducing drainage volume 
through haemostasis. Without a trial assessing the differing FS compositions, it is not possible 
to conclude which is the dominant factor. 
 
It is important to clarify that only Woods et al(37) has provided robust evidence for the omission 
of surgical drains in thyroidectomy. Lee et al(98) used pressure bandages instead of surgical 
drains in both arms of their study on rhytidectomy; however not all head and neck procedures 
are amenable to the use of pressure bandages. Conboy and Brown(104) provide evidence 
through a small case series that surgical drains can be omitted in parotidectomy so long as FS 
is used. Therefore, any future trials comparing FS to standard of care without a drain need 
careful consideration with regards to patient safety, especially if the procedure in question is 
not amenable to pressure dressings e.g. lateral neck dissection. Furthermore, consideration 
should be given to how well a trial of this design is likely to recruit. Lack of surgeon equipoise 
is a recognised barrier to recruitment(105) and it is possible that many surgeons who routinely 
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use drains will lack equipoise.  
 
Care should be taken when interpreting the numerical value of pooled mean differences shown 
in Figure 3 with regards to ‘retention time of drains’ (-1.24 days 95% CI -3.32 to 0.85) and 
‘hospital length of stay’ (-2.09 days 95% CI -5.18 to 0.99). This is because of the substantial 
statistical heterogeneity and because the analysis was performed over different surgical pro-
cedures that may not be directly comparable. Instead, it is more appropriate to look at the 
‘relative’ effect of FS on these outcomes. Overall, it is fair to say that the relative effect of FS is 
beneficial however not statistically significant.    
 
The meta-analysis on AEs (Clavien-Dindo grade II or worse) demonstrated that FS is safe for 
use in the head and neck anatomical region and may have a protective benefit albeit not to a 
statistically significant level (I = 0%, RR 0.69, p = 0.29). The analysis on ‘haematoma/seroma 
formation that required invasive treatment’ showed that FS had a tendency for greater benefit 
(I2 = 0%, RR 0.49, p = 0.07) but it was mainly the rhytidectomy and parotidectomy trials that 
contributed to this result. There were surprisingly few significant complications reported in the 
‘surgery involving neck dissection’ studies. This can be explained by the fact that the studies 
excluded patients who were at high risk of complications (e.g. previous surgery, radiotherapy, 
bleeding disorders or anticoagulation). 
2.5 Summary 
To summarise the key findings of this study, each of the questions posed in the introduction 
has been addressed. 
1) Is there evidence that FS reduces the volume of wound drainage? Overall FS has 
been shown to reduce the mean total volume drained (-26.86ml, 95% CI -43.41 to -
10.31, P = 0.001, I2 = 97%), however there is substantial statistical heterogeneity. 
Within the sub-group analyses ‘thyroidectomy’ and ‘surgery involving neck dissection’ 
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suffered from wide confidence intervals crossing the line of no effect. The evidence to 
support the use of FS in reducing the in mean total volume drained is stronger in the 
sub-group analysis of ‘rhytidectomy’. Whilst overall FS reduced mean total volume 
drained, it debatable whether a difference of 26.86ml is clinically relevant. This is de-
pendent on the circumstances in which FS is used. If FS is being used in surgery that 
creates a large area of dead space and requires prolonged drainage (e.g. ND), then a 
difference of 26.86ml is unlikely to be clinically relevant. However, if the area of dead 
space is relatively small (e.g. rhytidectomy), a reduction in drainage of 26.86ml could 
justify not using a drain at all. 
2) Is there evidence that FS reduces the time of surgical drain retention? There was 
a tendency for patients who received FS to have reductions in the retention time of 
drains however this was not statistically significant. Most studies found that this reduc-
tion was less than 0.5 days and so did not translate to a clinically significant outcome. 
One study found that FS reduced the time of drain removal by 3.75 days which is 
clinically significant15, however no other study reproduced this outcome leading to the 
substantial statistical heterogeneity (I2 = 99%) as shown in Figure 9A.   
3) Is there evidence that FS reduces the time to discharge or time to being declared 
surgically fit for discharge? Again, there was a tendency for FS to reduce the hos-
pital length of stay but this was not statistically significant and hampered by substantial 
statistical heterogeneity (Figure 9B).  
4) Is there evidence that FS reduces the rate of clinically significant AEs defined as 
Clavien-Dindo(23) grade II or worse, or the rate of haematoma/seroma for-
mation? There was a tendency for FS to reduce the rate of clinically significant AEs 
(Figure 10A) albeit not to a statistically significant level. The evidence for FS reducing 
the rate of haematoma or seroma was stronger (Figure 10B). It is important to note 
that many studies had no complications in either arm. This is likely to be a conse-
quence of a conscious decision by study designers to exclude patients at increased 
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risk of complications. 
5) Is there evidence that FS reduces post-operative pain? Meta-analysis of post-op-
erative pain was not possible due to the differing ways that studies reported it. Of the 
3 studies that did report pain, none found that FS made a statistically significant differ-
ence.  
6) Is there evidence that FS allows a quicker return to normal function as docu-
mented by patient reported outcome measures? None of the studies in this review 
looked at the effects of FS on health-related quality of life and whether it expedited the 
return to normal function. 
7) Is FS considered to be an acceptable intervention by patients? All studies apart 
from 1 found that FS was an acceptable intervention for patients. This study reported 
difficulties in recruitment but did not explain why patients were averse to participation. 
8) Is FS a cost-effective intervention? No studies performed detailed cost analyses. 
One study reported a crude cost-benefit analysis and found FS resulted in a saving of 
755 Euro per patient driven by reduced hospital length of stay.   
2.6 Conclusion 
 
In conclusion this systematic review has found that the evidence for the use of FS in soft-tissue 
head and neck surgery is encouraging. However, the value of these results is constrained by 
heterogeneous, sometimes poor, methodology and reporting of trials leading to necessary cau-
tion when interpreting. As such the ability for robust conclusions to be drawn from meta-anal-
yses are necessarily limited. All the trials included in this systematic review excluded patients 
who were at increased risk of developing complications. Given that we are faced with an ageing 
population who may have multiple co-morbidities, future trials should include these patients so 
that our understanding of the role of FS in head and neck surgery may improve. Further clinical 
trials incorporating robust methodology are needed, this is particularly the case with regards to 
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lateral neck dissection where there is a paucity of randomised data and where the potential for 
greatest benefit exists, through avoidance of severe complications and reduction in hospital 
length of stay. 
2.7 Influence of this work on future trial design 
Through the process of conducting this systematic review the design of any future trial can be 
improved to make the results more applicable to a broader range of surgeons and policy mak-
ers. Key areas for improvement are discussed below. 
1. Conducting the study over multiple centres. All the studies included in the system-
atic review were single-centre studies. To make the results more generalisable, includ-
ing multiple centres would make the trial more pragmatic in design and allow a greater 
impact of the findings on clinical practice. 
2. Broader inclusion criteria. Many of the included studies excluded patients that were 
deemed to be at high-risk of complications. With the incidence of HNC increasing in 
an ageing population with multiple co-morbidities, this eligibility criteria may not accu-
rately represent the patients it will be used on in routine clinical practice.(1, 2) Further-
more, excluding patients at high-risk of complications may overestimate the benefit of 
FS. 
3. Computer generated randomisation sequences. Like many of the included trials, 
using computer generated randomisation sequences is a considerably more robust 
approach to minimising selection bias when compared to techniques like sealed enve-
lopes.  
4. Revealing the allocation at the point of wound closure. Surgeons who know the 
allocation prior to starting the operation have scope to introduce performance bias. 
This can be minimised by revealing the allocation intra-operatively and at the point of 
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wound closure. However, consideration needs to be given to including mechanisms to 
monitor adherence to this process.   
5. Consider using a low Thrombin concentration FS. Low Thrombin concentration FS 
has been engineered specifically to aid adherence of tissues and close dead 
space.(51) All the trials that have used this type of FS have shown encouraging re-
sults.(78-81) Whilst some trials that used a high Thrombin concentration FS have also 
shown benefit,(92, 94, 100) the extra time afforded by the delayed onset of polymeri-
sation is likely to improve the ease of use for the broad range of surgeons recruiting to 
a multicentre trial.  
6. Selecting an appropriate control. Apart from Hornig et al all the included trials used 
standard of care without FS as the control arm. Hornig et al opted for a saline placebo 
control. Superficially this seems like a more robust control because surgeons are also 
blinded (double-blind). However, the consistency of saline is different to FS and it is 
very likely that surgeons can tell the difference both when the solution is viewed in the 
syringe and when it is applied to the wound. In order to produce an appropriate placebo 
a safe product that has a very similar consistency and appearance is required. Alt-
hough placebo control might represent an ideal inclusion for trial design, production 
would likely be prohibitively expensive. Accepting that it might be difficult to justify such 
costs, alternative means of ensuring validity of outcome (such as assessor blinding) 
could be employed.  
7. Outcome assessors and patients should be blinded. This is required to minimise 
detection bias and should be considered a minimum requirement. Because the patient 
is under general anaesthesia blinding them to the allocation is relatively straightfor-
ward. It is important to select outcome assessors who are not present in theatre while 
the intervention is being administered.  
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8. Performing an intention-to-treat analysis. This is important to account for attrition 
bias that occurs when unequal numbers of participants that do not complete the trial. 
This will provide useful information to surgeons in policy makers when deciding 
whether to adopt FS in their practice.  
9. Minimising conflicts of interest. The studies by Hester et al were industry funded 
and included authors who were stakeholders in the product. Whilst there is no evidence 
that the studies were conducted unethically, conflicts of interest do sow seeds of doubt 
in the reader thereby minimising the impact of the work.  
These points for consideration demonstrate that undertaking the systematic review prior to de-
signing a future trial is a valuable process. The justification for a future definitive RCT is dis-
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Chapter 3.  RATIONALE FOR THESIS 
3.1 Rationale for Randomised Controlled Trial 
To date there are only two RCTs that have assessed the role of FS in lateral ND (as opposed 
to central ND).(94, 95) These trials have randomised a total of 75 patients between them. Both 
trials were single centre studies conducted in specialised healthcare settings with only 1 or 2 
surgeons operating on all the patients. This implies that the trials were more on the explanatory 
end of the continuum and raises doubt regarding the external validity of the findings and 
whether they are applicable to UK surgeons working within the NHS. Furthermore, the outcome 
measures for both trials focused on drainage volumes or hospital length of stay; whilst these 
are important outcomes for service providers, there is currently no published evidence that 
these outcomes are meaningful to patients. Huang et al failed to recruit adequate numbers of 
patients due to “challenging recruitment” but provided no further detail on the specific chal-
lenges.(95) Vidal-Perez et al was a relatively well conducted trial that was deemed to be at low 
risk of bias and demonstrated very positive outcomes in favour of FS.(94) However, the trial 
should be considered an outlier in the meta-analysis undertaken in Chapter 2. Whilst it demon-
strated evidence of efficacy, the results have not been reproduced by other authors. Further-
more, the trial only included patients with thyroid cancer who are unlikely to be representative 
of all head and neck surgery patients. Olson et al retrospectively reviewed the National Cancer 
Database and demonstrated that the incidence of thyroid cancer is increasing within the US 
and possibly related to an evolving patient demographic.(106) The increased incidence is pri-
marily driven by the early diagnosis of papillary thyroid cancers and associated with patients 
who have better access to healthcare and higher socioeconomic status.(106) This patient de-
mographic is not likely to be representative of patients with mucosal HNC which has a higher 
incidence in deprived populations.(1)  
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In 1967 Schwartz and Lellouch stated that explanatory trials confirm a clinical hypothesis 
whereas pragmatic trails inform clinical or policy decisions.(107) More recently Zwarenstein et 
al published recommendations to improve the reporting of pragmatic trials. Table 7 summa-
rises the key differences the authors described between trials that adopt an explanatory and 
pragmatic attitude.(108)  
 
Table 7 Key differences between explanatory and pragmatic trials taken from Zwarenstein et 
al.(106) 
 Explanatory attitude Pragmatic attitude 
Question Efficacy: can the intervention 
work? 
Effectiveness: does the intervention 
work when used in normal practice? 
Setting Well resourced, 'ideal' setting Normal practice 
Participants Highly selected; poorly adherent 
participants and those with condi-
tions which might dilute the effect 
are often excluded 
Little or no selection beyond the clinical 
indication of interest 
Intervention Strictly enforced and adherence is 
monitored closely 
Applied flexibly as it would be in normal 
practice 
Outcomes Often short-term surrogates, or 
process measures 
Directly relevant to participants, fun-




Indirect: little effort is made to 
match the design of the trial to the 
decision making needs of those in 
the usual setting in which the inter-
vention will be implemented 
Direct: the trial is designed to meet the 
needs of those making decisions about 
treatment options in the setting in 




The PRECIS-2 tool provides a framework for assessing where a trial design lies on the explan-
atory-pragmatic continuum.(109) The assessment of trial design is based on nine domains 
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using a five-point Likert scale, 1 being ‘very explanatory’ and 5 being ‘very pragmatic’. The nine 
domains are as follows: 
1. Eligibility criteria. A pragmatic approach would have broad inclusion criteria and min-
imal exclusion criteria such that participants are representative of patients that would 
receive the intervention in usual care. An explanatory approach would exclude partici-
pants who are unlikely to respond or adhere to the intervention/study protocol or ex-
clude participants based on demographics or tests that are not applied in usual 
care.(109) 
2. Recruitment. A pragmatic approach would recruit participants from a normal clinical 
environment with no overt recruitment effort. Overt recruitment efforts such as search-
ing medical records for eligible patients, sending out letters, using a media campaign 
or providing cash incentives would move the study design more towards the explana-
tory end of the continuum.(109) 
3. Setting. A pragmatic approach would mirror the setting where the results of the trial 
will be applied. Characteristics include geography, healthcare system and demo-
graphic of the population. Running the trial in a single centre or only in academic/spe-
cialist centres when the results are meant to be applicable to all centres makes the trial 
more explanatory.(109) 
4. Organisation. A pragmatic approach would mirror how care is organised and deliv-
ered in usual care and not make use of extra resources. Increasing staffing levels to 
deliver the intervention, providing significant additional training, requiring investigators 
to have a minimum level of experience or certification all make the design more ex-
planatory.(109) 
5. Flexibility of delivery. A pragmatic approach would mirror how the intervention will 
be delivered in usual care and allow investigators the flexibility to deliver it as they see 
fit.  Having a highly specified protocol-driven intervention and having measures in place 
to monitor compliance of those delivering the intervention would make the trial more 
explanatory.(109) Within the context of surgical trial design, it is considered important 
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to maintain the fidelity of the ‘core steps’ of the intervention to ensure it is delivered in 
a standardised fashion. Whilst this concept is at odds with a truly pragmatic trial design, 
it is possible to vary the degree to which the fidelity of the intervention is moni-
tored.(110) 
6. Flexibility of adherence. A pragmatic approach would allow participants to flexibly 
engage with the intervention as they would in usual care. Excluding participants who 
may not adhere to the intervention, withdrawing participants that do not adhere to the 
intervention well enough and introducing measures to monitor participant adherence 
would all make the trial more explanatory.(109)  
7. Follow-up. A pragmatic approach would avoid extra visits beyond those required in 
usual care. The most pragmatic designs often avoid any follow-up altogether and col-
lect data via other means e.g. electronic medical records. More frequent follow-up than 
usual care, contacting participants if they do not attend appointments, collecting more 
extensive data than would be typical outside the trial and having longer follow-up ap-
pointments all make the design more explanatory.(109)  
8. Primary outcome. A pragmatic approach would select an outcome that is significant 
to patients as well as being relevant to commissioners. It is also important to measure 
the outcome as it would be measured in usual care. Selecting surrogate or composite 
outcomes, having central adjudication of the outcome or selecting an outcome that is 
more important to providers than patients make a trial more explanatory.(109) 
9. Primary analysis. A pragmatic approach would be to employ an ‘intention-to-treat’ 
analysis using all available data and not making special allowances. Adopting a ‘per 
protocol’ analysis makes the trial more explanatory.(109) 
 
In order to better understand the applicability of the current trials-based evidence for FS in ND, 
the PRECIS-2 tool has been used to analyse the design of the trials by Huang et al and Vidal-
Perez et al.(94, 95) The PRECIS-2 wheel in Figure 11 summarises the findings.  
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Figure 11 PRECIS-2 wheels for existing trials evaluating Fibrin Sealant in Neck Dissection. 




The black line in Figure 11 represents the trial by Vidal-Perez et al(94) and demonstrates the 
trial had a mixture of pragmatic and explanatory design features. Eligibility was restricted to 
patients who were medically fit and had a BMI<30 making it a very explanatory design feature. 
Recruitment was from consecutive patients attending a clinic with no overt recruitment effort. It 
falls short of maximum points because participants were recruited from only one clinic and no 
information is provided regarding the number of eligible patients who turned down participation. 
In terms of setting, the trial was conducted in a single specialist centre by two experienced 
surgeons making it a very explanatory design feature. Whilst it appears that no additional 
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organisational features were included in the trial design, only 2 surgeons who had experience 
of over 1000 cases operated on participants. Requiring the surgeons to have this level of ex-
perience is an explanatory design feature. Flexibility in delivery of the intervention was very 
explanatory because both surgeons followed a strict surgical protocol outlined in the paper. 
Flexibility of adherence was pragmatic since patients were not excluded based on their likeli-
hood to adhere to the trial. Similarly, no patients were reported to have been withdrawn from 
the trial due to a lack of adherence. As the intervention was administered only once during 
surgery and data was collected during the patient’s hospital admission, there was very little 
opportunity for non-adherence to trial processes hence it fell short of the maximum 5 points. 
The Follow-up arrangements were pragmatic because no extra visits were required for the trial 
and no extra data was collected beyond usual care. It falls short of maximum points because 
the follow-up period was incredibly short (until discharge from hospital). The primary outcome 
was length of hospital stay which is a very short-term metric. Whilst reducing hospital admission 
benefits both patients and commissioners of care, there is no reference to suggest reducing 
length of hospital admission was the most important outcome for patients. Primary analysis 
scored maximum points because there were no dropouts, and an ‘intention-to-treat’ analysis 
was performed.     
 
The red line in Figure 11 represents the trial by Huang et al(95) and demonstrates a predom-
inantly explanatory trial design. Eligibility was very explanatory because patients who were not 
between the age of 20-80 years and patients who had coagulation disorders, previous treat-
ment to the neck, or a reluctance to participate were excluded. Like the trial by Vidal-Perez et 
al, no overt recruitment effort is reported but recruitment was from a single clinic. In terms of 
setting, the trial was conducted in a single centre and participants were operated on by a single 
surgeon. This is clearly a very explanatory design feature. Organisation had both pragmatic 
and explanatory features because no significant extra organisational features were employed 
but slightly more data than usual care was collected in terms of pain and a very specific anal-
gesia regimen was employed. Flexibility of delivery was limited to the technique of a single 
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surgeon and therefore very explanatory. Flexibility of adherence was also very explanatory 
because patients who were unlikely to adhere to the trial were excluded and participants who 
later did not adhere to the trial were also excluded. Follow-up was mainly pragmatic because 
no extra visits were required, but like the trial by Vidal-Perez et al(94), the follow-up period was 
incredibly short. The primary outcome measure was post-operative drainage volume. This is 
an explanatory outcome measure as it may be considered a surrogate for overall wound heal-
ing and there is no evidence that volume matters to patients. Primary analysis was performed 
on a ‘per protocol’ basis making it explanatory in nature. Whilst both trials had elements of 
pragmatism, areas where they could be more pragmatic are in the domains of eligibility, setting 
and flexibility of delivery.  
 
Ultimately the aim of a future definitive DEFeND trial would be to guide clinical decision making.  
Therefore, based on the considerations detailed above, a pragmatic trial design seems the 
most obvious choice. If one assumes that Huang et al(95) and Vidal-Perez et al(94) also wished 
for their trials to guide clinical practice, why did they opt for such explanatory designs? The 
answer to this question is likely to be multifactorial and may include the following reasons:  
1. Explanatory trials tend to be smaller, more rapidly conducted and therefore 
cheaper.(111)  
2. A desire to produce a positive trial outcome. Reporting bias arises when the dissemi-
nation of research findings is influenced by the nature and direction of results. Statisti-
cally significant results that indicate an intervention works are more likely to be pub-
lished and cited.(88) Explanatory trials are more likely to overestimate benefit and un-
derestimate harm.(112)  
3. The authors may lack understanding of the explanatory-pragmatic continuum and how 
discerning clinicians and policy makers are likely to interpret the results before imple-
menting change in their own practice. 
4. The explanatory trial was performed to test efficacy of FS prior to a planned pragmatic 
trial that is yet to be undertaken. This seems unlikely as both studies were published 
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several years ago and, at the time of writing, neither authors have registered further 
trials.  
5. Not all research questions are suitable for pragmatic trials. As discussed above, the 
standardised delivery of a surgical intervention does encounter some conflicts with a 
truly pragmatic trial design e.g. the balance between flexibility of delivery and fidelity of 
the intervention. This point is discussed further in the chapter.  
 
Given the nature and quality of the current evidence for FS in ND, there are essentially two 
options to move forward. The first option is to carry out further explanatory trials to prove ‘effi-
cacy’ before undertaking a larger pragmatic trial to prove ‘effectiveness’. This may be a valid 
approach because currently there are no trials that assess the efficacy of low-thrombin con-
centration FS in ND. The second option is to progress to a more pragmatic trial design. As 
mentioned previously, pragmatic trials are more likely to inform clinical decision making and 
commissioners of care. As discussed previously (Chapter 1.  and Chapter 2, FS are products 
with a well-established safety profile that are widely used across several areas of surgery and 
already authorised for use by the FDA, MHRA and EMA. They are no longer considered novel 
investigational products and therefore it is possible to utilise existing data to inform a more 
pragmatic design which will ultimately be more informative. Whilst in theory the argument for a 
pragmatic trial seems strong, trials assessing surgical interventions may present challenges to 
this endeavour.  
 
Pragmatic trials require participants to be representative of patients who would receive the 
intervention in usual care. However, recruitment to surgical trials is rarely even close to 
100%.(105) In an observational study of surgical RCTs registered on ClinicalTrials.gov, recruit-
ment problems are the main reason why approximately 20% of surgical RCTs are stopped 
early.(113) Therefore, depending on the recruitment rate and the profile of patients who decline 
trial participation, the trial’s recruitment may not be truly representative of the population. De-
sign features such as minimisation of eligibility criteria, reduction in number and complexity of 
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study visits, reduction of research burden will improve participation but are only partial 
measures.(114)  
 
Multicentre trials need local investigators to take responsibility for recruitment, treatment, and 
follow-up. Many clinicians outside of academic centres do not participate in clinical trials. This 
means that patients being treated in the majority of (non-academic) centres will not have the 
option to participate or would need to have care transferred to a recruiting centre. This will 
further reduce the patient pool and hinder the ability to deliver a truly pragmatic trial.(114)  
  
In a pragmatic surgical trial, the intervention should be delivered within a usual care setting by 
surgeons and ancillary staff with typical expertise and experience. This means that a pragmatic 
trial design needs to allow a certain level of flexibility to deliver the intervention whilst still re-
taining trial rigor. However, a trial that is dominated by poor adherence to the protocol, partic-
ularly in the ‘core steps’ of the intervention, becomes of decreasing value.(110) The trial design 
needs to strike a balance between providing enough flexibility that the trial is considered prag-
matic whilst also providing investigators with enough guidance to maintain a degree of fidelity 
and standardisation of the intervention. 
 
Follow-up in pragmatic trials needs to be as unobtrusive as possible, ideally bypassing the 
patient and collecting data from electronic health records. However, the granularity of data in 
electronic records beyond major clinical events such as death, readmissions and returns to 
theatre is often sub-optimal and cannot be relied upon.(114) Most patients who undergo sur-
gery are followed-up routinely by their surgical teams. Therefore, limiting data collection to 
these visits seems the most prudent approach without becoming burdensome on enrolled pa-
tients. Pragmatic outcomes should be important to patients and, in addition to major clinical 
events, may often include outcomes relating to symptoms, disability and quality of life. How-
ever, these metrics are seldom consistently recorded in routine practice and require engage-
ment with the patient.(114) Using web-based forms or apps on hand-held devices may reduce 
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research burden and the number of visits required but may also exclude patients who are not 
computer literate or do not have access to the necessary electronic devices.  
 
Another challenge related to undertaking a pragmatic trial of FS in ND is the timing of the trial. 
Appropriate timing of surgical trials is often considered a key stumbling block in determining 
equipoise.(115)  Buxton’s law states that “it is always too early for rigorous evaluation until 
suddenly it is too late”.(116) This relates to the phenomenon that a new surgical technique is 
initially unstable and subject to refinement as the surgeon learns. The point at which the tech-
nique does stabilise, the surgeon may become convinced of it’s worth and lack the equipoise 
to randomise. This phenomenon can be related to the proposal for a pragmatic trial because 
FS is “CE” marked, FDA approved and has been available to surgeons for several years but is 
not widely used in ND. This demonstrates some degree of community equipoise, but individual 
surgeon equipoise may be more problematic. Based on Buxton’s law, some surgeons may lack 
equipoise on an individual basis because they have had time to evaluate FS in their own prac-
tice. Demonstrating community equipoise means that a future trial has met an essential crite-
rion to justify ethical randomisation however, there is uncertainty regarding the willingness of 
individual surgeons to recruit.  
 
In summary, this discussion has demonstrated that the current evidence for FS in ND falls 
towards the explanatory end of the continuum and lacks necessary external validity and gen-
eralisability. Whilst there is evidence in support of FS as being of potential benefit to pa-
tients/healthcare systems, there is a need for a future RCT that is pragmatic in nature to better 
inform clinicians and commissioners of care. A truly pure pragmatic design may not be possible 
or suitable for this specific research question, however, there is certainly scope to make the 
design more pragmatic when compared to existing/prior trials undertaken in this space. This 
future trial would then be more applicable to clinicians working in a similar healthcare environ-
ment.  
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3.2 Rationale for Pilot & Feasibility Study 
3.2.1 Definitions 
The NIHR define pilot studies as smaller versions of the main study to test whether the com-
ponents work well together and are primarily focused on processes.(117) It defines feasibility 
studies as those that are done to answer whether the main study can be done.(118) The con-
ceptual framework by Eldridge et al provides a more fluid definition where the relationship be-
tween pilot and feasibility studies is not mutually exclusive. The framework is summarised in 
Figure 12 and describes feasibility as an overarching concept of which three distinct types of 
study are a subset. These are: non-randomised pilot studies; feasibility studies that are not pilot 
studies; randomised pilot studies.(119) 
 
 
Figure 12 Conceptual framework of pilot and feasibility studies by Eldridge et al.(117) 
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Randomised pilot studies are those studies in which the future RCT is conducted on a smaller 
scale (piloted) to see if it can be done. These studies reflect the design of the definitive trial 
but, due to uncertainty, may explore a different approach to specific processes. Non-random-
ised pilot studies are those in which the intervention and associated processes are piloted 
without randomisation. This may include a single arm design to assess the processes associ-
ated with the intervention only. Feasibility studies that are not pilot studies are those that an-
swer whether components of a definitive trial can be done without necessarily implementing 
the intervention or its associated processes.(119)  
3.2.2 Role of pilot & feasibility studies 
Pilot and feasibility studies (PFS) have an important role and, if used appropriately, can provide 
important evidence that informs the design, planning and justification of a definitive trial. Fur-
thermore, they may prevent research waste by identifying problems that may limit the success-
ful delivery of a definitive trial.(120, 121)  
 
It is well documented that surgical trials are challenging and present issues beyond those en-
countered in drug trials. These may include uncertainties around equipoise and recruitment (as 
mentioned in the last section), the nature of the intervention itself and the most appropriate 
outcome measure(s).(122, 123) Recently published research into the value of surgical PFS 
protocols has demonstrated that the full potential of these studies has not been realised within 
surgical research.(124) Furthermore, there is a lack of understanding regarding the role of PFS 
with many authors conducting formal hypothesis testing. An incomplete understanding of all 
the uncertainties may be demonstrated in the design of PFS in some funding applications. The 
end points of these studies are often skewed towards the priorities of funders (e.g. recruitment) 
without giving necessary thought to the uncertainties that are specific or unique to the study. 
This research also highlighted issues surrounding the perceived lack of value of PFS amongst 
surgeons and journal editors.(124)  
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Some guidance on the role of PFS within surgical research can be gleaned from strategic guid-
ance such as the IDEAL framework. IDEAL began with a series of meetings at Balliol College 
between 2007 – 2009 to discuss the specific challenges of surgical innovation.(125) This led 
to a landmark publication in the Lancet in 2009.(126) The IDEAL Framework is now a widely 
accepted set of recommendations that describe the stages of surgical innovation. These rec-
ommendations formalise an approach to surgical research that accommodates the complexi-
ties with a view to improving quality. These stages are: Idea, Development, Exploration, As-
sessment, and Long-term study.(126) Figure 13 summaries the stages. The concepts and 
recommendations of IDEAL were later extended in 2019 to provide more practical details for 
investigators wishing to implement them.(127)
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Figure 13 IDEAL Framework. Stages of surgical innovation. (Figure taken from McCulloch et al (124))
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If using the framework to guide further evaluation of FS in ND, it is important to identify where 
the current research sits within the framework. IDEAL stage 1 describes the first use of a new 
procedure or device in a patient. This usually takes the form of a small case series that uses 
safety and technical success as its outcomes.(127) Given that FS are “CE” marked and FDA 
approved for human use, the criteria for IDEAL stage 1 have already been met. Stage 2a de-
scribes the iterative modifications to the technique towards a stable version i.e. when and why 
modifications to the technique or indications occurred to avoid repetition of failures.(127) The 
criteria for Stage 2a (development) appear to have been met because several FS products 
have been used by surgeons for several years and the technique for use is clearly described 
by the manufacturers. Additionally, Summary of Product Characteristic (SmPC) documents are 
available for a wide range of FS products on the market and provide detailed information on 
composition, dose, pharmacology, preparation, administration and safety.(51) In the context of 
stage 2a, the development of FS seems more akin to drug development than the development 
of a novel surgical technique.  
 
A stage 2b study should address any uncertainties that might compromise the successful de-
livery of a future IDEAL stage 3 RCT.(127) Based on this definition, most PFS (including DE-
FeND) sit comfortably within this category. A possible exception being feasibility studies that 
are not pilot studies where the primary objective is to refine and stabilise a novel intervention 
i.e. demonstrating that a novel intervention can be delivered appropriately within a definitive 
trial.  
 
The current best evidence for FS in ND includes two small single-centre explanatory trials that 
lack the external validity to inform wider clinical decision making and policy.(94, 95) Whilst 
these trials do assess the efficacy of FS in ND, it is debatable whether  they meet the criteria 
of an IDEAL stage 3 assessment. Based on the IDEAL framework and updated recommenda-
tions published in 2019, a stage 3 assessment should include more patients with broader eli-
gibility criteria and more surgeons e.g. an early majority.(127) This provides further support for 
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a more pragmatic trial design. Whilst these trials may not stand up to scrutiny in terms of a 
stage 3 assessment, they do provide some information regarding feasibility. By virtue of their 
existence, they teach us that a definitive trial can be done and is therefore feasible according 
to the NIHR definition.(118) Unfortunately, their reporting is not robust or detailed enough to 
address uncertainties around the feasibility of specific design features and the processes re-
quired for the delivery of a more pragmatic trial design. On this basis a further PFS is indicated, 
however, the type of PFS is dependent on the specific uncertainties that need to be addressed.  
The anticipated uncertainties of running a more pragmatic RCT on the role of FS in ND are 
summarised below. This is based on: the systematic review reported in Chapter 2(82); a review 
by Cook that described the challenges of surgical trials in general(115); a survey by Kaur et al 
that reported the barriers to recruitment for surgical trials in head and neck oncology.(105)  
3.2.3 Barriers to an immediate and definitive DEFeND trial 
3.2.3.1 Recruitment 
As previously mentioned, the timing of DEFeND may have implications on individual surgeon 
equipoise and their willingness to recruit patients. Additionally, Kaur et al reported that the most 
significant barrier to recruitment in head and neck surgery trials was ‘patient refusal because 
of treatment preference’.(105) There is evidence that this treatment preference is related to the 
way surgeons convey equipoise and allow their own personal bias to influence the patient’s 
decision.(128) Therefore, uncertainty surrounding individual surgeon equipoise and their ability 
to convey equipoise is likely to influence recruitment to DEFeND.  
 
A pragmatic trial design should include multiple centres with varying levels of expertise such 
that an assessment of ‘real-world’ effectiveness can be made.(129) All previous studies of FS 
in ND have been single-centre, furthermore, how centres with limited experience in recruiting 
to surgical trials will perform is unknown. To this end the DEFeND PFS needs to address these 
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uncertainties by recruiting across multiple centres with surgeons of varying levels of expertise 
in delivering the intervention and recruiting to surgical trials. 
3.2.3.2 Inclusion criteria 
In keeping with a pragmatic trial design, eligibility criteria need to be broad whilst also acknowl-
edging that not all NDs are equal. Some NDs are part of complex operations that require free-
flap reconstruction. Free-flaps are technically demanding and of great importance to the pa-
tient’s wound healing and function. Free-flap failure is associated with returns to theatre, pro-
longed hospital admission, significant morbidity, and psychological distress. FS is thrombo-
genic and the evidence for its use in free-flaps is predominantly based on animal models or in 
targeted pipetting to position the pedicle.(130, 131) There is no evidence supporting its use as 
a pressurised spray delivery (in keeping with the DEFeND protocol) over microvascular anas-
tomoses in humans. Surgeons are understandably reticent to risk compromise to free tissue 
transfer, not least because any failures are closely audited both locally and nationally.(132) 
Given the lack of evidence supporting its use and following discussions with surgeons from 
Aintree University Hospital (Lead Site) it was apparent that recruitment of these patients was 
extremely unlikely. Concerns regarding thrombosis at the microvascular anastomosis and ease 
of re-entering the necks to salvage a free-flap were raised. Since none of the existing research 
of FS in ND has included free-flap patients, one may argue that this specific use of FS has not 
progressed far enough along the stages of IDEAL and further early-stage studies are required 
to assess safety.(127) The counter argument to this approach is to include free-flap patients 
within the PFS and provide evidence of surgeons’ reluctance to recruit, thus informing the de-
finitive trial design. However, the ethics of the latter approach are questionable when there is 
a dearth of evidence to support safety. 
 
In the post RT/CRT salvage setting surgeons may opt to perform limited NDs that focus on 
removing isolated malignant lymph nodes without dissection of other levels. Therefore, a judge-
ment needs to be made regarding how to maximise the patient pool while also defining what 
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constitutes an adequate ND and protecting patients who may be at increased risk of serious 
adverse events (SAE) secondary to FS.  
3.2.3.3 Trial design  
The systematic review reported in Chapter 2 revealed that some trials were at high-risk of bias 
in allocation concealment i.e. the surgeon new the allocation prior to starting the operation.(82) 
Because FS is an adjunct to wound closure and used at the end of the procedure, the surgeon 
can theoretically introduce bias and influence the outcome by altering their approach or perfor-
mance. Also, if the surgeon lacks equipoise, they may decide to withdraw the patient from the 
trial prior to surgery if the allocation does not suit them.  Like DEFeND, the PANasta Trial(133) 
is a surgical RCT that is in the Liverpool Cancer Trials Unit (LCTU) portfolio. PANasta random-
ised patients during surgery, however the LCTU had a problematic experience with this pro-
cess. Randomisation during surgery is dependent on the surgeon accessing software on an 
NHS computer in an operating theatre. For randomisation to be successful it requires appro-
priate internet access/bandwidth and security settings that enable access to, and adequate 
functioning of, the software. Both cannot be guaranteed at specific and time-critical points dur-
ing surgery, therefore risking the patient not being randomised at all. The DEFeND trial needs 
to learn from the experiences of PANasta and adopt an alternative approach of revealing the 
allocation during surgery and immediately before wound closure. This would require novel 
mechanisms in the trial design and administrative processes to monitor adherence. The eval-
uation and refinement of these processes prior to a definitive trial are warranted, further sup-
porting the need for a PFS.  
 
Minimising bias in the assessment of outcomes that are subjective (e.g. severity of signs and 
symptoms) is dependent on an effective blinding strategy. Because the operating surgeon is 
unblinded, there is uncertainty regarding their influence over blinded patients and outcome 
assessors. This is especially the case in busy NHS surgical departments where stopping the 
operating surgeon from reviewing the patient post-operatively is neither realistically governable 
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nor pragmatic. The operating surgeon may inadvertently and indirectly convey their bias onto 
patients and outcome assessors. Therefore, a PFS is required to assess the fidelity of the 
proposed blinding strategy. 
3.2.3.4 Outcomes 
The choice of primary outcome is a critical decision in trial design. In order that the results of a 
future IDEAL Stage 3 trial are adopted into clinical practice, the outcome measures need to be 
meaningful to patients first and foremost. Existing trials looking at FS in ND use outcomes like 
drain volume, length of drain time and length of hospital stay. Whilst these outcomes impact 
on patient flow and productivity and are undoubtedly relevant to healthcare providers, their 
importance to patients is less clearly defined.  
 
There is currently no published core outcome set (COS) for head and neck surgical trials to 
guide this decision-making process for the DEFeND trial. Some guidance can be gleaned from 
a ‘core information set’ for informed consent prior to surgery that has been published using the 
Delphi technique.(17) Key stakeholders included patients, surgeons and allied health profes-
sionals. The final core information set included “details of drips, drains and tubes” and supports 
unpublished qualitative data from the ‘Aintree Head & Neck Patient Research Forum’ that 
demonstrated patients have an aversion to surgical drains as they are uncomfortable and an 
impediment to mobilisation. ‘Time to drain removal’ is a very short-term outcome measure and 
would move the DEFeND trial away from a pragmatic design. The decision to remove a drain 
is often a clinical decision based on the volume and appearance of the drainage fluid. Surgeons 
often use various arbitrary volume cut-offs in the decision to remove drains, none of which are 
particularly evidence based. Using ‘time to drain removal’ as a primary outcome measure may 
require standardisation in the protocol to minimise bias and make results comparable between 
patients. However, in doing so, the trial becomes more explanatory in nature.    
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Relevant to the DEFeND trial, the ‘core information set’ also included ‘the likelihood of wound 
problems’ and ‘details of major or common complications including pain, swelling and bleeding 
that may require a return to theatre’.(17) Complications after major surgery are a significant 
cause of morbidity and mortality and have been shown to have a negative impact on long-term 
quality of life and psychosocial well-being.(134, 135) In surgical oncology, complications can 
also delay adjuvant RT/CRT which is known to adversely affect survival.(136) Whilst complica-
tions after surgery may be a more pragmatic and patient centred outcome, it is not without 
potential issues. The assessment of complications and their severity is subjective and therefore 
at risk of bias if the blinding strategy is ineffective. The Clavien-Dindo classification of surgical 
complications is a well-established tool for assessing the severity of complications, however it 
is not specific to HNS and therefore open to interpretation.(137) Additionally, because Clavien-
Dindo is not specific to HNS, the grade of complication may not be proportional to the morbidity 
and/or severity of symptoms experienced by the patient. Therefore, guidance on the appropri-
ate grading of complications may be beneficial. Given these uncertainties regarding the use of 
Clavien-Dindo as a primary outcome measure a PFS may provide valuable insights into its 
most effective use. Specific issues that may need addressing include uncertainty regarding 
interobserver variability and how to report the outcome measure. For example, should all com-
plications regardless of severity be reported or only those that reach a prespecified severity? 
For patients who suffer more than one complication, should the severity of the most serious 
complication be reported or should the severity of all complications be combined in the form of 
a summary metric?  
3.2.3.5 Trial conduct 
The definitive trial will include multiple centres with varying levels of expertise in delivering the 
intervention and recruiting to surgical trials. The key purpose of a PFS is to ascertain how well 
the components of the trial work together. An assessment of trial conduct is therefore of fun-
damental importance. Feedback from research naïve centres regarding difficulties with trial 
conduct is incredibly valuable to refine the design of a definitive trial. This is because the 
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components of a pragmatic trial design need to work effectively across varying centres and 
research environments.  
 
Kaur et al. found that an important key barrier to recruitment to HNS trials was a lack of clinic 
time to accommodate research.(105) A PFS will enable an assessment of resource use and 
highlight areas where centres may require further support. Modifying trial design to minimise 
additional resource use and engaging with the local Clinical Research Network (CRN) are both 
ways that this barrier may be addressed.  
3.2.3.6 Fidelity of the intervention 
There is arguably some conflict between a truly pragmatic trial design that allows investigators 
the freedom to use the intervention as they would in usual practice, and a surgical trial design 
that wishes to ensure fidelity and standardisation of the intervention. The manufacturers of FS 
provide instructions that lay out a series of steps on storage, preparation and administration. 
From the perspective of a surgical trial, it is important that all of these steps are followed.(51, 
61) In comparison to learning an entirely novel surgical technique that requires the acquisition 
of new skills, the use of FS is far less involved. FS does not require the acquisition of new 
surgical skills but rather an awareness of, and the ability to follow, a set of instructions. The 
most pragmatic trial design would hand FS to surgeons, allow them to read and interpret the 
instructions themselves and start using it on trial participants. Whereas a very explanatory trial 
design would insist participating surgeons have a certain level of expertise and include 
measures that ensure every step of the intervention is monitored e.g. photographic or video 
evidence demonstrating compliance. Clearly, if the aim of a definitive trial is to evaluate ‘real-
world’ effectiveness then the pendulum should swing more towards the pragmatic end of the 
continuum. However, in order to deliver a trial that assesses the intervention in a robust man-
ner, some measures that ensure fidelity and standardisation of the intervention are re-
quired.(110) A PFS will provide valuable insights regarding where the balance of flexibility of 
standardisation should lie in a definitive trial.    
 
  77 
 
Whilst surgical learning curve is of critical importance in the development of novel surgical 
techniques, its importance in using FS in ND is less clear. Does a surgeon’s ability to follow 
instructions and administer FS improve over time? If so, how should this be evaluated? These 
are important questions to which the answers are currently unknown. Cook discussed two main 
options for controlling the impact of learning curve in surgical trials, firstly in the design of the 
trial and secondly in the analysis.(138) In terms of design, Cook proposes entry criteria for 
surgeons who have reached a prespecified level of experience or expertise. This approach 
pushes the pendulum back towards the explanatory end of the continuum and is preferably 
avoided. In terms of analysis, Cook proposes a post hoc assessment of learning curve that 
quantifies its effect and adjusts for it in the results. This latter approach is far more in keeping 
with a pragmatic design however, large numbers of patients are required.(138) Within the con-
text of the DEFeND PFS, comparing surgeons who have differing levels of expertise in using 
FS is important to understand if learning curve needs to be accounted for in the definitive trial.  
3.2.3.7 Sample size calculation for a definitive trial 
Whilst a PFS should not be used for formal hypothesis testing, obtaining data that would inform 
a sample size calculation is legitimate. This is particularly the case when embarking on a prag-
matic design when all previous studies have been explanatory. Clearly selection of the most 
appropriate primary outcome measure is a prerequisite for any calculation. Clinical outcomes 
from the DEFeND PFS will provide some information on baseline event rates to allow an esti-
mate of effect size. This information will also be critical in deciding whether to proceed with a 
definitive trial at all in an effort to avoid research waste.(121)   
3.3 Rationale for Randomised External Pilot Trial 
Based on the uncertainties described in the previous section, we are not currently able to con-
fidently deliver a definitive DEFeND trial and a PFS is certainly justified. According to Eldridge’s 
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‘conceptual framework’ the different types of feasibility studies include feasibility studies that 
are not pilot studies, non-randomised pilot studies, randomised pilot studies as well as internal 
pilot studies.(119) Internal pilot studies are studies that form part of a definitive trial in which 
mechanisms exist to assess the viability of the trial and allow decisions regarding progression.  
This process avoids research waste by either stopping the trial early or allowing modifications 
to remediable issues.(139) Given the number of uncertainties about conducting DEFeND and 
surgical trials more broadly, an internal pilot does not seem an appropriate method. There is a 
possibility that significant changes to the trial design will be required and therefore a separate 
study conducted prior to a definitive trial is a more prudent approach.  
 
The NIHR define feasibility studies as those which ask the question “can the trial be 
done?”(118) Given that there have been many RCTs assessing the role of FS in many different 
surgical fields, the answer is broadly positive i.e. we know surgical trials assessing FS can be 
done by virtue of the fact that so many exist. However, if we ask “can a multi-centre trial as-
sessing the role of FS in the field of HNS be done?” the answer is less certain. This is because 
none of the previous trials assessing FS in HNS have been multi-centre. Many of the uncer-
tainties are related to trial process as well as feasibility of specific design features. On this basis 
an external pilot study is the best approach. The uncertainty regarding pre-operative randomi-
sation and intra-operative allocation reveal means that a randomised external pilot trial (REPT) 
is the logical way forward.(119)  
 
‘Feasibility studies that are not pilot studies’ is essentially an umbrella term for all other types 
of feasibility work.(119) At the time of proposing the DEFeND REPT it was thought that all 
necessary feasibility work could be conducted as part of the REPT. Reflections of whether this 
was appropriate or whether some feasibility work should have been done before starting the 
REPT will be provided in the discussion chapter of this thesis. 
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3.4 Thesis Objectives 
Objective 1: To provide an in-depth narrative of the set-up of DEFeND.  
Objective 2: To provide a detailed description of the design of the DEFeND REPT and justify 
why these features were chosen. 
Objective 3: To assess whether the key components of the DEFeND REPT work well together 
and whether a future definitive trial is feasible. 
Objective 4: To explore the different types of outcome measures used in surgical trials and 
how this may inform the outcome measures used in DEFeND. 
Objective 5: To discuss key learning points from the process of delivering the DEFeND REPT 
and how this would inform future surgical trial design in Head & Neck. 
Objective 6: To use the knowledge and understanding gained from DEFeND REPT to decide 
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Chapter 4.  INSTITUTING THE RANDOMISED EXTERNAL 
PILOT TRIAL 
This chapter will provide a narrative of the PhD candidate’s involvement in setting up the DE-
FeND REPT and interactions with various stakeholders. 
4.1 Interaction with the Clinical Trials Unit and Sponsor 
The DEFeND Randomised External Pilot Trial (REPT) was funded by the NIHR via the Doctoral 
Research Fellowship (DRF) stream (project reference DRF-2017-10-117). The study was de-
livered by the PhD candidate with the support of his supervisory team and through the North 
West Surgical Trials Centre (NWSTC) and the University of Liverpool (UoL). Interaction with 
the NWSTC commenced before the funding application process. The NWSTC is one of five 
Royal College of Surgeons of England surgical trials centres and was established in 2013.(140) 
At that time, the NWSTC was embedded within the Liverpool Cancer Trials Unit (LCTU). Fol-
lowing a recent merger of the two CTUs based within the UoL, the NWSTC has subsequently 
been subsumed within the renamed Liverpool Clinical Trials Centre (LCTC).  
Early interaction with the NWSTC and LCTU involved negotiating their support for the DRF 
application and adoption for the study. As the DEFeND REPT design phase was an integral 
part of the doctoral research training, NWSTC and LCTU similarly agreed to embed the PhD 
candidate within their structures. This involved providing office space within the unit so that 
mentorship and support could be provided by senior trial co-ordinators and the operational 
director. In addition to providing the infrastructure and mentorship to deliver the DEFeND 
REPT, the NWSTC agreed to provide a practical training in surgical trials methodology and 
delivery. Following a successful application, the PhD was registered with the UoL and the 3-
year DRF commenced in October 2017. Early in the process, the UoL issued a letter confirming 
their intention to sponsor the study pending approval of all the necessary working documents. 
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In broad terms the agreed format of the DRF was to setup the study in first year, recruit in the 
second year and analyse/write up in the third year.     
During the DRF the PhD candidate was embedded within the NWSTC and began the process 
of setting up the trial. This was achieved by the candidate being supervised in the role of Trial 
Co-ordinator while simultaneously completing the Principal Investigator (PI) role within the lead 
site (Aintree University Hospital). Before embarking on this project, it was necessary to engage 
with the MHRA and establish whether they considered FS to be an investigational medicinal 
product (IMP). The MHRA agreed that FS was not an IMP and that DEFeND was therefore 
not a Clinical Trial of an Investigational Medicinal Product (CTIMP). This was important to es-
tablish early as it would have significant implications regarding the study’s regulatory require-
ments.  
4.2 Overview of the PhD Candidate’s Role in Trial Set-
up 
4.2.1 Protocol development 
The pre-trial systematic review Chapter 2 provided valuable insights into what any future trial 
should look like (Section 2.7). The overall design of the trial underwent a robust review process 
both in the preparatory and assessment phases of the application. In the preparatory phase 
advice from the Research Design Service (RDS) was sought and the proposed trial design was 
heavily critiqued by the candidate’s supervisory team (including senior trial coordinators from 
LCTU and the operational director). The DRF application required a detailed description of the 
trial design that was peer reviewed and examined in-depth during the selection process.  
At the start of the DRF the PhD candidate held meetings with his supervisory team to finalise 
the trial protocol and construct the working document. Due attention was given to the feedback 
provided throughout the application process. The Patient Information Sheet (PIS), Informed 
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Consent Form (ICF) and GP letter were also written by the PhD candidate and approved by 
patient members of the Aintree Head & Neck Research Forum, ensuring essential patient and 
public engagement. Copies of these documents can be found in Appendix A.  (A.1 Protocol, 
A.2 Patient Information Sheet, A.3 Informed Consent Form, A.4 GP Letter). An in-depth de-
scription of the trial design and rationale behind specific features will be provided in the Chapter 
5.   and Chapter 6.  . 
4.2.2 Research Ethics Committee and Health Research Authority approval 
Because the proposed study design involved patients that would be identified, randomised and 
treated within the NHS, ethical approval was a mandatory requirement. The PhD candidate 
commenced the process of obtaining ethical approval by completing and submitting the Inte-
grated Research Application System (IRAS) form. The process also allowed for the NIHR Clin-
ical Research Network (CRN) application form to be completed simultaneously, an essential 
component for subsequent portfolio adoption and CRN support for trial delivery. Supporting 
documentation included the protocol, PIS, ICF, GP letter, CVs of named investigators, a model 
Research Site Agreement, Statement of Activities and Schedule of Events. The research site 
agreement, statement of activities and schedule of events is discussed later in section 4.4. The 
PhD candidate and Primary Supervisor attended the Northwest – Greater Manchester East 
Research Ethics Committee (REC) application review panel in person. This facilitated provision 
of direct responses to REC queries and was considered best practice in support of a critical 
element of research conduct. The following list of changes was requested by the REC (clarifi-
cation is provided in brackets to add context to some points): 
1. Changes to the PIS. 
a. Make it clear throughout that the participants are taking part in the pilot study 
and not the main clinical trial.  
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b. Under the heading “Do I have to take part?” please state that it would be of 
interest to understand the reason for withdrawal however this information does 
not have to be disclosed.  
c. Remove the picture of the Fibrin Sealant.  
d. Please specify to Patients that the Fibrin Sealant would be sprayed directly on 
their wound, the Participant Information Sheet does not give detail to this.  
e. Include two additional risks, allergy and fluid collection.  
f. Remove the word “only” when stating risks.  
g. The heading “What if there is a problem?” should detail the risks involve with 
taking part not addressing complaints. Please see the HRA website for guid-
ance if needed.  
h. Please include a heading regarding the complaint’s procedure, refer to the 
HRA website for guidance if needed.  
i. Participant Information Sheet Part 2 does not detail any points of contact for 
complaints. Please specify Researcher details and also Research Governance 
which has already been listed in A4 of the IRAS Form.  
j. Remove text regarding Patient samples being sent around Europe, ensuring 
patients are aware that their samples will eventually be destroyed (samples 
were taken for a sub-study that the PhD candidate was not involved in and did 
not influence the DEFeND trial).  
2. Within the Informed Consent Form remove the three points in italics (these points re-
ferred to a sub-study that the PhD candidate was not involved in and did not influence 
the DEFeND trial). 
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3. Please provide script which will be used alongside the power point presentation (this 
refers to a power point presentation that was produced to assist investigators in ex-
plaining the premise of the trial using visual aids, however, this was not considered 
necessary and was never used). 
After these amendments were made, approval from the REC and Health Research Authority 
(HRA) was granted on 15/05/2018 (reference 18/NW/0209).  
Following this approval, the trial was registered with the International Standard Randomised 
Controlled Trial Number (ISRCTN) database on the 16/05/2018 (reference ISRCTN99181100). 
Registration of clinical trials improves research transparency and is important to fulfill the ethi-
cal obligations towards trial participants and the research community as a whole. It does this 
by preventing duplication of research and allowing researchers to access information that may 
guide healthcare decisions, thereby reducing publication bias and selective reporting. Trial reg-
istration is also a requirement for publication in many peer reviewed journals.(141, 142)  
There was a need to make a subsequent substantial amendment to the protocol due to the 
addition of a Patient Reported Outcome Measure (PROM). There were no further changes to 
the trial protocol following this and the REC and HRA approved the final version of the protocol 
on 10/09/2018. A substantial amendment is defined as a change to the protocol or other sub-
mitted document that affects: the safety or physical or mental integrity of trial subjects; the 
conduct or management of the trial; the scientific value of the trial; the quality or safety of any 
IMP used in the trial. (Ref ct-toolkit) The addition of a PROM was thought to constitute a change 
in the conduct of the trial.  
4.2.3 Construction of working documents and university sponsorship 
A list of the key working documents the PhD candidate constructed is provided below. They 
were produced utilizing prior templates created by the LCTU and guidance from senior trials 
unit staff. Once these working documents were signed off by the Chief Investigator (CI) and 
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senior LCTU staff, the UoL confirmed sponsorship of the study. Copies of these documents 
are provided in Appendices A.5 – A.12. The details that are specific to trial design will be dis-
cussed further in Chapter 5.  . 
1. Risk assessment (A.5). Some host organisations will only sponsor trials of a certain 
risk level. This document seeks to define the overall risk of the trial design and protocol 
to enable that decision. Risk was assessed on the basis of the intervention, safety of 
participants, trial results, resources and governance. The DEFeND study was consid-
ered to be of low risk overall. Design features such as the use of electronic Case Report 
Forms (eCRF) and the organisational complexity (being multi-centre surgical trial and 
including a relatively research naïve site) did mean that specific components were 
deemed to be of intermediate risk.   
2. Internal delegation plan (A.6). The purpose of this document is to identify the trial re-
lated processes and activities that will take place within the UoL and document the 
roles and responsibilities of study personnel.  
3. Data management plan (A.7). This aims to ensure that the data are of the highest 
quality, that there is conformity across trial teams, and demonstrates that there are 
robust systems to provide quality checks and validation. The PhD candidate and su-
pervising Database Developer took responsibility for all data management tasks. 
Tasks that were specifically performed by the PhD candidate included eCRF develop-
ment (see section 4.3), developing data entry guidelines, developing and administrat-
ing the data query processes and data quality assurance.   
4. Monitoring plan (A.8). Trial monitoring is carried out to ensure the rights and safety of 
participants are protected as well as ensuring the reported trial data are accurate, com-
plete and verifiable from source documents. The DEFeND trial used central monitoring 
with triggered monitoring visits. Details of the criteria for monitoring visits is provided 
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in the document (A.8). Also included are details of central monitoring of recruitment, 
safety, protocol and regulatory compliance and source data verification. 
5. Safety plan (A.9). This document details the process of recording and reporting ad-
verse events. It includes what type and severity of adverse event (AE) should be re-
ported as well as what constitutes an expected and unexpected AE. Once the AE has 
been reported, the document details what events need to be expedited, how causality 
is assigned and how the event will be reported to the REC, sponsor and investigators. 
6. Randomisation instructions (A.10). This document details the process of randomising 
patients into the DEFeND trial.  
7. Unblinding instructions (A.11). This document details the process of unblinding pa-
tients in the event that the allocation needs to be known.  
8. Trial Steering Committee (TSC) charter (A.12). This document details the roles and 
responsibilities of the TSC and its relationship with other oversight committees.  
4.2.4 Patient & public involvement 
The study design and protocol were developed through collaboration with the Aintree Head & 
Neck Cancer Patient Research Forum, as consumers and patient advocates. A focus group of 
five members met to discuss the research question and proposed research project. The group 
had worked with each other on previous studies and were comfortable sharing their personal 
experiences of surgery. The group was sent a plain English summary of the research prior to 
the meeting. The meeting was moderated by the PhD candidate and followed a semi-structured 
process. The patients were asked open ended questions about their thoughts on the proposed 
research and could express their views freely. The meeting was not recorded, and anonymity 
of patients was maintained.  The PhD candidate reflected on the meeting and made changes 
to the trial design according to the issues raised.  
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4.2.4.1 Research question & trial design 
Regarding the overarching aim of this research, to improve the outcomes of patients undergo-
ing ND, the group felt that reducing complications was an important patient centred outcome 
for a future trial. They also reported that drains in the neck caused considerable discomfort and 
restricted mobility. They felt that any technique that reduced complications and allowed quicker 
removal of drains would substantially improve the patient experience. 
Regarding trial design, the group raised concerns about the possibility of allergic reactions to 
FS. Aprotinin, the antifibrinolytic constituent of FS is a bovine protein and known to cause al-
lergic reactions. The incidence of allergic reactions to the Aprotinin component of FS is reported 
to be 0.5 per 100,000 exposures. Furthermore, allergic reactions are much more frequent in 
patients who have had previous exposure. To address this patient concern and minimise the 
risk of allergic reactions, the eligibility criteria were changed to exclude patients who had a 
known previous exposure to Aprotinin or an allergy to dairy products (as Aprotinin is a bovine 
protein). The possibility of formal allergy testing of patients with Aprotinin via a skin prick test 
was explored. The use and funding of additional resources as well as the logistical complexities 
of obtaining this test result within a suitable timeframe, was thought to create a significant bar-
rier to recruitment. Given Allergic reactions were so rare and would occur in a monitored patient 
with a secured airway (under general anaesthesia), the balance of risk versus benefit fell on 
the side of not pursuing this approach.    
4.2.4.2 Trial management 
The chairman of the Aintree Head & Neck Research Forum offered formal ongoing support for 
the study and was appointed as the patient representative for the TSC. Having him as a TSC 
member enabled easy access to the opinions of patients within the research forum.  
4.2.4.3 Developing patient information resources 
Effective communication with participants is vital to trial success.(143) It stands to reason that 
being given excessive and complex information regarding the study can be overwhelming for 
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patients who are due to undergo surgery for cancer. Furthermore, in a survey of ‘what makes 
a study successful’ 92% of study personnel thought that a simple consent process was im-
portant.(144) The involvement of patient representatives in the construction of participant in-
formation resources (i.e. PIS, ICF) is therefore highly valuable. They are able to provide a 
patient’s perspective on the suitability of content, format and language.  
Patients from the Aintree Head & Neck Research Forum were provided with drafts of the PIS 
and ICF and asked to comment on them. By and large they were happy with the content, format 
and language requesting only minor changes. These documents were then reviewed by the 
REC who requested the changes specified in section 4.2.2.  
4.3 Case Report Form Development  
Once the protocol was finalised, work on the Case Report Form (CRF) began. It was decided 
to implement an electronic CRF (eCRF) as this has several advantages over the more tradi-
tional paper CRF. eCRFs are better suited to large multicentre studies due to their ease of 
administration. Repetitive data (e.g. Participant ID) are generated automatically and data from 
different pages can be linked. Furthermore, if investigators miss data or enter invalid formats, 
immediate data alerts are generated to promote efficient resolution. Ultimately this results in 
better data quality that is available for central review immediately. Paper CRFs prone to data 
errors and require investigators to upload data, an additional step that may introduce further 
errors.(145) A potential disadvantage to eCRFs is that they require training to be delivered to 
sites and continuous IT support. Furthermore, access to the eCRF software via NHS computers 
can be problematic in trusts with high levels of internet security. This problem was encountered 
when opening the DEFeND trial at the second site. The NHS trust had to make a special al-
lowance for the software thus increasing bureaucracy and delaying site opening.  
Direct entry into the eCRF was not done for the ‘Day of Surgery’ form which contained operative 
details. In this instance surgeons completed a paper CRF that was later transcribed into the 
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eCRF by research staff at site. The reasons for this were essentially pragmatic and logistical, 
but also critical to maintenance of blinding. Research staff at site were blinded to the allocation 
and therefore, not allowed in the operating theatre. Relying on surgeons, who may not be fa-
miliar with the research process, to access and complete the eCRF may have resulted in miss-
ing data that could not be easily completed retrospectively. Within the context of a busy oper-
ating list, a surgeon who has forgotten their eCRF login details may not enter any data at all. 
Furthermore, because surgical trainees rotate through departments regularly, keeping up with 
the provision of eCRF training and login details adds complexity which threatens the quality of 
data. Because all surgeons routinely complete operative notes, providing them with a paper 
CRF to complete at the same time seemed the most reliable and pragmatic approach. 
The MACRO Electronic Data Capture System (version 4) produced by Elsevier was used as 
the eCRF platform.(146) This platform was used because the LCTU had significant expertise. 
LCTU provided all necessary training for the PhD candidate to design and implement the eCRF 
within MACRO for the DEFeND REPT. MACRO is compliant with the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good 
Clinical Practice (GCP) standards. 
The development of the eCRF was a complex process that was conducted over several stages. 
Several novel approaches not previously implemented by the LCTU were also incorporated 
into the design. Once the protocol had been finalised, the first stage in eCRF development was 
to acknowledge that data needed to be collected for each patient encounter (using the 
CONSORT diagram and SPIRIT figure presented in the next chapter). These encounters were 
then classified as ‘Screening’, ‘Baseline’, ‘Day of Surgery’, ‘Inpatient Assessment’, ‘Follow-up 
1’, ‘Follow-up Unscheduled’, ‘Follow-up 2’ and ‘Premature Discontinuation’. The ‘Inpatient As-
sessment’ and ‘Follow-up Unscheduled’ encounters were set to automatically repeat i.e. once 
data for one episode had been entered another encounter would automatically be generated. 
This would allow data entry for multiple inpatient days and unscheduled follow-up visits. Having 
classified each patient encounter within MACRO, the individual data forms were constructed. 
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In addition to screening and baseline data, each form would correspond to different outcome 
measures. This would enable individual forms to be attached to each patient encounter. Figure 
14 demonstrates an example of the ‘Data Management” page. The first row of headings 
demonstrates each patient encounter, and the first column of headings demonstrates the indi-
vidual data collection forms. The green ticks signify that the data collection form has been 
completed satisfactorily for a specific encounter, the blue box icons signify that the data collec-
tion form is empty and the sun icon signifies that data has been entered but there is a ‘data 
query’ (e.g. missing data field or data error).  In this example the patient was randomised, 
underwent surgery as planned and was discharged on the first post-operative day. They at-
tended all follow-up visits with no unscheduled visits however, data entered in the ‘WHQVali-
dation’ form was incomplete. The trial monitor can easily review these ‘Data Management’ 
pages for each patient currently in the trial and ask sites to make necessary corrections to 
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Figure 14 Example Data Management page of electronic case report form.
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Having established the Data Management page, the next stage in eCRF development was the 
construction of the individual data collection forms (vertical headings in Figure 14).  
4.3.1 Pre-randomisation forms 
The pre-randomisation forms included the ‘Screening’, ‘Eligibility Criteria’, ‘Baseline Data’, 
‘NDII’ and ‘PainVAS’ forms. These forms were required to be completed fully before the soft-
ware enabled the patient to be randomised. The process of completing these forms prior to 
randomisation ensured that only patients who had been adequately consented and met the 
eligibility criteria could be randomised. Using the MACRO eCRF software to prevent the acci-
dental randomisation of ineligible patients was a novel element designed by the PhD candidate 
and had not been implemented by the LCTU in previous trials.  
4.3.1.1 Screening form 
The contents of the ‘Screening’ form are demonstrated in B.1. The form requires investigators 
to enter some basic patient identification data. The key design feature in the page is that once 
the investigators click “yes” to the “Trial consent form signed?” question, an automated email 
is generated to the trial specific email address informing the central trial team that they need to 
authorise a consent form. The investigators at site were required to upload a scanned copy of 
the original signed consent form via secure file upload system for the DEFeND trial located 
within the LCTU online portal.  
4.3.1.2 Eligibility criteria form 
The contents of the ‘Eligibility Criteria’ form are demonstrated in B.2. This form takes the inves-
tigators step-by-step through the eligibility criteria. If the investigator ticked a response that 
suggested the patient was ineligible, the eCRF would be locked and no further data could be 
entered unless the response changed. Once the eligibility criteria had been met, the investiga-
tor was required to electronically sign-off their responses using their login details. This elec-
tronic signature then generated an automated email to the PI to double check and ratify the 
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eligibility criteria. Responsibility to ensure only eligible patients were recruited to the study at a 
particular site was delegated to the PI. Only once this process of checks was complete could 
the patient be randomised. 
4.3.1.3 Baseline data 
Baseline data included details on patient demographics recorded in the ‘Baseline Data’ form 
(B.3) and pre-operative patient reported outcome measures (PROMS). The preoperative 
PROMS recorded were the ‘Neck Dissection Impairment Index’ (NDII) form (B.4) and the ‘Neck 
Pain Scale’ form (B.5). Investigators transcribed the patient’s responses into the NDII form and 
the eCRF automatically calculated a raw and standardised NDII score. This was done by writ-
ing a computer code that reproduced the calculation.(147) Further details on these PROMS 
can be found in Chapter 6.  .  
4.3.2 Randomisation form 
The ‘Randomisation Form’ is a key design feature of the eCRF and can be seen in B.6. This 
form was automatically populated by the completion of previous forms. Once the consent form 
was uploaded it was authorised by two independent central trial team members. If satisfactory, 
they electronically signed-off the consent form. Once two independent checks had been com-
pleted the investigators at site could progress through the form. The boxes for ‘eligibility criteria 
signed-off by PI’ and baseline PROM data were auto-populated. Once they had all been pop-
ulated with a positive response, the investigator at site could electronically sign-off the pre-
randomisation checklist as complete. Only then could the patient be randomised.  
To randomise a patient the investigators accessed the Treatment Allocation RanDomIsation 
System (TARDIS) software version 3.8 and selected the patient ID to be randomised from a 
dropdown list of patients who had completed their pre-randomisation checks. As patients were 
stratified according to site, the investigator was required to select which hospital the patient 
was being treated in. The patient was then randomised and a message sent from TARDIS 
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informing MACRO. Importantly the allocation was not visible to the investigators who random-
ised the patient and was not revealed in MACRO to maintain the blinding strategy. Once the 
patient was randomised an automated email was sent to the consultant in charge of the pa-
tient’s care which contained a link to reveal the allocation. This link was only to be selected at 
the time of wound closure and included relevant warnings to this effect as a step to ensure the 
allocation was revealed appropriately.  
This process was designed by the PhD candidate with assistance from a member of the LCTU 
Information Systems team. Assistance was required to create effective lines of communication 
between the software packages and enable automated emails.  
4.3.3 Surgery form 
As previously mentioned, the Day of Surgery form was a paper CRF that was completed by 
the surgical team in theatre and later transcribed in the eCRF by the research team. B.7 demon-
strates the paper CRF, and B.8 demonstrates the eCRF version. There were two key design 
features of the eCRF. Firstly, the list of surgeons present in theatre was cross-referenced with 
clinicians who performed outcome assessments to alert investigators if they were unblinded. 
Secondly, the start and finish times of surgery were recorded as well as an automatically pop-
ulated time for when the surgeon revealed the allocation. This alerted investigators if the sur-
geon revealed the allocation before the start of surgery thereby deviating from the protocol. 
This feature also allowed investigators to review how far into the surgery the allocation was 
revealed because FS should be used towards the end of surgery (at the point of wound clo-
sure). 
4.3.4 Outcome measure forms 
The outcome measure forms included the ‘Post-Operative Complication Form’ (B.9), ‘Drain 
Output Data Form’ (B.10), ‘Hospital Discharge Form’ (B.11), End of Trial Form (B.12), NDII 
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Form (B.4), Neck Pain Scale Form (B.5), Wound Healing Questionnaire (WHQ) Form (B.13) 
and the WHQ Validation Form (B.14).  
4.3.4.1 Post-operative complication form 
Post-operative complications were assessed by surgeons. If the surgeon was not granted ac-
cess to the eCRF they would be supported by a research practitioner who was conversant with 
the process. There were two important design features in this form aimed at ensuring outcome 
fidelity (B.9). Firstly, the name of surgeon making the assessment was recorded and cross-
referenced with the names of the surgeons present in theatre.  If there was a match, an alert 
would be generated informing investigators of a data error. Investigators could still override the 
alert and continue to enter data with the full knowledge that an unblinded individual was as-
sessing outcomes. This would constitute a deviation from the protocol and trigger a root cause 
analysis to identify why this occurred and how it may be prevented in the future. 
Complications were assessed using the the Clavien-Dindo classification to grade severity(23). 
Within the context of HNS, there are recognised issues with inter-observer variability.(137) To 
minimise the possibility of this, common complications were listed and a description of what 
constituted each grade of severity provided (see B.9). It was thought that providing this de-
scription would help reduce inter-observer variability. For rare complications an ‘Other Compli-
cations’ question was included, however, this required investigators to make their own assess-
ment of the most appropriate grade of complication. 
4.3.4.2 Drain output data form 
The Drain Output Data form was perhaps the most complex form as it needed to implement 
the standardised protocol for drain removal (demonstrated in B.10). At the start of the study 
design process, it was believed that the criteria for drain removal needed to be standardised 
because the secondary outcomes ‘drain volume’ and ‘time to drain removal’ were considered 
integral to the research question. Surgeons may use different criteria to remove a drain and a 
non-standardised approach would produce heterogenous data (depending on how many 
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patients were recruited by each surgeon). This may allow detection bias to creep into the study 
design. For example, a surgeon present in theatre who reviews the patient post-operatively 
may influence the clinical outcome by recommending when the drain should be removed. A 
standardised approach adopts a drain protocol that takes the decision away from clinicians. 
However, in hindsight this also made the trial design less pragmatic.   
The drain protocol/algorithm was developed by the PhD candidate and summarised in Figure 
15. The reasoning behind this algorithm is discussed in detail in section 6.2.1.2. Essentially the 
drainage volume was measured at two different time points within a twenty-four-hour period 
(morning and evening). Given the busy nature of surgical wards it was felt important not to have 
a specified time for drain measurement as this may result in frequent protocol deviations. In-
stead, the time for drain measurement was flexible and focus placed on the rate of drainage 
rather than the volume at a specified time. The rate of drainage was automatically calculated 
by the eCRF once the investigators entered two time points between which the volume was 
measured. After surgery the patient would have their drain measured and emptied that same 
evening. The time and volume of this measurement would be recorded in the fluid balance 
chart of the patient’s medical records. The following morning the drain would be measured 
again by research staff with access to MACRO. They would record the time and volume meas-
ured in the morning as well as the time of measurement the previous evening. This would 
provide the eCRF with two time points and volume with which to calculate a rate of drainage. 
The flow diagram in Figure 15 demonstrates the algorithm that was programmed into MACRO 
by the PhD candidate. If the rate of drainage was less than 1.25ml/hr the eCRF would inform 
research staff to remove the drain. If the rate was greater than 2.09ml/hr research staff were 
informed to leave the drain in situ and re-measure in the evening. Importantly, in keeping with 
safe surgical practice, no drains were removed in the evening. This practice stems from the 
fact that the act of drain removal may on rare occasions result in bleeding and therefore is not 
performed at night when there are fewer nursing and surgical staff on site. Furthermore, pa-
tients tend not to be discharged home late at night and therefore immediate drain removal at 
this time would be unlikely to derive benefit (such as reduced length of stay). If the rate of 
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drainage fell between 1.25ml/hr and 2.09ml/hr, research staff were instructed to re-measure in 
the afternoon. This was because this intermediate rate may signify a slowing of drainage and, 
if re-measured in the afternoon, may result in safe removal of the drain whilst also providing an 
opportunity to discharge the patient from hospital that day. 
 
Figure 15 Drain removal algorithm 
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The research staff were required to enter the exact time and date of drain removal as this may 
have been different to the time of drain measurement. The eCRF was programmed to add all 
the drain volumes together to provide a total volume drained as well as a daily volume.   
4.3.4.3 Hospital discharge form 
The Hospital Discharge Form shown in B.11 recorded the time and date of hospital discharge. 
The name of the outcome assessor making the decision to discharge the patient was cross-
referenced with the list of surgeons present in theatre. If there was a match, the eCRF would 
alert the research staff that the outcome assessor was unblinded and deviating from the pro-
tocol. This would enable the research staff to ask another clinician to assess whether the pa-
tient was suitable for discharge. If an unblinded outcome assessor was allowed to make the 
decision to discharge, the trial monitor would be aware of the deviation and would need to 
instigate a root cause analysis. 
4.3.4.4 End of trial form 
The End of Trial Form shown in B.12 was a relatively simple design that required direct re-
sponses to the questions and was not linked to any other forms. In order to assess the fidelity 
of the blinding process the patient, research nurse and blinded surgeon were asked whether 
they thought the patient received the intervention or not. They graded the confidence of their 
response using a 5-point Likert scale that was used to assess the fidelity of the blinding process 
(5.8)  
Research staff were also requested to record the number of lymph nodes harvested within the 
neck dissection. This information was derived from the final pathology report and used as a 
quality assurance indicator to monitor whether patients were undergoing adequate dissec-
tions.(148) The final box on the form was a free-text box where research staff transcribed the 
patient’s response to a question regarding the minimal clinically important difference (MCID). 
The reasoning behind the question is discussed further in section 5.12.4. 
 
  100 
4.3.4.5 Patient reported outcome measure (PROM) forms 
The PROM forms include the ‘NDII Form’ (B.4), the Neck Pain Scale Form (B.5) and the Wound 
Healing Questionnaire (WHQ) form (B.13). The rationale behind selecting these PROMs is 
provided in section 6.2.2. These forms simply reflected details provided in their relevant publi-
cations.(147, 149, 150) The NDII and Neck Pain Scale were recorded at baseline as well as at 
the final visit. The WHQ form was recorded at the final visit only. The questions were delivered 
to patients either by printing off the eCRF form and asking patients to complete the questions 
independently or by research staff reading out the questions to the patient. The WHQ was 
developed by researchers at the University of Bristol and is not validated for use in HNS pa-
tients.(149) Permission to use the WHQ was obtained through collaboration. They requested 
that the WHQ Validation questionnaire (B.14) was completed by surgeons assessing the pa-
tient at the final visit. Anonymised data from the WHQ and WHQ Validation forms was sent to 
them in the form of a spreadsheet on a monthly basis.  
4.3.4.6 Electronic case report form completion guidelines 
Research staff at site were trained to use MACRO during the process of site opening. The PhD 
candidate instructed them on how to login, create a new patient and enter data. Once their 
training was complete the LCTU provided them with their own personal login details. In addition 
to this initial training research staff were provided with the eCRF completion guidelines (B.15) 
as part of the investigator site file. Furthermore, the PhD candidate, in the role of Trial Monitor 
and Trial Co-ordinator, was easily accessible to troubleshoot and assist research staff at site 
to ensure data quality. B.16 shows the working document for the Data Query process. This is 
the process by which site staff can enter queries and communicate with the Data Monitor (PhD 
candidate) through the MACRO platform. However, this process was often bypassed by re-
search staff who preferred to liaise directly with the Data Monitor (PhD Candidate).  
Before the eCRF was made ‘live’ for use on trial participants, the PhD candidate and IT depart-
ment practiced data entry with artificial patients and scenarios. Once both parties were satisfied 
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that the eCRF was fit for purpose, the IT department then undertook its routine authorisations 
as part of the ‘Green Light Process’ (see section 4.4.2). 
4.4 Site Initiation and Green Light Process 
The DEFeND trial recruited patients from two sites, Aintree University Hospital (Lead Site) and 
Queen Victoria Hospital (QVH). Aintree University Hospital (AUH) was chosen because it is 
one of the busiest HNC centres in the UK and a leading centre for HNC research. Furthermore, 
both the PhD candidate and Chief Investigator (CI; Schache) are based within the trust (PhD 
candidate is a trainee and Schache is an Honorary Consultant Head & Neck Surgeon). Both 
the PhD candidate and CI have close links with QVH, having worked there as higher surgical 
trainees. Furthermore, following the recent appointment of an academic Head & Neck Surgeon, 
QVH had expressed an interest in expanding their clinical trials portfolio. Prior to their involve-
ment in DEFeND, QVH had a very limited experience of delivering surgical trials. At the time 
their lack of experience was considered beneficial to assessing the pilot and feasibility out-
comes of the trial. QVH is a non-academic centre which is representative of many HNC ser-
vices in the UK. Therefore, insights gained from their performance in delivering the study was 
thought to be valuable for improving the design of a definitive trial.  
During the set-up phase, subsequent to REC and HRA approval was granted, both sites were 
required to confirm their capacity and capability to deliver the study. These decisions were 
primarily made by the respective Research & Development (R&D) departments and based 
upon the protocol, research site agreement, statement of activities and schedule of events. The 
research site agreement is a contract between the sponsor (UoL) and the research site. A 
model agreement taken from the IRAS website(151) was used. In keeping with HRA recom-
mendations this model agreement was unmodified. The Statement of Activities provides the 
research site with clarity on what funding the sponsor will provide for research costs and better 
understand the overall cost of the study. The Schedule of Events provides the research site 
with all the ‘per-participant’ activities and classifies the funding of them as either NHS treatment 
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cost, NHS support cost or research cost. NHS treatment costs are the patient care costs that 
would continue to be incurred if the service continued to be provided after the study had 
stopped e.g. the cost of performing a ND. NHS support costs are the additional patient care 
costs associated with the study which would end once the study has finished e.g. the time 
taken to consent the patient for the study. The research cost is the cost of the study itself and 
related to activities undertaken to answer the research question. Research costs would end 
when the study ends.(152)  
The funder (NIHR) is a member of the Association of Medical Research Charities (AMRC) and 
certain activities were undertaken by staff employed by the NHS or NIHR Clinical Research 
Network (CRN). Under these circumstances the research activities are further classified as 
either ‘Part A’ or ‘Part B’. The cost of ‘Part A’ activities are paid in full by the funder whereas 
the cost of ‘Part B’ activities are paid by the Department of Health. ‘Part A’ activities include 
screening, assessment of eligibility, randomisation, study specific investigations, follow-up ap-
pointments in addition to standard care. ‘Part B’ activities include local study co-ordination, data 
collection and time taken by the PI/CI to explain the study to professional colleagues.(152)  
4.4.1 Site initiation visits 
The site initiation visits for both the lead and second site were conducted by the PhD candidate. 
The purpose of the visits was to ensure the sites understood the protocol in detail and had an 
opportunity to raise any questions or concerns. The PhD candidate attended both sites in per-
son and gave presentations summarising the trial protocol and important trial related pro-
cesses. An entire day was set aside for each visit. Topics covered included screening, recruit-
ment, informed consent, randomisation, PI obligations, GCP, contents of the investigator site 
file, delegation logs, data protection, eCRF completion, safety reporting, monitoring, patient 
withdrawals and close out. In addition to the presentations the PhD candidate also delivered 
individual training for research staff on maintaining the screening log, uploading consent forms, 
eCRF completion, randomisation and safety reporting. Having taken an integral role in 
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designing the study and completing all the regulatory processes, the PhD candidate was well 
positioned to answer questions as well as address potential barriers (e.g. communicating with 
the second site’s IT department to authorise access to the eCRF software on NHS computers). 
4.4.2 Green light process 
The Green Light Process is essentially a process of bringing together all the regulatory and 
administrative approvals and documents that are required to open the trial to recruitment. A 
checklist was completed and signed-off by both the Operational Director of the LCTU and the 
CI. The following requirements needed to be met before the Green Light Process was com-
plete: 
1. The sponsor (UoL) had given the green light following REC/HRA approval and the 
authorisation of working documents described in section 4.2.1, 4.2.2 and 4.2.3.  
2. The LCTU IT department had tested and authorised the randomisation process and 
eCRF for use on trial participants.  
3. The research sites had confirmed their capacity and capability as well as undergone 
their site initiation visits. 
4. Clinical Co-ordinators had been assigned and tested in their ability to assess adverse 
events appropriately and in a timely fashion. This involved them reading the Safety 
Plan (A.9) and undertaking a test case of a fictional patient. In the test case they were 
required to read the adverse event report (Located in Appendix 1 of the Safety Plan in 
A.9), access the LCTU Pharmacovigilance database and assign severity, expected-
ness and causality. This needed to be performed correctly and within the predeter-
mined timeframe for the Clinical Co-ordinator to be deemed competent.  
5. First TSC had been convened to review the trial protocol and to agree upon how future 
meetings will operate.  
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Following the completion of the Green Light Process AUH recruited and randomised the first 
patient on 8th November 2018. With both the PhD candidate and CI supporting surgeons and 
research practitioners to recruit patients, AUH was able to recruit quickly and effectively. QVH 
however did not randomise their first patient until 4th February 2019. This was mainly due to 
their very cautious R&D department that was inexperienced in opening clinical trials. Areas 
where they differed from AUH included taking longer to read and sign the research site agree-
ment. It became apparent that they wished to minimise the time between opening the site and 
recruiting the first patient, so it appeared that there was a deliberate delay to site opening until 
a suitable first patient had been identified. Another concern they raised included limited re-
search practitioner support and their ability to recruit patients and complete the eCRF in a 
timely fashion. Making contingency plans to cover all the research activity added to the delay 
in site opening. 
QVH follows a slightly different model of HNC services compared to AUH. The catchment area 
for QVH is a vast area in the Southeast of England which encompasses several NHS trusts 
and Head & Neck Multidisciplinary Team (MDT) meetings. Patients are managed in outpatient 
clinics locally (spoke) but operated on centrally at QVH (hub). Concerns were raised by QVH 
regarding whether patients could be approached and consented at the ‘spoke’ sites before they 
attended QVH. This was a legitimate concern however, with site opening already delayed by 
four months and recruitment limited to twelve months, opening the spoke sites was considered 
untenable. A decision was made to not open spoke sites and for the PI and research practi-
tioners were asked to work around this issue. A discussion around this decision and its impli-
cations on the results of the DEFeND REPT is provided in section 8.1.2.  
A detailed description of the trial design and rationale behind the choices made is provided in 
Chapter 5. The rationale behind the clinical outcome measures that were chosen to inform a 
future definitive trial is provided in Chapter 6.   
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Chapter 5.  TRIAL DESIGN 
5.1 Overview 
The study design design being piloted is that of a two arm, parallel group trial with block ran-
domisation in a 1:1 allocation ratio. The interventional arm constitutes the application of FS to 
the surgical wound in addition to SoC the control arm constitutes SoC alone. For the purposes 
of this study SoC constitutes the surgeon performing the ND as they normally would and es-
tablishing complete haemostasis. Patients in both arms had a single surgical drain placed and 
the wound closed with resorbable sutures across the platysma layer and metal clips to close 
the skin. The use of FS or any other adjunct to haemostasis in ND is not commonplace within 
the UK. For this reason, the selection of SoC as the comparator is justified. 
 
Data was collected and entered directly into the eCRFs by research staff at sites located within 
the trial’s electronic database (MACRO version 4). Delegated staff were given training and 
access to the software and were expected to input data directly into the eCRF in real time. 
Each delegated person had a unique username and password to identify who entered the data 
for audit purposes. Details of the various forms that made up the eCRF have been previously 
reported in section 4.3 and each forms is shown in Appendix B. 
 
The Consolidated Standards of Reporting Trials (CONSORT) diagram is shown in Figure 16. 
The protocol was prepared in line with the Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) guidelines. The working document can be seen in Appendix A.1 
and the published version can be accessed at: https://pilotfeasibilitystudies.biomedcen-
tral.com/articles/10.1186/s40814-020-00618-w. In keeping with best practice, the protocol was 
submitted for publication in the journal “Pilot & Feasibility Studies” while recruitment was still 
ongoing.(153) The “SPIRIT 2013 Checklist: Recommended items to address in a clinical trial 
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protocol and related documents” can be found in the supplementary information associated 
with the published protocol. The SPIRIT Figure shows the different data collection steps of the 
pilot trial (Table 8).   
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Figure 16 Study flow diagram (CONSORT diagram). 
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Table 8 SPIRIT figure 






















































































































Identify potential participant X X         
Approach potential participant to dis-
cuss study X X   
      
Medical history  X         
Physical examination  X         
Assessment of eligibility criteria  X         
Review of concomitant anticoagulant 
medications  X X X X X X X X X 
Review of previous treatment to ipsilat-
eral neck  X   
      
Demographic assessment  X         
Signed consent form    X       
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Wound Drainage 
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Histological Lymph 
Node Yield          X  
5.2 Trial Registration & Governance 
The DEFeND REPT was prospectively registered with the ISRCTN registry. ISRCTN99181100 
was assigned on 16 May 2018. DEFeND was also registered on the UK CRN study portfolio 
(Protocol Number: 37896).  The University of Liverpool was the sole sponsor for this study 
(sponsor@liverpool.ac.uk) and had responsibility for trial oversight, indemnity, monitoring trial 
conduct and governance. All items from the World Health Organization Trial Registration Data 
Set can be found at:  https://doi.org/10.1186/ISRCTN99181100. The study was funded through 
the NIHR Doctoral Research Fellowship programme (project reference DRF-2017-10-117). 
The funder and sponsor had no role in study design, data collection, trial management, analysis 
of results or dissemination.  
 
Research ethics approval was granted by Northwest – Greater Manchester East Research 
Ethics Committee (REC), reference 18/NW/0209, on 14/05/2018 and subsequently by the 
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Health Research Authority on 15/05/2018. Written informed consent was obtained from all par-
ticipants in accordance with this approval. One substantial amendment to the protocol was 
made and approved on 10/09/2018 which was prior to recruitment of the first participant. The 
REC agreed that an Independent Data Monitoring and Safety Committee was unnecessary. A 
Trial Management Group monitored progress approximately monthly. The Trial Steering Com-
mittee (TSC) was convened at the start, mid-point and end of recruitment.  
5.3 Pilot & Feasibility Objectives 
The specific pilot and feasibility objectives for DEFeND REPT are listed below and discussed 
in more detail in section 5.12. 
1. Proportion of eligible patients randomised to the study 
2. Reasons for failure to screen potentially eligible patients 
3. Recruitment rate 
4. Reasons for failure to randomise 
5. Number of patients lost to follow-up 
6. Reasons for loss to follow-up 
7. Reasons for failure to reveal allocation at a specific time point during surgery 
8. Fidelity of the blinding process (both patients and outcome assessors) as detected by 
blinding indices. 
9. Accuracy of data recording summarised by the number of key data items with missing 
or incomplete data entries. 
10. Protocol adherence measured by the number of major or minor protocol deviations 
observed through the study. 
11. Determining the minimal clinically important difference (MCID) through semi-structured 
interviews of trial participants. 
12. The relevance of learning curve in a definitive trial 
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5.4 Setting 
The minimum requirements for sites to participate in this study as stipulated in the 
protocol (A.1) were as follows: 
1. Sites will either have or be part of a comprehensive Head & Neck Multidiscipli-
nary Team (MDT). This requirement is based on the national requirement to discuss 
all patients with HNC in an MDT. Therefore, identifying patients who have been dis-
cussed in an MDT was thought to be the most pragmatic design option. 
2. Have surgical expertise in the management of HNC. This was clearly important 
because sites are required to perform ND as part of the treatment for HNC. Most HNS 
services in the UK are centralised and therefore offer a level of expertise. In keeping 
with a pragmatic design, no minimum level of expertise was stipulated.    
3. Have sufficient caseload to recruit 2 patients per month. This was based on two 
sites recruiting fifty patients over a twelve-month period.  
4. Demonstrate enthusiasm to participate in the study. In order to optimise the 
chances of success in recruiting to the study and adhering to the protocol a demon-
stration of enthusiasm is important. From a REPT perspective, the amount of infor-
mation gleaned from a site will be extremely limited if they fail to drive the study for-
ward. 
5. Provide information to all supporting staff members involved in the trial or other 
aspects of the patient’s management. Clearly everybody involved in the patient’s 
journey needs to understand that they are part of a trail and the implications this has 
on their care. 
6. Acknowledge and agree to conform to the administrative and ethical require-
ments and responsibilities of the study, including signing up to GCP. This is a 
mandatory requirement for any research study. 
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This study was set within two UK hospitals offering tertiary HNS services (Aintree University 
Hospital NHS Foundation Trust & Queen Victoria Hospital NHS Foundation Trust). The deci-
sion to select two centres was considered important because a future definitive trial with a 
pragmatic design would need to be multi-centre. Both institutions met the minimum requirement 
for participation and service a large population with a mix of both urban, suburban and rural 
communities. Aintree University Hospital (AUH) was the lead site and has a strong research 
portfolio in HNC research. Four of the academic surgeons have experience as Chief Investiga-
tors (CI) and a dedicated team of HNC Research Nurses (RN) are on hand to optimise recruit-
ment and trial conduct. Queen Victoria Hospital (QVH) is representative of most non-academic 
centres across the UK. It has fewer RNs and considerably less experience in delivering RCTs. 
Understanding the experiences of QVH in delivering DEFeND REPT will be key to the design 
of the future definitive trial. As previously mentioned in section 4.4, the decision to select QVH 
as a second site over other possible sites was based on the PhD candidate and CI’s having 
close links. Because QVH expressed an interest in taking part in the study, there was a basis 
for a constructive working relationship on the study. 
5.5 Eligibility Criteria 
Every effort was made to keep eligibility criteria as broad as possible such that, in keeping with 
a pragmatic trial design, the participants in the trial were representative of those who would 
receive FS if it was part of usual care. The rationale for each of the eligibility criteria is discussed 
in detail in this section. The criteria evolved through the trial design and set-up process. They 
were initially drafted by the Trial Management Group (TMG; PhD candidate and supervisory 
team) and revised by patients from the Aintree Head & Neck Research Forum. They were also 
evaluated through the process of DRF peer review and REC approval. Finally, they were 
agreed by the TSC in their first meeting, before the first participant was recruited.   
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5.5.1 Inclusion criteria 
5.5.1.1 Patients due to undergo lateral neck dissection 
The rationale for including patients due to undergo lateral ND has already been discussed. The 
systematic review reported in Chapter 2 concluded that there was a paucity of randomised data 
with regards to the use of FS in lateral ND. To date there are only two RCTs that have assessed 
the role of FS in lateral ND (as opposed to central ND).(94, 95) These trials have randomised 
a total of 75 patients between them. Both trials were more on the explanatory end of the con-
tinuum and raise doubts regarding the external validity of their findings.  
5.5.1.2 Neck dissection to include a minimum of three levels 
As previously discussed in section 1.4, the potential benefits of FS include haemostasis and 
tissue adhesion to reduce surgical dead-space. Also discussed in section 1.5.1 were the po-
tential benefits of tissue adhesion using low-thrombin concentration FS in lymphadenectomy 
procedures. It stands to reason that a smaller wound, with less volume of surgical dead-space, 
has the potential to heal more quickly and with less complications than a larger wound. During 
the early stages of trial design, the TMG felt that it was important to establish a definition for 
what constituted the minimum extent of ND. As stated in section 1.2, ND is a surgical procedure 
that involves removal of lymph nodes (lymphadenectomy) and surrounding tissues from within 
the neck. There is no widely recognised minimum criteria for what defines a ND. However, 
there is evidence that a minimum of eighteen nodes harvested results in better survival out-
comes and should therefore be used as a quality performance indicator.(148, 154, 155) The 
2016 UK Multidisciplinary Recommendations published by the British Association of Head & 
Neck Oncologists (BAHNO) state that ND for most mucosal, cutaneous and salivary malignan-
cies (whether elective or therapeutic) should involve at least three levels.(156-160) These rec-
ommendations are advisory and in an individual case it may not always be appropriate to per-
form a three-level ND. For example, in the salvage setting when a patient suffers a neck recur-
rence having already undergone a ND, it may not be possible to harvest eighteen nodes nor 
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may they be suitable to undertake a three-level ND. In these cases, surgeons often carry out 
very limited dissections. 
 
Based on the afore mentioned BAHNO recommendations, the TMG took the decision to include 
patients who had a minimum of three levels dissected. There was an intention to use the clinical 
outcomes of this small REPT in conjunction with the systematic review (Chapter 2) to justify a 
definitive trial and the TMG wished to exclude patients who had excisional lymph node biopsies 
(e.g. sentinel lymph node biopsy). This was because the surgical wounds associated with these 
biopsies have smaller incisions and less dead space. It was argued that these patients repre-
sented a very different cohort to those undergoing a full ND that were not included in the sys-
tematic review. Therefore, the potential benefits of FS in this cohort should be assessed outside 
the DEFeND trial.  
 
Whilst the criteria for a minimum of three levels dissected was in keeping with a national rec-
ommendation, it did narrow the eligibility criteria and nudge the trial design towards the explan-
atory end of the continuum. In hindsight, the extent of ND could have been used as a variable 
for stratified randomisation and undergoing lymph node biopsies could have been made an 
exclusion criterion. Excluding patients who had a ND with less than three levels meant an op-
portunity to fully assess the PFS objectives and inform a definitive pragmatic trial design may 
have been underutilised.    
5.5.1.3 Patients who have capacity to consent 
The following paragraphs have been taken from the General Medical Council (GMC) guidance 
on ‘consent to research’.(161) 
“Seeking consent is fundamental in research involving people. Participants’ consent is legally valid and 
professionally acceptable only if they have the capacity to decide whether to take part in the research, 
have been properly informed, and have agreed to participate without pressure or coercion.”  
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“You must only undertake research involving an adult who lacks capacity if it is related to their inca-
pacity or its treatment. You must not involve in research adults who lack capacity if the same or similar 
research could be undertaken by involving only people with capacity.”  
Clearly this research is not related to incapacity or its treatment. Therefore, patients were re-
quired to have capacity in order to give their informed consent to participate in this study. 
5.5.2 Exclusion criteria 
5.5.2.1 Under eighteen years of age 
In their document ‘0-18 years: guidance for all doctors’(162), The GMC states that:  
“Children or young people should be involved in research only when research on adults cannot provide 
the same benefits. They can be involved in research that has either: 
a. potential benefits for children or young people generally, as long as the research does not go 
against their best interests or involves only minimal or low risk of harm (this would be research 
that involves, for example, asking questions or taking blood samples, the assessment of the risk 
depending on the view of the child or young person), or 
b. potential therapeutic benefits for them that outweigh any foreseeable risks, which should be 
kept as low as possible.” 
The SmPC states that ARTISS FS has been used on patients between the age of 1.1 – 18 
years safely within the context of a clinical trial.(51) Nevertheless the DEFeND trial does not 
specifically require children or young people to be involved. Therefore, excluding them would 
be in keeping with GMC guidance. 
5.5.2.2 Bilateral neck dissection 
During the design phase, the TMG took the decision to exclude patients undergoing bilateral 
ND. This was due to perceived logistical problems that may be created by patients undergoing 
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bilateral procedures. For example, would the clinical outcomes for bilateral ND be recorded 
individually for each side or as one large wound? If we considered each side individually, should 
they be randomised separately? Bilateral NDs are in essence two ND wounds in continuity 
creating a single large wound. Whilst this type of wound normally requires a minimum of two 
surgical drains (one for each side of the neck), it may not have been possible to consider them 
entirely independent wounds in terms of drainage. Theoretically, once one drain was removed, 
a proportion of the remaining drain’s volume may have been derived from the contralateral 
wound. This would be more or less likely depending on the orientation of the drain inside the 
wound. The uncertainty regarding whether a bilateral ND should be considered one wound, or 
two individual wounds was managed by excluding them all together.  
 
The ‘Drain Output Data’ form described in section 4.3.4.2 required investigators to input the 
drainage volumes between two time points to calculate the rate of drainage. This calculation 
then informed investigators whether the drain should be removed, re-measured in the after-
noon or kept in situ. Creating a similar eCRF that could accommodate multiple drains would 
have increased complexity and the likelihood of errors. For example, investigators may have 
easily mistaken the volumes between drains when transcribing the data into the eCRF leading 
to the wrong drain being removed. Given these perceived logistical issues the eCRF was not 
designed to record multiple drain volumes, therefore precluding bilateral NDs. Furthermore, the 
TMG took the view that the number of bilateral NDs performed in patients who did not require 
a vascular pedicle (to reconstruct the index tumour defect) would be incredibly small and would 
not impact on recruitment.  
 
Whilst the exclusion of bilateral NDs may not have impacted recruitment, the approach to this 
issue moved the trial towards a very explanatory design (similar to the excluding NDs less than 
three levels). In hindsight the perceived logistical issues were self-inflicted by the PhD candi-
date and, with greater insight into what constituted a pragmatic trial design, may have been 
easily surmounted. The algorithm used in ‘Drain Output Data’ form created by the PhD 
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candidate was ultimately a very explanatory design feature. A more pragmatic approach would 
have been to not collect drain volume data at all and allow blinded surgeons to remove drains 
as they would in usual care. As will become apparent from the results of this study, patients 
are more concerned with early discharge from hospital than the volume of fluid in their drain. 
‘Time to hospital discharge’ was therefore a more patient centered and pragmatic outcome 
measure. The impact of individual surgeons using a different number of drains or different cri-
teria for drain removal could have been managed either by using stratified randomisation, or 
simply randomising sufficient numbers of patients to dilute the overall effect. If opting to use 
stratified randomisation, preliminary surveys of surgeons’ drain practices would have been re-
quired to establish the stratification variables.   
5.5.2.3 Presence of a vascular pedicle for reconstruction 
The decision to exclude patients whose ND wounds contained a vascular pedicle for recon-
truction was made by the TMG early in the design phase and has previously been discussed 
in section 3.2.3.2. There was a lack of evidence regarding the safety of using FS delivered 
through a pressurised spray over microvascular anastomoses in humans. One may argue that 
this specific use of FS has not progressed far enough along the stages of IDEAL and further 
early-stage studies are required to assess its safety.(127) Therefore, the ethics of including 
these patients was questionable. If a future definitive trial is performed, the TMG should be 
open to the possibility that future research may provide evidence of safety and be willing to 
make amendments to the protocol that allows inclusion of this cohort of patients.  
5.5.2.4 Pregnancy or breast feeding 
The SmPC for ARTISS (51) states the following: 
• “The measures taken (to prevent transmission of infection) may be of limited value against 
non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for 
pregnant women (fetal infection)…” 
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• “The safety of fibrin sealants/haemostatics for use in human pregnancy or breastfeeding has 
not been established in controlled clinical trials. Animal studies have also not been per-
formed. Therefore, the product should be administered to pregnant and lactating women only 
if clearly needed.” 
Based on this information patients who were pregnant or breast feeding were excluded from 
the trial. Females of childbearing age were offered a voluntary pregnancy test as part of the 
study if they wished to participate. The Eligibility form shown in B.2 demonstrates how eligibility 
for females of childbearing age was determined. In the event that the patient became pregnant 
after recruitment to the trial, there was a requirement to complete a ‘Pregnancy’ form that would 
be reported in the same way as Serious Adverse Event (SAE). Details of this process can be 
found in section 6 and Appendix 6 of the Safety Plan demonstrated in A.9 of this thesis.  
5.5.2.5 Increased risk of allergic reaction 
The relevant section of the SmPC(51) states the following: 
• “ARTISS contains aprotinin. Even in case of strict local application, there is a risk of anaphylac-
tic reaction linked to the presence of aprotinin. The risk seems to be higher in cases where there 
was previous exposure, even if it was well tolerated. Therefore, any use of aprotinin or apro-
tinin containing products should be recorded in the patients' records.” 
• “As synthetic aprotinin is structurally identical to bovine aprotinin the use of ARTISS in patients 
with allergies to bovine proteins should be carefully evaluated.” 
As already mentioned in section 1.4.3, Aprotinin is an antifibrinolytic agent that prevents prem-
ature proteolytic degradation of the FS polymer. The statements from the SmPC quoted above 
clearly recognise Aprotinin hypersensitivity as a risk to patients. Representatives from the Ain-
tree Head & Neck Research Forum (as discussed in section 4.2.4.1) requested that measures 
to reduce the risk of allergic reactions be undertaken. The possibility of formal skin prick testing 
was explored but, due to requirements to access third party resources, were found to be 
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prohibitively complex and a potential barrier to recruitment. Therefore, to ensure the concerns 
of patient representatives were adequately met, the eligibility criteria were adjusted to minimise 
the risk of allergic reactions. Eligibility criteria defined an ‘increased risk of allergic reaction’ as 
follows: 
• Known hypersensitivity reaction to Aprotinin. As would be expected, patients with 
a known hypersensitivity reaction to Aprotinin were excluded from the trial. 
• Previous exposure to FS within the last six months. As stated in the SmPC, there 
is an increased risk of Aprotinin hypersensitivity if the patient has been previously ex-
posed. In an analysis of over 12,000 Aprotinin exposures, Dietrich et al found that the 
risk of Aprotinin hypersensitivity decreased with time.(163) The study of cardiac sur-
gery patients found the rate of hypersensitivity after previous exposure to Aprotinin to 
be 4.1% within six months, 1.9% between six to twelve months and 0.4% after twelve 
months. Based on this study an exposure after six months was considered an accepta-
ble risk by the Aintree Head & Neck Research Forum and TSC.   
• Known allergy to dairy products. As stated in the SmPC patients with allergies to 
bovine proteins should be “carefully evaluated”. Based on this statement a decision 
was taken to exclude patients who are known to have an allergy to dairy products. 
Cow’s milk allergy has an estimated prevalence of 1 in 200 adults.(164, 165) 
5.6 Recruitment Process  
Patients eligible for the DEFeND REPT were screened through outpatient clinics and weekly 
Head & Neck Multidisciplinary Team (MDT) meetings. In keeping with a pragmatic approach, 
this was representative of how patients are engaged during usual care. Patients were not tar-
geted using invitation letters, advertising or incentives.  
 
The steps that were completed on all patients to ensure they met eligibility criteria included: 
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• Clinical examination 
• Detailed medical history including previous treatment to the head & neck 
• Clinical decision to offer a lateral neck dissection 
Research staff at site documented the outcome of screening assessments in a secure online 
“Screening log” managed by LCTU. This was an electronic log found in the LCTU portal that 
investigators were given access to during the SIV. The log generated a screening number and 
recorded the patient’s initials, the date they were approached, the date they were screened, 
who screened them, the date of randomisation and reasons provided if they were not random-
ised.    
 
There were no restrictions regarding concomitant care or interventions during the trial. Eligible 
patients were approached within the outpatient clinic setting and provided with a full explana-
tion of the trial. Patients also received an up-to-date version of the Patient Information Sheet 
(PIS) (see A.2). Once the patient had the opportunity to read the PIS, ask any questions and 
agree to participation they were consented to the trial (see A.3 Patient Informed Consent Form 
(ICF)). 
 
The removal of the (24 hour) cool-off period prior to signing the ICF was agreed by the REC; 
patients were simply given as much time as they needed. The rationale for such an approach 
was to reduce patient burden; the recruiting hospitals both provide centralised service for HNS 
with many patients travelling long distances to attend appointments. In keeping with a prag-
matic approach, every effort was made to harmonise the research process with standard clini-
cal care. Removal of the cool-off period enabled patients to avoid extra hospital visits and pro-
vide informed consent on the day of being approached if they wished. No patients were asked 
to provide informed consent on the day of surgery.  
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The DEFeND REPT piloted a novel way of authorising ICFs electronically. The previous ap-
proach required sites to send the signed ICFs to the LCTU via facsimile. The LCTU would 
authorise the ICF and store the hard copy in a secure location within the UoL. Facsimile is a 
diminishing technology and has been superseded by electronic transfer of documents. The 
new method required sites to scan and securely upload a PDF of the signed ICF to the LCTU’s 
online portal using the patient’s unique trial number as the file name (see section 4.3.1.1 and 
B.1 Screening Form for further details). The ICF was checked by two independent members of 
the central trial team and assessed for validity (checking version number, completeness, sig-
natures and dates). Once validated, the assessors electronically signed-off the relevant eCRF 
and the uploaded PDF was permanently deleted (see section 4.3.2 and B.6 Randomisation 
Form for further details). This meant the only evidence for consent was the original hard copy 
stored in the patient’s medical records. This approach left no patient identifiable documents 
stored within the LCTU/UoL premises.  
 
Once informed consent was given by the patient, site research staff entered baseline data into 
the eCRF. The following electronic checks needed to be completed before the software allowed 
the patient to be randomised: 
• Eligibility criteria had been entered and electronically signed-off by the principal inves-
tigator (PI) (see B.2 Eligibility Form). 
• The signed ICF had been uploaded, validated and electronically signed-off by 2 inde-
pendent LCTU staff (see B.6 Randomisation Form). 
5.7 Allocation 
Randomisation lists were computer generated by the statistician prior to the recruitment of the 
first patient. Patients were randomised using a 1:1 ratio. Lists were produced based on the 
principle of randomly permuted blocks with random block sizes of two and four. Using permuted 
blocks helped assign the two arms to equal numbers of patients. Each block comprised two or 
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four randomly ordered allocations with an equal number of patients receiving each alloca-
tion.(166) Tables comparing the baseline characteristics of patients and their surgery were 
produced to evaluate the balance between treatment arms. Continuous variables were sum-
marised as medians with associated inter-quartile ranges (IQR) and categorical variables were 
summarised as frequencies of counts and associated percentages. 
 
Surgical interventions are complex not only because of the nature of the intervention itself but 
also the influence of external or associated factors. Figure 17 shows the main constituent 
elements of a surgical intervention taken from the review by Cook.(138) This figure demon-
strates that the outcome of a surgical intervention may be influenced by the surgeon and their 
operative team as well as the standard of perioperative care. Patients were stratified according 
to the hospital in which they received their treatment to ensure that variations of surgical teams 
and standards of perioperative care between sites did not lead to unbalanced randomisation. 
Kernan et al reported that stratification can protect against type I and type II errors in trials of 
less than one hundred participants.(166) An important caveat to this advantage is to keep the 
number of strata as small as possible. This improves statistical efficiency by making it more 
likely that equal numbers of patients are assigned to each allocation.(166) This approach to 
randomisation using permuted blocks and stratification according to site was considered the 
most appropriate way of ensuring balance between treatment arms in a study of this size. A 
definitive trial will have more participants and may benefit from further stratification such as the 
extent of surgery as mentioned in sections 5.5.1.2 and 5.5.2.2. 
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Figure 17 Main constituent elements of a surgical intervention taken from Cook(136) 
 
Based on the LCTU’s experience of trials that randomise intra-operatively (PANasta Trial 
(133)), randomisation for DEFeND REPT was undertaken pre-operatively (see section 3.2.3.3 
for rationale). Randomisation was performed by the trial co-ordinator (PhD candidate) using 
the “Treatment Allocation RanDomIsation System” (TARDIS) software version 3.8. The alloca-
tion was concealed to everyone including the person performing the randomisation. Once ran-
domisation had been performed, the surgeon caring for the patient received an automated 
email which contained a password protected link to reveal the allocation (see B.6 Randomisa-
tion Form). Once the patient had undergone their ND and immediately prior to the point of 
wound closure, the surgeon opened the link to reveal the allocation. The exact time and date 
the reveal occurred was automatically recorded in the eCRF and cross-referenced against the 
start and finish times of surgery as a quality assurance step to minimise performance bias. 
5.8 Blinding  
Patients, outcome assessors, ward staff and research staff (both centrally and at site) were 
blinded to the allocation. Only members of the surgical team present in theatre when the allo-
cation was revealed knew which treatment arm the patient had been allocated to. These 
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individuals were not permitted to inform colleagues or assess trial outcomes. The operation 
notes, medical case notes and any other documentation that left the operating theatre were not 
allowed to state the allocation. The surgical team was asked to enter the details of surgery on 
a paper CRF that was later transcribed into the eCRF by site research staff (see B.7 and B.8 
Day of Surgery Forms). This included a list of clinicians who were present in theatre at the time 
of the allocation reveal. If one of these clinicians later assessed an outcome the eCRF would 
alert research staff of a breach in protocol. The effectiveness of this blinding strategy was as-
sessed at the patient’s last visit using blinding indices (see section 5.12.3). 
 
The patient was unblinded if they suffered a SAE and knowledge of the allocation was required 
for the ongoing clinical management of the condition. The requirement for unblinding was very 
unlikely as FS is administered only once in the theatre environment. A severe hypersensitivity 
reaction, air embolism or transmission of an infective agent constituted a SAE. If these did 
occur, severe hypersensitivity and air embolism would have occurred during or immediately 
after administration of FS in the theatre setting. Staff caring for the patient at this time would 
not be blinded so there would not be a delay in diagnosis and emergency management. 
 
If the patient was diagnosed with an infectious disease that was not diagnosed pre-operatively, 
they would be unblinded. Based on the ‘Serious Hazards of Transfusion’ 2017 annual re-
port(167) the following infectious diseases are known to have been transmitted via blood prod-
ucts in the UK: 
• Hepatitis A, B, C or E 
• Human Immunodeficiency Virus  
• Parvovirus (B19) 
• Cytomegalovirus 
• Human T-cell Lymphotropic Virus types I and II 
• Malaria 
• Variant Creutzfeldt-Jakob Disease or any other prion disease 
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If the patient was newly diagnosed with any of the above infectious diseases, they would be 
unblinded and immediately referred to the appropriate medical specialists for treatment. 
5.9 Storage, Preparation & Administration of Fibrin 
Sealant 
The DEFeND REPT used the 2ml pre-filled double chamber syringe preparation of ARTISS FS 
manufactured by Baxter Healthcare LTD. ARTISS was chosen because of its low thrombin 
concentration that allows surgeons the time to manipulate the tissues before the polymerisation 
is complete (see section 1.4.3). 
5.9.1 Storage protocol 
ARTISS has a shelf life of 2 years and should be stored in its protective packaging and trans-
ported in a frozen state at less than -20oC.(51) 
5.9.2 Preparation protocol 
The “Quick Thawing” technique, as described by the manufacturer, was used to prepare the 
FS for use. Quick Thawing is done by placing the FS in a sterile water bath at 33°C to a maxi-
mum of 37°C for 5 minutes. An infrared thermometer is used to check the water temperature 
prior to immersing the FS. Once thawed the FS may be stored at 33 – 37°C for a maximum of 
4 hours. Inspection of both chambers after thawing should reveal clear or slightly opalescent 
viscous liquids. Solutions that are cloudy/discoloured, contain deposits/particulate matter or 
solidified should be discarded.(51) (See C.1 Quick Thaw Protocol). 
 
The FS is delivered into the wound as a fine spray driven by medical grade air. The “EasySpray” 
pressure regulator device is setup as per the manufacturer’s instructions (Baxter Healthcare 
LTD) and the spray pressure set to 1.5 bar. The scrub practitioner uses the Sprayset tubing to 
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attach the FS syringe to the EasySpray pressure regulator. Precise details on how this is done 
can be found on the manufacturer’s website (http://www.baxterspraysafety.com/uk.html). (See 
C.2 EASYSPRAY Quick Reference Guide)  
5.9.3 Administration protocol 
The administration of FS requires at least 3 people including a scrub practitioner, assistant and 
surgeon. While the FS is being thawed the surgeon should irrigate the wound with 100ml of 
sterile Normal Saline, dry the wound with sterile gauze swabs, secure the surgical drain and 
place several resorbable parachute sutures (4 – 6) across the platysma layer. These sutures 
should be loosely clipped and not tied to ensure good access to the wound. The drain should 
be held temporarily outside of the wound to ensure the perforations are not occluded by the 
FS. The prepared Sprayset should not be held any closer than 10 cm to the wound to avoid 
the risk of air embolism. Once the administration of FS has commenced the surgeon has 60 
seconds to deliver up to 2ml and manipulate the skin flaps into position prior to polymerisation. 
It is therefore important to strictly adhere to the time using a stopwatch. The assistant should 
retract any structures (e.g. sternocleidomastoid muscle) to ensure the surgeon can reach shel-
tered areas and administer the FS evenly in a thin layer across the entirety of the wound. Once 
administration is complete the drain and skin flaps are repositioned, and even pressure applied 
to the wound (using a large rolled up gauze swab) while the surgeon ties off all the parachute 
sutures. It is very important that the surgeon does not lift the skin edges up while tying the 
sutures as this may break any adhesive bond between tissue layers. The surgical vacuum drain 
should then be activated, and the assistant should maintain pressure on the neck for a full 3 
minutes. After 3 minutes clips/staples are used to close the skin edges. When spraying the FS, 
changes in blood pressure, pulse, oxygen saturation and end tidal CO2 should be monitored 
because of the possibility of air embolism. (See C.3 Surgical Protocol) 
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5.10 Surgical Quality Assurance 
Surgical interventions are complex because they are associated with multiple interacting com-
ponents and concomitant ‘co-interventions’ such as anaesthesia and elements of perioperative 
care.(110, 138) Furthermore, the same surgical intervention performed by different surgeons 
on different patients may vary in its execution and subsequent treatment effect. The topic of 
‘quality assurance’ is therefore very relevant to surgical trial design. As mentioned in section 
3.2.3.6, there is arguably some conflict between a truly pragmatic trial design that allows inves-
tigators the freedom to use the intervention as they would in usual practice, and a surgical trial 
design that wishes to tightly control the fidelity and standardisation of the intervention. The 
latter being more in keeping with an explanatory design. Having said this, most trials lie some-
where within the explanatory – pragmatic continuum rather than at the extremes. The aim of 
the definitive DEFeND trial will be to evaluate the ‘real-world’ effectiveness of FS in ND through 
a pragmatic approach. It was therefore appropriate to not enforce tight controls on the delivery 
of the intervention in the DEFeND REPT. Nevertheless, in order to deliver a trial that evaluates 
the intervention in a robust and fair manner, some measures that ensured fidelity and stand-
ardisation of the intervention were required.(110) When considering these measures, it was 
important to consider what impact they would have on recruitment and the smooth running of 
the trial and aim to strike a balance between adequate standardisation and practicality. Given 
that the definitive DEFeND trial will include multiple centres and investigators of varying levels 
of experience in delivering surgical trials, reducing complexity was considered advantageous.  
 
Foster et al(168) performed a systematic review of the different mechanisms of ensuring quality 
assurance in multicentre trials in laparoscopic colorectal surgery. The review found that the 
different mechanisms included credentialling of surgeons, standardisation of surgical technique 
and monitoring.(168) The role of each of these quality assurance measures in the DEFeND 
trial design are discussed. 
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5.10.1 Credentialling of surgeons 
In the context of explanatory trials evaluating a novel surgical technique, credentialling of sur-
geons may be seen as a vital element in trial design. This is because surgeons need to demon-
strate that they have sufficiently stabilised in their learning curve to facilitate a fair evaluation 
of the novel technique compared to a control. Once a technique has become more widely 
adopted by a surgical community, it is likely that a proposed trial design would lie more towards 
the pragmatic end of the continuum and the role for credentialling becomes more nuanced. For 
example, excluding surgeons the basis of expertise means that the surgical community in which 
the intervention will be used is not being fully represented.  
Within the context of the DEFeND trial, FS is not a novel product and the safety profile is well 
established. The manufacturers of FS provide instructions that clearly lay out a series of steps 
on storage, preparation and administration. These instructions were included in the protocols 
provided in Appendices C.1, C.2 and C.3. Unlike a novel surgical technique, the use of FS does 
not require the acquisition of new surgical skills. The surgical steps required for the administra-
tion of FS (separate to the ND) include administering the FS and the placement and tying of 
parachute sutures. These additional steps require only basic surgical skills and therefore are 
within the skill set of any surgeon who is competent to perform a ND. Indeed, performing a ND 
competently and safely undoubtedly requires the surgeon to demonstrate a greater range of 
surgical capabilities. Based on this assertion, the DEFeND TMG decided not to implement a 
specific credentialling step in the trial design. Instead, they took a pragmatic view and con-
cluded that if a surgeon was skilled enough to perform a ND on NHS patients, then they were 
skilled enough to administer FS in DEFeND.  
5.10.2 Standardisation & monitoring of the intervention 
Blencowe et al developed a typology for designing surgical interventions based on a systematic 
review of 80 RCTs evaluating 160 interventions. The typology was informed by how surgical 
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interventions were described, standardised and monitored within these RCTs. An overview of 
the typology is demonstrated in Figure 18. 
For the purposes of DEFeND, the intervention was described as ‘closure of the ND wound with 
FS’. If the typology described in Figure 18 is applied, the overall technical purpose of the inter-
vention was ‘reconstruction’. The ND itself was common to both arms of the study and surgeons 
were permitted to perform it according to their normal practice. In terms of trial design, the only 
specified difference between the two arms was the way in which the wound was closed. The 
individual steps of the surgical intervention are detailed in C.3 (Surgical Protocol).  
In terms of standardisation, the surgical protocol in C.3 describes exactly how the intervention 
should be delivered. This protocol was taught to sites at the SIV, and access to an educational 
video demonstrating the protocol on a live patient was provided to each investigator (See sec-
tion 5.11 for details). Furthermore, the flow chart shown in C.3 was laminated and displayed in 
each head and neck theatre across both sites.  Each of the nine steps describing the interven-
tion were considered to be important to ensure the intervention was delivered according to the 
manufacturer’s instructions. However, there were no mechanisms within the trial design to 
monitor or enforce the delivery of each step. This implies that according to the typology, each 
step was optional and applied with complete flexibility.  
The lack of monitoring (fidelity of the intervention) may be seen as problematic because data 
on how well surgeons adhered to the protocol may provide valuable information on how to 
interpret the trial results e.g. enabling comparisons between intention-to-treat (ITT) and per-
protocol analyses. At the time of trial design, the TMG thought that the logistical requirements 
for effective monitoring were prohibitively complex and resource intensive. It was also seen as 
a very explanatory approach to trial design. Consideration was given to real-time video evi-
dence and an objective marksheet completed by an unblinded investigator. 
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Figure 18 Overview of typology of surgical interventions(108)
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Any requirement for video recording would have needed to be included in the PIS and ICF and 
a clear explanation of how the footage would be stored and disposed of provided. Real-time 
video evidence may have been recorded by either a fixed operating theatre camera or a mobile 
camera. Because not all operating theatres have fixed cameras, concerns were raised that this 
may create a barrier to recruitment/randomisation or lead to missing footage. Commercially 
available mobile cameras represent a more flexible approach that can be purchased for sites 
as a research cost (part A; payable through the funder). The video footage could either be 
uploaded via a ‘live stream’ or recorded to a memory card. Live stream via a mobile camera 
requires a very good internet bandwidth and a connection to a smartphone. In the same way 
that the LCTU considered intraoperative randomisation to be problematic (section 3.2.3.3), live 
stream would present similar, if not greater, problems. For this reason, recording to a patient 
specific memory card would have been the most reliable approach. This memory card would 
have been labelled with the patient’s unique trial ID number and stored in the medical records. 
A major advantage of this approach would be accurate start and finish times of the surgery that 
may be cross-referenced with the time of allocation reveal. This would ensure that surgeons 
do not reveal the allocation too early and would be accurate to the nearest minute. Eventually 
unblinded members of the central trials team would have to evaluate the video footage. The 
TMG thought that these team members would require some surgical knowledge to appreciate 
whether the footage was compliant with the protocol. Within the context of a large multi-centre 
trial, this would result in several hundred hours of video footage that could only be evaluated 
by a limited number of individuals and was considered to be prohibitively resource intensive.  
In hindsight, the resource intensiveness would have been dependent on the amount of detail 
required from the video footage. For example, if the only information required was whether the 
FS was applied or not, this could have been determined by fast-forwarding the footage to the 
wound closure and observing whether the FS was applied. This could have been done by an 
untrained individual in a matter of minutes.  
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If monitoring the fidelity of the intervention was undertaken, the steps in the protocol that would 
have been ‘mandatory’ were:  
• Thawing the FS for five minutes at a temperature between 33 – 37 oC (confirmed by a 
reading from an infrared thermometer) 
• Setting the EasySpray pressure regulator to 1.5 bar 
• Placement of a drain  
• Placement of parachute sutures 
• Administration of FS 
• Repositioning of skin flaps and application of pressure to the wound within one minute 
of starting the administration of FS 
• Application of pressure for three minutes 
• Tying off the parachute sutures without lifting the skin edges (and disrupting adhesion)  
Under these circumstances, decisions regarding the flexibility of standardization for each man-
datory step would be required. Furthermore, there would need to be consensus amongst the 
TSC regarding what actions should be taken if the intervention was applied outside these pa-
rameters e.g. would it constitute a deviation from the protocol and instigate the ‘root cause 
analysis’ associated with such an event? Unless the intervention was applied with complete 
flexibility, the trial design would have moved towards the explanatory end of the continuum.  
The other option for monitoring was the completion of an objective marksheet that would be 
completed by an independent investigator at site e.g. a research nurse. The investigator could 
have made simple observations regarding the mandatory steps described in the previous par-
agraph. However, this would have created logistical issues because the marksheet would re-
veal the allocation to all those who read it. The marksheet would require its own document 
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pathway to prevent threatening the fidelity of the blinding process, thereby increasing the com-
plexity of the trial. Furthermore, this approach would place greater pressure on investigator 
staffing levels at sites. Not all sites in a future multi-centre trial will have the capacity to place 
an unblinded investigator in theatre for several hours whilst also having enough blinded inves-
tigators to carry out outcome assessment. Of course, this level of capacity could be made an 
eligibility criterion for sites to participate in the trial but in doing so, will exclude centres with 
less resources and push the trial design towards the explanatory end of the continuum. Another 
significant problem with this approach is that there may be significant interobserver variability 
in what constituted adherence an/or deviation from the protocol. This would ultimately under-
mine the value of monitoring. 
Whilst both have their own advantages and disadvantages, the use of mobile video camera 
footage would have been the most likely approach to be chosen. Having a central trial team 
member evaluate the video footage is a more independent approach and less likely to be bi-
ased by inter-observer variability. Including this design feature would have increased the costs 
and resources required to deliver the trial and therefore, needed to be justified whilst having a 
positive impact on the interpretation of the results. Within a pragmatic trial design, the outcomes 
of the ITT analysis are the most important because the prognostic balance between arms af-
forded by randomization is preserved. The per protocol analysis is an inherently biased inter-
pretation of the results. Therefore, if the per-protocol analysis is going to be disregarded, what 
is the justification of monitoring the fidelity of the intervention?  
The added value of monitoring is that it informs the surgical audience (reviewers and surgeons 
interpreting data for their practice) of how fair the analysis was and where the problems with 
the intervention may lie e.g. if the definitive trial outcome was negative, it may have been be-
cause either the FS itself was inefficacious or because other elements of the protocol made 
the FS ineffective. Under circumstances where the trial was negative and the monitoring re-
vealed good compliance with the protocol, one may assume that FS itself was inefficacious. 
Under circumstances where the trial was negative and the monitoring revealed poor 
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compliance with the protocol, one may assume that the protocol itself was either flawed or too 
difficult to follow and hold judgement regarding the efficacy of FS. Whilst the difference between 
these interpretations is subtle, the latter scenario is still unlikely to convince surgeons or com-
missioners of care to justify the additional cost of using FS in ND. The extra information afforded 
by the process of monitoring would certainly be ‘nice to know’ however, it is debatable whether 
this information is critical to the interpretation of trial results and therefore may not justify the 
additional complexities, resources and cost. 
5.11 Training 
A detailed explanation of the of the protocols for storage, preparation and administration of FS 
(Appendices C.1, C.2, C.3) was provided during the SIV. Investigators, including recruiting sur-
geons were given the opportunity to ask questions and raise any concerns with the protocol. 
Every effort was made to guide sites on how to apply the protocol within their unique environ-
ments and practices. In addition to this, sites were provided with access to online educational 
videos that were produced specifically for the DEFeND trial by the PhD candidate in conjunc-
tion with a professional video production and editing company (Aspect Pictures). shown videos 
during the SIV. These videos used a live patient example to demonstrate the protocol for the 
preparation and administration of ARTISS as described in section 5.9 and Appendices C.2 and 
C.3. The first video described the protocol for the preparation of ARTISS and the second de-
scribed the protocol for administering ARTISS in ND. The online videos were accessed at the 
web addresses provided below and could have been downloaded by sites if needed. Theatre 
staff and surgeons who were not experienced with using FS in ND were encouraged to view 
the videos before the start of surgery.   
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Part 2: Administration 
https://vimeo.com/442683279 
 
As discussed in section 5.10.1, surgeon credentialling was not a requirement in the trial design. 
The educational videos demonstrated how ARTISS should be used but ultimately surgeons 
were free to use it with complete flexibility. This high degree of flexibility in delivery of the inter-
vention is in keeping with a pragmatic trial design. In addition to educational videos, laminated 
posters of flow charts summarising the steps of both preparation and administration of ARTISS 
were displayed in operating theatres as an aide memoire (shown in Appendices C.1, C.2 and 
C.3).  
5.12 Randomised External Pilot Trial Outcomes 
As this was a REPT, data analyses took the form of descriptive statistics. Continuous variables 
were summarised as medians (IQR) and categorical variables were summarised as frequen-
cies of counts and associated percentages. 
5.12.1 Recruitment & retention outcomes 
In the financial year 2019/20 the NIHR awarded over £250 million of funding to 310 research 
projects.(169) A substantial proportion of this expenditure was invested in RCTs which repre-
sent the most powerful research design to evaluate healthcare interventions and guide policy 
and practice. However, the recruitment of participants to publicly funded RCTs is a frequently 
reported problem. In a review of 151 RCTs funded by the NIHR Health Technology Assessment 
(HTA) stream, only 56% achieved their target sample size with a median recruitment rate (par-
ticipants per centre per month) of 0.92 (IQR 0.43 – 2.79).(170) Problems with recruitment are 
also reported in HNS trials of which a future definitive DEFeND trial would be one.(105) The 
potential barriers to recruitment in a future definitive DEFeND trial were discussed in section 
3.2.3.1 as justification for a pilot and feasibility study (PFS). In a review of PFS of surgical 
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interventions funded by the NIHR, Fairhurst et al found that addressing uncertainties around 
trial recruitment was cited as the most common reason for performing PFS.(124) This is be-
cause recruitment is pivotal to the success of a definitive trial and the data from PFS can identify 
potential recruitment problems and avoid research waste.(120) 
Since recruitment is pivotal to the success of a definitive DEFeND trial, it was important to use 
the REPT to understand why any barriers were encountered. This would enable refinements 
to the definitive trial design that work to overcome these barriers. For this reason, both quanti-
tative and qualitative recruitment data were collected. The quantitative data indicated what re-
cruitment would be like with the current trial design and the qualitative data indicated what 
aspects of recruitment required further optimisation and why. Each of the recruitment and re-
tention outcomes is discussed in turn.  
5.12.1.1 The proportion of eligible patients randomised to the study  
This was calculated as the proportion of screened patients that were randomised. As men-
tioned in section 5.6, sites were requested to keep a screening log of all potentially eligible 
patients. This log provided the data for the calculation. If the site did not honour their require-
ment to keep a screening log, data from theatre records was used to approximate the number 
of potentially eligible patients. 
Based on surgical activity data it was predicted that approximately 180 patients would be po-
tentially eligible over the twelve-month study period across both sites. The recruitment target 
over this period was 50 patients which could be achieved if 30% of the predicted eligible pa-
tients were randomised. Randomising greater than 30% of eligible patients was used as an 
indicator for effective recruitment. 
5.12.1.2 Reasons for failure to screen potentially eligible patients 
Qualitative data from unstructured interviews with investigators at sites was used to create a 
narrative of the difficulties encountered with screening. Holding the dual role of Trial Co-
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ordinator and PI for the lead site, the PhD candidate was ideally placed to monitor screening 
closely. The PhD candidate also had a close working relationship with the PI from the second 
site to understand any difficulties they faced.  
This approach certainly provided useful information but perhaps was not as thorough as it could 
have been. In hindsight, more granular qualitative data could have been obtained by carrying 
out a survey and/or semi-structured interviews of all investigators across both sites. There 
would certainly have been some advantage to understanding the views of all investigators in-
dividually, without any potential biases or filters imposed by the PI. For example, the PI may 
have wished to suppress some views that presented the site in a negative light.   
5.12.1.3 Recruitment rate 
Recruitment rate was measured as the number of patients randomised per month. This was 
calculated by simply dividing the number of patients recruited by the number of months the 
study was open. Calculations for overall recruitment rate and recruitment rate per site were 
performed as well as recruitment rate for each arm of the study. The same calculations were 
also performed for the number of patients that were randomised and successfully revealed. 
With a recruitment target of 50 patients, it was predicted that at least 4.17 patients would be 
recruited per month i.e. each site would recruit over two patients per month. Recruiting greater 
than 4 patients per month was used as an indicator for effective recruitment. 
5.12.1.4 Reasons for failure to randomise 
For any patient that was eligible but not randomised, investigators at site were required to 
provide a reason in the free-text box provided within the online screening log (see section 5.6). 
The various reasons were categorised according to a crude thematic analysis. A bar chart was 
used to present the frequencies of each theme identified to provide an indication of their relative 
importance. Numerical values from the bar chart were interpreted with caution and with the 
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understanding that no inferences could be drawn about the prevalence of phenomena ob-
served beyond the sample.  
If the site did not maintain a screening log, data to carry out thematic content analysis was 
missing. Under these circumstances the PI for that site was contacted for an unstructured in-
terview to understand both why the log was not being maintained and why patients who were 
eligible were not being randomised. Whilst this provided useful information, it was recognised 
that this approach was sub-optimal and potentially biased.      
5.12.1.5 Number of patients lost to follow-up 
This was simply reported as the number of patients who were successfully recruited but did not 
attend one or more of their follow-up appointments. This data was important to identify any 
barriers to the retention of patients.  
5.12.1.6 Reasons for loss to follow-up 
If participants did not attend one of their follow-up appointments, investigators at site were 
required to contact them and either make a new appointment or ask why they did not attend. 
As per the PIS, patients were not obliged to give an answer to this question. This qualitative 
data was analysed using the same methods of inductive thematic analysis described in section 
5.12.1.4.  
5.12.2 Outcomes related to trial conduct 
The rationale behind assessing outcome relating to trial conduct has been discussed in section 
3.2.3.5. A key purpose of the DEFeND REPT is to ascertain how well the components of the 
trial work together in different research environments that may have varying research experi-
ence and/or resources.  
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5.12.2.1 Reasons for failure to reveal the allocation  
One of the key learning points from the systematic review reported in Chapter 2 was that per-
formance bias can be reduced by revealing the allocation intra-operatively (see section 2.7). 
The process of pre-operative randomisation and revealing the allocation at a specific time-point 
during surgery was novel and previously untested in a clinical trial environment. As mentioned 
in sections 4.3.2 and 5.7, once the patient was randomised an email containing a password 
protected link to reveal the allocation was sent to the surgeon caring for the patient. The sur-
geon was required to access this email and reveal the allocation intraoperatively at the point of 
wound closure. This process required several design features of the eCRF (MACRO) and ran-
domisation software (TARDIS) to work well together and for the surgeon to access the alloca-
tion efficiently. Specifically, the steps in the process were: 
• Completion of all pre-randomisation and randomisation eCRFs prior to surgery 
• MACRO informing TARDIS that the pre-randomisation checks were authorised by two 
independent members of the central trial team. The patient’s trial specific ID would then 
be added to a drop-down menu in TARDIS for selection by the investigator delegated 
to randomise 
• Pre-operative randomisation of a specific patient by the investigator delegated to ran-
domise prior to the start of surgery 
• TARDIS sending an automated email to the correct surgeon containing a link to reveal 
the allocation of the correct patient 
• The surgeon accessing the link within the email at the correct time point intraopera-
tively and being successfully able to login and reveal the allocation 
• TARDIS communicating the time and date of the allocation reveal back to MACRO   
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A failure to reveal the allocation at the point of wound closure could be due to a failure of any 
single, or combination of, the above steps. Compliance with the above steps was monitored by 
MACRO alerting the data monitor (PhD candidate) if the allocation was not revealed between 
the start and finish times of surgery. Data on the length of time between the start of surgery 
and the allocation reveal was also recorded by MACRO. If the allocation was revealed outside 
the start and finish times of surgery, a deviation from the protocol was noted and root cause 
analysis instigated (see next section 5.12.2.2 for further details).   
5.12.2.2 Protocol adherence 
Any deviations from the protocol (including failure to reveal the allocation intra-operatively) in-
stigated a root cause analysis. This was an important outcome of the REPT because it would 
inform investigators of logistical issues with trial delivery. Once a deviation from the protocol 
was noted, the PhD candidate completed a corrective and preventative action (CAPA) form. 
This included a description of the events and their impact on the sponsor, LCTU and trial. The 
form was completed with oversight from the Quality Assurance Department of the LCTU and 
corrective and preventative actions proposed along with timelines for completion by a named 
responsible individual.  
Protocol adherence was measured as the number of minor/major protocol deviations observed 
throughout the study. Details of each protocol deviation were reported from the information 
provided in the relevant CAPA form.  
5.12.2.3 Accuracy of data recording 
Having an accurate and as complete dataset as possible is clearly important to the interpreta-
tion of the results and study conclusions. The REPT represented an opportunity to evaluate 
how well sites were able to record data in the eCRF and identify any areas where the trial 
design prohibited optimal data entry.  
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Accuracy of data recording was assessed by reporting the type and number of missing data 
units by treatment arm and site. Possible data outliers were classified as ‘mild’ or ‘severe’ based 
on the following equation: 
Mild outliers:  UQ + 1.5 × IQR to UQ + 3 × IQR 
LQ – 1.5 × IQR to LQ – 3 × IQR 
Severe outliers:  values more extreme than the above 
(UQ = Upper Quartile, LQ = Lower Quartile, IQR = Inter Quartile Range) 
If the prevalence of missing data was deemed to be high for a particular outcome measure, 
investigators at that site were contacted and questioned. This took the form of an unstructured 
interview led by the PhD candidate to understand why data was missing and how the trial could 
be designed differently to prevent it.  
5.12.3 Fidelity of the blinding process 
One of the key learning points from the systematic review reported in Chapter 2 was that de-
tection bias can be reduced by blinding outcome assessors and trial participants (see section 
2.7). As discussed in section 3.2.3.3, this is particularly relevant if the outcomes measure is 
subjective (e.g. severity of signs and symptoms). Evaluating the fidelity of the blinding process 
was particularly relevant to DEFeND because the operating surgeons were unblinded and 
there was uncertainty regarding their transfer of bias (intentionally or unintentionally) on to pa-
tients and outcome assessors. The methods used to ensure effective blinding are described in 
section 5.8.  
It is widely acknowledged that perfect blinding is practically impossible in any RCT, let alone a 
surgical RCT. It is therefore relevant to assess the level of blinding that can be achieved for a 
given trial design. Blinding indices represent an established method of quantifying the level of 
blinding and use statistical modelling and a respondent’s answer to a generic 
 
  143 
questionnaire.(171) The level of blinding achieved in the DEFeND REPT was measured to 
assess whether effective blinding could be achieved. This information would be used to inform 
the design of a definitive trial.  
The two most commonly used blinding indices in clinical trials are by James et al (172) and 
Bang et al.(173) An important assumption in the James Blinding Index (JBI) is that when a 
respondent claims to “not know” the treatment allocation, this is an honest answer and not one 
that is socially desirable or one that avoids making a judgement. JBI is a single index value 
that combines blinding data from both arms. In practice RCTs can exhibit varying blinding be-
haviours both in magnitude and direction. The JBI is limited because it cannot distinguish im-
portant differences between the arms of a trial.(174) 
Whereas JBI places great value on respondents who “don’t know”, the Bang Blinding Index 
(BBI) sees this as a limitation. Instead, the BBI places greater emphasis on decisive responses 
which can be in either a positive or negative direction. Furthermore, BBI can be applied sepa-
rately to each arm of the study and distinguish between nine different blinding scenarios (each 
of the two arms of the study can be classified as either blinded, unblinded or opposite guessing 
leading to nine different combinations).(171, 174) The BBI was chosen to evaluate the level of 
blinding achieved in the DEFeND REPT because it had the potential to provide more granular 
data on the level of blinding achieved.  
In the DEFeND REPT, Respondents had a choice of 5 possible answers: strongly believed 
they received FS, somewhat believed they received FS, somewhat believe they did not receive 
FS, strongly believe they did not receive FS and don’t know (see B.12 End of Trial Form). The 
calculation for BBI produced a numerical value between 1 and -1. A value of 1 implies a com-
plete lack of blinding because respondents always answered correctly; a value of 0 implies 
perfect blinding because respondents answered correctly and incorrectly an equal number of 
times; a value of -1 implies ‘opposite guessing’ because respondents always answered incor-
rectly and may represent a type of unblinding.(173)  
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Respondents were asked to guess the treatment allocation at the end of the trial. This timing 
of BBI was chosen because unblinding can occur at any point during the trial follow-up period. 
Some authors draw a distinction between unblinding due to trial design and unblinding due to 
of the treatment effects or side effect profile of the intervention.(174) If the intervention is truly 
effective or has a very different side effect profile compared to the control, participants and 
investigators can infer the treatment allocation with a high degree of certainty. Under these 
circumstances a trial can be exceptionally well designed to prevent unblinding but still suffer 
the consequences of detection bias. In order to detect this phenomenon, Desbiens recom-
mended performing blinding assessments at different time points during the trial.(175) One 
may have suspected this phenomenon if the results of the blinding assessment performed be-
fore any treatment effects became apparent were better than the results of the blinding assess-
ment at the end of the trial. Detection of this phenomenon was not considered relevant to DE-
FeND because FS has a short half-life and was applied only once during the trial. Furthermore, 
some of the main treatment effects and side effects of FS (e.g. wound adherence and allergic 
reactions) have an immediate onset making early blinding assessment impractical.    
5.12.4 Determining the minimal clinically important difference in clinical 
endpoints through semi-structured interviews of trial participants 
5.12.4.1 Rationale for determining MCID 
As discussed in section 3.2.3.4, the selection of a patient centred primary outcome is critical to 
the design of a pragmatic trial. There is currently no published core outcome set (COS) for 
HNS trials to guide this selection in DEFeND. However, a published ‘core information set’ for 
HNS provided some valuable insights.(17)  
 
The core information set included “details of drips, drains and tubes” and supports unpublished 
qualitative data from the ‘Aintree Head & Neck Patient Research Forum’ demonstrating that 
patients have an aversion to surgical drains as they are uncomfortable and an impediment to 
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mobilisation. The ‘core information set’ also included “the likelihood of wound problems” and 
“details of major or common complications including pain, swelling and bleeding that may re-
quire a return to theatre”.(17) Complications after major surgery are a significant cause of mor-
bidity and mortality and have been shown to have a negative impact on long-term quality of life 
and psychosocial well-being.(134, 135) In surgical oncology, complications can also delay ad-
juvant RT/CRT which is known to adversely affect survival.(136) The meta-analysis in Chapter 
2 also suggested that FS may have a role in protecting patients from complications, albeit not 
to a statistically significant level and in the face of substantial statistical heterogeneity. Based 
on these different sources of information, at the start of the trial it was thought that reporting 
the rate and severity of complications via the Clavien-Dindo classification as a primary outcome 
measure would be the most pragmatic approach.(23) However, because this decision was in-
ferred from different sources, whether ‘complications’ truly represented the most pragmatic 
and patient centred outcome could not be claimed with a high degree of certainty. 
 
It was thought that the pre-trial inference of using ‘complications’ as the primary outcome could 
be elucidated by asking trial participants directly what they thought were the most important 
clinical endpoints and MCID. The process was not conceived or designed to provide an in-
depth qualitative analysis that comprehensively explored the patient’s experiences, rather it 
was hoped that it may provide supporting evidence to use ‘complications’ as a primary out-
come. If so, the patient’s views on the MCID would be useful in a future sample size calculation. 
5.12.4.2 Qualitative methods 
On the final follow-up visit, trial participants were asked what they thought was the MCID in 
clinical endpoints to justify the expense of FS. In attempt to standardise the way the question 
was asked, investigators read out the following:  
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“Fibrin sealant costs approximately £100 per application. Depending on the results of a future 
clinical trial we may consider introducing fibrin sealant into routine practice for all patients un-
dergoing the same operation that you had.  
In your opinion as a patient and taxpayer, what would be the smallest improvement the fibrin 
sealant would need to offer in a patient’s recovery to make it a worthwhile expense?” 
 
This question led to a short discussion where the participant had scope to discuss any issues 
they wished and was best described as a semi-structured interview. Investigators then sum-
marised the participants response in a free-text box found in the End of Trial eCRF (B.12). The 
responses were openly coded through a thematic analysing method.(176) Each code at-
tempted to identify and label comments that were relevant to the research question. Patterns 
within the coded data were identified and overarching themes developed. Each theme was 
defined and had a central organising concept that unified the data within it. Visual mapping was 
used to explore the relationship between codes and themes. A narrative summarising the 
themes was provided leading to a discussion as to whether the findings supported the use of 
‘complications’ as a primary outcome measure. 
 
There are several limitations to the applied qualitative methodology. Firstly, the semi-structured 
interviews were conducted by untrained investigators in a busy clinic environment. Secondly, 
the investigators summarised the patient’s comments into the eCRF thereby processing the 
information and potentially applying personal biases (both in the selection and interpretation of 
what was written). Thirdly, only patients who had completed follow-up were interviewed. It is 
likely that these patients considered the potential benefits of FS mentioned in the PIS favoura-
bly. Patients who did not participate or did not complete follow-up have equally valuable views 
and opinions that were not collected. Ideally, a separate study conducted by trained investiga-
tors using audio recordings of interviews would have provided a much richer and more repre-
sentative source of qualitative data. Therefore, the findings were not generalisable to patients 
outside of the current study.  
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5.12.5 The Relevance of learning curve in a definitive DEFeND trial 
5.12.5.1 Methods for evaluating learning curve in surgical trials 
Surgical interventions are complex because, as previously shown in Figure 17, the outcome of 
the intervention may be influenced by several associated or external factors. Furthermore, as 
discussed in section 3.2.3.6, the fidelity of the intervention and surgical learning curve can have 
a significant impact on the analysis and outcome of the trial. Surgical learning curve can be 
defined as an improvement in a surgeon’s performance in delivering a novel technique over 
time.(138) If cases undertaken during a surgeon’s learning phase are included in the analysis 
of a trial, an imbalance in expertise between established and novel techniques may be appar-
ent. This may lead to false estimates of treatment effect and false conclusions against the novel 
technique (type II error).(177) 
Cook defined two distinct, but related, learning curves.(138) Firstly, a technology learning curve 
related to the iterative process of refining a novel technique. Secondly, a personal learning 
curve driven by individual surgeon aptitude, training and expertise.(138) The DEFeND trial is a 
relatively late evaluation of FS in ND given that sprayable forms of FS have been approved for 
use in the UK since 2014 (see section 1.4.2 for further details).(59) The safety profile and tech-
niques for storage, preparation and administration (described in section 5.9) have become well 
established over this time. This implies that the technology learning curve is less relevant to 
the trial design of DEFeND than the personal learning curve.  
Cook also described two main options for controlling for learning curve.(138)  These were in 
the trial design by implementing entry criteria for surgeons, and in the analysis of the trial by 
adjusting for the learning curve effect.(138) The most frequently utilised approach is incorpo-
rating expert mentoring and completion of a predetermined number of cases by each recruiting 
surgeon in the trial design.(178) However, this approach may be problematic because sur-
geons learn at different rates and their learning may be influenced by external factors. For 
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example, within the context of a multi-centre trial, different mentoring schemes may result in 
different learning effects across different centres.(179)  
Learning curves can be characterised as having three features: the initial level of performance, 
the learning rate represented by a non-linear improvement in performance over time, and an 
asymptote or plateau representing the level at which performance stabilises.(177) Patient out-
comes (e.g. complications) or surgical process outcomes (e.g. operative time) can be used as 
performance proxies by analysing them as a function of the number of cases completed.(180) 
Patient outcomes are the preferred performance proxy because they directly measure the suc-
cess of the procedure in improving the health of the patient. However, when the patient out-
comes are associated with rare events and/or produce non-continuous data, a prohibitively 
large number of cases may be required to model the learning effect. Under these circum-
stances surgical process outcomes may prove more convenient.(181) 
Papachristofi et al (182) recommended performing assessments of individual surgeon learning 
curve using a two-phase model in early studies undertaken before a definitive trial. The two 
phases being: the learning phase (represented by improvement in performance over time), and 
final performance level (represented by the asymptotic part of the learning curve). The authors 
advised using the data from early studies to enable an estimate of the time required by each 
surgeon to overcome the learning effect. This estimation was based on tracking the perfor-
mance of surgeons over time.(182) Since different surgeons will reach different final perfor-
mance levels, Papachristofi et al advocated predefining an expertise level beyond which sur-
geons are deemed adequately experienced to participate in the trial. To overcome the issue of 
different surgeons reaching their asymptote at different rates of learning, Papachristofi et al 
also advocated only initiating an RCT once enough surgeons had reached the predefined level 
of expertise.(182) Basing a predefined expertise level on the learning curve of small sample of 
surgeons appears to be an explanatory design feature. A pragmatic trial should seek to include 
surgeons that have the expertise and aptitude that represents the surgical community in which 
the intervention will be used. Excluding surgeons who do not meet the predefined level means 
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that, by definition, the entirety of the surgical community that will use the intervention will not 
be represented. This is especially the case if the predefined expertise level is set too high. 
Conversely, if the expertise level is set too low, more surgeons will be included but a proportion 
of them may still be in their learning phase opening the door to type II error (as described in 
the first paragraph of this section).(179) Based on this discussion, adopting a predefined ex-
pertise level to guide an estimate of the time required to overcome learning effect is equivalent 
to adopting a ‘one size fits all’ approach to quantifying learning curve.  
The Bayesian hierarchical model described by Cook et al involves adjusting for learning effect 
in the final statistical analysis.(177) The main advantages of this approach are that there is no 
need to define entry criteria for surgeons (in keeping with a pragmatic approach), the complex 
structure of the data can be modelled and the surgeon’s prior experience incorporated. Disad-
vantages include: a lack of power to detect treatment differences at various levels of experience 
(if a relatively low numbers of cases are performed by each surgeon participating in the trial), 
modelling is time intensive, a possible increase in type I error if investigating many different 
performance proxies.(177) Because analysing learning effect has high data requirements, 
Cook et al recommended using the hierarchical model only if the trial has at least ten partici-
pating surgeons who have performed at least ten procedures during the trial.(177) 
5.12.5.2 Methods for evaluating learning curve in DEFeND 
The learning curve for using FS in ND has not been previously quantified. When designing the 
DEFeND trial it was not known if using FS in ND was associated with a learning effect and, if 
it was, how many cases a surgeon needed to perform before they were deemed sufficiently 
expert. As stated in section 5.10.1 the TMG did not incorporate surgeon credentialling into the 
trial design. This resulted in surgeons with varying levels of expertise participating in the trial. 
Although surgeons were provided with access to training resources (see section 5.11), they 
were permitted to deliver the intervention with complete flexibility. All of these design features 
were considered very pragmatic but, if a learning effect did exist, they opened the interpretation 
of clinical outcomes to type II error (as described in section 5.12.5.1). This would obviously be 
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problematic in a definitive trial but not so much of an issue in the REPT where no formal hy-
pothesis testing was planned. 
The DEFeND REPT aimed to recruit 50 patients and would therefore only have data from 25 
patients to evaluate the learning curve associated with using FS in ND. As mentioned in section 
5.12.5.1, analysing and quantifying learning curve requires much more data. Whilst using the 
DEFeND REPT to quantify the learning curve may have been unrealistic, simply identifying the 
presence of a possible learning effect was perhaps more achievable. If evidence for learning 
effect existed, learning curve would either need to be quantified in a separate pre-trial study or 
by using the Bayesian hierarchical model in the definitive trial analysis.(138)  
In order to identify the existence of a learning effect associated with using FS in ND it was 
important to establish the prior experience of participating surgeons. From pre-trial interactions 
with recruiting surgeons, it became apparent that the Ear, Nose & Throat (ENT) surgeons from 
AUH used FS in ND as a matter of routine. This is evidenced by two articles advocating the 
use of FS in ND published by their department in 2015 and 2020.(101, 103) The Oral & Maxil-
lofacial (OMF) surgeons from AUH and all the surgeons (ENT and OMF) from QVH did not use 
FS in ND routinely and, in some cases, had no experience of using it at all. This provided a 
useful scenario to evaluate the existence of a learning effect since one group had already 
reached the asymptotic part of their learning curve and the others were at the start or early on. 
On this basis, the AUH ENT surgeons were classified as ‘experienced’ and all other surgeons 
were classified as ‘inexperienced’. If the ‘experienced’ surgeons performed better than the ‘in-
experienced’ surgeons in the interventional arm and both performed equally in the control arm, 
the existence of learning effect may be inferred. It is important to note that the term ‘inexperi-
enced’ only referred to the use of FS in ND and did not refer to surgical experience more 
broadly.   
Of course, there may be many reasons why a difference in performance between experienced 
and inexperienced surgeons might exist. For example, because randomisation was not strati-
fied by surgical specialty, there may be imbalances in patient co-morbidities and how much of 
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the procedure was performed by trainees. It was also noted that ENT surgeons tend to perform 
more level II-IV NDs whilst OMF tend to perform more level I-III NDs (based on the primary 
tumour site and likely nodal drainage patterns). It was postulated that the anatomy of level I 
may be less conducive to the adhesive effects of FS. The mandible is a rigid structure that 
moves during function (speech, mastication) that may shear the adhesion of the skin flaps to 
the underlying muscular wound bed. For this reason, a comparison between NDs involving 
level I and NDs not involving level I was also made.  
The selection of performance proxies was based on patient outcomes of interest and included 
surgical complications and drainage volume. Surgical process measures were not deemed to 
be helpful in this analysis because the intervention was delivered at the end of surgery and the 
manufacturer stipulated that it needed to be delivered within a very specific time frame. There-
fore, traditional process measures like blood loss (which would have occurred before the inter-
vention was administered) and operative time were not considered useful discriminators. 
1.1 Follow Up 
Follow-up was limited to two scheduled visits, the first for the removal of clips at 7-14 days and 
second for a clinic visit at 4-6 weeks to coincide with the discussion of pathology results. Any 
unscheduled visits were also recorded in the eCRF. It was important for patients to exit the trial 
before the start of radiotherapy as this would likely confound their responses to the Patient 
Reported Outcome Measures (PROM). In keeping with a pragmatic trial design, follow-up was 
kept to a minimum and tied in with routine postoperative visits. Details on what data was col-
lected at each of these visits can be found in the SPIRIT figure (Table 8) 
5.13 Data Monitoring 
Formal interim analyses of the accumulating data were performed at 6 monthly intervals after 
the recruitment of the first patient. A formal Independent Data Monitoring and Safety Committee 
 
  152 
(IDMSC) was not convened. In keeping with the guidance outlined in the document 'Guideline 
in Data Monitoring Committees' published by the Committee for Medicinal Products for Human 
Use,(183) it was thought that an IDMSC was not required. This is because patients were 
treated for a very short period (single administration during surgery) and FS is well character-
ised from a safety perspective and already widely used within healthcare. Although there were 
potential risks to patients, these were rare and known. 
 
The independent members of the TSC (Chairperson, expert, statistician) took responsibility for 
reviewing any interim safety data. The independent members were asked to give advice on 
whether the accumulated data from the trial, together with results from other relevant trials, 
justified continuing recruitment of patients or further follow-up. Given this is a REPT, it was 
anticipated that the TSC would only recommend termination on grounds of safety. 
 
For further details please see A.8 Monitoring Plan. 
5.14 Safety 
Surgical complications and adverse reactions to fibrin sealant graded Clavien-Dindo IV or 
above (see Table 1) were the only events reported to assess safety. As the Clavien-Dindo 
classification constitutes an outcome measure of the trial, the presence of post-operative com-
plications along with their grade was recorded in the eCRF. All complications related to the ND 
surgery and/or use of FS that were Clavien-Dindo IIIb or below and met the definition of serious 
were exempt from SAE reporting. Such events were ‘expected’ and were recorded in the rele-
vant section of the eCRF.  Post-operative complications related to either ND or use of FS that 
were Clavien-Dindo IV or above were ‘unexpected’.  
 
The LCTU was required to notify the main REC of all Suspected Unexpected Serious Adverse 
Reactions (SUSARs) occurring during the study according to the following timelines: fatal and 
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life-threatening within 7 days of notification; non-life threatening within 15 days. All investigators 
were to be informed of any SUSARs occurring throughout the study.  
 
Site staff (except for the surgical team) were blinded therefore the SAE reporting form did not 
state the allocation. For the purposes of SAE reporting, it was assumed that the patient was 
randomised to the FS arm (i.e. interventional arm). Causality was assigned to the following: 
• Anaesthetic 
• Generality of surgery (including surgical airway, primary tumour resection)  
• ND surgery 
• Use of FS 
Pregnancy was listed as an exclusion criterion. If a patient became pregnant after recruitment 
to the trial, there was a requirement to report this in the same way as an SAE. The guiding 
principles in this event were: 
• If the patient had not yet received treatment, or completed treatment, the patient should 
be withdrawn from the trial. 
• Once treatment was complete, i.e. the patient was in follow-up phase, it may be pos-
sible to retain the patient to the conclusion of the trial. 
• Decisions should be made between the treating clinician and the CI in the best interests 
of the patient regarding retention in the trial. 
For further details please see A.9 Safety Plan. 
1.2 Sample Size 
As this was a REPT, no formal power/sample size calculation based on clinical data was per-
formed. It was estimated that over the study period of 12 months, approximately 50 patients 
would be recruited at rate of 30%. Based on this, 50 patients (25 in each arm) would produce 
a standard error of approximately 6.5% and a 95% confidence interval of approximately (17 – 
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43%) was be obtained. With respect to surgical complications, being the clinical outcome of 
current greatest interest, even if a response rate of 50% was observed then a 95% confidence 
interval of (0.36, 0.64) would be observed which provides enough precision for a future sample 
size calculation. The future sample size calculation will be performed using intention-to-treat 







































  156 
Chapter 6.  SELECTION OF DEFINITIVE TRIAL OUTCOMES 
The selection of an appropriate primary outcome measure is critical to trial design as it will both 
define and answer the research question. Furthermore, it will dictate other key aspects of the 
design such as how data is collected, the frequency and length of follow-up and the sample 
size calculation. In keeping with a pragmatic design, if the results are to influence clinical prac-
tice it is important that the primary outcome measure is meaningful to both patients and 
healthcare professionals. Ensuring that trials report outcomes that are meaningful is an im-
portant rationale for developing a Core Outcome Set (COS). In addition to this, COS address 
difficulties caused by heterogeneity in outcome measurement and outcome reporting bias 
within trials.(184) As previously stated there is currently no published COS for HNS. In this 
regard HNS research falls behind other surgical disciplines. In the absence of a COS, it was 
thought that ’complications’ represented the most suitable and pragmatic primary outcome for 
DEFeND. This choice was inferred from a core information set(17) and the meta-analysis pre-
sented in Chapter 2. 
It was hypothesised that there may be some underlying commonality in all COS relevant to 
surgery. Identifying this commonality may guide what outcomes should be included in the DE-
FeND REPT. While the specific outcomes will vary across the COS for different surgical disci-
plines, classifying them into broad themes may provide some useful insight into the research 
priorities of surgical patients in the broadest sense and identify areas for future development in 
HNS research. Furthermore, the crude qualitative data collected from trial participants regard-
ing clinical endpoints and MCID may elucidate these findings. 
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6.1 Review of Surgical Core Outcome Sets 
6.1.1 Introduction 
The COMET Initiative was launched in 2010 and funded by the MRC Northwest Hub for Trials 
Methodology. The aims of this initiative were to promote the development and uptake of COS. 
The COMET Initiative website contains a searchable database of COS that are either in devel-
opment or published.(185) The aim of the scoping review was to search the COMET Database 
for surgically relevant COS and identify commonality in themes to guide the selection of out-
come measures for DEFeND. 
6.1.2 Methods 
The COMET Database was accessed via the COMET Initiative website on 02/07/2020: 
http://www.comet-initiative.org. A review protocol was not prospectively published. The inclu-
sion criteria were: COS For Surgical Interventions; COS designed for use in clinical research; 
COS developed for any target population; COS published in any year. The exclusion criteria 
were: patients or their carers were not key stakeholders; COS not published in a peer reviewed 
journal. 
Search criteria that were entered into the search engine were as follows: 
Type of intervention: Surgery 
Target population: No limitations placed 
Methods: No limitations placed 
Stakeholders involved: No limitations placed (at this point in search) 
Study type: COS for clinical trials or clinical research 
Publication status: Published 
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To increase sensitivity a broad basic search was conducted by entering the word “Surgery” into 
the “Search the COMET database” tab found on the Home page. Duplicates identified through 
the 2 search strategies were removed and final list limited to: COS clinical research/clinical 
trials; Published in peer reviewed journal; Stakeholder involvement included Patients OR con-
sumers OR caregivers OR support group representatives OR families OR charities  
Data on COS was extracted from the cited publication. Data extraction included: disease name, 
disease category, study title, year of publication and the list of final COS. The data was sum-
marised in table form. Each core outcome was coded and assigned a theme that was broadly 
representative of its purpose and nature. 
6.1.3 Results 
The search yielded a total of 19 COS that met the eligibility criteria. These COS are listed in 
Table 9. The articles were published between 2014 – 2020 and encompassed a broad range 
of disease categories. A total of 207 individual core outcomes were identified. The codes used 
to label each core outcome are shown in Table 10. The broad themes assigned to the codes 
are also shown in this table. The bar chart in Figure 19 attempts to illustrate the frequency of 
themes present in all the COS combined.
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How to evaluate the clinical outcome of 
joint-preserving treatment for osteonecro-
sis of the femoral head: development of a 
core outcome set (186) 
2019 1) Pain, 2) Range of motion of hip flexion, 3) Walking distance, 4) Stable rat-




Cancer Sentinel node biopsy for prostate cancer: 
report from a consensus panel meeting 
(187) 
2017 1) Sensitivity, 2) specificity, 3) negative predictive value, 4) positive predictive 
value, 5) false negative rate, 6) false positive rate, 7) number of positive 
nodes, 8) number of SN outside eLND template, 9) number of patients with 






A core outcome set for localised prostate 
cancer effectiveness trials (188) 
2017 1) Death from prostate cancer, 2) death from any cause, 3) local recurrence, 
4) distant recurrence, 5) disease progression, 6) need for salvage therapy, 7) 
faecal incontinence, 8) bowel function, 9) stress incontinence, 10) urinary 
function, 11) sexual function, 12) overall quality of life, 13) positive margins, 
 





Study Title Year List of Core Outcomes 
14) perioperative death, 15) thromboembolic disease, 16) bothersome or 






An international multi-stakeholder Delphi 
consensus exercise to develop a core out-
comes set (COS) for surgical fixation of rib 
fractures (189) 
2019 1) ARDS, 2) Empyema, 3) Pneumonia, 4) Reintubation, 5) Respiratory fail-
ure, 6) iatrogenic mediastinal injury, 7) iatrogenic thoracic injury, 8) iatrogenic 
vascular injury, 9) mortality, 10) 7 day mortality, 11) 30 day mortality, 12) 
chronic pain, 13) dyspnoea, 14) lung function, 15) ventilation, 16) pulmonary 
toilet, 17) disability, 18) physical function, 19) quality of life, 20) HR QoL, 21) 
return to activities, 22) return to work, 23) invasive mechanical ventilation 
Obesity Endocrine & 
metabolic 
A Core Outcome Set for the Benefits and 
Adverse Events of Bariatric and Metabolic 
Surgery: The BARIACT Project (190) 
2016 1) Weight, 2) diabetes status, 3) cardiovascular risk, 4) overall quality of life, 
5) mortality, 6) technical complication of operation, 7) re-operation, 8) dys-





The outcomes of Perthes’ disease:  
Development of a core outcomes set for 
clinical trials in Perthes’ disease (191) 
2020 1) Complications of treatment, 2) pain, 3) activity of daily living, 4) quality of 
life, 5) family life, 6) psychological impact, 7) school attendance, 8) sleep 
quality, 9) sports participation, 10) requirement for further surgery, 11) hip 
 





Study Title Year List of Core Outcomes 
mobility, 12) acetabular coverage and hip congruency, 13) evidence of ar-
thritic change, 14) femoral head shape 
Acute Ap-
pendicitis 
Child health Core outcome set for uncomplicated acute 
appendicitis in children and young people 
(192) 
2020 1) Bowel obstruction, 2) wound infection, 3) wound complication, 4) negative 
appendicectomy, 5) recurrent appendicitis, 6) intra-abdominal abscess, 7) 
antibiotic failure, 8) quality of life, 9) stress/psychological distress, 10) time 
away from full activity, 11) length of stay, 12) readmission to hospital, 13) re-








Developing a core outcome set for fistulis-
ing perianal Crohn’s disease (193) 
2018 1) Quality of Life, 2) lifestyle restriction, 3) lifestyle restriction based on toilet-
ing needs, 4) depression, 5) inability to attend school or work, 6) restriction of 
sexual activity and avoidance of intimacy, 7) incontinence, 8) score of peria-
nal disease activity, 9) perianal abscess, 10) new/recurrent fistula, 11) un-
planned surgical re-intervention, 12) faecal diversion or proctectomy, 13) fis-
tula response on MRI, 14) MRI score responsive to change 
 












Cauda Equina Syndrome Core Outcome 
Set (CESCOS): An international patient 
and healthcare professional consensus for 
research studies (194) 
2020 1) Incontinence of urine, 2) urinary retention, 3) sensation of bladder fullness, 
4) faecal incontinence, 5) physical ability to have sexual intercourse, 6) peria-
nal sensation, 7) sensation in genitals, 8) leg muscle strength, 9) pain due to 
abnormal sensation or non-painful stimulus, 10) complications including 11) 
death, 12) global QoL, 13) occupational role functioning, 14) social function-







NETS1HD study: development of a 
Hirschsprung's disease core outcome set 
(195) 
2017 1) death, 2) long-term faecal incontinence, 3) objective score of bowel func-
tion, 4) unplanned re-operation, 5) long-term voluntary bowel movements, 6) 
long-term psychological stress, 7) long-term urinary incontinence, 8) QoL, 9) 





European Society of Coloproctology 
(ESCP) Core Outcome Set (COS) for 
haemorrhoidal disease: An international 
2019 PROM of 1) SYMPTOMS to include: blood loss, pain, prolapse, itching, soil-
ing. Secondary outcomes are complications: 2) incontinence, 3) abscess, 4) 
fistula, 5) urinary retention, 6) anal stenosis. 7) Recurrence, 8) Patient satis-
faction 
 





Study Title Year List of Core Outcomes 








Development of a gastroschisis core out-
come set (197) 
2018 1) Death, 2) sepsis, 3) growth, 4) number of operations, 5) severe GI compli-
cations, 6) time on parenteral nutrition, 7) liver disease, 8) QoL 
NA Rehabilitation What outcomes are important in the as-
sessment of Enhanced Recovery After 
Surgery (ERAS) pathways? (198) 
2015 1) Complications, 2) GI recovery, 3) pain control, 4) global recovery, 5) hospi-






A core outcome set for adult cardiac sur-
gery trials: A consensus study (199) 





Developing a core outcome set for hip 
fracture trials (200) 
2014 1) Pain, 2) ADLs, 3) Mobility, 4) HRQoL, 5) Mortality 
 











Development of a core outcome set for re-
search and audit studies in reconstructive 
breast surgery (201) 
2015 1) implant related complications, 2) flap related complications, 3) major com-
plications, 4) unplanned surgery for any reason, 5) donor site problems/mor-
bidity, 6) self-esteem, 7) emotional well-being, 8) normality, 9) QoL, 10) phys-





Cancer Development of a Core Outcome Set for 
Clinical Effectiveness Trials in Esophageal 
Cancer Resection Surgery (202) 
2017 1) overall survival, 2) in hospital mortality, 3) inoperability, 4) need for another 
operation, 5) respiratory complications, 6) conduit necrosis and anastomotic 
leak, 7) severe nutritional problems, 8) the ability to eat and drink, 9) prob-
lems with acid indigestion or heartburn, 10) overall QoL 
Arthritis Rheumatol-
ogy 
Outcome Domains and Measures in Total 
Joint Replacement Clinical Trials: Can We 
Harmonize Them? An OMERACT Collab-
orative Initiative (203) 
2015 1) Pain, 2) function, 3) satisfaction, 4) revision, 5) adverse events, 6) death, 
7) cost, 8) patient participation 
Colorectal 
cancer 
Cancer Core Outcomes for Colorectal Cancer 
Surgery: a consensus study (204) 
2016 1) Long-term survival, 2) cancer recurrence, 3) resection margins, 4) anasto-
motic leak, 5) perioperative survival, 6) surgical site infection, 7) stoma rates 
 





Study Title Year List of Core Outcomes 
and complications, 8) conversion to open operation, 9) physical function, 10) 
sexual function, 11) faecal incontinence, 12) faecal urgency 
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1. HRQoL / QoL 
2. Patient reported symptoms / out-
comes 
3. Pain 
4. Psychological well being 
5. Patient satisfaction 
6. Activities of Daily Living (ADL) 
7. Ability to work / attend school 
Complications 1. Surgical complications 




1. Blood tests 
2. Physiological tests (lung function) 
3. Physical measurements (range of 
motion, distance walked) 
4. Pathology 
5. Imaging 




1. Returns to theatre 
2. Need for further (invasive) treat-
ment including interventional radi-
ology, intubation, mechanical 
ventilation 
3. Operative time 
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4. LoS 
5. Admission/Readmission to hospi-
tal 
6. Financial 




Figure 19 Bar chart demonstrating the number of core outcomes assigned to each domain 
6.1.4 Discussion 
The results of this scoping review demonstrate that humanistic outcomes and complications 
are well represented in surgically relevant COS. Humanistic outcomes can be defined as those 
that are of interest to patients and include symptom status, functional status and QoL.(205) 






Humanistic Complications Measurements Resource Use Mortality
Frequency of Themes in Surgically Relevant 
Core Outcome Sets (n = 207)
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express their unique perspective on health and well-being.(206) Complication outcomes can 
be defined as those that report adverse events that occur during or after surgery. Traditionally 
complications are Clinician Reported Outcome Measures (ClinROM) because they require a 
clinician to examine the patient and make a diagnosis. However, instruments like the Wound 
Healing Questionnaire (WHQ) developed for the Bluebelle study have demonstrated that com-
plications like SSI can be successfully reported with the use of PROMs (see section 6.2.2.2 for 
further details).(149) Both humanistic and complication outcomes can be considered ‘subjec-
tive’ outcomes because they require an individual to express their views, whether that is a 
patient describing their own health status or a clinician diagnosing a complication. Often these 
outcomes are reported on a severity scale e.g. pain VAS or Clavien-Dindo classification.(206)  
Measurements, resource use and mortality can be considered objective measures because 
they are not subject to the same degree of individual interpretation.(206) Measurement out-
comes are those that require the patient to undergo a ‘test’ that is reported objectively e.g. 
blood or physiological tests. To some extent pathology and radiology reporting may also be 
considered subjective outcomes. However, the degree of subjectivity may be minimised by 
having clearly defined diagnostic criteria. Resource use and mortality are associated with spe-
cific events (or duration of events) that occur during a patient’s care. These are often recorded 
by healthcare providers as part of routine practice.    
Because this review only included COS that included patients or carers in the list of stakehold-
ers, the high prevalence of humanistic and complication related core outcomes suggest that 
they are both important and patient-centred ways of assessing surgical techniques and inno-
vations. 
According to the COMET database, a COS for HNC is currently in development. This COS is 
specifically for clinical trials involving Oropharyngeal Carcinoma (OPC).(207) Whilst the treat-
ment for OPC may involve surgery and there may be some crossover, currently no COS spe-
cifically developed for HNS trials exists (either published or in development). A specific HNS 
COS should include patients who have undergone surgery for HNC irrespective of site.   
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It is not possible to use the results of this review to second guess what a future COS in HNS 
would look like. The definite trend towards using subjective outcomes to assess surgical tech-
niques and innovations lends itself PROMs. There are many PROMs that are specific to pa-
tients that are undergoing treatment for HNC. However, their focus is primarily on QoL and the 
symptoms associated with RT and/or CRT. Currently the NDII is the only HNS specific 
PROM.(208) 
One of the problems with using ClinROMs to assess complications (e.g. Clavien-Dindo classi-
fication) is that they do not define when a complication becomes significant for an individual 
patient. This is because the threshold for significance will vary between patients. Using Clin-
ROMs in clinical trials requires investigators to decide the threshold on behalf of all patients 
(e.g. complications that are Clavien-Dindo grade IIIB or above). A well designed and respon-
sive PROM may be able to provide a much more holistic assessment of a surgical intervention. 
The WHQ validation work for the Bluebelle study has shown it is possible to merge humanistic 
and complication outcomes by developing an instrument that can effectively diagnose SSI by 
patient report.(149) 
In conclusion there is a need for a COS that is specific to HNS to guide the development of 
meaningful outcome measures. Where possible subjective outcomes should take the form of 
PROMs that can provide a patient centred and holistic assessment of new surgical techniques 
and innovations. 
6.2 Selection of Outcome Measures 
The clinical outcome measures and PROMS selected for the DEFeND REPT were based on 
the findings from previously published research (including the core information set by Maine et 
al (REF)), the systematic review reported in chapter 2 and the review of COS reported in sec-
tion 6.1. Where instruments specific to ND or HNS were absent, alternatives were sought from 
the broader surgical literature. It was understood that these instruments may not have been 
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appropriately validated for use in DEFeND however, by including them, the feasibility of using 
such instruments in HNS trials could be ascertained. If using these instruments was feasible, 
this may highlight a potential unmet need in terms of future methodological research in HNS.  
6.2.1 Clinical outcomes 
In terms of clinical outcomes, aside from descriptive statistics, informal comparisons between 
allocated groups were made using difference in medians (IQR) for continuous variables and 
difference in rates for categorical variables. Statistical comparisons between treatment groups 
took the form of Wilcox Test for continuous outcomes and Fishers Test/Chi-Square Test for 
categorical outcomes unless otherwise stated. No formal hypotheses were being tested and 
the nominal 95% CI and p = 0.05 was used to determine statistical significance. No adjustments 
for multiple comparisons were made. 
6.2.1.1 Clavien-Dindo classification of surgical complications 
‘Complications’ were selected as the primary outcome measure for the DEFeND REPT. The 
rationale for this decision is discussed in section 3.2.3.4 and is further supported by the findings 
of the review of surgical Cos reported in section 6.1. The Clavien-Dindo classification is a widely 
accepted tool to grade the severity of surgical complications (Table 1).(23) Because it is a 
generic classification, grading is open to interpretation when applying it to specific HNS com-
plications. For example, Monteiro et al found that there was imperfect inter-observer reliability 
in scenarios where patients underwent a surgical procedure that did not require returning to 
the operating theatre.(137) To avoid this issue within the context of DEFeND, the severity of 
common/established complications associated with ND were graded and provided to investi-
gators as a guide to conform to the Clavien-Dindo classification (see Appendix D.  Clavien-
Dindo Classification of Surgical Complications Adapted to Common Head & Neck Complica-
tions). The table in Appendix D.  was included in the Protocol (See A.1) for investigators to use 
as a reference if they had doubts regarding appropriate grading of a complication. Furthermore, 
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the Post-operative Complication form in the eCRF (see B.9) was designed to mirror the table 
in Appendix D. by asking investigators to grade the complication based on a description rather 
than allowing them to freely insert a grade. It was thought that providing a description would 
help reduce inter-observer variability. For rare complications an ‘Other Complications’ question 
was included, however, this required investigators to make their own assessment of the most 
appropriate grade of complication. An assessment of complications using the Clavien-Dindo 
classification was carried out at every patient encounter after surgery i.e. every day of the pa-
tient’s hospital stay and at subsequent scheduled and unscheduled follow-up visits (B.9 Post-
operative Complication Form).  
Using the original Clavien-Dindo classification shown in Table 1 does not accommodate for the 
cumulative morbidity of experiencing more than one complication i.e. from a patient’s perspec-
tive, experiencing multiple minor complications may be just as taxing as experiencing one ma-
jor complication. The Comprehensive Complication Index (CCI) uses the Clavin-Dindo grade 
for each complication a patient experiences and produces a numerical value between 0 (no 
complication) to 100 (death).(209) In patients that experience multiple complications, the CCI 
uses an algorithm to combine the numerical value of each complication and produce a number 
for overall morbidity. Further details on the CCI can be found at: 
https://www.assessurgery.com/about_cci-calculator/ 
Slankamenac et al provided external validation for the CCI utilising three previously published 
RCTs that reported specific complications after different surgical procedures.(210) These com-
plications included pancreatic fistula after pancreaticoduodenectomy, anastomotic stricture af-
ter oesophagogastrostomy and overall complications after colonic resection. Slankamenac et 
al reported superiority of using CCI compared to using specific complications or traditionally 
reported morbidity endpoints. They found that CCI reduced sample-size by virtue of it being a 
continuous outcome measure and was closely associated with length of hospital stay, length 
of ITU stay and in-hospital costs. When calculating the sample size for these trials a MCID of 
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10 CCI points was used. This was derived from the fact that 10 points reflects one grade of 
difference in the traditional Clavien-Dindo classification.(210)     
The authors of the CCI were contacted for permission to use their tool in DEFeND. The algo-
rithm is copyrighted and was accessed by using their ‘online calculator’.    
6.2.1.2 Drain outcomes 
The drain outcomes collected included: 
• Time (hours) for daily wound drainage volume to reach <1.25ml/hr. 
• Time (hours) to drain removal (as dictated by drainage volume). 
• Total wound drainage volume (ml). 
The core information set published by Main et al reported that “details of drips, drains and 
tubes” was important to patients and other key stakeholders. This is in keeping with un-
published qualitative data from the ‘Aintree Head & Neck Patient Research Forum’ that demon-
strated patients have an aversion to surgical drains as they are uncomfortable and an impedi-
ment to mobilisation. However as discussed in section 3.2.3.4, ‘Time to drain removal’ is a very 
short-term outcome measure and using it as a primary outcome measure in the DEFeND trial 
would move away from a pragmatic design. 
 The decision to remove a drain is often a clinical decision based on the volume and appear-
ance of the drainage fluid. Surgeons often use various arbitrary volume thresholds in the deci-
sion to remove drains based on a balance of risk between retaining drains long enough to 
prevent fluid collections and removing them before they instigate SSI, none of which are par-
ticularly evidence based. Using ‘time to drain removal’ as a primary outcome measure may 
require standardisation in the protocol to minimise bias and make results comparable between 
patients. However, in doing so, the trial becomes more explanatory in nature.    
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Section 1.3 provided some background to surgical drain practices in ND. The threshold for 
drain removal is based on a balance of risk between retaining drains long enough to prevent 
fluid collections and removing them before they instigate SSI. The majority of surgeons in North 
America use volume as the main indicator for drain removal with 30ml in a 24-hour period being 
the most popular threshold.(35, 36) The threshold of 30ml/24hrs is also common amongst dif-
ferent surgical specialties working in different anatomical areas but there is a surprising lack of 
objective evidence supporting it.(39, 40) However, there is considerable variations in practice 
with some authors advocating higher volume thresholds and/or measuring drain volumes more 
frequently.(41-44)  
In a pragmatic design it is important that trial outcomes are generalisable (external validity). 
There is currently no published UK based consensus on the most appropriate threshold for 
drain removal and number of drains used in ND. Based on the perception that UK HNS practice 
tends to be similar to North American practice and that the purpose of a drain is the same 
irrespective of the clinical setting, a threshold of 30ml in a 24-hour period was chosen and use 
of only one drain permitted. Anecdotally, this threshold and number of drains corresponds to 
the PhD candidates experience of working for different Head & Neck Surgeons in the UK 
throughout his training. It is recognised that carrying out a pre-trial survey of UK Head & Neck 
Surgeons to establish whether there was consensus amongst respondents would have been a 
more robust approach to defining the threshold and number of drains. 
When designing the trial, it was considered important to ensure some standardisation in the 
way drain volumes were recorded. At that time, taking the decision to remove the drain away 
from surgeons was though to minimise detection bias. On that basis the following drain protocol 
was stipulated:  
• Use of a single size 18 HandyVacTM drain. This drainage system by ConvaTec has a 
collection bag with a tap for emptying contents as shown in Figure 20. 
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• Drain volumes were recorded at least twice daily (morning and evening) and the con-
tents of the drainage bag were emptied into a measuring cylinder for precise measure-
ment.  
• Drain volumes were entered in the eCRF in real time. As described in section 4.3.4.2, 
the eCRF was programmed to calculate the rate of drainage (volume/time) and inform 
investigators whether the drain should be removed using the algorithm shown in Figure 
15 (also see B.10 Drain Output Data Form). 
• It was thought that estimation of drain volume using the scales found on drain bottles 
and bags would result in significant interobserver variability and was not precise 
enough for the drain removal algorithm in Figure 15. 
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Figure 20 HandyVac(TM) wound drainage system by ConvaTec 
In retrospect, measuring drain volumes and stipulating a specific drain protocol were very ex-
planatory design features. In a future definitive trial, alternative approaches will need to be 
sought. In a pragmatic design, surgeons should be allowed to remove the drain based on their 
own practice. For this approach to produce fair and meaningful results, consideration needs to 
be given to stratification of randomization and how effectively outcome assessors are blinded 
to the allocation. For example, strata could be based on site if there was agreement that drain 
practices would remain identical within each site. Alternatively, strata could be based on indi-
vidual surgeon practices irrespective of site. The latter approach would benefit from a pre-trial 
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survey of recruiting surgeons to establish all combinations of drain removal thresholds and 
numbers of drains used. If drain practices are highly variable, stratifying based on individual 
surgeon practice may be problematic if infrequent practices do not recruit enough patients (see 
section 5.7 for further explanation). In both scenarios surgeons would need to understand that 
the same protocol would apply for both interventional and control arms. The effective blinding 
of outcome assessors is vital to producing unbiased results as discussed in section 3.2.3.3.  
6.2.2 Patient reported outcome measures 
According to the review of surgical COS reported in section 6.1, humanistic outcomes have an 
important role if surgical research and PROMs are integral to their measurement. The inclusion 
of PROMs in DEFeND was thought to be important however, it quickly became apparent that 
there was a paucity of instruments validated specifically for HNS.  
6.2.2.1 Neck Dissection Impairment Index 
The NDII was chosen because it is the only validated ND specific health related quality of life 
(HRQoL) instrument.(147) Other similar instruments include ‘Disability of the Arm, Shoulder 
and Hand’ (DASH)(211), ‘QuickDASH’(212), ‘Shoulder Pain and Disability Index’ (SPADI)(213) 
and the University of Washington Quality of Life (UW-QoL) shoulder subscale.(214) Doctoral 
research from the Nova South-eastern University entitled ‘Shoulder-Specific Patient Reported 
Outcome Measures for Use in Patients with Head and Neck Cancer: An Assessment of Relia-
bility, Construct Validity, and Overall Appropriateness of Test Score Interpretation Using Rasch 
Analysis’ concluded that NDII was the most appropriate instrument for patients with HNC.(215)    
Appendix B.4 shows the NDII eCRF and provides details on the questions patients were asked. 
The raw scores were standardized to a value that was a fraction of 100 according to the original 
publication using the following equation: 
Standardized score = [(raw score – 10) / 40] x 100 
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The NDII is validated for use in patients who have undergone selective or modified radical ND 
and in the validation research, was used eleven months post-operatively.(147) However in the 
DEFeND REPT, patients undertook a baseline NDII pre-operatively and another at Follow-up 
visit two (4 - 6 weeks). Although the NDII is not validated for use 4 - 6 weeks after surgery, 
there is evidence that the NDII score at this early juncture is representative of longer-term 
HRQoL.(216) In a recently published RCT, NDII was used as the primary outcome measure 
six months after surgery. The authors of this RCT quoted evidence from the physiotherapy 
literature that demonstrated that the majority of shoulder function recovery after ND is complete 
by this point. An MCID of 18.1 points was used in the sample size calculation of this RCT based 
on a telephone survey of 25 patients who had undergone ND.(217) If the NDII is to be used in 
a definitive trial, consideration for extending the follow-up period to a minimum of six months 
must be considered.   
6.2.2.2 Wound Healing Questionnaire 
The WHQ is not validated for HNS however it was felt important to include this instrument to 
understand how it can be applied to HNS trials. It has already been proposed that complications 
represent an important patient centred outcome in HNS specifically and surgical research more 
broadly. However, instruments like the Clavien-Dindo classification and CCI are not without 
fault and are not specific to HNS. The WHQ was developed and validated for use in the Blue-
belle study; a feasibility study of different wound dressing strategies for the prevention of SSI 
in elective and unplanned abdominal surgery.(149) Whilst its specific application is not relevant 
to DEFeND, the WHQ represents a PROM that can effectively diagnose a surgical complica-
tion. In addition to diagnosis, the PROM allows the patient to express their unique perspective 
on their experience of said complication(s). It was felt that if the WHQ was successfully de-
ployed in DEFeND, a strong argument can be made for the development of a similarly designed 
HNS specific instruments in the future.  
Colleagues involved in designing and validating the WHQ from the University of Bristol were 
contacted, and permission sought to include the WHQ in the DEFeND trial. Permission was 
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given on the provision that anonymized and contemporaneous data on WHQ as well as the 
clinician diagnosed validation used in the original study was sent every month. Patients re-
cruited to the DEFeND study completed the WHQ at Follow-up visit two (4-6 weeks). Appendix 
B.13 demonstrates the questions that patients were asked when completing the WHQ. The 
clinician diagnosed validation questions requested by the Bluebelle study team were based on 
the Centres for Disease Control and Prevention (CDC) criteria of SSI and shown in Appendix 
B.14. Blinded clinicians assessed the patient using the CDC criteria at visit two.  
As already mentioned above, the WHQ was not designed for use in HNS trials and has not 
been validated in HNS patients. Whilst there was no intention to validate the WHQ within the 
small DEFeND REPT, it was thought that using the data that was requested by the Bluebelle 
study team to perform our own basic assessment may provide some insight into how success-
ful an instrument like the WHQ would be in a HNS trial. The patient responses to the WHQ in 
DEFeND patients was examined against a clinician diagnosis of SSI. The clinician diagnosis 
of SSI was recorded as ‘no SSI’ or ‘SSI of any type’ and based on the results of the ‘face-to-
face’ assessment form shown in Appendix B.14. ‘Sensitivity’ and ‘1 – specificity’ values of WHQ 
for different thresholds were used to plot a receiver operating characteristic (ROC) curve. The 
performance of the WHQ to discriminate between patients who had SSI and those that did not 
was measured by the area under the curve (AUC). An AUC value approaching 1.0 indicated 
good discrimination, whereas a value approaching 0.5 indicated poor discrimination. 
6.2.2.3 Neck pain scale 
Pain is a commonly reported symptom after surgery(218) and was included in DEFeND as a 
relatively easy to administer PROM. It was thought that pain may correlate with wound healing 
and certain surgical complications thereby providing additional information of the role of FS in 
ND. Originally it was planned to use a visual analogue sale (VAS) to provide a numerical value 
that was measured between zero and ten. However, this required the use of a paper CRF that 
patients needed to physically mark. Within the context of an eCRF, investigators found it much 
easier to administer a Numeric Rating Scale (NRS) and simply ask patients to score their pain 
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out of ten (zero being no pain and ten being the worst pain possible). The Neck Pain eCRF is 
shown in Appendix B.5. Pain scores were taken at every patient encounter including baseline, 
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Chapter 7.  RESULTS 
7.1 Description of Baseline Subject Characteristics 
The baseline measures of variables that were considered important/relevant are presented in 
Table 11. The inclusion of patients who had previous treatment to the neck was considered an 
important and pragmatic design feature however, only nine such patients were recruited. The 
three patients who had previous ipsilateral or contralateral radiotherapy were in the ‘No FS’ 
arm, and the three patients who had previous neck surgery were in ‘FS’ arm. Three patients 
were reported as previously having ‘Other Neck Treatment’ (2 from QVH, 1 from AUH) but in 
all cases further details were not provided.  
Whilst every effort was made to include patients at high-risk of complications, most patients 
were low risk. A minority of patients had previous treatment to the neck (18%), were current 
smokers (16%), were immunosuppressed (2%), anticoagulated (12%) or on antiplatelet ther-
apy (6%).  
The ‘No FS’ arm had five patients with a Performance Status (PS) of 2 and one patient with a 
PS of 4. The ‘FS’ arm had no patients with a PS >1. Overall, this suggests that patients in the 
‘FS’ arm were better functioning before surgery.  
 
Table 11 Baseline demographics 
Covariate Level Fibrin Sealant (n=26) 
No Fibrin 
Sealant (n=25) Total (n=51) 
Previous Neck 
Treatment 
No Previous  
Treatment 
21 (81%) 21 (84%) 42 (82%) 
Ipsilateral RT 0 (0%) 1 (4%) 1 (2%) 
Contralateral RT 0 (0%) 2 (8%) 2 (4%) 
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Covariate Level Fibrin Sealant (n=26) 
No Fibrin 
Sealant (n=25) Total (n=51) 
Ipsilateral ND 2 (8%) 0 (0%) 2 (4%) 
Ipsilateral Open Biopsy 1 (4%) 0 (0%) 1 (2%) 
Other 2 (8%) 1 (4%) 3 (6%) 
Height median (IQR) 1.78 (1.755, 1.828) 1.7 (1.65, 1.78) 1.77 (1.685, 1.795) 
Weight median (IQR) 84.7 (74.275, 99.55) 
71.4 (65.8, 
83.4) 81.3 (70.9, 89.5) 
BMI median (IQR) 27.55 (25.402, 31) 25.94 (24.5, 28.8) 26.91 (24.565, 29.725) 
WHO Perfor-
mance Status 
0 19 (73%) 17 (68%) 36 (71%) 
1 7 (27%) 2 (8%) 9 (18%) 
2 0 (0%) 5 (20%) 5 (10%) 
4 0 (0%) 1 (4%) 1 (2%) 
Smoking 
Current  4 (15%) 4 (16%) 8 (16%) 
Ex-Smoker 13 (50%) 8 (32%) 21 (41%) 
Never Smoked 9 (35%) 13 (52%) 22 (43%) 
Immunosuppres-
sive treatment 
No 25 (96%) 25 (100%) 50 (98%) 
Yes 1 (4%) 0 (0%) 1 (2%) 
Antiplatelet  
No 24 (92%) 24 (96%) 48 (94%) 
Yes 2 (8%) 1 (4%) 3 (6%) 
Anticoagulated 
No 22 (85%) 23 (92%) 45 (88%) 
Yes 4 (15%) 2 (8%) 6 (12%) 
Hb median (IQR) 143 (133.5, 149) 140 (127.5, 149) 141.5 (128.25, 149) 
Platelets median (IQR) 228 (175.5, 289) 294 (288.5, 342) 288.5 (210.5, 321) 
White cells median (IQR) 6.8 (6.05, 8.75) 8.85 (5.925, 10.3) 7 (6, 9.6) 
PT median (IQR) 10 (10, 11) 10 (10, 11) 10 (10, 11) 
aPTT median (IQR) 25 (24, 26) 26 (25, 28) 25 (24, 27) 
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Covariate Level Fibrin Sealant (n=26) 
No Fibrin 
Sealant (n=25) Total (n=51) 
Randomisation 
Randomised but not 
revealed 1 (4%) 2 (8%) 3 (6%) 
Randomised and  
revealed 
25 (96%) 23 (92%) 48 (94%) 
 
The distribution of surgical characteristics across both treatment arms is presented in Table 
12. Again, there is an approximately even distribution of variables. Notable differences include:  
1. Three patients had a level I-V ND (modified radical ND) and were all in the ‘No FS’ 
arm. Modified radical ND is associated with a larger surgical dead space therefore, this 
difference favours the ‘FS’ arm. 
2. Patients in the ‘No FS’ arm had less intra-operative blood loss. Low intra-operative 
blood loss is often associated with uncomplicated surgery or meticulous surgical tech-
nique. This difference therefore favours the ‘No FS’ arm. 
3. Patients in the ‘FS’ arm had slightly longer operations by approximately 25 minutes. 
This may be related to the time it takes to prepare and administer the FS.  
4. One patient in the ‘No FS’ arm is reported to have 0 levels of the neck dissected. This 
was due to an administrative error. The patient in question was a late withdrawal from 
the trial because they were deemed inoperable during surgery. However, the ‘Day of 
Surgery’ eCRF had already been opened and data on the patients ASA entered. The 
number of levels dissected is automatically populated by the eCRF based on tick boxes 
(see Day of Surgery Form B.8). In this case the patient had no levels selected and the 
outcome box was automatically populated with ‘0’. This patient has not been included 
in any subsequent analyses. This also explains why the total number of patients in the 
table is 49 rather than 48. 
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Overall, the differences between the arms are small and may indeed negate each other. It is 
therefore assumed that any differences between the treatment arms, both in terms of baseline 




Table 12 Summary of surgical characteristics by treatment arm 
Covariate Level Fibrin Sealant No Fibrin Sealant Total 
Total  25 24 49 
Primary Resection 
No 10 (40%) 11 (46%) 21 (43%) 
Yes 15 (60%) 13 (54%) 28 (57%) 
No. Neck Levels 
0 0 (0%) 1 (4%) 1 (2%) 
3 19 (76%) 16 (67%) 35 (71%) 
4 6 (24%) 4 (17%) 10 (20%) 
5 0 (0%) 3 (12%) 3 (6%) 
Cutting Instrument 
Cold Steel 15 (60%) 18 (75%) 33 (67%) 
Cutting  
Diathermy 
3 (12%) 2 (8%) 5 (10%) 
Harmonic  
Scalpel 
7 (28%) 3 (12%) 10 (20%) 
Intra-operative 
Blood Loss median (IQR) 100 (40, 100) 50 (25, 100) 50 (27.5, 100) 
Length of surgery 
(hours) median (IQR) 2.467 (1.942, 2.958) 2.05 (1.683, 2.383) 2.2 (1.775, 2.617) 
Time to revealing 
Allocation (hours) median (IQR) 2.283 (1.667, 2.6) 2.05 (1.358, 2.375) 2.133 (1.55, 2.5) 
Time in Recovery 
Room (hours) median (IQR) 1.683 (1.3, 2.35) 1.642 (1.417, 1.987) 1.667 (1.367, 2.083) 
Nodal Yield median (IQR) 22 (17.8, 27.5) 22 (19, 28) 22 (18, 28) 
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7.2 Pilot/Feasibility Outcomes 
 
Figure 21 CONSORT flow diagram of the progress through the phases of the study (enrollment, 
allocation, follow-up, data analysis 
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7.2.1 Recruitment and retention outcomes 
7.2.1.1 Proportion of eligible patients randomised to the study 
The CONSORT flow diagram in Figure 21 summarises the progress through the different 
phases of the study. AUH screened a total of 125 patients. Of these patients 33 did not meet 
eligibility criteria. Of the 92 remaining patients, 46 (50%) were recruited and 42 (45.7%) were 
successfully randomised and revealed. For 13 patients the reason for failure to randomise is 
unknown. On the presumption that these patients did not meet eligibility criteria, the highest 
possible proportion of eligible patients recruited from AUH is 58.2% (46/79). The highest pos-
sible proportion of eligible patients randomised and revealed from AUH is 53.2% (42/79).  
QVH screened a total of 9 patients. All 9 of these patients met eligibility criteria. Of these pa-
tients 7 (77.8%) were recruited and 6 (66.7%) were successfully randomised and revealed. 
Data from operative records indicates that 22 potentially eligible NDs were performed at QVH 
during their recruitment period. On the presumption that all unscreened patients met eligibility 
criteria, the lowest possible proportion of eligible patients recruited from QVH is 31.8% (7/22). 
The lowest possible proportion of eligible patients successfully randomised and revealed from 
QVH is 27.3% (6/22).  
Overall, between both sites 134 patients were screened. It is known that at least 33 did not 
meet eligibility criteria. A total of 53 patients were recruited, and 48 patients were successfully 
randomised and revealed. Therefore, the overall proportion of eligible patients recruited is 
52.5% (53/101). However, based on the missing screening data, this value may range between 
31.8% – 58.2% in the definitive trial. Similarly, the overall proportion of eligible patients suc-
cessfully randomised and revealed is 47.5% (48/101) with a range of 27.3% - 53.2%.   
Prior to commencement of the REPT, it was predicted that a total of 180 patients would be 
eligible over a 12-month period and 30% of these would be randomised. In fact, AUH screened 
92 eligible patients over a 10-month period and QVH screened 9 over a 5-month period. Whilst 
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the observed number of eligible patients proved to be lower than predicted, the study has per-
formed better than predicted in terms of the proportion of these patients randomised.  
7.2.1.2 Reasons for failure to screen potentially eligible patients 
Qualitative data from unstructured interviews with investigators at sites was used to create a 
narrative of the difficulties encountered with screening.  
AUH has a strong track record of recruiting to Head & Neck clinical trials. This is in part due to 
engaged clinicians and an active Research Nurse (RN) presence. Prior to the Head & Neck 
MDT meetings, the RNs ‘pre-screen’ the electronic records of all the patients to be discussed. 
All actively recruiting trials that a patient may be eligible for are then recorded adjacent to the 
patient’s details on the MDT list. This serves as an effective ‘aide memoire’ for clinicians when 
making treatment decisions during the meeting. If the clinician agrees that the patient may be 
eligible, the patient is approached later that day when they attend the outpatient clinic. This 
highly sensitive process of screening is well established at AUH and would be difficult to im-
prove upon.   
Conversely, QVH had difficulty screening potentially eligible patients. However, once patients 
were successfully screened, a relatively high proportion (66.7%) were successfully randomised 
and revealed. A possible reason given for this was that QVH does not share the same research 
culture and infrastructure as AUH. QVH serves as a tertiary surgical ‘hub’ for several ‘spoke’ 
district general hospitals (DGH). HNMDTs are convened at the DGH sites on different days of 
the week which makes research support more challenging and labour intensive. The spoke 
DGH sites were not opened, therefore, patients were not allowed to be approached or con-
sented at these sites. Furthermore, QVH does not have the same number of RNs that can 
support research activity throughout the working week. The relatively high proportion of eligible 
patients randomised at QVH is by virtue of a pro-active PI. The PI was able overcome many of 
the infrastructure obstacles by actively engaging his surgical colleagues. However, by his own 
admission, if he did not engage them, potentially more eligible patients would have been lost.  
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7.2.1.3 Recruitment rate 
A total of 53 patients were recruited to the study but only 48 were randomised and revealed 
successfully. 3 were randomised but later withdrawn from the study and not revealed, the re-
maining 2 were recruited but never randomised. Of the 2 that were not randomized only 1 was 
reported to have an ‘unassigned’ treatment code in the analysis. The reasons for this are un-
clear as the correct number of unassigned patients should be 2. In all cases this was due to 
last minute changes in treatment plan that meant the patient was no longer eligible. Table 13 
demonstrates the number of patients recruited by site and Table 14 demonstrates the number 
of patients who were successfully randomised and revealed by site. The recruitment window 
differed between sites because AUH was opened first and started recruitment in November 
2018 whereas QVH opened for recruitment in February 2019. In total AUH was open for 10 
months and QVH for 5 months. The overall recruitment rate for the study was 5.3 pa-
tients/month [4.6 patients/month for AUH and 1.4 patients/month at QVH]. This was higher than 
the predicted 4 patients/month. 
 
Table 13 Recruitment by site 
Site Date of First Rand. 





Sealant Unassigned Total 
Aintree University Hospital 2018-11-08 2019-08-28 23 21 2 46 
Queen Victoria Hospital 2019-02-04 2019-07-07 3 4 0 7 
 
 
Table 14 Patients who were successfully randomised and revealed by site 
Site Date of First Rand. 
Date of Last 
Rand. Fibrin Sealant No Fibrin Sealant Total 
Aintree University Hospital 2018-11-08 2019-08-29 22 20 42 
Queen Victoria Hospital 2019-02-04 2019-06-17 3 3 6 
 




Figure 22 Cumulative recruitment 
 
 
The cumulative recruitment curve based on monthly randomisation figures is presented in Fig-
ure 22. Recruitment was steady across the study period apart from small dip in January 2019 
followed by an acceleration in March that corresponded to both sites being opened and recruit-
ing. Recruitment was considered successful because the target of 50 patients was exceeded 
two months ahead of schedule. 
7.2.1.4 Reasons for failure to randomise 
The relative frequencies of reasons that patients were not randomised are presented in Figure 
23. Both sites saw approximately 22% of patients declining to participate (AUH 22/101 (21.7%); 
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Only five eligible patients were lost because they were seen in ‘spoke’ sites that were not open 
to the study. However, the true number is likely to be higher because QVH faced problems 
screening patients from spoke sites.  
There is some concern regarding the exclusion of patients because of ‘investigator decision’ 
and ‘social issues’. Four patients were lost because the investigator decided against recruiting 
the patient to the study. Three patients were lost because the investigator or RNs recruiting the 
patient felt that the patient’s social circumstances were such that they would hinder compliance 
with the trial thereby moving the trial away from its pragmatic design.  
 
 
Figure 23 Relative frequency of various reasons for failure to randomise 
 
 
Whilst recruitment was successful issues were encountered across both sites. Below is a brief 
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QVH recruitment problems 
As mentioned previously QVH provides tertiary Head and Neck surgery services to several 
‘spoke’ DGH sites. Patients are seen, diagnosed and treatment planned at these spoke sites. 
The patient then attends QVH for their surgery. This model provides administrative barriers to 
recruitment because each spoke sites needs to confirm ‘capacity and capability’ and undergo 
the ‘green light process’ to open the trial. Because this process can take several weeks, and 
the recruitment window for QVH was already shortened, a decision was made not to open the 
spoke sites.  
 
The trial protocol stipulated the use of a single surgical drain. This was a requirement of the 
drain protocol described in section 4.3.4.2 (drain output data form) and 6.2.1.2 (drain out-
comes). Some surgeons at QVH voiced concerns over the use of a single drain as this was a 
deviation from their normal practice of using two drains. These surgeons were primarily con-
cerned about complications and their medicolegal sequelae. They asked that the investigators 
provide evidence to support the use of a single drain. Even though this evidence was duly 
provided, these surgeons did not recruit any patients to the trial.  
 
AUH recruitment problems 
Overall AUH did not struggle to recruit patients. However, the proportion of eligible patients 
randomised rate was lower than QVH. A small number of patients were lost because they were 
from spoke DGH sites that were not open. However, this was less of an issue than QVH be-
cause most patients are discussed in the MDT and seen in clinic at AUH prior to their surgery. 
7.2.1.5 Number of patients lost to follow-up 
A total of two (4%) patients who were successfully randomised and revealed did not complete 
follow-up. Both patients were in the ‘No FS’ arm. A total of seven recruited patients did not 
attend their second and final follow-up appointment. Two were in the ‘FS’ arm and five in the 
‘No FS’ arm. This includes two patients who were recruited but never randomised, three 
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patients who were randomised but never revealed and two patients who were successfully 
randomised and revealed but did not complete their follow-up.  Overall, there was a tendency 
for patients in the ‘No FS’ arm to not complete follow-up.  
7.2.1.6 Reasons for loss to follow-up 
In both cases described above loss to follow-up was because the second follow-up visit did not 
coincide with the patient’s routine clinical follow-up. Both patients were not willing to make a 
trial specific visit. However, they did attend their first follow-up visit. This attrition rate of patients 
was better than expected prior to commencement of the trial. In the vast majority of cases the 
second follow-up visit did coincide with the patient’s routine clinical follow-up. 
7.2.2 Outcomes related to trial conduct 
7.2.2.1 Reasons for failure to reveal allocation 
The times that allocations were revealed were cross referenced with the start and finish times 
of surgery. As mentioned in section 5.12.2.1, the eCRF highlighted patients who had their al-
location revealed outside this time window. Only one patient had their allocation revealed be-
fore the start of surgery. This was due to the recruiting surgeon misunderstanding the protocol. 
A Corrective & Preventative Action (CAPA) was undertaken (see Appendix E.1 CAPA number 
1). 
The summary of surgical characteristics by treatment arm presented in Table 12 shows that 
the allocation was revealed a median of two hours after the start of surgery. The lower limit of 
the IQRs for either arm was not below one hour suggesting good compliance with this aspect 
of the protocol. Figure 24 shows a histogram of the time to revealing allocations measured in 
hours.  As observed, there is a single patient with negative time which relates to the protocol 
deviation described in E.1 CAPA number 1. 
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Figure 24 Histogram of length of time between start of surgery and reveal time 
 
On a separate occasion LCTU IT staff were uncontactable within normal working hours to re-
solve an issue with revealing the allocation during surgery. The recruiting surgeon was unable 
to remember their password and reveal the allocation. This resulted in prolonging the patient’s 
surgery. Because the issue could not be resolved in a timely fashion, the patient was empirically 
placed in the control arm. Coincidentally the patient had also been randomised to the control 
arm. A second CAPA was undertaken (see Appendix E.2 CAPA number 2).  
7.2.2.2 Protocol adherence 
All randomised patients underwent their allocated treatment. Only two CAPAs were undertaken 
throughout the entire study period (see E.1 and E.2). They can be summarised as follows: 
1. A surgeon revealed the allocation prior to the start of surgery 
Time to Reveal
Time (Hours)
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2. A surgeon documented the use of FS in the operation note thereby unblinding the 
outcome assessors. 
3. Trials unit IT staff were uncontactable within normal working hours to resolve an issue 
with revealing the allocation during surgery. This resulted in prolonging the patient’s 
surgery. 
The PI from QVH provided the following feedback on their experience of the DEFeND REPT 
protocol:  
It was thought that the trial was labour intensive  
RN support was limited and was not available throughout the entire working week. This issue 
made completion of eCRFs in real time (for drain volume and removal) particularly difficult. Out 
of hours research duties required surgical trainee involvement. The trainees were not always 
familiar with the study and some were not motivated to engage. 
 
Issues with clinician engagement.  
The trial required the PI to be constantly aware of potentially eligible patients and drive recruit-
ment through his presence in the department. Surgical colleagues were not proactive recruiters 
and potentially eligible patients were lost if the PI was absent. As mentioned previously, some 
surgeons were not happy to place only one drain in the wound and did not recruit to the trial. 
Trainee engagement may have been related to issues with accessing trial software to complete 
the eCRF. Trial recruitment is also not currently a SAC requirement to progress in training. Not 
every clinician had a valid GCP certificate at the start of the trial.  
 
Adherence to protocol.  
Adherence to the protocol was good. There was good use of the trial protocol videos and flow 
charts. The PI played the videos regularly to theatre staff and surgeons to ensure adherence 
to the protocol. The PI suggests a quality assurance step to assess staff on their familiarity with 
the protocol would be beneficial.  
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The experience from AUH was more positive. RN support and clinician engagement was good, 
and the trial was delivered ahead of time and target.  
7.2.2.3 Accuracy of data recording 
The quality of the study data was assessed as the number of missing data points and possible 
outliers as well as any protocol deviations and issues with allocation concealment that were 
observed. 
Missing Data 
The distribution of missing data between treatment arms is shown in Table 15. Overall, there 
is an even distribution. PT and aPTT blood tests that measure the patient’s clotting was missing 
in 33% and 35% of patients respectively. Table 16 demonstrates that QVH had a relatively 
higher rate of missing data, particularly in recording pre-operative blood tests. The relatively 
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 Total 26 25 2 53 
Hb 3 (12%) 2 (8%) 0 (0%) 5 (10%) 
Platelets 3 (12%) 2 (8%) 0 (0%) 5 (10%) 
White cells 3 (12%) 3 (12%) 0 (0%) 6 (12%) 
PT 9 (35%) 8 (32%) 1 (50%) 17 (33%) 
aPTT 10 (38%) 8 (32%) 1 (50%) 18 (35%) 
 Total 25 23  48 
Drain Drain volume 0 (0%) 1 (4%) - 1 (2%) 







0 (0%) 1 (4%) - 1 (2%) 
Blood Loss 0 (0%) 1 (4%) - 1 (2%) 
Length of Sur-
gery 
2 (8%) 3 (13%) - 5 (10%) 
Time to Reveal 0 (0%) 2 (9%) - 2 (4%) 
 Time to  
Recovery Room 
2 (8%) 2 (9%) - 4 (8%) 
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Table 16 Summary of missing data by site 
 

















 Total 7 46 53 
Hb 2 (29%) 3 (7%) 5 (10%) 
Platelets 2 (29%) 3 (7%) 5 (10%) 
White cells 3 (43%) 3 (7%) 6 (12%) 
PT 7 (100%) 11 (24%) 18 (33%) 
aPTT 7 (100%) 12 (26%) 19 (35%) 
 Total 6 42 48 
Drain Drain volume 0 (0%) 1 (2%) 1 (2%) 







0 (0%) 1 (2%) 1 (2%) 
Blood Loss 0 (0%) 1 (2%) 1 (2%) 
Length of Sur-
gery 
1 (17%) 4 (10%) 5 (10%) 
Time to Reveal 0 (0%) 2 (5%) 2 (4%) 
 
Possible Outliers 
The summary of possible outliers presented in Table 17 demonstrates there was good balance 
of outliers between treatment arms with the majority categorised as ‘mild’. The main difference 
of note is that the two ‘severe’ outliers for blood loss were both in the ‘FS’ arm. Because in-
creased intra-operative blood loss if often associated with difficult or complicated surgery, this 
favours the ‘No FS’ arm.  This will be somewhat neutralised by the fact that there were four 
‘mild’ outliers for blood loss in the ‘No FS’ arm compared to two in the ‘FS’ arm.  
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Table 17 Summary of possible outliers by treatment arm 
 





  Total 		 25 23 48 











Mild 2 (8%) 4 (17%) 6 (13%) 
Severe 2 (8%) 0 (0%) 2 (4%) 
Length of 
Surgery 
Mild 0 (0%) 1 (4%) 1 (2%) 
Severe 1 (4%) 0 (0%) 1 (2%) 
Time to Re-
veal 
Mild 0 (0%) 1 (4%) 1 (2%) 
Severe 0 (0%) 1 (4%) 1 (2%) 
 
7.2.3 Fidelity of the blinding process 
The Bang Blinding Index (BBI) (173) for allocation concealment was performed by asking pa-
tients, research nurses and surgeons to predict which treatment arm patients were allocated 
to. 
7.2.3.1 Fidelity of blinding patients 
The responses patients gave when asked to guess their treatment allocation is provided in 
Table 18. Whilst 15/24 patients managed to correctly predict they received FS, 10/21 patients 
in the ‘No FS’ arm incorrectly thought they received FS. Overall, there was a tendency for 
patients to believe they received the intervention (whether they truly did or not). The BI and 
associated 95% CI for the FS arm indicates a tendency towards unblinding. The BI and asso-
ciated 95% CI for the ‘No FS’ arm indicates a tendency towards ‘negative guessing’. Overall, 
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believe they did 
NOT receive  
Fibrin sealant 
Strongly believe 




Fibrin Sealant 10 5 2 2 5 
No Fibrin Sealant 6 4 0 2 9 
 
 
Bang index of FS arm: 0.43 (V = 0.02, 95% CI 0.29 – 0.57) 
Bang index of No FS arm: -0.36 (V = 0.02, 95% CI 0.22 – 0.50) 
(V = variance estimate, CI = confidence interval) 
 
7.2.3.2 Fidelity of blinding Research Nurses 
The responses RNs gave when asked to guess the patient’s treatment allocation is provided 
in Table 19.  Whilst RNs managed to correctly predict the patient received FS in 19/24 occa-
sions, they also incorrectly thought the patient received the FS on 16/21 occasions. Overall, 
there is a tendency for RNs to believe the patients received the intervention (whether they truly 
did or not). The BI and associated 95% CI for the FS arm indicates a tendency towards un-
blinding. The BI and associated 95% CI for the ‘No FS’ arm indicates a tendency towards neg-
ative guessing. Again, there is an overall tendency towards the ‘wishful thinking’ phenomenon 
which suggests blinding has been effective. 
 










believe they did 
NOT receive  
Fibrin sealant 
Strongly believe 




Fibrin Sealant 7 12 4 0 1 
No Fibrin Sealant 5 11 5 0 0 
 
 
  200 
 
Bang index FS arm: 0.47 (V = 0.01, 95% CI = 0.37 – 0.57) 
Bang index No FS arm: -0.38 (V = 0.02, 95% CI = -0.52 – -0.24) 
(V = variance estimate, CI = confidence interval) 
 
7.2.3.3 Fidelity of blinding surgeons 
The responses surgeons gave when asked to guess the patient’s treatment allocation is pro-
vided in Table 20. Most surgeons reported not knowing what treatment patients received and 
did not attempt a random guess. The BI and associated 95% CI for the FS arm indicates a 
tendency towards unblinding. The BI and associated 95% CI for the ‘No FS’ arm indicates 
successful blinding.  
 










believe they did 
NOT receive  
Fibrin sealant 
Strongly believe 




Fibrin Sealant 2 2 1 0 19 
No Fibrin Sealant 0 2 1 1 15 
 
 
Bang index FS arm: 0.22 (V = 0.01, 95% CI = 0.12 – 0.32) 
Bang index No FS arm: -0.03 (V = 0.02, 95% CI = -0.17 – 0.11) 
(V = variance estimate, CI = confidence interval) 
7.2.4 Determining the minimal clinically important differenc  
The participant responses regarding clinical endpoints and MCID were summarised in the End 
of Trial eCRF by investigators. Responses from 42 patients (no response recorded for six pa-
tients) are shown in Table 21. These responses have been unmodified from the way the 
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investigator recorded them. Table 21 also demonstrates the assignment of codes for each re-
sponse and the overarching theme(s). The visual mapping used to explore the relationship 
between codes and themes is shown in Figure 25. 
7.2.4.1 Assignment of codes 
An explanation and context for each code is provided below. The term ‘response’ is used to 
describe all the words entered within the eCRF. The term ‘comment’ is used to describe parts 
of the ‘response’ that are relevant to the research question.  
• “Reducing length of stay”. This was the most frequently applied code and demon-
strated that many patients considered timely discharge an important priority. The code 
was assigned to comments made in different contexts. This included: comments that 
conveyed a wish to minimise the consumption of finite resources; comments that de-
scribed a dislike for hospital environments; comments that conveyed a wish to heal 
and recover quickly. This demonstrated that participants recognised a health economic 
benefit to their improved recovery and timely discharge.  
• “Speed of healing”. This was a frequently assigned code that was applied to com-
ments that conveyed the importance of quick wound healing. This code was often as-
sociated with responses that also included codes for “quicker recovery”, “less compli-
cations” and “reducing length of stay”. The code was often associated with responses 
that conveyed a patient’s wish to get back to normal as quickly as possible after sur-
gery.     
• “Less complications”. This code was assigned to comments that were made in dif-
ferent contexts (similar to “reducing length of stay”). This included: comments that con-
veyed a wish to optimise wound healing through the avoidance of complications; com-
ments that conveyed a wish to reduce the consumption of hospital resources through 
the avoidance of complications. This suggests that many participants recognised that 
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complications were not only associated with poor healing but also associated with an 
increased drain on finite resources. 
• “Better healing”. This code was applied to comments that prioritised wound healing 
in a broader sense and focused on the quality (rather than speed) of wound healing. It 
was associated with responses that also included codes for “less complications”, 
“quicker recovery” and “reduction of pain”.  
• “Quicker recovery”. This code was applied to comments that viewed healing in a 
more holistic manner. This included comments that considered energy levels, physical 
function and psychosocial well-being. Conversely, “speed of healing” was associated 
with comments that focused specifically on healing of the surgical site.  
• “Reduction in pain”. This was a relatively infrequently applied code that was associ-
ated with responses that also contained codes for “better healing”, “less complications” 
and “easier to manage wound”. It appears to reflect a belief that a wound that is less 
painful is also less likely to be associated with complications or impaired healing.  
• “Reducing hospital costs”. This code was applied to comments where the patient 
recognised that their care incurred a financial cost to the NHS, and they considered 
reducing this cost a priority. This code was associated with responses that also con-
tained codes for “less complications”, “reducing length of stay” and “need for less med-
ication”. This suggests that some patients wished to reduce the financial cost of their 
care so that more finances were available for other healthcare users.   
• “Easier to manage wound”. This code was only applied once and was associated 
with a response that also included a code for “reduction in pain”. 
• “Need for less medication”. This code was used only once and associated with a 
response that also included a code for “reducing hospital costs”. 
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7.2.4.2 Development of themes 
Through the analysis of codes and patient responses two dominant overarching themes were 
developed. 
• Improved wound healing and recovery from surgery. An overarching theme that 
described the patient’s priority to undergo surgery with as little impact on their physical 
function and day-to-day life as possible. Patients wanted their wounds to heal as 
quickly and as painlessly as possible without complications. Some patients recognised 
that their improved wound healing would also have health economic benefits through 
the consumption of less resources.   
• Less use of hospital resources. An overarching theme that described the patient’s 
priority to not utilise excessive hospital resources. This sentiment sometimes origi-
nated from an altruistic sense of not burdening the NHS and thinking about the impact 
of their own care on other healthcare users. However, for some patients this sentiment 
originated from a dislike of hospital environments and wanting to get home as soon as 
possible. Many patients recognized a connection between improved wound healing 
and the consumption of less resources. Consideration was given to whether “less use 
of hospital resources” was in fact a sub-theme of “improved wound healing and recov-
ery from surgery”. However, the sub-optimal qualitative methodology and brevity of 
recorded patient responses meant that this could not be explored further. Many re-
sponses were assigned a single code for “reducing length of stay” and the context in 
which these responses were made was unknown.  
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Table 21 Raw data demonstrating the thematic analysis of patient responses to the MCID question. The table also demonstrates how comments were as-
signed codes that were developed into two central themes. (MCID = Minimal Clinically Important Difference). 
Response Codes Themes 
No infection, shorter stay in hospital, no bleeding or 
seepage from the wound 
Less complications; reducing length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources 
Speed of healing is an important priority as well as ex-
periencing less pain. Reduction in healing time by 50% 
Speed of healing; reduction in pain Improved wound healing and recovery from surgery 
Being in hospital the least amount of time. That would 
save on hospital fee and staffing etc 
Reducing length of stay; reducing hospital costs Less use of hospital resources 
Speed of recovery and quicker healing. Quicker heal-
ing of scar and wound 
Speed of healing; quicker recovery Improved wound healing and recovery from surgery 
Reduction of hospital stay by at least 1 day Reducing length of stay Less use of hospital resources 
Length of stay. As retied T&O surgeon patient feels 
that if glue reduces cost then beneficial 
Reducing length of stay; reducing hospital costs Less use of hospital resources 
Priority was less time in hospital and quick discharge. 
If reduces LOS by one day it would be worthwhile 
Reducing length of stay Less use of hospital resources 
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Response Codes Themes 
Speed of healing. If it makes a difference the speed of 
healing is probably the most important 
Speed of healing Improved wound healing and recovery from surgery  
Saves money. Reducing length of stay by 1 day. Going 
back to normality quicker. Getting out and about and 
having energy to go for a walk. 
Reducing hospital costs; reducing length of stay; 
Quicker recovery 
Less use of hospital resources 
Improved wound healing and recovery from surgery 
Better healing, less infection Better healing; less complications Improved wound healing and recovery from surgery  
Speed of healing, quicker discharge. Scar settled well. 
If wound heals 2-3 days quicker that would be signifi-
cant. Coming out of hospital sooner is also important 
Speed of healing; reducing length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources 
Hate being in hospital. Reduce hospital stay even if 
only one day 
Reducing length of stay Less use of hospital resources 
Faster overall healing – I would like overall healing in 
3-4 weeks 
Speed of healing Improved wound healing and recovery from surgery  
Scar healing and help recovery Better healing; quicker recovery Improved wound healing and recovery from surgery 
Cause less pain and easier to remove staples Reduction in pain; easier to manage wound Improved wound healing and recovery from surgery  
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Response Codes Themes 
Reduction in pain and infection through improved heal-
ing 
Better healing; less complications; reduction in pain Improved wound healing and recovery from surgery  
Reduction in length of stay- discharge day after surgery Reduced length of stay Less use of hospital resources 
Less time in hospital the better- I would want this to re-
duce LOS by at least 1 day 
Reduced length of stay Less use of hospital resources 
Wound healing leading to hospital stay reduction by at 
least one day 
Speed of healing; Reduced length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources 
Reduction in hospital stay and saving money for the 
hospital and benefitting patients. I would like this to be 
that you are discharged at least the day after surgery. 
Reduced length of stay; reducing hospital costs Less use of hospital resources 
Early discharge – the day after surgery Reduced length of stay Less use of hospital resources 
Surgical assistance leading to effective wound healing 
and subsequent reduction in LOS. I would want that to 
be the same as my hospital stay- 2days 
Better wound healing; easier to manage wound; re-
duced length of stay 
Improved wound healing and recovery from surgery 
Less use of hospital resources 
Home one day earlier Reduced length of stay Less use of hospital resources 
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Response Codes Themes 
Recovery period as short as possible, quick healing. 
Back to normal as soon as possible 
Speed of healing; quicker recovery Improved wound healing and recovery from surgery 
Reduction in complications, pain and hospital stay Less complications; reduction in pain, reduced length 
of stay 
Improved wound healing and recovery from surgery 
Less use of hospital resources 
Improvement in speedy recovery – early discharge by 
at least 1 day 
Quicker recovery; reduced length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources 
Successful healing, obviously no infection and quicker 
discharge by as much as is practical 
Better healing; less complications; reduced length of 
stay 
Improved wound healing and recovery from surgery 
Less use of hospital resources 
Less time in hospital Reduced length of stay Less use of hospital resources 
Reduction in aftereffects; improved healing for patients 
and therefore saving the hospital money with earlier 
discharge 
Better healing; less complications; reducing hospital 
costs; reduced length of stay 
Improved wound healing and recovery from surgery 
Less use of hospital resources 
Preventing infection Less complications Improved wound healing and recovery from surgery 
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Response Codes Themes 
Substantial benefits over traditional ways- with signifi-
cant quicker healing of the wound with faster discharge 
and less returns to hospital with wound issues 
Speed of healing; less complications; reduced length of 
stay; reducing hospital costs 
Improved wound healing and recovery from surgery 
Less use of hospital resources 
Reduces inpatient time by at least one night, reduces 
re-admissions for wound problems and speeds up the 
healing process to avoid infection 
Reduced length of stay; less complications; speed of 
healing 
Less use of hospital resources  
Improved wound healing and recovery from surgery 
Reduction in pain and speedy healing effects would 
make it a worthwhile expense 
Reduction in pain; speed of healing  Improved wound healing and recovery from surgery 
Reducing aftercare – time spent in hospital and healing 
potential to be maximised 
Reduced length of stay; reducing hospital costs, better 
healing 
Improved wound healing and recovery from surgery 
Less use of hospital resources  
Faster recovery- eating and drinking sooner. Earlier 
discharge – hospital stay at least halved 
Quicker recovery; reduced length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources  
Speedier recovery and quicker discharge from hospital-
not really able to quantify how much quicker 
Quicker recovery; reduced length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources  
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Response Codes Themes 
Faster recovery- less time spent in hospital. Less medi-
cation – more money saved by the hospital 
Quicker recovery; reduced length of stay; reducing 
hospital costs; need for less medication 
Improved wound healing and recovery from surgery 
Less use of hospital resources  
Earlier discharge from hospital Reduced length of stay Less use of hospital resources  
Quicker turnaround for healing process – less resources 
used from the hospital 
Speed of healing; reducing hospital costs Improved wound healing and recovery from surgery 
Less use of hospital resources  
I want to see a good healing process with less swelling. 
No complications to reduce hospital resources and 
length of stay 
Better healing; less complications; reducing hospital 
costs; reduced length of stay 
Improved wound healing and recovery from surgery 
Less use of hospital resources  
 
Improvement in post-operative condition, general well-
being leading to an earlier discharge 
Better healing; quicker recovery; reduced length of stay Improved wound healing and recovery from surgery 
Less use of hospital resources  
Heal up as quickly as possible Speed of healing Improved wound healing and recovery from surgery 
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Figure 25 Visual mapping was used to explore the relationship between codes and themes. The 
themes are in larger boxes corresponding to the colour of their codes. Codes in blue boxes relate 
to the “improved wound healing and recovery from surgery” theme. Codes in green boxes relate 
tot he “less use of hospital resources” theme. Codes in purple boxes are translational codes that 
relate to both themes. 
 
The visual mapping in Figure 25 shows a complex interconnected framework that attempts to 
describe how patients responded to the research question. Even though the two dominant 
themes were not directly connected to one another, they were connected indirectly through the 
transitional codes “less complications” and “reducing length of stay” (purple boxes). This im-
plies that many patients recognised that complications were not only associated with poor heal-
ing but also associated with increased length of stay. They also recognised that there was a 
health economic benefit to their improved healing and timely discharge. 
 
The most frequently applied code was “reducing length of stay” and in many cases was the 
only code applied to a response. This means that many patients considered timely discharge 
an important priority. However, the use of a poorly conceived qualitative methodology meant 
the context in which several responses were made is unknown. Without exploring the context, 
it is unclear whether patients considered it a priority from a health economic, avoidance of 
hospital environments or improved healing perspective. 
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7.2.5 Relevance of learning curve 
Surgeons were classified as being either ‘experienced’ or ‘inexperienced’ in using FS in ND 
according to the criteria discussed in section 5.12.5.2. The performance proxies used to inves-
tigate the presence of a learning effect were surgical complications using the CCI and drainage 
volume (ml). To account for the theory that the anatomy of level I is less conducive to the 
adhesive effects of FS (as described in section 5.12.5.2), a comparison between NDs involving 
level I and NDs not involving level I was also made. 
The mean CCI by surgeon experience is demonstrated in Table 22. The mean rather than the 
median CCI was chosen because many patients who did not suffered any complication had a 
CCI of 0. In most circumstances the median CCI was 0 and therefore not a useful discriminator. 
This table demonstrates that FS reduced the mean CCI when used by experienced surgeons. 
However, the mean CCI in the FS arm was comparable to the No FS arm when FS was used 
by inexperienced surgeons. Equally, in the No FS arm the difference between inexperienced 
and experienced surgeon was comparable.   
 
Table 22 Mean Comprehensive Complication Index (CCI) by treatment arm and surgeon expe-
rience 




Fibrin Sealant 10.7 4.5 
No Fibrin Sealant 8.8 10.9 
 
The CCI by dissection level is demonstrated in Table 23. This table demonstrates that when 
FS was used in NDs that included level I, it was associated with an increase in mean CCI. 
However, when FS was used in NDs that did not include level I, it was associated with a 
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decrease in mean CCI. In the No FS arm the difference between a ND including level I and not 
including level I was comparable. 
 
Table 23 Mean Comprehensive Complication Index (CCI) by treatment arm and inclusion of Le-
vel 1 in neck dissection. 
Treatment Arm Not Level I Level I 
Fibrin Sealant 2.6 22.4 
No Fibrin Sealant 11.2 7.0 
 
In the FS arm there was a notable difference in mean CCI between experienced and inexperi-
enced surgeons. The presence of a learning effect may be one explanation for this difference. 
However, there was also a notable difference in the FS arm between NDs including level I and 
not including level I. Out of the 19 NDs performed by inexperienced surgeons, 10 included level 
I. Out of the 29 NDs performed by experienced surgeons, only 2 included level I. Because 
inexperienced surgeons performed more NDs that included level I, it is not clear whether the 
increased mean CCI was associated with a learning effect or the type of ND. 
The median total drain volume (ml) by surgeon experience is demonstrated in Table 24. This 
table demonstrates that when experienced surgeons used FS the median total drain volume 
between treatment arms was comparable. However, when the FS was used by inexperienced 
surgeons the drain volume was higher in the FS arm.  
 






Fibrin Sealant 189.5 60 
No Fibrin Sealant 88.5 67 
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The median total drain volume (ml) by dissection level is demonstrated in Table 25. This table 
demonstrates that in the FS arm dissection of level I was associated with a higher median drain 
volume. However, in the No FS arm the median drain volumes were the same. It also demon-
strates that when level I was dissected, the use of FS was associated with a higher median 
drain volume.  
 
Table 25 Mean total drainage volume (ml) by treatment arm and inclusion of Level 1 in neck dis-
section 
Treatment Arm Not Level I Level I 
Fibrin Sealant 67 108.5 
No Fibrin Sealant 79 79 
 
7.2.6 Safety 
No SAEs or SUSARs were reported during the study. No patients needed to be unblinded.  
7.3 Clinical Outcomes 
7.3.1 Clavien-Dindo classification of surgical complications 
Details of complications according to number and severity for each treatment arm is provided 
in Table 26. In total, 16 (33.3%) patients experienced at least one event. Overall, there were 
more complications in the ‘No FS’ arm (14 complications in ‘No FS’ arm 10 complications in 
‘FS’ arm). The numbers of neck SSI, wound breakdown and seroma were similar across both 
arms. There were more haematomas that required a return to theatre in the ‘No FS’ arm. ‘Other 
Complications’ in the ‘FS’ arm included a patient who bled from their oropharynx resection site 
that returned to theatre for haemostasis (grade IIIB) and a patient who pulled their drain out too 
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early (grade I) with no other sequelae. The oropharynx bleed was not directly related to the use 
of FS in the ND wound. Pulling the drain out too early is not a complication in the true sense 
but was reported as such by investigators at site. In the ‘No FS’ arm ‘Other Complications’ 
included: a patient who suffered a transient ischaemic attack (TIA) and started on antiplatelet 
therapy (grade II); a patient who suffered ‘Horner’s Syndrome’ secondary to ND but did not 
require any treatment (grade I); a patient who had leakage of serous fluid from their drain site 
(after the drain was removed) but did not require any treatment (grade I). 
 
Table 26 Description of complications and Clavien-Dindo grade by treatment arm 
Complication 
Fibrin Sealant No Fibrin Sealant 
Number Grade Number Grade 
Neck SSI 1 IIIA 1 II 
Other SSI 0  2 II, II 
Neck Haematoma 1 IIIB 3 IIIB, IIIB, IIIB 
Wound Breakdown 1 I 1 I 
Seroma 4 I, I, IIIA, IIIA 3 I, I, IIIA 
Chest Infection 1 II 1 II 
Other Complications 2 I, IIIB 3 I, I, II 
Total 10  14  
 
A description of the distribution of complications according to treatment arm and Clavien-Dindo 
grade is rovided in Figure 26. It shows that there are more complications in the ‘No FS’ arm 
for every grade apart from IIIA. From this data it appears as though FS was not protective 
against seroma formation. 
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Figure 26 Bar chart describing distribution of complications by Clavien-Dindo grade and treat-
ment arm 
 
The 24 complications reported in this study were distributed between 16 patients indicating that 
some patients experienced more than one complication. The CCI uses an algorithm to calcu-
late a patient’s overall morbidity using the Clavien-Dindo grade and provides a score between 
0 – 100. The algorithm takes account of patients who experience multiple complications and 
increases their score accordingly.  Table 27 demonstrates the mean and median CCI score 
for each arm. The ‘FS’ arm had a lower mean CCI score than the ‘No FS’ arm. Whilst the 
median CCI was 0 for both arms, the upper limit of the IQR was higher in the ‘No FS’ arm. 
These values in combination with the descriptive data in Table 26 and Figure 26 signal that 
FS may reduce the number and severity of complications. This was a REPT and not powered 
to detect a difference between treatment arms. Therefore unsurprisingly, the comparisons be-
tween treatment arms using the T-test and Chi-square test were not statistically significant.  
 
Because none of the complications reported were Clavien-Dindo grade IV or above no SAEs 
were reported. No patient suffered a severe hypersensitivity reaction, air embolism or new 







Grade  I Grade II Grade IIIA Grade IIIB Grade IV Grade V
No FS 5 5 1 3 0 0
FS 4 1 3 2 0 0
Grade of Clavien-Dindo per Treatment Arm
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diagnosis of a blood borne infection. Therefore, no patients needed to be unblinded through 
the course of the trial.  
 
Table 27 Description of mean and median Comprehensive Complication Index (CCI) across 
treatment arms. 
 Fibrin Sealant No Fibrin Sealant Total P-value 
Mean (SD) 6.5 (12.8) 9.9 (14.2) 8.1 (13.5) 0.3875 (T-test) 
Median (IQR) 0 (0, 6.5) 0 (0, 20.9) 
 0.4481 (T-test) 
0.6917 (Chi-Square test) 
SD = standard deviation, IQR = interquartile range 
 
7.3.2 Total wound drainage volume 
The summary (median [IQR]) of drain volumes on the natural and square root scales are shown 
in Table 28.  The median total wound drainage was lower in the ‘FS’ arm. A comparison be-
tween treatment groups is performed using a T-test was not statistically significant (p=0.482). 
Again, this study was not designed or powered to detect a difference.  
 
Table 28 Total wound drainage volume (ml) by treatment arm. 
Outcome Fibrin Sealant No Fibrin Sealant 
Natural Scale 76 (35, 164) 82 (54, 161) 
Sqrt Scale 8.718 (5.916, 12.806) 9.055 (7.347, 12.68) 
T-test (sqrt scale)  T=-0.709 [P =0.482] 
Sqrt = square root 
 
Boxplots for total drain volume by treatment arm on a natural and square root scale are shown 
in Figure 27. They demonstrate that volumes were very similar. However, the IQR was wider 
for the ‘FS’ arm.  
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A B  
Figure 27 Boxplots showing the total drain volume (ml) by treatment arm measured on the natu-
ral (A) and square root (B) scale. 
7.3.3 Drain outcomes 
The median (IQR) values for ‘time to threshold’, ‘time to drain removal’ and ‘length of stay’ by 
treatment arm are shown in Table 29. Overall, there is signal that FS may reduce ‘time to drain 
removal’ and ‘length of stay’. P-values do not indicate a statistically significant difference how-
ever, as mentioned previously, this study was not designed or powered to detect a difference. 
 
Table 29 Median time to threshold, time to drain removal and length of stay (days) by treatment 
arm. 
Outcome Fibrin Sealant No Fibrin Sealant P-value 
Time to Threshold 2.637 (2.625, 3.625) 2.625 (2.62, 3.628) 0.642 
Time to Drain Removal 2.667 (2.417, 3.576) 3.399 (2.5, 4.266) 0.503 
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7.3.3.1 Time to threshold 
The drain was removed once the rate of drainage reached below the threshold of 1.25ml/hr as 
described in the drain removal algorithm in Figure 15. Table 29 demonstrates that the median 
(IQR) time in days it took to reach this threshold was approximately 2.6 days for both arms. 
7.3.3.2 Time to drain removal 
Patients in the ‘FS’ arm had a median (IQR) time to drain removal in days that was lower than 
patients in the ‘No FS’ arm (2.667 days in the FS arm and 3.399 days in the No FS arm). 
7.3.3.3 Length of stay 
Patients in the ‘FS’ arm had a median (IQR) length of stay in days that was slightly lower than 
patients in the ‘No FS’ arm (3.476 days in the FS arm and 3.735 days in the No FS arm).  
7.4 Patient Reported Outcomes 
7.4.1 Neck Dissection Impairment Index  
NDII values were collected on 53 patients at baseline and 48 patients at follow-up. Table 30 
summarises the median (IQR) NDII scores for baseline and follow-up by treatment arm. It 
shows that the baseline NDII was the same but patients in the ‘FS’ arm had a lower median 
NDII at follow-up. A lower score is associated with better function and HRQoL. 
 
Table 30 Median Neck Dissection Impairment Index (NDII) at baseline and follow-up by treat-
ment arm. 
 Fibrin Sealant No Fibrin Sealant 
Baseline  11 (10, 13) 11 (10, 12) 
Follow-Up 16.5 (13.75, 22.25) 20 (14, 22) 
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 Fibrin Sealant No Fibrin Sealant 
Difference 4.5 (0, 11.5) 7 (2, 11) 
7.4.2 Neck pain scale 
The median (IQR) pain VAS that was observed over the duration of the study by treatment arm 
is provided in Table 31. It shows that pain VAS was low for all patients and very similar across 
both treatment arms. 
 
Table 31 Median Neck Pain Scale at baseline and follow-up by treatment arm. 
 Fibrin Sealant No Fibrin Sealant Overall 
Baseline 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Follow-up 1 1 (0, 2) 1 (0, 3) 1 (0, 3) 
Follow-up 2 1 (0.75, 2) 1 (0, 2) 1 (0, 2) 
 
 
The mean pain VAS across treatment arms is provided in Figure 28. The blue line represents 
patients in the ‘FS’ arm and the red line represents patients in the ‘No FS’ arm. The figure 
shows that the pain VAS was slightly lower in the ‘No FS’ group but the standard error of the 
means (SEM) overlapped suggesting no significant difference.  
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Figure 28 Profile plot to show the change in Neck Pain Scale over the study duration by treat-
ment arm. Blue line represents interventional arm. Red line represents control arm. 
7.4.3 Wound Healing Questionnaire 
The median (IQR) of WHQ between treatment arms is provided in Table 32. Overall patients 
in the ‘FS’ arm had a lower WHQ score than patients in the ‘No FS’ arm. A lower median 
WHQ score is associated with a lower rate of SSI and corresponds well to the findings in Ta-
ble 26. As with previous clinical outcomes, the study was not powered to detect a difference 
and the p value is not significant.  
Table 32 Median Wound Healing Questionnaire (WHQ) score by treatment arm. 
Fibrin Sealant No Fibrin Sealant Total T test 




















Mean Pain VAS by treatment arm over time
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The WHQ has been validated in patients undergoing abdominal surgery but not in HNS.(149) 
It was felt important to include this instrument in the DEFeND REPT to understand how it can 
be applied to HNS trials. If the WHQ was successfully deployed, a strong argument could be 
made for the development of a similarly designed HNS specific instrument. 
The permission from colleagues at the University of Bristol to use the WHQ in DEFeND was 
dependent on providing them with anonymized and contemporaneous data on WHQ as well 
as the clinician diagnosed validation. As previously mentioned, there was no intention to use 
the small sample size of the DEFeND REPT to formal validate the WHQ in HNS. However, it 
was thought that the data being collected may provide some insight into how successfully the 
WHQ was deployed.  
The box plot for WHQ score according to a diagnosis of SSI is shown in Figure 29A. It demon-
strates that a higher WHQ was indeed associated with a diagnosis of SSI. The ROC curve 
which demonstrates an AUC of 0.95 is shown in Figure 29B. This indicates that the WHQ was 
a very good discriminator between HNS patients who had SSI and those that did not. A WHQ 
score of 5 was the most sensitive cut-off with a sensitivity of 1.0 and specificity of 0.76. A WHQ 
score of 14 was the most specific cut-off with a sensitivity of 0.75 and specificity of 1.0. These 
results correlated well with the Bluebelle validation study that produced an AUC of 0.91 and a 
cut-off between 6 – 8.(149)  
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Figure 29 A: Box plot demonstrating median Wound Healing Questionnaire (WHQ) score by cli-
nician diagnosis of SSI. B: Receiver Operating Characteristic curve demonstrating performance 











































  224 
Chapter 8.  DISCUSSION 
8.1 Summary of the Work 
8.1.1 Distribution of baseline and surgical characteristics 
The even distribution of variables across both treatment arms is supportive of effective an ran-
domization strategy, however, some differences between treatment arms were noted. Patients 
in the FS arm had better performance status (PS) and all patients who had modified radical 
NDs were in the ‘No FS’ arm. These findings suggest that patients in the FS arm tended to 
have an improved premorbid physiological state and/or that they received less extensive NDs. 
However, in contradiction to this, nodal yield was very similar across both treatment arms and 
patients in the ‘No FS’ arm had less intra-operative blood loss. Randomisation was only strati-
fied by site; therefore, differences would not be unexpected in a study with a small sample size. 
In summary, randomisation has been effective and if this strategy was employed in a larger 
definitive trial, it is expected that the differences would be inconsequential to the outcome. 
8.1.2 Recruitment & retention Outcomes 
8.1.2.1 Screening and recruitment 
The overall recruitment rate for the study was 5.3 patients/month (4.6 patients/month for AUH 
and 1.4 patients/month for QVH). The overall recruitment rate was higher than the predicted 
four patients/month. This prediction was based on 30% of 180 eligible patients being recruited 
over 12-months. The study saw a higher proportion of patients being recruited from a smaller 
pool of eligible patients. The net effect being that the recruitment target of 50 patients was 
reached two months ahead of schedule.  
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Whilst the overall profile of recruitment was a positive finding, there was considerable disparity 
between AUH and QVH. AUH outperformed QVH which was unable to achieve their target of 
two patients per month. A total of 22 potentially eligible patients underwent surgery at QVH 
during the study period but only nine were screened. To some extent this disparity was ex-
pected and was the reason why QVH was chosen as a site. As a pragmatic design is being 
proposed for the definitive trial, it was important to evaluate the performance of a non-academic 
centre. It was thought that AUH performed well because it has a strong track record of recruiting 
well to head and neck trials. The surgeons were therefore familiar with the research process 
and recruiting patients to trials. Furthermore, several surgeons were advocates of using FS in 
ND and keen to engage in the trial. This is evidenced by their publication of two retrospective 
studies on the subject. (101, 103) AUH is also endowed with a dedicated team of RNs who can 
harmonise the screening and recruitment process into daily practice. 
Conversely QVH faced several challenges and obstructions to explain why they may have 
struggled more with recruitment. Firstly, the green light process and trial opening took longer 
than expected because the Research & Development department had little experience of open-
ing trials and were naturally cautious. This resulted in a narrowed window for recruitment. As a 
result, a decision was taken to not open spoke sites (see sections 4.4.2 and 7.2.1.4 for further 
details). At the time It was felt that opening spoke sites would narrow their recruitment window 
even further and be detrimental to their overall ability to recruit enough patients. However, the 
decision to press on with recruitment may have hindered their ability to recruit efficiently. It was 
normal practice for QVH to invite patients to a clinic one week ahead of their surgery to obtain 
informed consent. It was felt that this appointment would provide an ideal opportunity to take 
informed consent for DEFeND also. However, by not opening spoke sites, patients were not 
approached and given the PIS before this appointment. Despite the REC waiving the need for 
a 24-hour cool-off period for taking consent (see section 5.6), the issue with spoke sites may 
have created an avoidable barrier to recruitment. After recruitment was completed, it was real-
ised that the trade-off between maximising the recruitment window and optimising recruitment 
efficiency by opening spoke sites was false. Opening spoke sites as a Patient Identification 
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Centres (PIC) was not considered. Opening spoke sites as PICs is far easier and less time 
consuming than opening them formally. This would have allowed patients to have been 
screened and given the PIS at spoke sites before they attended QVH. In retrospect this was 
an oversight and utilisation of PICs would have solved the issue previously described.  
QVH surgeons were unfamiliar with the research process. This unfamiliarity with discussing 
clinical trials with patients and conveying equipoise as well as the perception that involvement 
is onerous is a systemic issue with recruitment to surgical trials. (124) Two of the seven sur-
geons had fundamental issues with the trial protocol e.g. they were unhappy to change their 
practice and use one drain instead of two on trial patients. They cited medicolegal reasons as 
to why this was an insurmountable issue for them. Provided the protocol and GCP guidance is 
followed carefully, any medicolegal claims are very unlikely to attribute blame on the surgeon. 
Upon reflection this may have been a symptom of their unfamiliarity with the research process 
and a lack of necessary research infrastructure. If efforts are not made to integrate research 
with routine clinical practice, it will be labour intensive and inefficient.(219) Supporting the de-
velopment of a culture of research is fundamental to improving recruitment to clinical trials and 
RN support is a key element. The RNs at QVH worked on a part-time basis and did not provide 
complete cover across the working week. This meant that clinicians who were unfamiliar with 
the research process were required to actively engage in the research process. One of the 
most challenging aspects of the trial design that QVH reported was the need for real-time data 
entry into the eCRF. It is the role of the local CRN to support research activity at sites. Due to 
limited resources, it is up to sites to negotiate the type of support required. Ultimately if a site 
is motivated to recruit to portfolio trials, support from the local CRN should be forthcoming. 
In summary, overall recruitment and specifically recruitment at AUH exceeded expectations. 
QVH did not perform as well as AUH due to a combination of reasons. The lack of research 
culture and infrastructure is not unique to QVH and needs to be factored into any future prag-
matic trial design. The recruitment capabilities of QVH may have been inhibited by not using 
spoke sites as PICs. At the time of opening, investigators were not aware of PICs and a 
 
  227 
decision not to open spoke sites was made under false pretenses. As a result, QVH's true 
recruiting potential may not have been realised. Selection of a more research capable second 
site may have yielded better recruitment figures. However, this approach may not have pro-
vided the same insights in terms of potential barriers to recruitment in a definitive multi-centre 
trial.       
8.1.2.2 Reasons for failure to randomise 
Approximately 20% of patients declined to participate in the study and this value was consistent 
across both sites. Five potentially eligible patients were not randomised because of a failure to 
use spoke sites as PICs. However as already discussed, QVH failed to screen thirteen poten-
tially eligible patients who originated from spoke sites. Therefore, the true number of patients 
not randomised because of spoke sites is likely to be higher.   
A total of four patients were lost because the surgeon decided against recruiting the patient. 
These patients were all from AUH and most likely excluded due to the surgeon(s) lacking eq-
uipoise. This is surmised because all surgeons at AUH were supportive and contributed pa-
tients. Approximately half of these surgeons use FS in their normal practice. Therefore, if a 
surgeon declined to recruit an eligible patient, it is most likely due to strong convictions about 
the benefit of FS (both in favour and against).  
A total of three patients were lost because investigators felt that the patient’s social circum-
stances were such that they would hinder compliance with the trial. Whilst this may have been 
for genuine reasons and in the patient’s best interest, social issues were not an exclusion cri-
terion. Every eligible patient should have had the opportunity to decide upon their participation. 
Investigators not recruiting patients who met eligibility criteria for social reasons were inadvert-
ently allowing selection bias to enter the study. This behaviour would need to be addressed 
prior to a definitive trial through education. 
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8.1.2.3 Patients lost to follow-up  
Overall, loss to follow-up was not a significant issue and, where it did occur, was due to conflicts 
between clinical and trial related follow-up. A total of seven (13%) patients who were recruited 
did not make it to the second follow-up visit. However only three of these were successfully 
randomised and revealed. The others were withdrawn before surgery as they no longer met 
eligibility criteria. In all three cases the patient was not willing to attend their second follow-up 
visit because the 4 – 6 week window did not coincide with their clinic visit. PROMs like the 
WHQ can be used by patients to report trial outcomes without the need for specific follow-up 
visits. For example, they can be employed via smart phone apps or telephone interviews. Con-
sideration should be given to the development and validation of PROMs specific to HNS that 
address the priorities of patients and are suitable for remote completion by patients.  
 
8.1.3 Outcomes related to trial conduct 
8.1.3.1 Protocol adherence 
A series of electronic checks within the eCRF were in place to monitor compliance with the 
timing of the allocation reveal. Once the patient was randomised, the surgeon was sent an 
email containing a password protected link to reveal the allocation. The time and date of this 
reveal was cross referenced with the start and finish times of surgery. The principle being that 
the surgeon should only reveal the allocation towards the end of surgery when the FS is used. 
This was thought to minimise the risk of performance bias because the surgeon did not know 
the allocation whilst performing the ND. Overall, there was good compliance with this aspect 
of the protocol. The median (IQR) length of surgery across both treatment arms was 2.2 hrs 
(1.8 – 2.6 hrs) and the median time to allocation reveal was 2.1 hrs (1.6 – 2.5 hrs). The histo-
gram in Figure 24 shows that the protocol was breached for 1 patient where the surgeon re-
vealed the allocation 6 – 8 hrs before the start of surgery. The event was investigated by un-
dertaking a CAPA (see E.1 CAPA number 1). It was related to a misunderstanding of the 
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protocol early in the trial and was not repeated. In summary, allocation concealment until the 
point of wound closure was well adhered to and the electronic checks to monitor this were 
effective.  
On one occasion the surgeon forgot their password to reveal the allocation (see E.2 CAPA 
number 2). The PI was contacted and unable to resolve the situation. Only the LCTU IT de-
partment had access to the treatment codes and could reveal the allocation over the telephone. 
Unfortunately, they were uncontactable even though attempts were made during normal office 
hours. This was particularly problematic because the allocation reveal was time sensitive, the 
length of General Anaesthesia was prolonged and the theatre list delayed. At the time a deci-
sion was made to empirically place the patient in the ‘No FS’ arm. This event highlighted a 
significant issue that needs to be resolved before a larger multi-centre trial is commenced. In a 
larger study there will be more surgeons over more sites and the time of allocation reveal may 
not occur within office hours. Therefore, a strategy to overcome this issue locally without time 
delay needs to be devised. A potential solution is a ‘forgot password’ tab on the login page. 
This gives the surgeon the opportunity to resolve the situation at once and without seeking 
help. Installing a trial ‘hotline’ in the IT department that is manned during office hours adds 
another layer of security. Staff are unlikely to ignore phone calls if they know it is from a hotline 
that will only be used in an emergency. If these measures fail, then the PI must take the default 
position of allocating the patient to the ‘No FS’ arm. Every time these events occur, investiga-
tors should contact the trials unit so a root cause analysis can be instigated (CAPA). The in-
tention-to-treat principle would apply to the final analysis these cases. 
8.1.3.2 Accuracy of data recording 
Accuracy of data recording was broadly similar across both treatment arms and sites. As shown 
in Table 15 & Table 16, blood test results were the most frequent missing data items, especially 
clotting (PT, aPTT). The most likely reason for this being that these blood tests were not routine, 
and investigators were not willing to take extra blood samples for trial purposes. Blood results 
are not part of any analysis apart from the distribution of baseline characteristics. Given that 
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this REPT has shown that the randomisation strategy is effective, there is no requirement to 
collect these blood results in a future definitive trial. 
Data on the length of surgery was missing in five patients. This outcome requires theatre staff 
to enter the start and finish time of surgery into a paper CRF. The RNs later transcribe this 
information into the eCRF. It is likely that paper CRFs were not fully completed because theatre 
staff are busy and may have forgotten. This missing data was overlooked by the trial co-ordi-
nator who had responsibility for central data monitoring. Had the missing data been identified, 
RNs could have been instructed to check theatre records to complete data entry. The DEFeND 
REPT data monitoring plan (see A.8 Monitoring Plan) relied on central monitoring with triggered 
visits. A future definitive trial will have considerably more data and would benefit from additional 
scheduled monitoring visits. Furthermore, using email alerts sent to the Trial Co-ordinator (TC) 
and PI regarding incomplete data may improve the accuracy of data recording. 
8.1.4 Fidelity of blinding process 
Overall, there was a tendency for patients and RNs to think that the patient received the inter-
vention whether they truly did or not. This phenomenon is reflected in the BI for patients and 
RNs. The BI and associated 95% CI for the FS arm was above 0 indicating patients and RN 
were able to correctly guess the allocation more than random guessing. However, in the ‘No 
FS’ arm the BI and associated 95% CI was below 0 (i.e. negative) indicating a tendency for 
‘opposite guessing’ (i.e. incorrectly guessing the allocation more than random guessing). The 
observed pattern may be understood as 'wishful thinking' or 'lack of idea about control treat-
ment', both of which are frequently seen in blinded trials. In general, blinding is a qualitative 
and empirically unverifiable issue. The BI is a function of the proportions of correct and incorrect 
guesses and therefore serves as proxy measure. ‘Wishful thinking’ could reflect a situation 
where anything looking like treatment is perceived as the interventional arm (e.g. patients in 
both arms underwent ND). Alternatively, it may represent an underlying tendency for patients 
to wish to receive ‘better’ treatment. The latter implies that patients believed being in the 
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interventional arm was better than being in the control arm. This may be a manifestation of how 
surgeons explained the trial to patients or how patients interpreted the PIS. If surgeons were 
convinced of the benefit of FS, they may have conveyed this bias to patients. If the patient had 
a smooth post-operative course, then they may have naturally believed they received the FS. 
The PIS (see A.2) was critiqued by patients from the Aintree Head & Neck Research Forum 
prior use in the study and no comments were made regarding bias. However, the wording 
would need to be reviewed prior to a definitive trial. 
The behaviour witnessed in the choices made by RNs is more difficult to explain. Being familiar 
with the research process, they will know that the allocation was split equally between treat-
ment arms. Despite this knowledge the RNs thought that patients received the intervention in 
most cases. There was also a tendency to select the response prefixed with ‘somewhat believe’ 
indicating a non-committal response. It is likely that the RN would have documented the pa-
tient’s response before their own. Possible explanations for this behaviour may be a lack of 
equipoise or having an ‘agreeable’ personality trait. As with patients, bias towards the interven-
tional arm may have been conveyed through surgeons and/or the PIS. Also, RNs would have 
followed the patient through their surgical journey and may have developed rapport. The RNs 
may have chosen to agree with the patient because they did not wish to undermine the patient’s 
belief.  
Surgeons demonstrated a distinctly different behaviour pattern to patients and RNs. They re-
sponded with the answer “don’t know” rather than guessing in most cases. This is likely be-
cause they were familiar with the research process and were effectively blinded. The surgeon’s 
behaviour and the wishful thinking phenomenon are associated with effective blinding.   
8.1.5 Determining the minimal clinically important difference 
The main aim of this analysis was to ascertain whether ‘complications’ was a suitable patient 
centred primary outcome for DEFeND. Unfortunately, the findings did not identify ‘complica-
tions’ as a dominant theme within responses. Avoidance of complications was important to 
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several patients and, as described in section 7.2.4, was linked to both wound healing and health 
economic benefits. However, more patients conveyed a wish to have improved wound healing 
that went beyond avoiding complications and included a return to normal function as quickly as 
possible. Based on these findings, it was possible to conclude that ‘complications’ represented 
a patient centred and pragmatic outcome. However, it was not clear if ‘complications’ repre-
sented the best primary outcome for DEFeND. The two dominant themes developed in this 
analysis generate more questions regarding the best primary outcome than answers. This 
demonstrates a need for a more robust qualitative methodology to be applied in a separate 
study.  
In retrospect, expecting investigators to effectively explain the concept and relevance of MCID 
to patients was unrealistic. This is especially the case when investigators were untrained in 
qualitative interviewing and not given adequate time in busy clinics. Some patients did manage 
to convey relevant endpoints such as “a reduction in length of stay by one day”, “half the length 
of stay”, “wound healing 2-3 days quicker”, “reduction in healing time by 50%”. However, these 
responses were elicited from a small minority of patients and it was not possible to make any 
meaningful conclusions from them. Furthermore, because of the short comings of the method-
ology used in this analysis no inferences on MCID were made beyond the current sample of 
patients. 
In summary, the analysis was hindered by a poorly conceived methodology that did not provide 
enough detail regarding the context of many responses. Two dominant themes were identified 
(“improved wound healing and recovery from surgery” and “less use of hospital resources”) but 
further (separate) qualitative work is required to delve further into patient experiences and un-
derstand their priorities more fully. Whilst ‘complications’ and ‘length of stay’ were found to 
represent patient centred outcomes, it appeared that patients additionally prioritised the speed 
and quality of healing. Therefore, outcome measures like the Clavien-Dindo classification and 
‘time to discharge’ may not have gone far enough to elicit the full extent of patient priorities. 
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8.1.6 Relevance of learning curve 
It was not possible to use the findings of this REPT to quantify or even identify the presence of 
a learning effect associated with using FS in ND. This is because the sample size was too small 
and individual surgeons did not perform the intervention frequently enough to track their per-
formance or provide surgeon specific metrics. The data raised the possibility that the efficacy 
of FS may have been dependent on either surgeon experience, dissection of level I or a com-
bination of these factors. However, it was not clear which of these two factors was the most 
important. The findings of this REPT highlight a need to undertake further research to establish 
whether a learning effect exists prior to a definitive trial. This future research should include an 
estimation of the time required by each surgeon to overcome the learning effect. The data may 
be used to guide the decision on how to control for learning curve in the definitive trial i.e. 
implementing entry criteria for surgeons (credentialling) or adjusting for learning effect in the 
final analysis.  
It was previously argued that extrapolating the learning curve data taken from a small number 
of surgeons and applying it to the wider surgical community was adopting a “one-size-fits-all” 
approach to surgical learning. Due to individual differences in learning, if this data is used to 
set the parameters for credentialling surgeons it is possible that surgeons who meet the entry 
criteria will be at different stages in their learning curve. Ideally, surgeons should be permitted 
to participate in the trial once they have reached the asymptotic part of their learning curve 
regardless of the parameters set by analysing the data from a small number of surgeons. The 
alternative to this approach would be to use the Bayesian hierarchical model described by 
Cook(177) and adjust for learning effect in the final analysis. At first glance this approach ap-
pears to be the most pragmatic because it does not require credentialling. However, for it to be 
effective, Cook recommended that the definitive trial include at least ten different surgeons who 
perform the intervention at least ten times.(177) In essence this approach may also result in 
using the data from a small number of surgeons and extrapolating their learning curve on to 
others. Additionally, within a busy NHS surgical practice, the operating surgeon is not always 
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the named consultant. Ensuring ten surgeons perform the intervention at least ten times may 
be prohibitively difficult within the context of a multi-centre surgical trial. Indeed, it may be ar-
gued that taking measures to ensure that only certain surgeons operate on trial participants is 
a very explanatory design feature. Therefore, within the context of a pragmatic surgical trial 
there is no single ideal method of controlling for learning curve. This argument justifies the need 
for separate research into quantifying the possible learning effect of using FS in ND.  
The data presented on surgical learning curve has major implications on quality assurance in 
a future definitive trial. Credentialling of surgeons was not thought to be necessary prior to 
recruitment into the DEFeND REPT and the intervention was delivered entirely flexibly and 
without monitoring. When designing the trial, it was thought that this approach would move the 
trial more towards the pragmatic end of the continuum. The justification for not credentialling 
surgeons was based on the assertion that using FS in ND did not require the acquisition of new 
skills. If a surgeon was skilled enough to perform a ND it was presumed they would have the 
necessary skills to correctly administer FS. Although this study did not confirm the presence of 
a learning effect, there was enough difference in performance between the experienced and 
inexperienced surgeons to question this previously held presumption. Even though surgeons 
were not required to acquire new skills, they were required to familiarise themselves with the 
protocol and this would inevitably require a period of learning. Like most surgical techniques, 
the administration of FS in ND is technique sensitive and requires adherence to the manufac-
turer’s procedural steps. Because some surgeons were learning on trial participants, the clinical 
outcomes reported in this study are likely to be subject to type II error. This needs to be taken 
into consideration when using the clinical data to guide the appropriateness of a future definitive 
trial.  
It was argued that the role of standardisation and monitoring of the intervention was related to 
whether the per protocol analysis of a definitive trial would influence the uptake of FS in ND 
amongst the surgical audience if the ITT analysis is negative. As already discussed, the prag-
matic approach is to deliver the intervention flexibly and conduct an ITT analysis that 
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demonstrates ‘effectiveness’. Within a pragmatic trial design, the outcomes of the ITT analysis 
are the most important because the prognostic balance between arms afforded by randomisa-
tion is preserved. The per protocol analysis is an inherently biased interpretation of the results. 
Therefore, if the per-protocol analysis is going to be disregarded, what is the justification for 
the additional resources and cost associated with monitoring the fidelity of the intervention? 
Based on the results of the REPT, the counter argument to this is that if a trial is delivered with 
poor compliance to the fidelity of the intervention the results will be subject to type II error. In 
the interest of transparency, this information should be reported in the final publication. There-
fore, within the context of a pragmatic HNS trial the intervention should still be delivered flexibly 
but also monitored so that compliance can be accurately reported. As previously discussed in 
section XXX, the best way to monitor compliance in a future DEFeND trial would involve mobile 
video cameras filming both the preparation and administration of FS. This footage would be 
monitored centrally by sites sending either a secure online file or Secure Digital (SD) card to 
the CTU. In addition to monitoring the intervention the date and time on the screen would be 
cross-referenced with the patient’s unique identification number, allocation, start and finish 
times of the surgery.  
8.1.7 Clinical outcomes 
8.1.7.1 Clavien Dindo classification of surgical complications 
As already discussed in section 6.2.1.1, the Clavien-Dindo classification (Table 1) is a generic 
and widely used tool that meets the definition of a pragmatic outcome measure. The CCI is a 
more recent tool that is derived from the Clavien-Dindo classification and accounts for the in-
creased burden of multiple complications. Furthermore, the CCI converts the Clavien-Dindo 
classification, which is an ordinal outcome measure, into a continuous outcome measure. This 
quality makes it more useful in clinical trials because there is evidence that it is more sensitive 
at detecting differences in treatment effect and can reduce the required sample size.(210) The 
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authors of the CCI recommend using a MCID of 10 points as this corresponds to one grade of 
difference in the traditional Clavien-Dindo classification.(210) 
Because the Clavien-Dindo classification is a generic tool, grading is open to interpretation 
when applying it to specific HNS complications. For example, Monteiro et al found that there 
was imperfect inter-observer reliability in scenarios where patients underwent a surgical pro-
cedure that did not require returning to the operating theatre.(137) To avoid this issue within 
the context of DEFeND, the severity of common/established complications associated with ND 
were graded and provided to investigators as a guide to conform to the Clavien-Dindo classifi-
cation (see Appendix D.  Clavien-Dindo Classification of Surgical Complications Adapted to 
Common Head & Neck Complications). The table in Appendix D.  was included in the Protocol 
(See A.1) for investigators to use as a reference if they had doubts regarding appropriate grad-
ing of a complication. Furthermore, the complication form in the eCRF (see B.9) was designed 
to mirror the table in Appendix D.  by asking investigators to grade the complication based on 
a description rather than allowing them to freely insert a grade. It was thought that providing a 
description would help reduce inter-observer variability. Examples of where the Clavien-Dindo 
classification may be suboptimal for HNS include patients who develop a deep space neck 
infection after ND and undergo drainage and packing of the wound on the ward. This compli-
cation may either be classified as grade I or grade IIIA. The neck wound often needs to be 
packed repeatedly, this will be uncomfortable for the patient and prolong hospital admission. 
On this basis, the most appropriate grade is IIIA but some investigators may report it as grade 
1. Another example of where the Clavien-Dindo classification may not represent the signifi-
cance of the complication adequately is in the management of oro-cutaneous communications 
or fistulas between the upper aerodigestive tract and the ND skin incision. In patient who un-
dergo resection of a primary mucosal tumour and neck dissection, it is common for saliva and 
food debris to collect around the resection wound and leak into the neck. Under these circum-
stances a patient may be kept ‘nil by mouth’ and fed via a nasogastric tube until the leaking 
wound heals. This complication would be classified as a grade II. However, the patient’s expe-
rience of not being allowed to eat and a prolonged hospital admission does not seem 
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proportional to a grade II. This is in stark contrast to a patient who requires a course of oral 
antibiotics for a superficial wound infection that would also be grade II according to the Clavien-
Dindo classification. 
In terms of interobserver variability, the steps taken to minimise this issue were considered 
effective. Having a description of the grade for each of the most frequently anticipated compli-
cations within the eCRF worked well. Neither sites reported difficulties with interpretation or 
implementation. On reviewing the reported complications, all events were correctly graded by 
sites except for one. This exception was related to a site considering premature removal of a 
drain as a complication. 
The results from the DEFeND REPT suggest that FS did reduce the CCI. Whilst the effect size 
was small, the results of this study may have been subject to type II error due to a lack of 
credentialing and possible learning effect. This study was not powered to detect a difference 
however, the results were used to decide upon the need for a definitive trial. Given the concerns 
regarding type II error, the overall CCI results were considered in combination with the CCI 
results for ‘experienced’ surgeons shown in Table 22. These surgeons would have likely met 
any credentialling criteria and had stabilised in their learning curve. The results in Table 22 
suggest that the effect size was slightly larger when FS was used by ‘experienced’ surgeons, 
however, it was still less than the suggested MCID of 10 points. 
The data from the semi-structured interviews used to determine the MCID suggested that. 
whilst ‘complications’ represented a patient centred outcome, it appeared that patients addi-
tionally prioritised the speed and quality of healing. Therefore, outcome measures like the Cla-
vien-Dindo classification may not have gone far enough to elicit the full extent of patient priori-
ties. Using a generic tool like the CCI may compromise the definitive trial by not not accurately 
representing the health experiences of patients. Since the choice of outcome measure is critical 
to trial design, a suboptimal instrument will result in suboptimal answers to the research ques-
tion. These findings support the need for further qualitative work to delve further into patient 
experiences and understand their priorities more fully. 
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8.1.7.2 Drain outcomes 
 
This study demonstrated that the collection of drain volume and removal outcomes were labour 
intensive for QVH due to the requirement for real time data entry and the pressures this placed 
on research support. Furthermore, they did meet the definition of pragmatic outcomes. None 
of the recruited patients prioritised drain volume or drain removal as an important outcome 
when asked about their priorities in the semi-structured interviews used to determine MCID. 
LoS appeared to be a far more relevant, and therefore pragmatic outcome measure. However, 
LoS is an incredibly short-term outcome measure that does not capture the full impact the 
surgery has on a patient and is affected by non-surgical and social factors. For this reason, 
drain outcomes should be eliminated from the definitive trial and LoS should be an important 
secondary outcome. These changes will mean sites will no longer be required to enter data in 
real time or change the type or number drains they normally use. With drain outcomes being 
eliminated from a definitive trial design the eligibility criteria can extend to include bilateral NDs. 
Excluding drain outcomes will thereby make the trial design more pragmatic as previously dis-
cussed in section 5.5.2.2.   
8.1.8 Patient reported outcomes 
8.1.8.1 Neck Dissection Impairment Index 
The NDII is validated for use in patients undergoing the types of NDs that were performed in 
this study, however it is not validated for use so soon after surgery. NDII has been validated 
for use at a minimum of 11 months postoperatively, however in this study it was used after just 
4 – 6 weeks. This is because postoperative RT is known to influence the outcome of NDII.(147) 
It was thought that performing the NDII before the patient started postoperative RT would en-
able a less confounded evaluation of FS in ND. The results of the REPT suggest that the use 
of NDII in DEFeND was both acceptable to patients and feasible. Signal form the informal 
assessment suggests that FS may improve the NDII at 4 – 6 weeks. In keeping with a pragmatic 
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approach, NDII should be assessed after 11 months irrespective of the effects of postoperative 
RT.  
8.1.8.2 Neck pain scale 
The results of the neck pain scale suggest that collecting this data is both acceptable to patients 
and feasible. However, pain scores were low for both arms and there was no signal suggesting 
FS influences post-operative pain. For this reason, the inclusion of pain as an isolated outcome 
measure in the definitive trial is superfluous. The results do not preclude the use of pain out-
comes within a broader PROM specific to HNS.  
8.1.8.3 Wound Healing Questionnaire 
The WHQ has been validated for patients undergoing abdominal surgery and is designed to 
be used within the same time frame as it was used in this study. Results suggest that the WHQ 
was both acceptable and feasible for use in DEFeND. Informal analysis suggests that FS may 
reduce the WHQ score albeit not to a statistically significant level. Furthermore, the WHQ has 
potential to be a very good discriminator between HNS patients who have SSI and those who 
do not. Data from this study was comparable to the data published for the Bluebelle study in 
terms of sensitivity and specificity of diagnosing SSI.(149)  
In summary, the data suggest that instruments like the WHQ can be successfully deployed in 
HNS trials and, in keeping with the findings of the review in section 6.1, development of PROMs 
specific to HNS is an important priority. 
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8.2 Strengths & Limitations of this Work 
8.2.1 Site selection 
This study was set within two UK hospitals offering tertiary HNS services (AUH and QVH). The 
decision to select two centres was considered important because a future definitive trial with a 
pragmatic design would need to be multi-centre. Both institutions met the minimum requirement 
for participation outlined in section 5.4. As the lead site AUH had a strong research portfolio in 
HNC research. Four of the academic surgeons had experience as Chief Investigators (CI) and 
a dedicated team of HNC Research Nurses (RN) were on hand to optimise recruitment and 
trial conduct. This research background and infrastructure certainly contributed to the strong 
recruitment performance demonstrated by AUH in this study.  
QVH was selected because it was thought that it was representative of most non-academic 
centres across the UK. It had fewer RNs and considerably less experience in delivering RCTs. 
Understanding the experiences of QVH in delivering DEFeND REPT was thought to be key to 
the design of the future definitive trial. As previously mentioned in section 4.4, the decision to 
select QVH as a second site over other possible sites was based on the PhD candidate and CI 
having close links. As expected, QVH did not recruit as well as AUH. However, the degree to 
which they struggled was not anticipated. They failed to meet their target of recruiting two pa-
tients per month. Several reasons were identified as to why recruitment problems were en-
countered. Firstly, It was not recognised that spoke sites could be opened as PICs which meant 
that the full potential of recruitment at QVH may not have been realised. Secondly, two of the 
seven surgeons at QVH did not recruit because they were not willing to make changes to their 
practice for trial patients. This issue should have been identified earlier and, if possible, con-
sensus amongst surgeons reached. If more surgeons did not accept the protocol, a different 
site should have been considered. Ultimately, finding consensus amongst a body of surgeons 
can be very difficult and one has to accept that this may not be possible despite best efforts. 
The main issue was the requirement for a single drain when they would normally use two. This 
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issue will be eliminated in a definitive pragmatic trial because drain outcomes will not be meas-
ured and surgeons will be allowed to continue with their usual practice. Removing drain out-
comes will also address another issue that QVH faced in terms of real time data entry. QVH 
found recording trail outcomes in real time labour intensive because they did not have enough 
availability of investigators trained in recording data in the eCRF. 
Using QVH as the second site was valuable because it identified problems with the trial design 
not encountered by AUH. Within the context of a future multi-centre trial, selecting sites with 
good research infrastructure will undoubtedly benefit recruitment. However, within the field of 
HNS research, these sites a few and far between. In order to conduct multi-centre trials in HNS 
selecting sites that have relatively little experience is likely to be a necessity. Whilst the recruit-
ment figures from QVH may suggest that site selection was a weakness of this study, in fact 
from a PFS perspective, their selection was a strength. As a result of the experiences reported 
by QVH, the need for further pre-trial work and the need for significant changes to the trial 
design have been identified (see section 9.1).     
8.2.2 Pragmatic trial design 
The aim of the DEFeND REPT was to evaluate the feasibility of a pragmatic trial design and 
assess whether these design features worked well together. Through delivering the study and 
developing a greater understanding of pragmatic and explanatory trial designs, several mis-
conceptions in the trial design have been identified. Pragmatic clinical trials should focus on 
outcomes that are relevant to patients, healthcare professionals and decision makers. The 
most pragmatic outcomes are those that are of obvious importance to patients and measured 
in the same way they would be in usual care.(109) In this study investigators were asked to 
use a single drain, to use a specific drain that had a collection bag that could be emptied into 
a measuring cylinder, to enter drain volume data into the eCRF twice daily and in real-time, to 
allow a computer algorithm to decide when the drain should be removed. All these aspects of 
the protocol are very much on the explanatory end of the continuum. In a pragmatic trial, 
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investigators should be allowed to use however many drains of whichever type they usually do. 
Furthermore, assessments of drain volume and removal should also be in keeping with their 
normal practice. 
Using the PRECIS-2 tool(109), an assessment can be made of how pragmatic the original 
DEFeND REPT design was and compare it to an ideal definitive trial design (based on what 
has been learnt by undertaking this work).  
1. Eligibility criteria. In keeping with a pragmatic approach, inclusion criteria were broad 
and exclusion criteria were kept to a minimum. However, the exclusion of patients who 
required less than three levels dissected or required a bilateral ND would prevent the 
eligibility criteria from scoring maximum points in terms of pragmatism. As already dis-
cussed, a future definitive trial would stratify for the extent of surgery and include these 
patients. Participants were broadly representative of the patients that would receive 
the intervention in usual care, and they were not excluded on the basis of tests that 
are not applied in usual care. 
2. Recruitment. In keeping with a pragmatic approach, participants were recruited from 
a normal clinical environment with no overt recruitment effort. 52.5% of eligible patients 
were recruited and it is not clear whether this resulted in certain groups of patients 
being excluded. Therefore, it is not possible to be certain whether the recruited patients 
were truly representative of the patients in whom the intervention will be used in usual 
care. Unfortunately, this is a problem with all surgical trials as recruitment is never even 
close to 100%.(105, 113) Recruitment may have been improved by opening spoke 
sites as PICs to truly represent the normal clinical environment. The trial design per-
taining to recruitment was therefore not as pragmatic as it could have been.     
3. Setting. The selection of both an academic and non-academic site was a pragmatic 
design feature. Furthermore, these sites were located in very different parts of the 
country in terms of the demographic of the population (for example, a deprived urban 
population in the Northwest versus a relatively affluent semi-urban/rural population in 
the Southeast). Whilst only two sites were selected for the REPT, several more sites 
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would be selected for the definitive trial thereby mirroring the setting in which the results 
of the trial will be applied. 
4. Organisation. According to the authors of the PRECIS-2 tool, a pragmatic approach 
should mirror how care is organised and delivered in usual care and not make use of 
extra resources. Increasing staffing levels to deliver the intervention, providing signifi-
cant additional training, requiring investigators to have a minimum level of experience 
or certification all make the design more explanatory.(109) In the DEFeND REPT there 
was no requirement for extra staff, the only training provided was at the site initiation 
visit and through educational videos and surgeon credentialling was not required. On 
this basis the trial design was very pragmatic. However as previously discussed, sur-
gical interventions are often associated with a learning effect. Evaluating the interven-
tion without accommodating for the learning effect (e.g. through credentialling) will 
have significant implications on both quality assurance and the interpretation of results 
in terms of type II error. Therefore, a definitive DEFeND trial cannot and should not 
attempt to meet these requirements for a pragmatic design. A surgical trial can only be 
truly pragmatic in terms of organisation if the intervention is already widely used and it 
is no longer associated with a learning effect. Therefore, a truly pragmatic surgical RCT 
should only need to be conducted under fairly exceptional circumstances (e.g. widely 
adopted and established surgical intervention is compared to other widely adopted and 
and established interventions for the treatment of the same condition).  
5. Flexibility of delivery. According to the authors of the PRECIS-2 tool, a pragmatic 
approach would mirror how the intervention will be delivered in usual care and allow 
investigators the flexibility to deliver it as they see fit.  Having a highly specified proto-
col-driven intervention and having measures in place to monitor compliance of those 
delivering the intervention would make the trial more explanatory.(109) In the DEFeND 
REPT surgeons were permitted to perform the ND as they normally would. Clear in-
structions on how to store, prepare and administer FS were provided via the site initi-
ation visit, educational videos and laminated posters located within operating theatres. 
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However, surgeons could choose to ignore these instructions and deliver the interven-
tion however they wished without the central trials team knowing there has been a 
protocol violation because of the lack of monitoring. These design features made the 
DEFeND REPT very pragmatic. As previously discussed, within the context of a surgi-
cal or complex intervention, a pragmatic approach should permit flexibility of delivery 
but should also monitor the fidelity of the intervention so that compliance can be re-
ported in the final publication. Whilst the reporting of compliance will not change the 
outcome of the trial, it will facilitate transparent reporting of the results and enable 
readers to conclude for themselves whether the fidelity of the intervention was a factor 
in the trial outcome.  
6. Flexibility of adherence. Because FS was administered once during surgery, the par-
ticipant’s flexibility of adherence to the intervention was not a significant issue. Three 
patients were incorrectly excluded from the REPT by investigators because they felt 
that the patient would not comply with the trial protocol due to social reasons. However, 
this was an independent decision by investigators rather than a specific fault in the trail 
design. 
7. Follow-up. In keeping with a pragmatic approach, the DEFeND REPT tried to keep 
extra visits beyond those required in usual care to an absolute minimum. Two patients 
were lost to follow-up because the second follow-up visit did not coincide with their 
routine clinical appointments. The most pragmatic designs often avoid any follow-up 
altogether and collect data via other means e.g. electronic medical records. Collecting 
more extensive data than would be typical outside the trial and having longer follow-
up appointments all make the design more explanatory.(109) Measuring outcomes like 
return to theatre, length of stay, hospital readmission and mortality can be done without 
the need for patients to be specifically followed-up for the trial. However, as demon-
strated in the review of surgical COS, ‘humanistic’ outcomes play an important role in 
evaluating surgical interventions. Within the field of HNS very few ‘humanistic’ out-
comes are recorded routinely outside of clinical trials, indeed there is a distinct lack of 
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such outcomes that are validated. An approach to recording ‘humanistic’ outcomes 
whilst keeping follow-up to minimum would be to employ smartphone apps that ask the 
patient to complete a validated PROM in their own time and without the need for a 
hospital visit. However, not all patients will have access to this technology or under-
stand how to use it. It is therefore important to undertake pre-trial work to understand 
what proportion of patients will comply with this design feature. Care needs to be taken 
not to exclude patients on the basis of their ability to comply with technology. Therefore, 
having alternative approaches to be more inclusive are vital to keeping the trial design 
pragmatic.   
8. Primary outcome. A pragmatic primary outcome is one that is significant to patients 
as well as being relevant to commissioners. Complications after surgery may be con-
sidered to be a pragmatic outcome because it is routinely evaluated in usual care as 
well as being relevant to patients and commissioners. Whilst the qualitative work pre-
sented in the MCID is fundamentally flawed, it does seem to suggest that patients 
prioritised the speed and quality of healing in addition to the avoidance of complica-
tions. Therefore, outcome measures like the Clavien-Dindo classification may not go 
far enough to elicit the full extent of patient priorities. Based on the findings of this 
study, further qualitative research is necessary. Firstly, to identify the priorities of pa-
tients and secondly to develop and validate PROMs that appropriately evaluate these 
priorities. 
9. Primary analysis. In keeping with a pragmatic approach, a future definitive trial will 
employ an ITT analysis using all available data and not making special allowances. 
Adopting a per protocol analysis is an inherently biased assessment because the prog-
nostic balance between arms afforded by randomisation is not preserved. However, 
within the context of a surgical trial, understanding the reasons for any differences 
between the ITT analysis and per protocol analysis may provide valuable insights into 
the intervention as well as providing readers with complete transparency of the results. 
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In summary, the PRECIS-2 wheels of the original DEFeND REPT design is compared in dia-
grammatic form to an ideal definitive trial design in Figure 30. The black line represents the 
original REPT design and the red line represents the future trial design. These wheels can be 
compared to the wheels of the published RCTs presented in Figure 11. It is clear to see that 
both original and future DEFeND trial designs are towards the pragmatic end of the continuum 
and both are markedly more pragmatic than the trials by Vidal-Perez et al(94) and Huang et 
al(95). The shapes of the original and future DEFeND trials are different and reflect some of 
the key learning points from undertaking this work as described above. It is important to note 
that even in an ideal trial design, the PRECIS-2 wheel does not score maximum pragmatism 
points in every category. Herein lies the difference between a pragmatic HNS trial design and 
a generic pragmatic drug trial. The former involves the delivery of a complex intervention with 
an associated learning effect. As previously discussed, it is important to quantify this learning 
effect and employ methods such as surgeon credentialling to ensure that the intervention is 
delivered by surgeons who are in the asymptotic part of their learning curve. Furthermore, 
whilst the intervention should be delivered flexibly, it is important to monitor the fidelity of the 
intervention to enable a robust and transparent analysis (that includes both ITT and per proto-
col analyses). With future qualitative work it will almost certainly be possible to improve the 
primary outcome measure to reflect the priorities of patients in a more comprehensive manner. 
If the primary outcome takes the form of a PROM that can be implemented through an App, 
the burden of hospital follow-up appointments may be significantly reduced. However, it is un-
likely that this PROM will be collected in routine clinical practice, at least initially. Conducting 
truly pragmatic trials is hugely challenging in the current HNS research landscape. This is be-
cause engaging surgeons working in non-academic centres can be difficult and often leads to 
recruitment problems. Ultimately this issue is complex and multi-factorial. Fletcher et al re-
ported that use of qualitative work to identify and overcome barriers, reduction of the clinical 
workload associated with participation in RCTs and the provision of extra training and protected 
research time were all potentially effective measures to improve engagement.(220) Addition-
ally, pragmatic trial designs rely on large numbers of patients. HNC is not as prevalent in the 
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UK as other cancers such as breast, prostate, lung and bowel.(221) Therefore, a relatively 
higher proportion of HNC patients from fewer centres need to be recruited to meet the large 
sample sizes required for pragmatic trials.     
 
Figure 30 PRECIS-2 wheels for originial DEFeND REPT trial design (black line) and future de-
finitive DEFeND trial design (red line). 
8.2.3 Methods used to explore recruitment 
Overall recruitment to the trial was successful as the recruitment target was reached ahead of 
schedule. This was driven by the success of AUH which compensated for the problems faced 
by QVH. The methods used to explore recruitment were suboptimal because the opportunity 
to use formal qualitative methods to delve deeper into the recruitment problems was not taken. 
The recruitment challenges faced by QVH were identified through unstructured interviews with 
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the PI. Only having the PI provide feedback is flawed because he may have chosen to exclude 
certain issues raised by other investigators. Whilst the PI may not have considered these is-
sues to be important or relevant, it is important to have given all investigators an opportunity to 
voice their opinions. Afterall, their concerns may have been highly relevant to the design of a 
future trial. Having said this, there was no reason to suspect the PI withheld any important 
recruitment challenges as all the points raised were encountered by the PhD candidate in his 
regular communication with sites.  
In hindsight, undertaking formal semi-structured interviews or surveys with investigators at site 
(including research nurses, surgeons, ward nurses and theatre staff) would have been benefi-
cial and provided much more granular information on any recruitment challenges. By conduct-
ing these interviews early in the REPT it would have been possible to introduce recruitment 
interventions, such as the ‘QuinteT Recruitment Intervention’, to understand the problems in 
greater depth and enable effective strategies to address them.(222) It would be fair to conclude 
that the value of such qualitative methods in the DEFeND REPT was underestimated at the 
start of the study. 
8.2.4 Electronic case report form design 
The design of the eCRF modernised many aspects of trial conduct when compared to other 
trials led by the NWSTC/LCTU which were more paper based. The key design features were: 
8.2.4.1 Informed consent process 
Once sites had consented a patient, they ticked the relevant box in the Screening Form (B.1) 
which generated an automated email to the central trials team. This informed them that an 
informed consent form (ICF) was waiting to be authorised on the LCTU’s secure server. The 
process required two members of the central trials team to independently authorise the ICF 
and electronically sign-off in the Randomisation Form (B.6). The last person to sign-off perma-
nently deleted the electronic copy of the ICF.  
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The previous approach used by the LCTU required sites to fax a copy of the ICF for central 
authorisation. The faxed copy was then stored in a locked filing cabinet for a pre-specified 
period of time beyond completion of the trial. This approach required storage space as well as 
being subject to strict data protection rules to preserve patient confidentiality. The approach 
used in the DEFeND REPT streamlined the process and did away with the need to store copies 
of the ICF in the LCTU premises. This process was authorised by the LCTU senior manage-
ment and the Quality Assurance team.  
In an issue not directly related to the eCRF, the REC waived the need for a minimum of 24 
hours between patients being informed of the study and signing the ICF. This was thought to 
be advantageous as it allowed patients to consent to the trail without the need for further hos-
pital visits, especially if they lived far from the site. However, if spoke sites were opened as 
PICs, it can be argued that this deviation from the norm is unnecessary. This is because the 
consent process for the trial can be more easily harmonised with the consent process for sur-
gery when patients are seen at spoke sites. There is no reason to suspect this change in pro-
cess will have any impact on the use of the eCRF.  
8.2.4.2 Randomisation and reveal process 
Before randomisation could be performed the pre-randomisation checklist (Randomisation 
Form B.6) needed to be completed. This involved authorisation of the ICF (as described 
above), authorisation of eligibility criteria by the PI, completion of the baseline NDII and Neck 
pain Scale and a final sign-off by an investigator to confirm the checklist was complete. This 
process was designed to prevent patients being inappropriately randomised. However, it was 
not able to prevent three patients being randomised but not revealed. These patients had last 
minute changes to their treatment plan which meant they were no longer eligible and it was not 
possible for investigators to predict these scenarios. Patients with HNC often have multiple co-
morbidities and occasionally may become too unwell to undergo major surgery. Furthermore, 
it is not uncommon for patients to have particularly fast growing or aggressive tumours that 
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become inoperable in the weeks that lead up to surgery. Overall, the pre-randomisation check-
list worked smoothly and did not create any barriers to the effective running of the trial. 
Once randomised, an automated email with a link to reveal the allocation was sent to the sur-
geon. The date and time of the allocation reveal was cross-referenced to the start and finish 
times of surgery. This was an entirely novel approach to revealing the allocation at a specific 
time point during surgery to minimise performance bias. It was therefore not surprising that all 
the CAPAs reported in the trial were related to this process (Appendix E. ). The process of 
cross-referencing the time of allocation reveal to the start and finish times of surgery worked 
very well and highlighted a deviation in the protocol by a surgeon very effectively. However, 
the process was time dependent and the importance of having fail safes and effective support 
for surgeons from the NWSTC/LCTU was identified as result of this REPT. Overall, the elec-
tronic processes involved in the randomisation and reveal process were effective and could be 
improved with some relatively straightforward changes.  
8.2.4.3 Reporting outcome measures 
Prior to commencing the study it was known that the Clavien-Dindo classification was prone to 
inter-observer variability when used in HNS.(137) To counteract this issue, the eCRF was de-
signed so that a description of the severity of common complications was provided to investi-
gators (B.9). This approach proved to be effective for common complications. There was only 
one instance when the investigator reported the premature removal of a drain by a patient as 
a complication under the ‘other complication’ option. Although this deviated from the protocol, 
it was not a complication. The eCRF could be improved by adding a note to clarify this position.  
As already discussed, the Drain Output Data form (B.10) was a very explanatory design feature 
and should not be included in a definitive trial. From a technical standpoint, the computer algo-
rithm worked very well in guiding investigators when to remove the drain. The form was de-
signed to minimise detection bias. However, QVH found it labour intensive because of the re-
quirement for real-time data entry and some surgeons resisted the requirement for using a 
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single drain. Understanding why this form was counterproductive in delivering a pragmatic trial 
was a key learning point from this REPT. 
In summary, the eCRF was successfully deployed and some key learning points in the design 
were learned through the REPT. Accuracy of data recording was to a high standard with very 
little missing data that was important to the trial outcomes. In a definitive trial, the same frame-
work can be safely used once the changes discussed have been implemented. 
8.2.5 Other trial processes 
8.2.5.1 Randomisation strategy 
The randomisation strategy was effective as evidenced by an even distribution of baseline and 
surgical characteristics across treatment arms. Any differences in baseline characteristics 
noted between study arms are likely to be evened out further in a study with a larger sample 
size. A larger sample size will also permit the use of further stratification criteria such as extent 
of surgery (as discussed in section 5.5.1.2 and 5.5.2.2). 20% of patients declined to enter the 
study implying most patients were supportive of the trial and accepting of randomisation.  
8.2.5.2 Blinding strategy 
The blinding strategy was effective as evidenced by the data from the Bang Blinding Index 
(BBI). Interestingly both patients and RNs exhibited the ‘wishful thinking’ phenomenon. This 
may have been due to recruiting surgeons lacking equipoise and patients and RNs picking up 
on cues relating to the benefits of FS in ND rather than any counter arguments e.g. the lack of 
high quality supporting evidence.  
8.2.5.3 Qualitative methods used to determine the minimal clinically im-
portant difference 
There are several limitations to the applied qualitative methodology used to determine the 
MCID. Firstly, the semi-structured interviews were conducted by untrained investigators in a 
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busy clinic environment. Secondly, the investigators summarised the patient’s comments into 
the eCRF thereby processing the information and potentially applying personal biases (both in 
the selection and interpretation of what was written). Thirdly, only patients who had completed 
follow-up were interviewed. It is likely that these patients considered the potential benefits of 
FS mentioned in the PIS favourably. Patients who did not participate or did not complete follow-
up have equally valuable views and opinions that were not collected. Ideally, a separate study 
conducted by trained investigators using audio recordings of interviews would have provided a 
much richer and more representative source of qualitative data. Therefore, the findings were 
not generalisable to patients outside of the current study. 
8.2.5.4 Safety 
The safety plan was not tested within the REPT as no SAE/SUSARs were reported throughout 
the study duration and no patients needed to unblinded. The Safety plan used in the REPT 
was derived from LCTU standard operating procedures and therefore there is no indication to 
change this process in a definitive trial. It is reassuring to note the that use of FS in ND can be 
considered safe for patients.   
8.2.6 Lack of pre-trial work 
Undertaking a survey of recruiting surgeons prior to commencing the trial to establish their 
usual practices may have demonstrated issues with potential protocol compliance. Such a sur-
vey could have also been used to help select the sites most likely to comply with the protocol. 
As already discussed, selecting sites based on their likelihood to comply with the protocol would 
have been an explanatory design feature. Ultimately much of the success of trials is judged on 
recruitment. A trial that has sufficient numbers of patients to answer the research question is 
more valuable than a trial that rigidly sticks to ideals and fails to recruit enough patients. Within 
the context of the REPT, QVH provided valuable information to guide future trial design and 
their inclusion was considered a strength. In a definitive trial however, the aim would be to 
recruit as many patients as efficiently as possible. As already discussed, opening sites like 
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QVH in a definitive trial may be a necessity because it is representative of many non-academic 
HNS centres. Using a survey as described above would enable the central trial team to priori-
tise the order of opening centres. This could be done by opening centres that are more likely 
to recruit well and comply with the protocol ahead of others. 
8.3 Contribution to Existing Knowledge 
8.3.1 Fibrin Sealants in neck dissection 
As a REPT this study was not designed or powered to detect a difference between treatment 
arms. Therefore, it is not possible to use this data to add to the existing knowledge regarding 
the effectiveness of FS in ND. At the start of this study several justifications for conducting an 
REPT prior to a definitive trial were provided. These will be discussed individually below: 
8.3.1.1 Recruitment 
There was uncertainty regarding the timing of the DEFeND trial and whether individual surgeon 
equipoise will impact on their ability to convey equipoise to patients and their willingness to 
recruit patients. The recruitment data from this study paints two contrasting pictures. AUH per-
formed very well and demonstrates that an academic HNS centre is capable of recruiting very 
well to surgical trials. Given the evidence of the ‘wishful thinking’ phenomenon demonstrated 
by the BBI, the AUH surgeons may not have conveyed equipoise effectively. However, if this 
was the case, it did not stop patients consenting to the study. This may be because FS is 
considered a safe intervention and has no bearing on the patient’s cancer treatment. The trial 
may have been easy to recruit to because of the low risks involved. Therefore, the timing of the 
trial and individual surgeon equipoise did not seem to have an impact on recruitment in AUH. 
The performance of QVH in the REPT was less than expected. Possible reasons for this have 
already been discussed in section 8.1.2.1. The findings from this study suggest that QVH did 
not struggle to recruit because of the timing of the trial. Instead, it was most likely due to 
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combination of trial design features that made participation laborious for investigators and a 
lack of surgeon engagement that may have been, in part, due to issues with equipoise. 
Changes to the trial design to make it less laborious, such as removing the need for real-time 
data entry, have been proposed and relatively simple modifications. Addressing surgeon en-
gagement equipoise is more complex and ultimately requires a mixed-methods evaluation to 
understand the barriers. As reported by Fletcher et al this may include qualitative work to iden-
tify and overcome barriers, reduction of the clinical workload associated with participation in 
RCTs and the provision of extra training and protected research time.  With the benefit of hind-
sight, it is recognised that opportunities to collect this data were missed by not incorporating 
robust qualitative methods (surveys, structured and semi-structured interviews) in the study 
design. Given the research landscape in HNS, PFS studies have an important role in minimis-
ing research waste and would benefit from the incorporation of mixed methodology to maximise 
the learning from the process.  
8.3.1.2 Trial design 
Randomising patients prior to surgery and revealing the allocation at a specific time-point intra-
operatively was shown to be feasible. Previous trials led by the NWSTC/LCTU had problems 
with randomising patients intra-operatively for reasons discussed in section 3.2.3.3. However, 
randomising pre-operatively presented its own problems in this study. Three patients were ran-
domised but later withdrawn from the study due to changes in treatment plan that meant they 
were not longer eligible. These patients would not have been lost if randomisation occurred 
intra-operatively at the point of wound closure. Given that these patients were a very small 
minority, the process of pre-operative randomisation and intra-operative reveal is still advo-
cated. Increase the sample size of a definitive trial to accommodate for this eventuality would 
be required. 
At the start of the study there was uncertainty whether the unblinded operating surgeons would 
have an influence of the fidelity of the blinding strategy. As already discussed, this was not born 
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out in the data from the BBI. Therefore, it is possible to effectively blind participants and inves-
tigators within a busy HNS practice.  
8.3.1.3 Trial Outcomes 
At the start of the study, complications were considered the most pragmatic outcome. Whilst 
the Clavien-Dindo classification represented the most widely used instrument to evaluate com-
plications, there was uncertainty regarding how it should be deployed. This was because of 
concerns regarding inter-observer variability and the possibility of patients suffering multiple 
complications. Providing investigators with a description of the most frequently encountered 
complications rather than allowing them to interpret the classification themselves, eliminated 
any problems with inter-observer variability in this study. Furthermore, using the CCI rather 
than the traditional Clavien-Dindo classification eliminated issues with reporting patients who 
suffer multiple complications.  
Whilst the qualitative work performed to determine the MCID was poorly conceived and deliv-
ered, it did raise the possibility that complications on their own might not go far enough to 
address the priorities of patients. The information gathered from trial participants can inter-
preted to suggest that patients not only want to avoid complications, but they also want their 
wounds to heal as efficiently as possible and minimise the use of healthcare resources. Using 
the CCI as the primary outcome measure may be an acceptable approach but there is currently 
no evidence that suggests it is the best option. Evidence from the review of COS presented in 
section 6.1 and the performance of the WHQ in trial participants suggest that PROMs devel-
oped specifically for HNS may be a more holistic and valuable way of evaluating interventions. 
Furthermore, PROMs can be completed by participants remotely, doing away with rigid follow-
up visits. In summary, the dearth of HNS specific outcome measures has been recognised and 
that a reliance on generic instruments may be sub-optimal. Addressing this unmet need should 
be a research priority in HNS. 
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8.3.1.4 Trial conduct 
The main question regarding trial conduct was whether the components of the trial worked well 
together. The findings of the REPT suggest that this was dependent on the research site. In 
AUH there were some teething problems that have been discussed in section 8.1.3.1 and were 
dealt with through a process of root cause analysis (CAPA). However, after these issues were 
addressed, the trial was delivered without problems. Whilst no protocol deviations were identi-
fied at QVH, they did report challenges with recruitment and labour intensiveness which have 
already been discussed in section 8.1.2. Perhaps the most important learning point from cen-
tres which rely heavily on a hub and spoke model for delivering HNS is the effective use of 
PICs. The findings of this REPT will help to harmonise the research process better with routine 
clinical care which should improve the performance of sites like QVH.  
8.3.1.5 Fidelity of the intervention 
This topic has already been discussed at length in both section 8.1.6 and 8.2.2. The findings 
of this REPT advocate the importance of identifying and quantifying learning effect and using 
this data to implement surgeon credentialling. The intervention should be delivered flexibly 
within the context of a pragmatic HNS trial but should also be monitored. It is accepted that 
reporting fidelity of the intervention through monitoring will not change the outcome of the ITT 
analysis. However, transparent reporting enables the surgical audience to make their own de-
cisions regarding the influence of fidelity of the intervention on trial outcome. 
8.3.1.6 Sample size 
One of the aims of this REPT was use the clinical outcome data to estimate the sample size of 
a future definitive trial. However, numerous issues have been identified that would make such 
a calculation inappropriate. Currently there are questions over the best outcome measure and 
whether the CCI meets the expectations and priorities of patients. Furthermore, not adjusting 
for learning effect has potentially exposed the data to type II error. It is now recognised that 
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considerable further research is required before the definitive DEFeND trial should be started 
(see Chapter 9.  Future Work) 
8.3.2 Head and neck surgical trials 
Once described as a “comic opera”, surgical trials in the UK have advanced considerably in 
recent years both in methodological rigor and recruitment.(223) As this work has demonstrated, 
surgical trials are associated with numerous methodological challenges due to the complexity 
of the intervention and lack of surgeon equipoise. In keeping with the IDEAL framework, the 
development of surgical innovation involves the progression from explanatory studies evaluat-
ing efficacy to pragmatic studies evaluating effectiveness.(126) The DEFeND REPT provides 
an example of why conducting HNS trials with a truly pragmatic design can be problematic 
apart from in exceptional cases. As discussed, the implications of learning effect on surgeon 
credentialing and monitoring of the intervention are both areas that require careful considera-
tion when designing a pragmatic HNS trial. 
Overall recruitment to this trial was very good however, it was driven primarily by the academic 
centre. The performance of QVH is cause for concern for recruitment to pragmatic HNS trials 
as it is representative of many HNS centres across the UK. It is likely that many of the recruit-
ment challenges reported by Kaur et al in 2013(105) still stand several years later. Many of the 
recruitment problems faced by QVH stem from a lack of research infrastructure leading to a 
lack of harmony between research processes with routine clinical care. Surgeons are the gate 
keepers to accessing patients with HNC and therefore their engagement with research is the 
key to unlocking improvements. This is largely a political issue for which much has been done 
in recent years not least by initiatives from the NIHR, Royal College of Surgeons and introduc-
tion of trainee research collaboratives. When designing pragmatic HNS trials, researchers need 
to take steps that help integrate the research process with routine clinical care. Key learning 
points from this work include making data collection less labour intensive and either integrating 
follow-up visits with routine clinical care or doing away with them all together. Whilst these are 
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all important points, the elephant in the room is the distinct lack of methodological research that 
identifies the research priorities of HNS patients and seeks to develop the best methods and 
instruments to evaluate them. Without this vital research, the quality of HNS research will fall 
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Chapter 9.  FUTURE WORK 
9.1 Changes to Trial Design 
Throughout the discussion chapter several changes to the current trial design have been pro-
posed. These have the potential to improve the performance of a definitive trial in both aca-
demic and non-academic HNS centres. The changes are summarised below: 
1. In terms of recruitment lessons regarding the use of PICs have been learned. Sites 
that use the ‘hub and spoke’ model will have spoke sites opened as PICs. This will 
enable patients to be identified and given information about the trial earlier in their 
treatment pathway and harmonise the research process with normal clinical care.  
2. Eligibility criteria will be extended to include patients who have two or more neck levels 
dissected and patients undergoing bilateral NDs. These changes are afforded by the 
abolishing the computer algorithm to decide on drain removal and stratifying patients 
based on extent of surgery. 
3. Monitoring of Intervention is deemed important for a pragmatic HNS trial to facilitate 
transparent reporting of trial outcomes based on compliance with protocol. The pro-
posed method for doing this involves the use of mobile video cameras placed on the 
surgeon’s body and stored in an SD card for central evaluation.  
4. Drain outcomes will be removed because they are no longer considered pragmatic. 
This will make the trial easier for non-academic sites because there will no longer be 
a requirement for daily real-time data entry. It will also facilitate the expansion of eligi-
bility criteria (as mentioned above) and permit surgeons to use as many drains as they 
wish. The latter point being an issue for two QVH surgeons in the REPT. LoS was 
found to be particularly important to patients and will be included in a definitive trial. 
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However, using LoS as a primary outcome measure is problematic because it is in-
credibly short term and is influenced by external factors e.g. social issues that delay 
discharge. Whilst it is an important outcome, LoS is unlikely to provide a comprehen-
sive evaluation of FS in ND. The CCI is a valuable and pragmatic outcome measure 
which has been shown to be feasible in a HNS trial however, it may not be an ideal 
choice. When questioning patients regarding the MCID, two dominant themes devel-
oped. These findings support the need for a more robust qualitative methodology to 
be applied in a separate study.  
5. Whilst it was argued that the inclusion of a site like QVH was valuable to the REPT, 
having sites that are slow to open and recruit will be problematic in a definitive trial. In 
keeping with a pragmatic approach, these sites are important to be included, but not 
at the expense of the success of the trial. Therefore, as Fletcher et al.(220) reported, 
the use of pre-trial qualitative work is essential to identify and overcome barriers, re-
duce clinical workload associated with the trial, identify the need for extra training and 
protecting research time. Unfortunately, the value of this work was not fully appreci-
ated prior to the REPT. Therefore, a further separate study is required prior to com-
mencing the definitve trial to address outstanding issues particularly regarding sur-
geon engagement and equipoise. Data from this study can be used to better predict 
which sites are likely to perform well in a definitive trial so that they may be prioritised 
for opening.  
6. The blinding strategy identified ‘wishful thinking’ amongst patients and RNs. Also, a 
small number of patients were not recruited because the surgeon decided against it. 
Both scenarios may be associated with a lack of equipoise that is either held by the 
surgeon or implied within the PIS. The approach to addressing surgeon equipoise is 
described above. Furthermore, it is proposed that the PIS is reviewed again by the 
Aintree Head & Neck Research Forum to look for unintentional bias towards the inter-
vention. 
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7. This study has identified that the use of FS in ND may be associated with a learning 
effect. However, suboptimal data has prohibited formal identification and quantifica-
tion. Therefore, a separate study is required prior to a definitive trial to address this. 
This learning effect data may then be used to set entry requirements for surgeons to 
participate in the definitive trial to ensure that they are in the asymptotic part of their 
learning curve when operating on trial participants. Furthermore, the outcomes used 
as performance proxies in this analysis need to be the same as in the definitive trial. 
This implies that this work should only be done once the work described in point 4 of 
this list have been addressed. 
8. The addition of a ‘forgot password’ tab when logging in to reveal the allocation and a 
trial specific ‘hotline’ to the IT department are proposed. These will work to minimise 
the possibility of surgeons not revealing the allocation during surgery in a timely man-
ner. 
9. A future definitive trial will have considerably more data and would benefit from addi-
tional scheduled monitoring visits. Furthermore, using email alerts sent to the Trial Co-
ordinator (TC) and PI regarding incomplete data may improve the accuracy of data 
recording. 
9.2  Appropriateness of a Definitive DEFeND Trial 
The findings of this REPT confirm that a definitive DEFeND trial in its current form is feasible 
from a methodological and intervention perspective. Recruitment data has shown that there 
are adequate numbers of patients who meet the eligibility criteria and are willing to be random-
ised. With the changes to the trial design and the pre-trial work summarised above, a definitive 
DEFeND trial would be well placed to answer the research question. Whilst the changes to the 
trial design can be implemented with immediate effect, the pre-trial work will be both extensive 
and time consuming. It is vitally important to learn from the weaknesses identified in the REPT 
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and address them systematically from first principles. In doing so, the proposed body of future 
work will provide important foundations for all HNS trials. Without laying these important foun-
dations the shortcomings identified by this REPT could be repeated and progress. 
Currently there is no published COS for HNS trials and addressing this unmet need should be 
the first priority. An important rationale for COS development is to ensure that trials report out-
comes that are relevant to patients and other key stakeholders. Developing a COS for HNS 
trials will provide a useful structure to understand the priorities of patients. Examples exist from 
other research areas where patients have identified outcomes that are important to them that 
might not have otherwise been considered by healthcare professionals.(224-226)  
Following the development of a HNS COS, the next steps should involve identification of the 
best instruments available to measure each core outcome. This would require a systematic 
review of all existing and relevant outcomes. This REPT has demonstrated a dearth of HNS 
specific outcomes so it is very possible that certain core outcomes will not have suitable instru-
ments. Under these circumstances the development and validation of novel instruments should 
be the next priority. It has been suggested that reliance on clinical outcome measures (e.g. 
presence of disease, length of stay, re-admission rates) only provides a partial view of a pa-
tient’s experience of healthcare because information on domains like pain, fatigue and degree 
of symptom bother are missing.(227) A well-developed and validated PROM has the potential 
to unlock a much more holistic evaluation of an intervention. For example, PROMs enable 
patients to assess whether their experience of treatment aligns with their expectations and may 
highlight areas of unmet need. One of the problems with using ClinROMs (e.g. Clavien-Dindo 
classification) is that they do not define when an outcome becomes significant for an individual 
patient. This is because the threshold for significance will vary between patients. Using Clin-
ROMs in clinical trials requires investigators to decide the threshold on behalf of all patients 
(e.g. complications that are Clavien-Dindo grade IIIB or above). The WHQ validation work for 
the ‘Bluebelle study’ has shown it is possible to merge humanistic and complication outcomes 
by developing an instrument that can effectively diagnose SSI by patient report.(149) 
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The development of a COS for HNS trials and subsequent identification, development and 
validation of appropriate instruments is an important priority for all future HNS trials. It requires 
an extensive body of work that may take several years to complete. At that point in the future 
the research question pertaining to the role of FS in ND may no longer be important. Further 
evidence or the development of novel interventions and techniques may render this research 
obsolete. If understanding the role of FS in ND is still considered important, it would be prudent 
to update the systematic review presented in Chapter 2.  
This REPT highlighted the need for identifying and quantifying the learning effect associated 
with FS in ND. However, it is important to wait until the COS for HNS has been developed and 
the appropriate instruments are in place before undertaking this research. Afterall. these in-
struments will form the basis of the performance proxies used to quantify the learning effect. 
Further qualitative research to identify and overcome barriers, reduce clinical workload associ-
ated with the trial, identify the need for extra training and protect research time will also be 
required at this stage. Only once this work has been completed can one really make an in-
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Chapter 10.  CONCLUSIONS 
The DEFeND REPT has demonstrated that a definitive trial is feasible and that many compo-
nents of the trial design have worked well together. The proposed changes have the potential 
to improve this even further. Whilst the evaluation of clinical outcomes measured in this REPT 
have favoured FS, the effect sizes have been small. The proposed path to a definitive DEFeND 
trial is certainly long and one needs to consider the small effect sizes when starting this journey.  
Ultimately the methodological work relating to COS development and the instruments with 
which to measure each of them by is more urgent and has far reaching benefits beyond the 
definitive DEFeND trial. How the intervention performs within a definitive trial is highly depend-
ent on the choice of primary outcome. If the findings of the trial are to influence policy and 
practice, then the chosen primary outcome needs to be relevant to patients. If we are to focus 
on what matters to patients, then they must be involved in determining which outcomes to 
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• General Information 
This document describes the DEFeND trial and provides information about procedures for entering patients into it. The 
protocol should not be used as an aide-memoir or guide for the treatment of other patients. Every care was taken in its 
drafting, but corrections or amendments may be necessary. These will be circulated to the registered investigators in the 
trial, but centres entering patients for the first time are advised to contact the coordinating centre (North West Surgical 
Trials Centre (NWSTC) part of Liverpool Cancer Trials Unit (LCTU)) to confirm they have the most up to date version. 




• Statement of Compliance 
• This study is designed to comply with the guideline developed by the International Conference on Harmonisation 
(ICH) for Good Clinical Practice (GCP) and will be conducted in compliance with the protocol, NWSTC/LCTU 
Standard Operating Procedures and EU Directive 2001/20/EC, transposed into UK law as the UK Statutory In-
strument 2004 No 1031: Medicines for Human Use (Clinical Trials) Regulations 2004. 
 
 
• UK Registration 
 
• This study will have Health Research Authority (HRA) Approval. All research sites will confirm capacity and ca-
pability to conduct the study and will sign a Research Site Agreement. 
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ABPI Association of the British Pharmaceutical Industry 
AE Adverse Event 
APTT Activated Partial Thromboplastin Time 
AR Adverse Reaction 
CI Chief Investigator 
CO2 Carbon Dioxide 
CRF Case Report Form 
CTIMP Clinical Trial of Investigational Medicinal Product 
CTU Clinical Trials Unit 
CV Curriculum Vitae 
DOB Date of Birth 
(E)CRF Electronic Case Report Form 
FDA United States Food & Drug Administration 
FS Fibrin Sealant 
GCP Good Clinical Practice 
GP General Practitioner 
HE Health Economics 
HRA Health Research Authority 
IB Investigator’s Brochure 
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ICER Incremental Cost Effectiveness Ratio 
ICF Informed Consent Form 
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IDSMC Independent Data and Safety and Monitoring Committee 
IEC Independent Ethical Committee 
IMP Investigational Medicinal Product 
INR International Normalised Ratio 
ISRCTN International Standard Randomised Controlled Trial Number 
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MCID Minimal Clinically Important Difference 
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MHRA Medicines and Health Products Regulatory Agency 
MREC Multi-centre Research Ethics Committee 
NDII Neck Dissection Impairment Index 
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NPSA National Patient Safety Agency 
NWSTC North West Surgical Trials Centre 
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PI Principal Investigator 
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R&D Research & Development 
RNA Ribonucleic Acid 
SAE Serious Adverse Event 
SAR Serious Adverse Reaction 
SAP Statistical Analysis Plan 
SOC Standard of Care 
SPC Summary of product characteristics 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TAME Acute Toxicity, Adverse Late Effects and Mortality Risk Generated by a 
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TMG Trial Monitoring Group 
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TSC Trial Steering Committee 
UAR Unexpected Adverse Reaction 
UKCRN United Kingdom Clinical Research Network 
VAS Visual Analogue Scale 
WHQ Bluebelle study Wound Healing Questionnaire 
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Title: Determining the Effectiveness of Fibrin Sealants in Reducing Com-
plications in Patients Undergoing Lateral Neck Dissection: A ran-
domised external pilot trial 
Phase: Randomised External Pilot Trial 
Sample Size: A minimum of 50 patients (UK) 
Main Inclusion Criteria: • Patients due to undergo lateral neck dissection 
• Neck dissection to include a minimum of 3 levels 
• Patients who have capacity to consent 
Main Exclusion Criteria: • Age < 18 years 
• Bilateral neck dissection 
• Presence of a vascular pedicle for reconstruction 
• Pregnancy or breast feeding 
• Known hypersensitivity reaction to Aprotinin 
• Previous exposure to Fibrin Sealant within 6 months 
• Known allergy to dairy products 
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Number of Sites: Aintree University Hospital, Liverpool UK Queen Victoria Hospital, East 
Grinstead UK 
Study Duration: 12 Months 
Description of Intervention: Application of Artiss fibrin sealant (Baxter Healthcare LTD) to the surgical 
wound. Up to 2ml driven by medical air at 1.5 bar, minimum 10 cm away 
from wound prior to closure. 
Objectives: The main objectives of this study are to assess if a future phase III trial is 
feasible and to ensure the individual aspects of the trial design work well 
together. 
 
The key objectives of this randomised external pilot study are to assess 
the following points: 
 
• Whether patients can be recruited and retained at a rate of 
approximately 4 patients per month across the 2 centres. 
• Determining the effectiveness of the blinding strategy using 
blinding indices. 
• Ensuring the administrative processes of randomisation and 
data management work well within the study. 
• Assess adherence to the conditions of the protocol. 
• Provide evidence to inform sample size calculation for a 
future study. 
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• Schematic of Study Design: 
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(day 7 - 14) 
Screening & 
Enrollment 
Allocation revealed at point of wound closure 
Patient undergoes planned surgery 
Randomised pre-operatively 
Baseline recording of pain (VAS) and Neck Dissection Impairment index (NDII) 
Informed consent taken 
Screening for eligibility and trial information 






Daily assessment of AEs (Clavien-Dindo) 
Daily recording of pain VAS 
 
Twice daily drain volume recording 
Daily assessment of drain removal Daily 
Assessment for hospital discharge 
Assessment of pilot study outcomes: missing data, 
recruitment, randomisation, blinding, protocol 
adherence, follow-up 
Assessment of AEs, NDII, WHQ, Pain VAS, 
blinding index, MCID 
Removal of clips/sutures 
 
Assessment of AEs 
Allocated to control Allocated to Fibrin Sealant 
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2 BACKGROUND INFORMATION 
 
2.1 Introduction 
The Problem Being Addressed 
Complications after major surgery are a significant cause of morbidity and mortality and have been shown to have a nega-
tive impact on long-term quality of life and psychosocial well-being.1, 2 In surgical oncology, complications can also delay 
adjuvant treatment (e.g. radiotherapy) which is known to adversely affect survival.3 Neck dissection is one of the most 
commonly performed ‘major operations’ in head and neck surgical oncology and it is estimated, from national audit data, 
that approximately 7000 major head and neck surgical resections are performed each year in England alone.4 Significant 
surgical complications occur in approximately 10 – 20% of patients undergoing neck dissection.5, 6 Such risks increase to 
40% in patients who have had previous chemo-radiotherapy to the area7 or when operating on higher risk patients of 
increasing age, with multiple co-morbidities and polypharmacy.8 Common surgical complications include: haematoma for-
mation, surgical site infection, wound breakdown/dehiscence, and fistula formation. Management of these complications is 
frequently painful, invasive and may involve returning to theatre. This inevitably delays recovery, which in turn may result 
in prolonged hospital stay and immobility; both of which are known risk factors for lower respiratory tract infections and 
venous thromboembolism. 
 
The Patient’s Perspective 
The direct impact on patients of complications following neck dissections has been borne out by recent and ongoing qual-
itative research. Currently unpublished doctoral research from colleagues at the University of Liverpool seeking a ‘Core 
Outcome Set’ for head and neck cancer has found that ‘need for further surgery or invasive treatment’ is considered ‘very 
important’ in >70% of patients through the Delphi method.9 This is reinforced by work done at the University of Bristol on 
a ‘Core Information Set’ for the broader topic of head and neck surgery that found ‘likelihood of wound problems’ and 
‘complications that may require a return to theatre’ are both core elements of importance to patients in the consent pro-
cess.10 Patients from the ‘Aintree Head & Neck Cancer Patient Research Forum’ have specifically highlighted their aver-
sion to surgical drains finding them both painful and a significant barrier to mobilisation. Patient opinion is further supported 
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by robust data from a meta-analysis on the use of surgical drains in thyroid surgery that found they increased post-operative 
pain and infection rates.11 Clearly drains serve an important role in preventing potentially life threatening complications 
due to neck swelling, however reduction in the duration of their use, through early safe removal, and in reduction of wound-
related complications will clearly translate to significant patient benefit in the immediate post-operative period. 
 
Fibrin Sealants 
A recent systematic review and meta-analysis on the use of Fibrin Sealants (FS) in head and neck surgery has found 
potential clinical advantages to both patients and healthcare organisations through reduction in complications and volume 
of wound drainage, thereby minimising the retention time of the drains.12 
 
FS are commercially available, US Food and Drug Administration (FDA) approved, products that have been investigated 
broadly across several areas of surgery.13 FS is applied to the raw surfaces of the surgical wound prior to closure providing 
an adjunct to haemostasis. The mechanism of action is through replication of the final stages of the clotting cascade through 
which thrombin cleaves fibrinogen to form a fibrin clot. The subsequent clot effectively seals small vessels and occludes 
cavity dead space by adhering the wound surfaces, both essential steps in avoiding haematoma formation that may com-
promise surgical site healing. Results of previous investigations of FS effectiveness in surgery have been variable and have 
frequently been unduly influenced by poor study design. 
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The key relevant findings of this systematic review and meta-analysis were: 
• There is a paucity of high-quality trials on the use of FS in Head and Neck surgery. 
• There was a tendency for FS to reduce drainage volume (mean difference 26.86ml, 95%CI -43.41 
to - 10.31, I2 =97%, p=0.001). 
• There was a suggestion that FS may reduce ‘mean retention time of drains’ by 1.24 days (95%CI -
3.32 to 0.85, I2 =99%, p=0.25) and ‘hospital length of stay’ by 2.09 days (95% CI -5.18 to 0.99, I2 
=97%, p=0.18) but these were not statistically significant. 
• Whilst not reaching statistical significance, FS may be protective against complications compared to 
standard of care with a relative risk of 0.69 (95% ci 0.35 to 1.38, I2 =0%, p=0.29). The benefit of FS 
was greater with regards to haematoma/seroma formation (RR 0.49, 95%CI 0.22 to 1.07, I2 =0%, 
p=0.07). 
• Patients at high-risk of complications (e.g. anticoagulation and previous surgery or radiotherapy) 
were excluded from all studies analysed, leaving the effects of FS in populations most likely to benefit 
not assessed. 
• The role of FS in lateral neck dissection is an area of need for further studies. Only 2 trials have 
been performed so far that have randomised 78 patients between them.14, 
15 Their inclusion criteria and findings varied greatly and substantial statistical heterogeneity impaired conclusive results 
in the meta-analysis. 
 
2.2 Rationale 
With an understanding of the evidence in combination with clinical experience it is felt that a surgical trial to determine the 
effectiveness of FS in reducing the rate and severity of complications in patients undergoing lateral neck dissection is 
warranted. This important clinical question is framed by patient opinion and guided by a clinical desire to reduce morbidity, 
and indeed it has the potential to translate to patient benefit. However given the difficulties in the delivery of Head and Neck 
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surgical trials,16 this external pilot study will be used to answer critical questions on how well key components of the 




The key objectives of this randomised external pilot study are to assess the following points: 
 
I. Whether patients can be recruited and retained at a rate of approximately 4 patients per month 
across the 2 centres. 
II. Determining the effectiveness of the blinding strategy using blinding indices. 
III. Ensuring the administrative processes of randomisation, allocation concealment and data manage-
ment work well within the study. 
IV. Assess adherence to the conditions of the protocol. 
V. Provide evidence to inform the sample size calculation for the future phase III multicentre random-
ised trial 
 
2.4 Potential Risks and Benefits 
 
2.4.1 Potential Risks 
Each of the following risks has been documented as either potential or theoretical in nature, their occurrence is expected 
to be highly unlikely should the trial protocol be adhered to. They are detailed in full below. 
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As Fibrin Sealants are derived from human blood they may contain infectious agents which can cause disease, such as 
viruses and theoretically, the agent that causes Creutzfeldt-Jakob Disease (CJD) in humans. The manufacturer states that 
certain measures have been taken to prevent infections. These include: selection of donors, 
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screening of individual donations for specific markers of infection and the inclusion of effective manufacturing steps for the 
inactivation/removal of viruses. Despite this, the possibility of transmitting infective agents cannot be totally excluded. The 
measures taken by the manufacturer are considered to be effective against viruses such as Human Immunodeficiency 
Virus (HIV), Hepatitis A, B and C. The measures taken may be ineffective against parvovirus B19. Parvovirus B19 infection 
may be serious for pregnant women as it may cause foetal infection. Pregnant women have therefore been excluded from 
taking part in this study. There have been no reports of transmission of infectious agents through the application of Fibrin 
Sealants in the literature. All patients will be informed of this potential risk during the consent process. 
 
Administration of Fibrin Sealants may result in allergic reactions in some patients. The precise frequency of severe life-
threatening reactions is unknown as they are incredibly rare. Patients who have a known allergy to Aprotinin (an ingredient 
of Fibrin Sealants that can cause allergic reactions) will be excluded from taking part in the study. The risk of Aprotinin 
hypersensitivity is increased in patients who have been exposed to it within 6 months or are allergic to bovine proteins (as 
the synthetic Aprotinin used in Fibrin Sealant is structurally identical to bovine Aprotinin). Therefore patients who have been 
exposed to Fibrin Sealant within 6 months prior to recruitment or are allergic to bovine proteins (e.g. dairy products), will 
be excluded from the study. 
 
Because the Fibrin Sealant is applied to the wound as a spray driven by ‘medical grade air’, it is possible that the patient 
may develop an ‘air embolism’. There have been 6 reported cases of air embolism following the administration of Fibrin 
Sealant. It is thought that these cases occurred because either the air pressure was too high or the spray device was held 
too close to the wound. The manufacturer recommends that the air pressure should be no higher than 1.7 bars and the 
spray device should be held no closer than 10 centimetres to the wound. These recommendations have been incorporated 
into the study protocol. Every surgeon that uses Fibrin Sealant on a patient in this study will undergo training by the research 
team. They will need to demonstrate their understanding of these recommendations by setting up the spray device and 
entering the correct settings into the machine. They will also need to demonstrate their spraying technique where the 
distance from the wound will be assessed. Only when they can demonstrate safe use of the Fibrin Sealant will they be 
accredited to use it on study participants. 
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Other more minor risks of using Fibrin Sealants include itchiness of the skin (occurs in 2/138 patients), a collection of fluid 
under the skin (occurs in 1/138 patients) and problems with skin grafts (5/138 patients). The latter risk is not relevant to this 
study as we will not be using the Fibrin Sealant on skin grafts. Problems with itchiness and fluid under the skin will reported 
as adverse events/complications and treated on a case-by- case basis. 
 
2.4.2 Known Potential Benefits 
There are no known patient benefits however, every effort has been made to minimise inconvenience to study participants 
by making the research pathway as similar to the normal clinical pathway as possible. As a result the patient has the 
opportunity to participate in research without a significant burden of extra tests or hospital visits. 
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3 SELECTION OF CENTRES/CLINICIANS 
 
Each participating centre will be required to offer the following minimum requirements: 
1) Centres will either have or be part of a comprehensive Head & Neck Multidisciplinary Team (MDT). 
2) Have surgical expertise in the management of Head & Neck Cancer. 
3) Have sufficient caseload to recruit 2 patients per month. 
4) Demonstrate enthusiasm to participate in the study. 
5) Provide information to all supporting staff members involved with the trial or with other aspects of 
the patient’s management. 
6) Acknowledge and agree to conform to the administrative and ethical requirements and responsibili-
ties of the study, including signing up to Good Clinical Practice (GCP). 
 
3.1 Centre/Clinician Inclusion Criteria 
1) Positive Site Specific Assessment (SSA) by the centre’s Research & Development (R&D) Depart-
ment. 
2) Completed Research Site Agreement. 
3) Receipt of evidence of completion of points 1) and 2) by NWSTC. 
4) Completion and return of ‘Signature & Delegation Log’ to NWSTC. 
5) Personnel on delegation log have attended the proposed site initiation and training days and have 
been accredited to perform the intervention. 
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6) Curriculum Vitae (CV) including a record of International Conference for Harmonisation (ICH) of 
GCP training – Principal Investigator (PI). 
7) CV including ICH GCP training – other personnel on the delegation log. 
8) Clinical Study Protocol Receipt Form. 
9) Patient Information Sheets (PIS) and Informed Consent Form (ICF) on trust letter headed paper. 
10) Completion of test SAE reported via web. 
 
3.2 Exclusion Criteria 
Those centres that do not fulfil the above inclusion criteria will not be permitted to participate in the trial. 
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4 TRIAL DESIGN 
 
4.1 Overall Design 
Determining the effectiveness of fibrin sealants in reducing complications in patients undergoing lateral neck dissection: a 
randomised external pilot trial (Acronym: DEFeND). The study design that is being piloted is that of a parallel group supe-
riority trial with patients being randomised in a 1:1 ratio to each arm. The interventional arm will constitute the application 
of ARTISS (Baxter Healthcare LTD) fibrin sealant to the surgical wound in addition to “standard of care”. The control arm 
will constitute “standard of care” alone (described in more detail in section 7). Both patients and outcome assessors will be 
blinded to the allocation. An approximate sample size justification of 50 patients (25 in each arm) has been chosen, as this 
will provide sufficient precision to calculate the sample size required for the future phase III trial. Currently the design of the 
pilot study mirrors the design of the future phase III trial, however it is expected that refinements will be necessary based 
on the pilot data. Patients will be stratified according to the hospital they receive their treatment. 
 
 
4.2 Pilot Study Outcomes 
The proposed outcome measures for this study can be divided into those that are specific to the pilot study and those that 
would potentially inform a future trial to determine the effectiveness of fibrin sealant in neck dissection. As this is a pilot 
study, no formal assessment of efficacy, cost or safety across treatment arms are made. All analysis shall take the form of 
summary statistics and graphical summaries. Continuous data shall be presented using medians (inter-quartile ranges) 
and categorical data shall be presented as frequencies of counts with associated percentages. 
 
The outcomes for the pilot study include: 
• Proportion of eligible patients recruited to the study, calculated
 as the screened:randomisation ratio. 
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• Reasons for failure to screen potentially eligible patients. 
• Recruitment rate measured as the number of patients randomised each month. 
• Reasons for failure to randomise. 
• Reasons for failure to reveal allocation at a specific time point during surgery. 
• Fidelity of the blinding process (both patients and outcome assessors) as detected by blinding indi-
ces. 
• Accuracy of data recording, summarised by the number of key data items with missing/incomplete 
data entries. 
• Number of patients lost to follow-up. 
• Protocol adherence, measured by the number of major/minor protocol deviations observed through 
the study. 
• Determining the minimal clinically important difference (MCID) in clinical endpoints by questioning 
recruited patients and recruiting clinicians. 
 
 
4.3 Clinical Endpoints of Future Phase III Trial 
Any surgeon who is in theatre after the revealing of allocation is unblinded and must delegate post-operative 
clinical decisions and reporting of clinical endpoints to an appropriate colleague who is blinded. 
 
• Clavien-Dindo classification of surgical complications (Appendix A). 
• Twice daily wound drainage volume (ml). 
• Assessment of time to drain removal in hours from departure from theatre. 
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• Assessment of time to being declared ‘medically fit for discharge’ and actual hospital 
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discharge in hours from the time of ‘end of surgery’. 
 
Patient reported outcomes to be assessed for use in the future phase III study are: 
• Neck Dissection Impairment Index (NDII). This is a procedure specific patient reported outcome 
measure (Appendix B). 
• Daily patient reported pain score using Visual Analogue Scale (VAS) (Appendix C). 
• Wound Healing Questionnaire (WHQ). This is a questionnaire currently in the process of validation 
to assess wound healing after surgery (Appendix D). 
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5 STUDY POPULATION 
 
The pilot study setting will be Aintree University Hospital and Queen Victoria Hospital. These are both specialist hospitals 
for the management of Head & Neck Cancer in the UK. 
 
5.1 Inclusion Criteria 
• Patients due to undergo lateral neck dissection 
• Neck dissection to include a minimum of 3 levels 
• Patients who have capacity to consent 
 
5.2 Exclusion Criteria 
• Age < 18 years 
• Bilateral neck dissection 
• Presence of a vascular pedicle for reconstruction 
• Pregnancy or breast feeding 
• Known hypersensitivity reaction to Aprotinin 
• Previous exposure to Fibrin Sealant within 6 months 
• Known allergy to dairy products 
 
5.3 Patient Transfer and Withdrawal 
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By completing the DEFeND consent process, patients are consenting to trial treatment, follow-up and data collection. If 
voluntary withdrawal occurs, the patient should be asked to allow continuation of scheduled evaluations, complete an end-
of-study evaluation, and be given appropriate care under medical supervision until the symptoms of any adverse event 
resolve or the subject’s condition becomes stable. 
 
5.3.1 Patient Transfers 
For patients moving from the area, every effort should be made for the patient to be followed-up at another participating 
trial centre and for this trial centre to take over responsibility for the patient or for follow-up via GP. A copy of the patient 
CRFs should be provided to the new site. The patient will have to sign a new consent form at the new site, and until this 
occurs, the patient remains the responsibility of the original centre. The NWSTC should be notified in writing of patient 
transfers. 
 
5.3.2 Withdrawal from Trial Intervention 
Patients may be withdrawn from treatment for any of the following reasons: 
1) At their request or at the request of a legal representative. 
2) A change in surgical plan after enrolment such that the patient no longer meets the eligibility criteria. 
3) The investigators deems further involvement in the study detrimental to the wellbeing of the patient 
 
If a patient wishes to withdraw from trial treatment, centres should nevertheless explain the importance of remaining on 
trial follow-up, or failing this, of allowing routine follow- up data to be used for trial purposes. Generally, follow-up will 
continue unless the patient explicitly withdraws consent for follow-up (see section 5.3.3). 
 
5.3.3 Withdrawal from Trial Completely 
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Patients who withdraw from the trial for other reasons have previously consented to follow-up in the trial. Data up to this 
time can be included in the trial if anonymised. They may need to reaffirm that they consent to follow-up through usual NHS 
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mechanisms. If the patient explicitly states their wish not to contribute further data to the study, a withdrawal CRF should 
be completed. 
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6 ENROLMENT AND RANDOMISATION 
 
6.1 Screening 
Patients eligible for the DEFeND trial will be screened through outpatient clinics and/or Head & Neck MDT. The steps that 
will be completed on all patients to ensure they meet enrolment criteria include: 
• Clinical examination 
• Detailed medical history including previous treatment/surgery to the head & neck 
• Clinical decision to offer a lateral neck dissection 
 
A pre-screening log of all potential patients should be kept at each site, including individuals who decide not to participate 
in or are found to be unsuitable for the study. 
 
Screening will be performed upon a patient’s possible eligibility for the study as above and must be documented on the 
NWSTC Web Portal “Screening and Enrolment log”. Screening details should be entered into the portal and this will auto-
matically generate a screening number and a confirmation email with these details will be sent to site staff. The screening 
log can be printed at any time off the Portal to allow for storage in the Investigator Site File. 
 
Step-by-step guides will be issued to research site staff and the process will also be demonstrated during site initiations. 
All patients will be issued a screening number and, where possible, for patients who are not randomised a reason is rec-
orded. The importance of this is in establishing the screening:randomisation ratio which is a key endpoint of the pilot trial. 
 
6.2 Enrolment/ Baseline 
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Once the criteria for successful screening are complete, and at that point indicate a patient likely to meet eligibility criteria, 
the patient may be given information about the trial by means of careful explanation with the help of a PowerPoint presen-
tation, Patient Information Sheets and introduction to the Research Practitioner. 
 
The patient will be told that their lack of participation will not impact on the quality of their care. If they wish to consent they 
will be told that they may change their mind at any time. After signing the consent form, any necessary additional investi-
gations are carried out prior to randomisation: 
• Demographics (height, weight, age, gender, smoking and alcohol status). 
• Pre-operative neck pain Visual Analogue Scale (VAS) and Neck Dissection Impairment Index (NDII) 
questionnaire (see Appendix B and C). 
• Blood tests including full blood count, clotting screen (INR and APTT), liver function tests 
• A pregnancy test (beta-hCG blood test) for women of childbearing age will be offered. 
 
If offered, the pregnancy test needs to be carried out prior to randomisation as it constitutes an eligibility criteria. The other 
information mentioned above should also be carried out before randomisation as it constitutes important baseline meas-
urements. 
 
Patients will be enrolled onto the study by NWSTC once the following documents have been forwarded by the local inves-
tigator or research nurse: 
 
1. Eligibility checklist 
2. Enrolment forms 
3. Copy of signed Patient Consent Form 
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When the patient has been enrolled a confirmation email will be sent to the site detailing the patients MACRO ID, site, 
patient initials, DOB, screening number, proposed date 
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of surgery, details of consent and a link to the patient in the Treatment Allocation Randomisation System (TARDIS). The 
investigator will also be sent a link to a bespoke web based application for the DEFeND study. This bespoke application 
should only be accessed during surgery at the point of wound closure. 
 
6.3 Randomisation 
The process of randomisation will be undertaken pre-operatively using the TARDIS software. The allocation will be con-
cealed to everyone including the person performing the randmisation. Once the patient has undergone their neck dissection 
and immediately prior to the point of wound closure, the theatre team will login to a bespoke wed based application. Once 
logged in to this application the surgical team will enter data regarding the surgery including start time and surgeons present 
in theatre. Once this data has been entered the allocation will be revealed. This allocation will be revealed for a period of 
30 minutes before being concealed once more. 
 
As part of the blinding strategy, any clinicians who will be assessing study outcomes must leave theatre prior to 
the revealing of treatment allocation. They must not return until the theatre has been cleared of any evidence of 
ARTISS usage. The surgeon administering the ARTISS will not be allowed to assess study outcomes for the patient and 
must delegate this responsibility to a suitable colleague. 
 
To randomise, the research nurse will need to create a patient file on the MACRO database and enter the baseline param-
eters. Following this the research nurse should follow the link to TARDIS in the enrolment confirmation email. The research 
nurse will be prompted to confirm eligibility of the patient along with the stratification factor, this will enable randomisation 
to one of the two treatment arms. As stated before, although the patient has been randomised, their allocation will be 
concealed. The allocation will be revealed for a 30 minute window in theatre. 
 
Patients will be randomised to either ‘ARTISS’ or ‘Standard of Care’ in a ratio of 1:1. Randomisation lists shall be produced 
by a statistician at the NWSTC prior to the recruitment of the first patient. Lists shall be produced based on the principle of 
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randomly permuted blocks with random block sizes of 2 and 4. Patients will only be stratified according to the hospital in 
which they receive their treatment. 
 
 
Randomisation 24 hours a day (including public holidays) via web 
 
Web site: www.lctu.org.uk/tardis 
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7 TRIAL TREATMENT/S 
 
7.1 Introduction 
Patients will be randomised in a 1:1 ratio between arm A and arm B. Arm A constitutes ARTISS (Baxter Healthcare LTD) 
in addition to “standard of care”. Arm B constitutes “standard of care” only. 
 
7.2 Arm A: Neck dissection with fibrin sealant and standard wound closure 
Interventional Arm: Application of ARTISS fibrin sealant to the surgical wound in addition to “Standard of care”. “Standard 
of care” will include the establishment of a dry surgical field after performing the neck dissection using electrocautery &/or 
surgical ties &/or clips. The wound should then be irrigated with 100ml of Normal Saline and dried. Up to 2ml of ARTISS 
will be sprayed into the wound adhering to the manufacturer’s instructions and surgical protocol steps as defined below. 
 
7.2.1 Formulation, Packaging, Labelling, Storage and Stability ARTISS is a Fibrin Sealant (FS) man-
ufactured by Baxter Healthcare LTD. Further details regarding this product can be found in the man-
ufacturer’s ‘product information 
sheet’ in Appendix E. For the purposes of this study we will be using the 2ml pre-filled 
double chamber syringe preparation. ARTISS is licenced for use in the hospital setting and by surgeons trained in its 
application. Baxter Healthcare LTD describes the therapeutic indications of ARTISS as “a tissue glue to adhere/seal sub-
cutaneous tissue in plastic, reconstructive and burn surgery, as a replacement or an adjunct to sutures or staples. In addi-
tion, ARTISS is indicated as an adjunct to haemostasis on subcutaneous tissue surfaces.” Baxter Healthcare LTD describes 
the contraindications of ARTISS as: 
a) Treatment of massive and brisk arterial and venous bleeding 
b) Intravascular application 
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c) Hypersensitivity to the active substances or to any of the excipients 
 
ARTISS has a shelf life of 2 years and should be stored and transported in a frozen state at < -20oC. The syringe must be 
kept in the outer container in order to protect from light. Unopened pouches, thawed at room temperature, may be stored 
for up to 14 days at controlled room temperature (not exceeding +25oC). It is important not refreeze or refrigerate after 
thawing. 
 
7.2.2 Preparation, Dosage and Administration of Study Treatment/s 
Preparation 
The inner bag and its contents are sterile unless the integrity of the outside package is compromised. It is recommended 
to thaw and warm the two sealant components using a sterile water bath at a temperature of 33 – 37°C. The water bath 
must not exceed a temperature of 37°C. When using a sterile water bath for thawing and warming, the pre-filled double 
chamber syringe assembly should be removed from the aluminum- coated plastic bags). The protective syringe cap should 
not be removed until thawing is complete and the joining piece is ready to be attached. Do not use ARTISS unless it is 
completely thawed and warmed (liquid consistency). 
 
There are several methods of thawing the ARTISS, some of which take over 1 hour. Given that the patient’s allocation will 
be revealed intra-operatively at the time point immediately prior to wound closure, this study will utilise the “Quick Thawing” 
technique. Quick thawing is done by removing the ARTISS from the aluminium-coated 
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plastic bags and placing it in a sterile water bath at 33°C to a maximum of 37°C. It is recommended to use an infrared 
thermometer to check the water temperature prior to placing the ARTISS syringe in the water bath. The prefilled syringe is 
kept in the water bath for 5 minutes ensuring the contents are completely immersed. It is important to note that ARTISS 
cannot be thawed in your hands or in a microwave. After ‘Quick Thawing’ ARTISS may be stored at 33 – 37°C for a 
maximum of 4 hours. A flow chart summarizing the “Quick Thaw” technique can be found in Appendix F. 
 
The Sealer Protein and the Thrombin Solutions should be clear or slightly opalescent. Do not use solutions that are cloudy 
or have deposits. Thawed products should be inspected visually for particulate matter and discoloration prior to administra-
tion or any variation in physical appearance. In the event of either being observed, the solution should be discarded. The 
thawed Sealer Protein Solution should be a slightly viscous liquid. If the solution has the consistency of a solidified gel, it 
must be assumed to have denatured (e.g. due to an interruption of the cold storage chain or by overheating during warm-
ing). In this case, ARTISS must not be used. 
 
The next stage is to set up the EASYSPRAY pressure regulator device. Ensure there is a charged 9V battery and connect 
it to an IV pole or trolley using the clamps on the back of the device. Use a suitable connection tube to connect the 
EASYSPRAY device to medical air. Set the spray pressure to 1.5 bar. 
 
Firmly attach the spray head to the nozzle of the double-chamber syringe containing the thawed ARTISS. Fasten the ‘pull 
strap’ to the double-chamber syringe to assure the spray head is tightly secured. Fit the EASYSPRAY connection tube to 
the luer-lock connector on the underside of the spray head. Attach the clip on the end of the sensor line to the syringe 
plunger (pressing this clip emits air through the spray set). The ARTISS is now ready for use. A copy of the quick reference 
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The administration of ARTISS requires at least 3 people including a scrub practitioner, assistant and surgeon. While the 
ARTISS is being thawed the surgeon should irrigate the wound with 100ml of Normal Saline, dry the wound with gauze 
swabs, secure the surgical drain and place several resorbable parachute sutures across the platysma layer. These sutures 
should be loosely clipped and not tied to ensure good access to the wound. The drain should be held temporarily outside 
of the wound to ensure the perforations are not occluded by the ARTISS. The prepared spray set should not be held any 
closer than 10 cm to the wound to avoid the risk of air embolism. Once the application of ARTISS has commenced the 
surgeon has 60 seconds to administer up to 2ml and manipulate the skin flaps into position prior to polymerisation. It is 
therefore important to strictly adhere to the time using a stopwatch during the application of ARTISS. The assistant should 
retract any structures (e.g. sternocleidomastoid muscle) to ensure the surgeon can reach these sheltered areas and apply 
the ARTISS evenly in a thin layer across the entirety of the wound. It is not absolutely necessary to use the full 2ml, it is 
more important to apply the ARTISS in a thin layer avoiding pooling and large droplet formation. Once the ARTISS has 
been applied the drain and skin flaps repositioned and even pressure applied to the wound (using a large rolled up gauze 
swab) while the surgeon ties off all of the parachute sutures. It is very important that the surgeon does not lift the skin edges 
up while tying the sutures as this may break any adhesive bond created by the sealant. The surgical vacuum drain should 
then be activated and the assistant should maintain pressure on the neck for a full 3 minutes. After 3 minutes clips/staples 
are used to close the skin edges. When spraying the ARTISS, changes in blood pressure, pulse, oxygen saturation and 
end tidal CO2 should be monitored because of the possibility of air embolism. A flow chart summarising this surgical pro-
tocol can be found in Appendix H. 
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Any unused product or waste material should be disposed of in accordance with local requirements. 
 
7.2.3 Dose Modifications 
A maximum of 2ml of ARTISS can be applied. It is at the surgeon’s discretion how much of the 2ml is applied. It is important 
that the ARTISS is applied in an even and thin layer avoiding pooling and droplet formation. 
 
7.2.4 Accountability Procedures for Study Treatment/s 
Baxter Healthcare LTD has agreed to support the study in terms of ensuring adequate supplies of ARTISS and the asso-
ciated equipment. If there any faults with the equipment Baxter Healthcare LTD will either repair or replace the equipment 
in keeping with their standard customer service procedures. 
 
7.2.5 Assessment of Compliance with Study Treatment/s 
Only surgeons who have received training and have been accredited will be permitted to use ARTISS within this trial. 
NWSTC will cross-reference the names of the surgeons on the operation note with the delegation log. Compliance will be 
granted if at least one member of the operating team present during the administration of ARTISS has received training. 
 
7.3 Arm B: Neck dissection with standard wound closure 
Arm B is the control arm and constitutes “standard of care” alone. This will include the establishment of a dry surgical field 
after performing the neck dissection using electrocautery &/or surgical ties &/or clips. Patients will have a surgical drain 
placed and the wound closed in the usual manner. 
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It is unlikely that this trial will require unblinding as the ARTISS is administered only once in the theatre environment. The 
surgeon applying the ARTISS will not be blinded. The patient, surgeons assessing outcomes, ward nurses and research 
nurses will be blinded. The main clinical endpoints of interest (Clavien-Dindo, removal of drain, fitness for discharge) require 
the assessment of a surgeon. Therefore operating surgeons (who are unblinded) need to delegate these assessments to 
suitable blinded colleagues. Details of potential risks/complications associated with ARTISS are provided in section 2.4.1. 
 
A severe hypersensitivity reaction, air embolism or transmission of an infective agent constitute a serious adverse event. If 
they occur, severe hypersensitivity and air embolism would be anticipated to occur during or immediately after administra-
tion in the theatre setting. Staff caring for the patient at this time will not be blinded so there will not be a delay in diagnosis 
and emergency management. Fortunately these adverse events are incredibly rare, however if they did happened, the 
patient, outcome assessors and nursing staff would be unblinded only if the information is required for the ongoing medical 
management of the condition. 
 
In the event that the patient is diagnosed with an infectious disease that was not diagnosed pre-operatively, they will be 
unblinded. Based on the ‘Serious Hazards of Transfusion’ 2016 annual report, the following infectious diseases are known 
to have been transmitted via blood products in the UK: 
 
1. Hepatitis A, B, C or E 
2. Human Immunodeficiency Virus (HIV) 
3. Parvovirus (B19) 
4. Cytomegalovirus (CMV) 
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5. Human T-cell Lymphotropic Virus (HTLV) types I and II 
6. Malaria 
7. Variant Creutzfeldt-Jakob Disease (vCJD) or any other prion disease 
 
If the patient is newly diagnosed with any of the above infectious diseases, they will be unblinded and immediately referred 
to the appropriate medical specialists for treatment. 
 
7.5 Concomitant Medications/Treatments 
There are no restrictions on concomitant medications/treatments. 
 
• 7.5.1 Data on Concomitant Medication 
Only data on concomitant anticoagulant and anti-platelet medication will be collected. 
 
7.6 Overdoses 
No case of overdose has been reported. 
 
7.7 Co-enrolment Guidelines 
Patients who are currently participating in another clinical trial of an investigational medicinal product (CTIMP) will not be 
recruited to this study. 
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Patients who meet the eligibility criteria and are participating in a subsequent study which is not a CTIMP, may be ap-
proached and recruited provided there are no consequences to the scientific validity of either study. Co-enrolment remains 
at the discretion of the Principal/Chief Investigators for the respective trials. 
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8 ASSESSMENTS AND PROCEDURES 
 
8.1 Schedule of Trial Procedures 
Participants will be involved in the study for 6 weeks from the date of surgery. Post- operative assessments, including daily 
in-patient and follow-up visits, must be conducted by a blinded member of the trial team. The randomising surgeon MUST 




























































































































Identify potential participant X X         
Approach potential participant to discuss 
study 
X X         
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Medical history  X         
Physical examination  X         
Assessment of eligibility criteria  X         
Review of concomitant anticoagulant med-
ications 
 X X X X X X X X X 
Review of previous treatment to ipsilateral 
neck 
X         
Demographic assessment  X         
Signed consent form    X       






Neck pain (VAS)    X  X X X X X 
Neck Dissection Im-
pairment Index (NDII) 
    
X 














    X      
Allocation revealed at 
point of wound clo-
sure 
   X      
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tional arm only) 
     
X 







Assessment of AEs 
(Clavien-Dindo) 
   X X X X X X 
Twice Daily Wound 
Drainage Volume 
(ml) 
    X     
Wound Drain Re-
moval 
     X     
Hospital Discharge      X     
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Full Blood Count**    X       




  X       
Microbiology Swab 
from Neck Wound & 
Oral Cavity 













       X  
 
Figure 1. Schedule of DEFeND enrolment, interventions and assessments (SPIRIT) 
(X) – As indicated/appropriate. 
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*At baseline, all procedures should be done before study intervention. 
**Full Blood Count must include Hb concentration, platelet count and white cell count 
 
8.2 Procedures for assessing Efficacy 
A central review process will be undertaken to assess the neck dissection specimen which should include 3 or more levels 
of the neck. Lymph node yield will be used as a proxy to assess the extent of surgery. 
 
8.3 Procedures for Assessing Safety 
Safety will be assessed through reporting on post-operative complications as described in section 10 and Appendix A. All 
post-operative complications that occur from the time of surgery up to data collection at week 6 will be reported. 
 
8.4 Other Assessments 
 
8.4.1 Quality of Life and Health Economics 
 
Neck Dissection Impairment Index (NDII) 
The NDII is a procedure specific Health Related Quality of Life (HRQoL) assessment tool. The tool is validated for use in 
patients who have undergone selective or modified radical neck dissection.18 Although the NDII is not validated for use 6 
weeks after surgery, there is evidence that the NDII score at this early juncture is representative of longer-term HRQoL.19 
A copy of the NDII questionnaire can be found in Appendix B. 
 
Incremental Cost-Effectiveness Ratio (ICER) 
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The health economic (HE) assessment of using fibrin sealant (ARTISS) will be piloted using the ‘incremental cost-effec-
tiveness ratio’ (ICER). This will calculate the average incremental cost associated with each surgical complication prevented 
when compared to ‘standard of care’ (SOC) treatment without ARTISS. This will be calculated using the following equation: 
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ICER = Overall cost of ARTISS arm – Overall cost of SOC arm 
 
No. of complications in ARTISS arm – No. of complications in SOC arm 
 
The variation in costs between the treatment arms will be calculated individually for each patient based on their time in the 
operating theatre (including returns to theatre), their length of stay within each ward type, their number of hospital visits in 
the immediate post-operative period (both planned and unplanned), and the cost of materials (including those required to 
administer ARTISS). 
 
8.4.2 Special Assays or Procedures 
Microbiology swabs will be taken for the sub-study (see section 8.5). This will include taking a standard hospital microbiol-
ogy swab from the neck wound and oral cavity. These samples will be taken intra-operatively by the surgeon and by nursing 
staff on the ward and outpatient department. A member of the Institute of Infection & Global Health, University of Liverpool, 




Development of novel biomimetic antimicrobial therapies to mitigate against bacterial wound infections following 
Head & Neck Cancer surgery. 
 
A promising strategy for the next generation of antimicrobial therapeutics will be to specifically target the bacteria’s signal-
ling pathways inhibiting biofilm formation and detachment. Theoretically, by disrupting bacterial signalling pathways, there 
should be a lower tendency for the bacteria to develop defence responses and resistant mutants. The gene-expression 
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patterns of biofilms differ from planktonic bacteria and deciphering the genetic basis of biofilm formation will allow for an 
inherent understanding of the formation of these sessile communities and their inherent resistance to antimicrobial agents. 
Biofilms develop an ordered structure whereby bacteria are embedded in a protective exopolysaccharide matrix. This, along 
with other factors, can make bacterial biofilms incredibly resistant to treatment. In addition, bacteria within biofilms can form 
multispecies communities which can further complicate treatment regimens with consequent negative clinical outcomes. 
 
Using clinical samples from infected and non-infected neck wounds, molecular characterisation of microbial communities 
through sequencing will allow the identification of the different bacterial species within the wounds and through network 
analysis, identify associations with the risk of poor clinical outcomes and prolonged treatment. Furthermore, as part of this 
work a model of biofilm dispersal will be developed to understand the risk of infection dissemination and enable testing of 
the novel therapeutics under infection–relevant conditions. This will provide the underpinning knowledge to rationally design 
efficacious antimicrobial therapeutics that do not lead to antimicrobial resistance. 
 
This aim will be realised though the following objectives: 
• Isolation of and 16S rRNA microbiome sequencing of clinical samples from infected and uninfected 
head and neck surgery patients. 
• Encapsulation of naturally derived antimicrobials in currently utilised, aerosol-applied, fibrin sealants 
for controlled and sustained release. 
• Testing of efficacy of antimicrobial/fibrin capsules on clinical isolates. 
• Benchmarking of efficacy of antimicrobial therapeutics on laboratory reference strains vs. clinical 
isolates. 
• Develop biofilm dispersal model. 
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This sub-study will not impact on the main study. Patients who develop neck infections within this study will require micro-
biology samples as part of their standard care. The only additional samples required for this sub-study will be non-invasive 
samples from the neck wound and oral cavity in the form of standard hospital microbiology swabs. 
 
8.6 Loss to Follow-up 
If any of the trial participants are lost to follow up, contact will initially be attempted through the PI at each centre. If the PI 
at the trial centre is not the participant’s usual clinician responsible for their speciality care then follow-up will also be 
attempted through this clinician. Where all of these attempts are unsuccessful, the patient’s GP will be asked to provide 
follow-up information they may have to the recruiting centre. 
 
All patients, whether lost to follow up or not, will have their data collected at week 6. 
 
8.7 Trial Closure 
Investigators will be informed when patient recruitment is to cease. 
 
Trial enrolment may be stopped at a site when the total number of participants for the trial has been obtained. 
 
The trial will close once all the subjects that have been randomised have completed six weeks of post-surgical follow up, 
all centres have completed and returned all necessary (e)CRF’s. 
 
The TSC may stop the trial prematurely. Such premature termination / suspension of the trial will be notified to the MREC 
as required. 
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The trial will be considered formally closed when the database is locked. 
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9 STATISTICAL CONSIDERATIONS 
 
9.1 Introduction 
This section contains an overview of all statistical considerations for the DEFeND trial including details on trial design 
patient randomisation and an overview of the statistical methodology used. Note that a separate Statistical Analysis Plan 
(SAP) will be produced to give full details of all data analysis in the study. 
 
9.2 Method of Randomisation 
Randomisation lists shall be produced by a statistician at the NWSTC prior to the recruitment of the first patient. Patients 
shall be randomised using a 1:1 ratio. Lists shall be produced based on the principle of randomly permuted blocks with 
random block sizes of 2 and 4. Patients will only be stratified according to the hospital in which they receive their treatment. 
 
9.3 Outcome Measures 
As DEFeND is an external pilot study, trial outcomes are categorised into those which address deliverability and feasibility 
of a larger study, those which address clinical outcomes of patients in the study and patient reported outcomes which will 
inform patient perspectives of the study and its interventions. 
 
9.3.1 Pilot Study Outcomes 
• Proportion of eligible patients recruited to the study, calculated as the screened to 
• randomisation rate. 
• Reasons for failure to screen potentially eligible patients. 
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• Recruitment rate measured as the number of patients randomised each month. 
• Reasons for failure to randomise. 
• Reasons for failure to reveal allocation at a specific time point during surgery. 
• Fidelity of the blinding process (both patients and outcome assessors) as detected by blinding indi-
ces. 
• Accuracy of data recording, summarised by the number of key data items with missing/incomplete 
data entries. 
• Number of patients lost to follow-up. 
• Protocol adherence, measured by the number of major/minor protocol deviations observed through 
the study. 
• Determining the minimal clinically important difference (MCID) in clinical endpoints by questioning 
recruited patients and recruiting clinicians. 
 
9.3.2 Clinical Endpoints of Future Phase III Trial 
• Clavien-Dindo classification of surgical complications (Appendix A) 
• Daily wound drainage volume (ml) 
• Time (hours) for daily wound drainage volume to reach <30ml/24hrs 
• Time (hours) to drain removal (as dictated by drainage volume) 
• Total wound drainage volume (ml) 
• Time (hours) to be declared medically fit for hospital discharge and time (hours) to actual hospital 
discharge 
• Incremental cost-effectiveness ratio 
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9.3.3 Patient Reported Outcomes 
• Neck Dissection Impairment Index (NDII). This is a procedure specific validated patient reported 
outcome measure (Appendix B) 
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• Daily patient reported pain score using Visual Analogue Scale (VAS) (Appendix C) 
• Wound Healing Questionnaire (WHQ). This is a questionnaire currently in the process of validation 
to assess wound healing after surgery (Appendix D). 
 
9.4 Sample Size 
As this is a pilot study, no formal power/sample size calculation based on clinical data is given. For this study the two main 
outcomes of interest are to determine accurate estimates of the rate of recruitment (being the number of patients recruited 
relative to the number eligible) and to collect sufficient clinical data to accurately estimate a sample size for a future study. 
It is estimated that over the study period, approximately 50 patients will be recruited at rate of 30%. Based on this, 50 
patients (25 in each arm) will produce a standard error of approximately 6.5% and a 95% confidence interval of approxi-
mately (17 – 43%) will be obtained. With respect to surgical complication rate, being the clinical outcome of current greatest 
interest, even if a response rate of 50% is observed then a 95% confidence interval of (0.36, 0.64) will be observed which 
provides sufficient precision for a future sample size. 
 
9.5 Interim Monitoring and Analyses 
Formal interim analyses of the accumulating data will be performed at 6 monthly intervals after the recruitment of the first 
patient. A formal Independent Data Monitoring and Safety Committee (ISDMC) will not be convened. In keeping with the 
guidance outlined in the document 'Guideline in Data Monitoring Committees' published by the Committee for Medicinal 
Products for Human Use, it is thought that an IDSMC is not required. This is because patients will be treated for a very 
short period of time (single administration during surgery) and Fibrin Sealants are well characterised and already widely 
used within healthcare. Although there are potential risks to patients, these are incredibly rare and known. 
 
The independent members of the TSC (Chairperson, expert, statistician) will take responsibility for reviewing all interim 
safety data. The independent members will be asked to give advice on whether the accumulated data from the trial, together 
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with results from other relevant trials, justifies continuing recruitment of further patients or further follow-up. Given this is a 
pilot/feasibility study, it is anticipated that the TSC will only recommend termination on grounds of safety. 
 
9.6 Statistical Analysis 
 
9.6.1 Patient Groups 
The primary analysis will be carried out on the full analysis set which will be depend on the intention to treat principle 
retaining patients in their initially randomised groups irrespective of any protocol violations 
 
9.6.2 Missing Data 
Missing data are expected to be small and final analyses are planned to be carried out on a complete case basis. If sub-
stantial missing data (>10%) are observed in either a study outcome or key prognostic covariate then multiple imputation 
using chained equations will be applied. 
 
9.6.3 Levels of Significance 
There are no formal comparison of treatment groups and therefore no levels of significance against which hypotheses 
should be tests. As a guide however, all reported results will be reported using nominal 95% confidence intervals. 
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9.6.4 Analysis of study outcomes 
As this is an external pilot study, all data analyses shall take the form of descriptive statistics. Continuous data shall be 
summarised as medians with associated inter- quartile ranges and categorical data shall be summarised as frequencies of 
counts and associated percentages. 
 
In terms of clinical outcomes, aside from descriptive statistics then informal comparisons between allocated groups will be 
made using difference in means for continuous covariates and difference in rated for categorical covariates. 
 
9.6.5 Analysis of study toxicity 
Adverse events (AEs) and serious adverse events (SAEs) shall be defined using CTC (Version 4) definitions. All AEs and 
SAEs shall be compared across groups using the TAME guidelines. Furthermore, the worst AE/SAE for each type for each 
patients shall also be retained and compared across treatment groups using a stratified Chi-Square test. 
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10.1 Terms and Definitions 
The following definitions have been adapted from European Directive 2001/20/EC and ICH GCP E6 
 
Adverse Event (AE) 
Any untoward medical occurrence (i.e. any unfavourable or unintended sign, symptom or disease) in a research participant 
to whom a surgical/clinical intervention has been administered, including occurrences which are not necessarily caused by 
or related to that intervention. Surgical complications and adverse reactions to ARTISS fibrin sealant will be the only 
events reported to assess safety. 
 
Surgical Complication 
Any deviation from the ideal postoperative course that is not inherent in the procedure and does not comprise a failure to 
cure (disease or condition that remains unchanged after surgery).20 
 
Unexpected Adverse Reaction (UAR) 
An adverse reaction the nature and severity of which is not consistent with the information about ARTISS set out in the 
summary of product characteristics. All UARs will be reported. 
 
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) 
Any adverse event or adverse reaction is classified as serious if it: 
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1) results in death 
2) is life-threatening* (subject at immediate risk of death) 
3) requires in-patient hospitalisation or prolongation of existing hospitalisation** 
4) results in persistent or significant disability or incapacity, or 
5) consists of a congenital anomaly or birth defect 
6) Important medical events that may not be immediately life-threatening or result in death or hospital-
isation but may jeopardise the patient or may require intervention to prevent one of the other out-
comes listed in the definition above should also be considered serious. 
 
*‘life-threatening’ in the definition of ‘serious’ refers to an event in which the patient was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it were more severe. 
**Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a precau-
tionary measure for continued observation. Hospitalisations for a pre-existing condition, including elective proce-
dures that have not worsened, do not constitute an SAE. 
 
10.2 Notes on Adverse Event Inclusions and Exclusions 
 
10.2.1 Include 
• Associated symptoms and events that are related to the trial surgery and/or use of ARTISS fibrin 
sealant that are Clavien Dindo grade IV or above (see Appendix A). 
• An exacerbation of a pre-existing illness/condition that is deemed to be related to the trial surgery 
and/or use of ARTISS fibrin sealant. 
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• An increase in frequency or intensity of a pre-existing episodic event/condition that is deemed to be 
related to the trial surgery and/or use of ARTISS fibrin sealant. 
• A condition (even though it may have been present prior to the start of the trial) detected after the 
trial surgery and/or use of ARTISS fibrin sealant. 
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• Continuous persistent disease or symptoms present at baseline that worsens following the trial sur-
gery and/or use of ARTISS fibrin sealant. 
 
10.2.2 Do Not Include 
• Events including signs, symptoms and disease that are not deemed a complication of the trial sur-
gery as per the definition above. 
• Generalised signs and symptoms of having undergone major head and neck surgery 
e.g. lethargy, difficulty with speech and/or swallow. 
• Associated symptoms and events that are related to the trial surgery and/or use of ARTISS fibrin 
sealant that are Clavien Dindo grade IIIb or below (see Appendix A). 
• Extended hospital stay due to a delay in planned surgery. 
• In-patient hospitalisation or prolongation of existing hospitalisation due to post- operative complica-
tions that are grade IIIb or below (see Appendix A). 
• Medical or surgical procedures - the condition which leads to the procedure is the SAE. 
• Pre-existing disease or conditions present before surgery that do not worsen. 
• An exacerbation of a pre-existing illness/condition that is not deemed to be related to the trial surgery 
and/or use of ARTISS fibrin sealant. 
• An increase in frequency or intensity of a pre-existing episodic event/condition that is not deemed to 
be related to the trial surgery and/or use of ARTISS fibrin sealant. 
• Situations where an untoward medical occurrence has occurred e.g. cosmetic elective surgery. 
• The disease being treated or associated symptoms/signs unless more severe than expected for the 
patient’s condition. 
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• Injury or accidents. 
• Abnormal laboratory results. 
 
10.2.3 Reporting of Pregnancy 
Pregnancy is listed as an exclusion criterion for entry to the DEFeND trial. 
 
In the event of a patient becoming pregnant after recruitment to the trial, this fact should be reported as soon as possible 
to the C.I through NWSTC (as if an SAE). The guiding principles in this event are:- 
1) If the patient has not yet received treatment, or completed treatment, the patient may be withdrawn 
from the trial. 
2) Once treatment is complete, i.e. the patient is in follow-up phase, it may well be possible to retain 
the patient to the conclusion of the trial. 
3) A decision will be made in the best interests of the patient between the treating clinician and the C.I. 
as to retention in the trial and any continuing cancer therapy. 
 
10.3 Notes Severity / Grading of Adverse Events (Surgical Complications) 
The assignment of the severity/grading should be made by a blinded surgeon who has been delegated this re-
sponsibility by the operating surgeon. Regardless of the classification of an AE as serious or not, its severity must be 
assessed according to medical criteria alone using the Clavien-Dindo Classification of Surgical Complications as detailed 
in Tables 1 and 2 in Appendix A.20 Table 1 describes the original Clavien-Dindo classification whereas Table 2 provides 
an interpretation of the Clavien-Dindo classification for some common/established complications after Head & Neck Surgery 
relevant to this trial. 
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10.4 Relationship to Trial Treatment 
The assignment of causality should be made by a blinded surgeon who has been delegated this responsibility by 
the operating surgeon using the definitions in Table 3. 
 
Causality should be assigned to the following: 
1. Anaesthetic 
2. Generality of surgery (including surgical airway, primary tumour resection) 
3. Neck dissection surgery 
4. Use of ARTISS fibrin sealant 
 
If any doubt about the causality exists the local investigator should inform the study coordination centre who will notify the 
Chief Investigators. In the case of discrepant views on causality between the investigator and others, the Research Ethics 
Committee (REC) will be informed of both points of view. 
 
Table 3: Definitions of Causality 
 
Relationship Description 
None There is no evidence of any causal relationship. N.B. An alternative cause 
for the AE should be given 
Unlikely There is little evidence to suggest there is a causal relationship (e.g. the 
event did not occur within a reasonable time after administration of the trial 
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intervention). There is another reasonable explanation for the event (e.g. the 
participant’s clinical condition, other concomitant treatment). 
Possibly There is some evidence to suggest a causal relationship (e.g. because the 
event occurs within a reasonable time after administration of the trial inter-
vention). However, the influence of other factors may have contributed to the 
event (e.g. the participant’s clinical condition, other 
concomitant treatments). 
Probably There is evidence to suggest a causal relationship and the influence of other 
factors is unlikely. 
Highly Probable There is clear evidence to suggest a causal relationship and other possible 
contributing factors can be ruled out. 
 
10.5 Expectedness 
Expectedness will be assessed against the following: 
1. Neck dissection surgery 
2. Use of ARTISS fibrin sealant 
 
Post-operative complications related to either neck dissection or use of ARTISS fibrin sealant that are Clavien-Dindo grade 
IIIb or below are expected for the DEFeND trial. 
 
Post-operative complications related to either neck dissection or use of ARTISS fibrin sealant that are Clavien-Dindo grade 
IV or above are unexpected for the DEFeND trial. 
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An AE (surgical complication) where the causal relationship to the study procedure (neck dissection and/or use of ARTISS 
fibrin sealant) is assessed by the investigator as “possible”, “probable”, “highly probable”, is graded as serious and unex-
pected (SUSAR) is subject to expedited reporting to the Research Ethics Committee (REC). This is the responsibility of 
NWSTC. 
 
10.6 Reference Safety Information 
The Reference Safety Information (RSI) to be used for this trial is as follows: 
 
• Appendix E: ARTISS Summary Product Information Sheet (section 4.8) 
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10.7 Follow-up After Adverse Events 
All adverse events should be followed until satisfactory resolution or until the investigator responsible for the care of the 
participant deems the event to be chronic or the patient to be stable. 
 
When reporting SAEs and SUSARs the investigator responsible for the care of the participant should apply the following 
criteria to provide information relating to event outcomes: resolved; resolved with sequelae (specifying with additional nar-
rative); not resolved/ongoing; ongoing at final follow-up; fatal or unknown. 
 
10.8 Reporting Procedures 
All adverse events should be reported from the point of consent until 6 weeks after surgery. Depending on the nature of 
the event the reporting procedures below should be followed. Any questions concerning adverse event reporting should be 
directed to the NWSTC in the first instance. 
 
10.7.1 Non serious ARs/AEs 
All non-serious expected and unexpected complications of surgery should be reported from the day of surgery at each 
post-operative study visit and throughout the follow up phase. All complications should be reported on the appropriate CRF 
and graded using the Clavien-Dindo Classification of Surgical Complications. 
 
10.7.2 Serious ARs/AEs/SUSARs 
All complications related to the neck dissection surgery and/or use of ARTISS fibrin sealant that are Clavien-Dindo grade 
IV or above must be reported as SARs, SAEs and SUSARs. They should be reported within 24 hours of the local site 
becoming aware of the event up to 6 weeks post-surgery. SARs, SAEs and SUSARs may be reported past 6 weeks if 
deemed appropriate to do so by the local investigator (e.g. the complication is considered to be related to the trial surgery). 
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The SAE form asks for the nature of event, date of onset, severity, corrective therapies given, outcome and causality. The 
responsible investigator should sign the causality of the event. Additional information should be sent within 5 days if the 
complication has not resolved at the time of reporting. 
 
All complications related to the neck dissection surgery and/or use of ARTISS fibrin sealant that are Clavien-Dindo 
grade IIIb or below that meet the definition of serious are exempt from SAE reporting. Such events should only be 
reported in the relevant section of the CRF. 
 
Clarification on the Clavien-Dindo grading of common/established complications following major head and neck 
surgery is provided in Table 2 within Appendix A. 
 
The NWSTC will notify the main REC of all SUSARs occurring during the study according to the following timelines; fatal 
and life-threatening within 7 days of notification and non-life threatening within 15 days. All investigators will be informed of 
all SUSARs occurring throughout the study. Local investigators should report any SUSARs and /or SAEs as required by 
their Local Research Ethics Committee and/or Research & and Development Office. 
 
10.9 Responsibilities – Investigator 
The Investigator is responsible for reporting all AEs that are observed or reported during the study, regardless of their 
relationship to study product. 
All SAEs must be reported immediately by the investigator to the NWSTC on an SAE form unless the SAE is specified in 
the protocol, IB or SPC as not requiring immediate 
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reporting. All other adverse events should be reported on the regular progress/follow- up reports. 
 
Minimum information required for reporting: 
• Study identifier 
• Study centre 
• Patient number 
• A description of the event 
• Date of onset 
• Current status 
• Whether study treatment was discon-
tinued 
• The reason why the event is classi-
fied as serious 
• Investigator assessment of the 




i. The SAE form should be completed by the responsible investigator i.e. the consultant named on the 
‘signature list and delegation of responsibilities log’ who is responsible for the patient’s care. The inves-
tigator should assess the SAE for the likelihood that that it is a response to an investigational medicine. 
In the absence of the responsible investigator the form should be completed and signed by a designated 
member of the site trial team and faxed to the NWSTC immediately. The responsible investigator should 
check the SAE form, make changes as appropriate, sign and then re-fax to the NWSTC as soon as 
possible. The initial report shall be followed by detailed, written reports. 
ii. Send the SAE form by fax (within 24 hours or next working day) to the NWSTC. 
 
Fax Number: 0151 794 8930/8931 
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iii. The responsible investigator must notify their local ethics committee (LREC) and R&D department of 
the event (as per standard local procedure). 
iv. In the case of an SAE the subject must be followed-up until clinical recovery is complete and laboratory 
results have returned to normal, or until the event has stabilised. Follow-up may continue after comple-
tion of protocol treatment if necessary. 
v. Follow-up information is noted on another SAE form by ticking the box marked ‘follow-up’ and faxing to 
the NWSTC as information becomes available. Extra, annotated information and/or copies of test results 
may be provided separately. 
vi. The patient must be identified by trial number, date of birth and initials only. The patient’s name should 
not be used on any correspondence. 
 
10.9.1 Maintenance of Blinding 
Systems for SUSAR and SAR reporting should, as far as possible, maintain blinding of individual clinicians and of trials 
staff involved in the day-to-day running of the trial. Unblinding clinicians may be unavoidable if the information is necessary 
for the medical management of particular patients. The safety of patients in the trial always takes priority. In each report, 
seriousness, causality and expectedness should be evaluated for all of the trial treatments unless criteria have been fulfilled 
(section 7.4) and unblinding has taken place. Cases that are considered serious, unexpected and possibly, probably or 
almost certainly related to one of the trial therapies (i.e. possible SUSARs) would have to be unblinded at the clinical trials 
unit prior to reporting to the regulator and re-evaluated for expectedness in light of the administered treatment. 
 
 
10.10 Responsibilities – LCTU 
The NWSTC, part of LCTU, is undertaking duties delegated by the trial sponsor/, University of Liverpool, and is responsible 
for the reporting of SUSARs and other SARs to the Research Ethics Committee as follows: 
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• SUSARs which are fatal or life-threatening must be reported not later than 7 days after the NWSTC is 
first aware of the reaction. Any additional relevant information must be reported within a further 8 days. 
• SUSARs that are not fatal or life-threatening must be reported within 15 days of the NWSTC first becom-
ing aware of the reaction. 
• A list of all SARs (expected and unexpected) must be reported annually. 
It is recommended that the following safety issues should also be reported in an expedited fashion 
VI. An increase in the rate of occurrence or a qualitative change of an expected serious adverse reac-
tion, which is judged to be clinically important; 
VII. Post-study SUSARs that occur after the patient has completed a clinical trial and are notified by the 
investigator to the sponsor; 
VIII. New events related to the conduct of the trial or the development of the IMPs and likely to affect the 
safety of the subjects, such as: 
o  A serious adverse event which could be associated with the trial procedures and which 
could modify the conduct of the trial; 
o A significant hazard to the subject population, such as lack of efficacy of an IMP used for 
the treatment of a life-threatening disease; 
o A major safety finding from a newly completed animal study (such as carcinogenicity). 
o Any anticipated end or temporary halt of a trial for safety reasons and conducted with the 
same IMP in another country by the same sponsor; 
IX. Recommendations of the independent members of Trial Steering Committee, if any, where relevant 
for the safety of the subjects. 
 
Protocol No: ISRCTN99181100 Page 363 of 
81 
DEFeND Protocol Version 2.0 Date 27/06/2018 
 
 
Staff at the NWSTC will liaise with the designated Clinical Co-ordinator who will evaluate all SAEs received for seriousness, 
expectedness and causality. Investigator reports of suspected SARs will be reviewed immediately and those that are SU-
SARs identified and reported to regulatory authorities and REC. The causality assessment given by the Local Investigator 
at the hospital cannot be overruled and in the case of disagreement, both opinions will be provided with the report. 
 
The NWSTC will also send an annual progress report to the Research Ethics Committee which will include all safety infor-
mation. 
 
Patient safety incidents that take place in the course of research should be reported to the National Patient Safety Agency 
(NPSA) by each participating NHS Trust in accordance with local reporting procedures. 
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11 ETHICAL CONSIDERATIONS 
 
11.1 Ethical Considerations 
Ethical review of the study is a legal requirement to safeguard the rights, dignity and welfare of people participating in 
research. Amendments made to the study after a favourable ethical and regulatory opinion will be submitted and approved 
prior to implementation. The requirement for ethical and regulatory authority approvals applies to all participating countries. 
Each participating PI will be named on the original ethics application form or on a subsequent substantial amendment. 
Written evidence of favourable NHS capacity and capability must be made available to the NWSTC prior to randomisation 
of subjects at site. 
 
Specifically for the DEFeND trial: 
1) There will be no involvement of patients who are children or deemed to lack capacity. There are no 
additional hospital visits required. 
2) Consent will be sought after a full explanation of the trial including potential risks and benefits. Con-
sent will not be taken on the same day as their surgery. 
3) The only additional investigation will be a wound swab. This is an entirely painless and non-invasive 
procedure with no associated risks. 
4) There will be no use of placebo. 
5) No patient will be denied any additional treatment. 
 
11.2 Ethical Approval 
The trial protocol has received the favourable opinion of the North West – Greater Manchester East Multi-centre Research 
Ethics Committee (MREC) but all participating sites must undergo site specific assessment of capacity and capability. A 
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copy of all site approval documents and a copy of the PIS and ICF on local headed paper should be forwarded to NWSTC 
before patients are entered. The NWSTC should receive a confirmation of capacity and capability for each new centre via 
the site’s R&D department 
 
 
11.3 Informed Consent Process 
Informed consent is a process initiated prior to an individual agreeing to participate in a trial and continues throughout the 
individual’s participation. Informed consent is required for all patients participating in NWSTC coordinated trials. In obtaining 
and documenting informed consent, the investigator should comply with applicable regulatory requirements and should 
adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki. 
 
Discussion of objectives, risks and inconveniences of the trial and the conditions under which it is to be conducted are to 
be provided to patients by staff with appropriate experience. An appropriate Patient Information and Consent forms, de-
scribing in detail the trial interventions/products, trial procedures and risks will be approved by an independent ethical 
committee (IEC) and the patient will be asked to read and review the document. Upon reviewing the document, the inves-
tigator will explain the research study to the patient and answer any questions that may arise. A contact point where further 
information about the trial may be obtained will be provided 
 
After being given adequate time to consider the information, the patient will be asked to sign the informed consent docu-
ment. A copy of the informed consent document will be given to the patient representative for their records and a copy 
placed in the medical records, with the original retained in the Investigator Site File. 
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The patient may withdraw from the trial at any time by revoking the informed consent. The rights and welfare of the patients 
will be protected by emphasising to them that the quality of medical care will not be adversely affected if they decline to 
participate in this study. 
 
11.4 Study Discontinuation 
The chief investigator can prematurely close this trial after consultation with the TSC. The local ethics committee will be 
informed. Reasons for trial termination include: 
1. The incidence or severity of SAE’s/morbidity in this trial indicates a potential health hazard caused 
by the study treatment. 
2. External evidence demanding trial termination. 
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12 REGULATORY APPROVAL 
 
This trial does not require regulatory approval as the MRHA do not consider DEFeND to be a clinical trial of an investiga-
tional medicinal product (CTIMP). 
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13 TRIAL MONITORING 
 
Site monitoring is conducted to ensure protection of patients participating in the trial, trial procedures, laboratory, trial inter-
vention administration, and data collection processes are of high quality and meet sponsor and, when appropriate, regula-
tory requirements. Provide a description of how site monitoring will be conducted. A monitoring plan based on the risk 
assessment and in line with NWSTC Monitoring SOPs should be developed to describe who will conduct the monitoring, 
at what frequency monitoring will be done, and what level of detail monitoring will be conducted. 
 
13.1 Risk Assessment 
In accordance with the NWSTC Standard Operating Procedure a risk assessment will be completed in partnership with the 
following: 
 
• Trial Sponsor 
• Chief Investigator 
• Trial Coordinator 
• Trial Statistician 
 
In conducting the risk assessment, the contributors will consider potential patient, organisational and trial hazards, the 
likelihood of their occurrence and resulting impact should they occur. 
 
The outcome of the risk assessment will be assigned according to the following categories: 
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1. Type A: no higher than that of standard medical care 
2. Type B: somewhat higher than that of standard medical care 
3. Type C: markedly higher than that of standard medical care 
 
This trial is a Non-CTIMP and the risk categories described above for CTIMPs (type A, B or C) have been applied to the 
DEFeND trial. 
 
As this is a surgical intervention trial comparing ‘ARTISS’ to ‘no ARTISS’, with no changes to the clinical procedure itself, 
this study is classed as Type A and thus will be of low risk. 
 
13.2 Source Documents 
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary 
for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certi-
fied copies) (ICH E6, 1.51). 
 
Original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, 
subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies 
or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm 
or magnetic media, x-rays, subject files, and records kept at the pharmacy and laboratory departments involved in the 
clinical trial (ICH E6, 1.52):62. 
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In order to resolve possible discrepancies between information appearing in the (e)CRF and any other patient related 
documents, it is important to know what constitutes the source document and therefore the source data for all information 
in the (e)CRF. Data recorded in the (e)CRF should be consistent and verifiable with source data in source documents other 
than the (e)CRF (e.g. medical record, laboratory reports and nurses” notes). Each participating site should maintain appro-
priate medical and research records for this trial, in compliance with ICH E6 GCP, section 4.9 and regulatory and institu-
tional requirements for the protection of confidentiality of subjects. 
 
For data where no prior record exists and which are recorded directly in the (e)CRF (e.g. inclusion/exclusion criteria, ad-
verse events and Quality of life questionnaires), the (e)CRF will be considered the source document, unless otherwise 
indicated by the investigator. 
 
In addition to the above, date (s) of conducting informed consent including date of provision of patient information, trial 
screening number, trial number, study treatment and the fact that the patient is participating in a clinical trial should be 
added to the patients’ medical record contemporaneously. 
 
13.3 Data Capture Methods 
All trial data will be captured using electronic Case Report Forms (eCRFs), transcribed to a MACRO Database. This data-
base is designed and maintained by the NWSTC. The eCRF is the primary data collection instrument for the study. All data 
requested on the eCRF must be recorded and all missing data must be explained. 
 
All eCRFs are entered directly into a MACRO database that can be accessed via a secure webpage by research site staff 
and the relevant staff at NWSTC. The client application is secured with a unique username/password combination allocated 
to each delegated member of the research team. When data is entered into an eCRF it is electronically stamped with the 
date, time and the person who entered it. If data is changed on an eCRF, it is electronically stamped with the change and 
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will be accompanied with the date, time, person and a reason for making the change or correction. The previous value is 
recorded in an audit trail for each data item. 
 
Each eCRF contains specific validation checks on the data being entered. If any values are outside what is expected, or 
data is missing, this is flagged up and will be raised as a discrepancy on the main database system. Regular reports will 
be generated to identify discrepancies in the data, and allow for follow up. Comprehensive guidelines for eCRF data entry 
will be provided to all staff who have been delegated the responsibility for data collection. Where the site is unable to upload 
data using the eCRF, e.g. internet unavailability, a backup paper CRF will be available to use and accessed from the 
NWSTC portal. In such cases the research staff will retrospectively enter the data onto the trial MACRO database following 
the visit. 
 
13.4 Monitoring at North West Surgical Trials Centre 
Data stored at NWSTC will be checked for missing or unusual values (range checks) and checked for consistency within 
patients over time. If any such problems are identified, they will be queried with the responsible site. 
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NWSTC will periodically send reminders for any overdue and missing data. 
 
13.5 Clinical Site Monitoring 
 
13.5.1 Direct access to data 
In order to perform their role effectively, monitors and persons involved in Quality Assurance and Inspection will need direct 
access to primary subject data, e.g. patient records, laboratory reports, appointment books, etc. Because this affects the 
participant’s confidentiality, this fact is included on the Patient Information Sheet and Informed Consent Form. 
 
13.5.2 Confidentiality 
Personal data recorded on all documents will be regarded as strictly confidential and will be handled and stored in accord-
ance with the Data Protection Act 1998. 
 
Participants will always be identified using only their unique trial identification number on the Case Report Forms and 
correspondence between the NWSTC and the participating site. Participants’ will give their explicit consent for the NWSTC 
to be sent a copy of their consent form. This will be used to perform central monitoring of the consent process. 
The Investigator must maintain documents not for submission to the NWSTC (e.g. Patient Identification Logs) in strict 
confidence. In the case of specific issues and/or queries from the regulatory authorities, it will be necessary to have access 
to the complete trial records, provided that patient confidentiality is protected. 
 
The NWSTC will maintain the confidentiality of all participant data and will not disclose information by which participants 
may be identified to any third party. Representatives of the NWSTC and sponsor may be required to have access to 
Protocol No: ISRCTN99181100 Page 373 of 
81 
DEFeND Protocol Version 2.0 Date 27/06/2018 
 
 
participant’s notes for quality assurance purposes but participants should be reassured that their confidentiality will be 
respected at all times. 
 
 
13.5.3 Quality Assurance and Quality Control of Data 
Systems of quality assurance, including all elements described in this protocol have been/will be implemented within rele-
vant institutions with responsibility for this trial. Standard Operating Procedures (SOPs) are implemented to ensure that 
clinical trials are conducted in compliance with regulatory requirements and Good Clinical Practice. Quality control is applied 
to each stage of data handling to ensure that data are accurate, reliable and processed correctly. 
 
The DEFeND trial investigational sites and all data (including sources) and documentation must be available for GCP audit 
and inspection by competent authorities (national and foreign) or IEC. Such audits/inspections may take place at any site 
where trial related activity is taking place, the Sponsor’s site(s), NWSTC or at any investigator’s site. 
 
As the main outcome of interest is surgical complications, graded according to the Clavien-Dindo classification, 
there is potential variation in how the severity of complication may be reported in the CRF. To ensure that the CRF 
accurately represents the clinical case notes, a blinded member of the research team will 
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regularly verify the source data and correlate the NHS case notes with the CRFs to ensure accuracy of data re-
porting. 
 
The site staff should assist in all aspects of audit/inspection and be fully cognisant of the NWSTC communication strategy 
for multicentre trials. This includes management system for the Green light process, conforming to the total Quality Man-
agement System currently operating within the NWSTC. 
 
13.6 Records Retention 
The investigator at each investigational site must make arrangements to store the essential trial documents, (as defined in 
Essential Documents for the Conduct of a Clinical Trial (ICH E6, Guideline for Good Clinical Practice)) including the Inves-
tigator Trial File, until the Sponsor informs the investigator that the documents are no longer to be retained. In addition, the 
investigator is responsible for archiving of all relevant source documents so that the trial data can be compared against 
source data after completion of the trial (e.g. in case of inspection from authorities). 
 
The investigator is required to ensure the continued storage of the documents, even if the investigator, for example, leaves 
the hospital or retires before the end of required storage period. Delegation must be documented in writing. The NWSTC 
undertakes to store originally completed (e)CRFs and separate copies of the above documents for the same period, except 
for source documents pertaining to the individual investigational site, which are kept by the investigator only. 
 
Essential documents should be retained for at least 5 years after the completion of the trial. These documents should be 
retained for a longer period however if required by applicable regulatory requirements or by an agreement with the Sponsor. 
It is the responsibility of the NWSTC to inform the investigator/institution as to when these documents no longer need to be 
retained. 
 
Protocol No: ISRCTN99181100 Page 375 of 
81 
DEFeND Protocol Version 2.0 Date 27/06/2018 
 
 
At the point where it is decided that the trial documentation is no longer required; the Investigator will be responsible for the 
destruction of all site trial specific documentation and the Sponsor/NWSTC will be responsible for the destruction of all trial 
related materials retained by the Sponsor/NWSTC. 
 
Verification of appropriate informed consent will be enabled by the provision of copies of participants’ signed informed 
consent forms being supplied to the NWSTC by recruiting centres. This requires that name data will be transferred to the 
NWSTC, which is explained in the PIS. The NWSTC will preserve the confidentiality of participants taking part in the study 
and the University of Liverpool is a Data Controller registered with the Information Commissioners Office. 
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DEFeND is sponsored by the University of Liverpool (sole sponsor) and co-ordinated by the NWSTC in the University of 
Liverpool. The University of Liverpool does not hold insurance against claims for compensation for injury caused by partic-
ipation in a clinical trial and they cannot offer any indemnity. As this is an investigator-initiated study, The Association of 
the British Pharmaceutical Industry (ABPI) guidelines for patient compensation by the pharmaceutical industry do not apply. 
However, in terms of liability, NHS Trust and Non-Trust Hospitals have a duty of care to patients treated, whether or not 
the patient is taking part in a clinical trial, and they are legally liable for the negligent acts and omission of their employees. 
Compensation is therefore available in the event of clinical negligence being proven. 
 
Clinical negligence is defined as: 
“A breach of duty of care by members of the health care professions employed by NHS bodies or by others consequent on 
decisions or judgments made by members of those professions acting in their professional capacity in the course of their 
employment, and which are admitted as negligent by the employer or are determined as such through the legal process”. 
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15 FINANCIAL ARRANGEMENTS 
 
DEFeND is a non-commercial, investigator-initiated and investigator-led trial. Patients recruited to the study may be reim-
bursed a maximum of £25 for travel costs incurred due to any extra hospital visits required specifically for the study. The 
trial is funded by the National Institute for Health Research, Research Doctoral Research Fellowship programme, conse-
quently having automatic endorsement from the UK Clinical Research Network (UKCRN). This organisation will be respon-
sible for providing local investigators with the necessary research infrastructure. 
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16 TRIAL OVERSIGHT COMMITTEES 
 
16.1 Trial Management Group (TMG) 
The composition of the TMG is as follows. 
 
Chief Investigator 
Other lead investigators (clinical and non-clinical) Trial statistician 
Speciality Trainees Trial Coordinator Data Manager 
 
The role of the TMG is to monitor all day-to-day aspects of the conduct and progress of the trial, ensure the trial protocol is 
adhered to and take appropriate action to safeguard participants and the quality of the trial itself. 
 
The TMG will meet approximately 3 times a year. 
 
The TMG will provide a recommendations to the TSC concerning any aspect of the trial. 
 
A smaller TMG sub-group comprising of the Chief Investigator, Doctoral Research Fellow, Trial statistician and Trial Co-
ordinator will meet on approximately a monthly basis to discuss trial management and progress. 
 
16.2 Trial Steering Committee (TSC) 
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The composition of the TSC is as follows. Membership details are available from the Trial Coordinator. 
 
Independent chairperson expert in the field of Head & Neck Surgery Independent expert in the field of Head & Neck Surgery, 
Independent statistician, 
Principal Investigator (other than the CI) Patient representative 
Chief Investigator Speciality Trainees Trial Statistician Trial Coordinator. 
 
The role of the TSC is to provide overall supervision for the trial and provide advice through its independent chairperson. 
The full role and responsibilities are stipulated within its Charter. 
 
As no formal Independent Data and Safety Monitoring Committee (IDSMC) will be convened, all interim safety data will be 
reviewed by the independent members of the TSC (chairperson, expert and statistician). The ultimate decision for the 
continuation of the trial lies with the TSC. 
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The frequency of TSC meetings will be decided at the initial meeting. It is expected that they will occur at 6 monthly intervals, 
with the first meeting to be held prior to the recruitment of the first participant. 
 
16.3 Independent Data and Safety Monitoring Committee (IDSMC) 
No formal Independent Data and Safety Monitoring Committee (IDSMC) will be convened for this study.  In keeping with  
the guidance outlined in the document 'Guideline in Data Monitoring Committees' published by the Committee for Medicinal 
Products for Human Use in 2005, it is thought that an IDSMC is not required. This is because patients will be treated for a 
very short period of time (single administration during surgery) and Fibrin Sealants are well characterised and already 
widely used within healthcare. Although there are potential risks to patients, these are incredibly rare and known. 
 
The independent members of the Trial Steering Committee (Chairperson, expert, statistician) will take responsibility for 
reviewing all interim safety data. The independent members will be asked to give advice on whether the accumulated data 
from the trial, together with results from other relevant trials, justifies continuing recruitment of further patients or further 
follow-up. Given this is a pilot/feasibility study, it is anticipated that the TSC will only recommend termination on grounds of 
safety. 
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The results from different centres will be analysed together and published as soon as possible. Individual Clinicians must 
undertake not to submit any part of their individual data for publication without the prior consent of the Trial Management 
Group. 
 
The Trial Management Group will form the basis of the Writing Committee and advise on the nature of publications. The 
Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/) will be respected. All pub-
lications shall include a list of participants, and if there are named authors, these should include the trial’s Chief Investiga-
tor(s), Statistician(s) and Trial Manager(s) involved at least. If there are no named authors (i.e. group authorship) then a 
writing committee will be identified that would usually include these people, at least. The ISRCTN allocated to this trial 
should be attached to any publications resulting from this trial. 
 
The members of the TSC and should be listed with their affiliations in the Acknowledgements/Appendix of the main publi-
cation. 
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18 PROTOCOL AMENDMENTS 
 
• 18.1 Version 1.0 (12/Feb/2018) 




18.2 Version 2.0 (27/Jun/2018) 
 
Change 1. Protocol 
The addition of a patient reported outcome measure. This addition has been adopted from the 'Bluebelle' study and consti-
tutes a wound healing questionnaire. Patient will be asked to complete this questionnaire only once before they exit the 
study. In order to validate the questionnaire for use in a future phase III trial clinicians will also complete a short 'face-to-
face' assessment of surgical site infection at the last clinic visit. Both questionnaires have been added to Appendix D of the 
protocol. 
 
Change 2. Protocol 
Addition of ISRCTN number 
 
Change 3. Protocol 
Update figure 1 (p. 26) schedule of trial procedures. This was reviewed by research nurses who considered the original 
version confusing. It appeared as though patients required several assessments for rows 1-9 and "laboratory tests" rows 
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1-3 of the table when in fact these only needed to be done once before recruitment. The table has been changed to 
accommodate this. 
 
Change 4. Protocol 
North West - Greater Manchester East REC added to section 11.2 
 
Change 5. Informed Consent Form 
Addition of a clause asking patients whether they wish to consent to the taking of microbiology wound swabs for a sub-
study. 
 
Change 6. Participant Information Sheet & Summary Participant Information Sheet 
Changes to inform patients of the additional wound healing questionnaire 
 
Change 7. HRA Schedule of Events 
The schedule of events has been updated to include the new wound healing questionnaire. Also ‘local recruiting surgeons’ 
will assess the blinding strategy in addition to ‘local research nurses’. 
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Appendix E: ARTISS Product Information Sheets 
 
ARTISS Solutions for Sealant 
Summary of Product Characteristics Updated 18-Nov-2015 | Baxter Healthcare Ltd 
1. Name of the medicinal product ARTISS Solutions for Sealant Deep frozen 
2. Qualitative and quantitative composition 
Component 1: 
Sealer Protein Solution 
 













1 prefilled double chamber syringe which contains Sealer Protein Solution (with Aprotinin), deep frozen <1 
ml><2 ml><5 ml>, in one chamber and Thrombin Solution (with Calcium Chloride), deep frozen<1 ml><2 
ml><5 ml>, in the other chamber results in <2 ml><4 ml><10 ml> total volume of product ready for use. 
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After mixing 1 ml 2 ml 4 ml 10 ml 
Component 1: Sealer protein solution Hu-





























ARTISS contains Human Factor XIII co-purified with Human Fibrinogen in a range of 0.6 – 5 IU/ml. 
For the full list of excipients, see section 6.1. 
1 Contained in a total protein concentration of 96 - 125 mg/ml 
2 1 EPU (European Pharmacopoeia Unit) corresponds to 1800 KIU (Kallidinogenase Inactivator Unit) 
3 Thrombin activity is calculated using the current WHO International Standard for Thrombin. 
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3. Pharmaceutical form Solutions for Sealant Deep frozen 
Colourless to pale yellow and clear to slightly turbid solutions. Component 1, Sealer Protein Solution: pH 6.5 – 8.0 Compo-
nent 2, Thrombin Solution: pH 6.0 – 8.0 
4. Clinical particulars 
4.1 Therapeutic indications 
ARTISS is indicated as a tissue glue to adhere/seal subcutaneous tissue in plastic, reconstructive and burn surgery, as a 
replacement or an adjunct to sutures or staples (see 5.1). In addition, ARTISS is indicated as an adjunct to hemostasis on 
subcutaneous tissue surfaces. 
4.2 Posology and method of administration 
ARTISS is intended for hospital use only. The use of ARTISS is restricted to experienced surgeons who have been trained 
in the use of ARTISS. 
Posology 
The amount of ARTISS to be applied and the frequency of application should always be oriented towards the underlying 
clinical needs of the patient. 
The dose to be applied is governed by variables including, but not limited to, the type of surgical intervention, the size of 
the area and the mode of intended application, and the number of applications. 
Application of the product must be individualized by the treating physician. In clinical trials, the individual dosages have 
typically ranged from 0.2-12 ml. For some procedures (e.g. the sealing of large burned surfaces), larger volumes may be 
required. 
The initial amount of the product to be applied at a chosen anatomic site or target surface area should be sufficient to 
entirely cover the intended application area. The application can be repeated, if necessary, to any small areas that may 
have not been previously treated. 
However, avoid reapplication of ARTISS to a pre-existing polymerized ARTISS layer as ARTISS will not adhere to a pol-
ymerized layer. 
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It is recommended that the initial application covers the entire intended application area. 
As a guideline for the gluing of surfaces, 1 pack of ARTISS 2 ml (i.e., 1 ml Sealer Protein Solution plus 1 ml Thrombin 
Solution) will be sufficient for an area of at least 10 cm2. 
The skin graft should be attached to the wound bed immediately after ARTISS has been applied. The surgeon has up to 
60 seconds to manipulate and position the graft prior to polymerization. After the flap or graft has been positioned, hold in 
the desired position by gentle compression for at least 3 minutes to ensure ARTISS sets properly and the graft or flap 
adheres firmly to the underlying tissue. 
The required amount of ARTISS depends on the size of the surface to be covered. The approximate surface areas covered 
by each pack size of ARTISS by spray application are: 
 
Approximate area requiring tissue adherence Required pack size of ARTISS 
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To avoid the formation of excess granulation tissue and to ensure gradual absorption of the solidified fibrin sealant, only a 
thin layer of the mixed Sealer Protein - Thrombin Solution should be applied. 
ARTISS has not been administered to patients > 65 years old in clinical trials. 
Paediatric Population 
Currently available data are described in section 5.1 but no recommendation on a posology can be made. 
Method of administration 
For epilesional (topical) use. Do not inject. 
For subcutaneous use only. ARTISS is not recommended for laparoscopic surgery. 
In order to ensure optimal safe use of ARTISS it should be sprayed using a pressure regulator device that delivers a 
maximum pressure of up to 2.0 bar (28.5 psi). 
Prior to applying ARTISS the surface area of the wound needs to be dried by standard techniques (e.g. intermittent appli-
cation of compresses, swabs, use of suction devices). Do not use pressurized air or gas for drying the site. 
ARTISS must be sprayed only onto application sites that are visible. 
ARTISS should only be reconstituted and administered according to the instructions and with the devices recommended 
for this product (see section 6.6). 
For spray application, see sections 4.4 and 6.6 for specific recommendations on the required pressure and distance from 
tissue per surgical procedure and length of applicator tips. 
4.3 Contraindications 
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ARTISS is not indicated to replace skin sutures intended to close surgical wounds. 
ARTISS alone is not indicated for the treatment of massive and brisk arterial or venous bleeding. 
ARTISS must never be applied intravascularly. 
ARTISS is contraindicated in the case of hypersensitivity to the active substances or to any of the excipients (see also 
section 4.4. Special Warnings). 
4.4 Special warnings and precautions for use 
For epilesional use only. Do not apply intravascularly. Life threatening thromboembolic complications may occur if the 
preparation is applied intravascularly. Soft tissue injection of ARTISS carries the risk of local tissue damage. 
Caution must be used when applying fibrin sealant using pressurized air or gas. 
• Any application of pressurized air or gas is associated with a potential risk of air or gas embolism, tissue 
rupture, or gas entrapment with compression, which may be life-threatening or fatal. 
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• Apply ARTISS as a thin layer. Excessive clot thickness may negatively interfere with the product´s 
efficacy and the wound healing process. 
• Life-threatening/fatal air or gas embolism has occurred with the use of spray devices employing a 
pressure regulator to administer fibrin sealants. This event appears to be related to the use of the 
spray device at higher than recommended pressures and/or in close proximity to the tissue surface. 
The risk appears to be higher when fibrin sealants are sprayed with air, as compared to CO2 and 
therefore cannot be excluded with ARTISS when sprayed in open wound surgery. 
• When applying ARTISS using a spray device, be sure to use a pressure within the pressure range 
recommended by the spray device manufacturer (see table in section 6.6 for pressures and dis-
tances). 
• ARTISS spray application should only be used if it is possible to accurately judge the spray distance 
as recommended by the manufacturer. Do not spray closer than the recommended distances. 
• When spraying ARTISS, changes in blood pressure, pulse, oxygen saturation and end tidal CO2 
should be monitored because of the possibility of occurrence of air or gas embolism (also see sec-
tion 4.2). 
• ARTISS must not be used with the Easy Spray / Spray Set system in enclosed body areas. 
• Only use application devices CE marked for the administration of ARTISS. 
ARTISS is not indicated for hemostasis and sealing in situations where a fast clotting of the sealant is required. Especially 
in cardiovascular procedures in which sealing of vascular anastomoses is intended ARTISS should not be used. 
ARTISS is not indicated for use in neurosurgery and as a suture support for gastrointestinal anastomoses or vascular 
anastomoses as no data are available to support these indications. 
Before administration of ARTISS care is to be taken that parts of the body outside the designated application area are 
sufficiently protected/covered to prevent tissue adhesion at undesired sites. 
Oxycellulose-containing preparations may reduce the efficacy of ARTISS and should not be used as carrier materials (see 
Section 6.2). 
Protocol No: ISRCTN99181100 Page 394 of 
81 
DEFeND Protocol Version 2.0 Date 27/06/2018 
 
 
As with any protein-containing product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reac-
tions may include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these 
symptoms occur, the administration must be discontinued immediately. 
ARTISS contains aprotinin. Even in case of strict local application, there is a risk of anaphylactic reaction linked to the 
presence of aprotinin. The risk seems to be higher in cases where there was previous exposure, even if it was well tolerated. 
Therefore any use of aprotinin or aprotinin containing products should be recorded in the patients' records. 
As synthetic aprotinin is structurally identical to bovine aprotinin the use of ARTISS in patients with allergies to bovine 
proteins should be carefully evaluated. 
In the event of anaphylactic/anaphylactoid or severe hypersensitivity reactions, administration is to be discontinued. If pos-
sible, remove any applied, polymerized product from the surgical site. Adequate medical treatment and provisions should 
be available for immediate use in the event of an anaphylactic reaction. State-of-the-art emergency measures are to be 
taken. In case of shock, standard medical treatment for shock should be implemented. 
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma 
include selection of donors, screening of individual 
Protocol No: ISRCTN99181100 Page 395 of 
81 
DEFeND Protocol Version 2.0 Date 27/06/2018 
 
 
donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the 
inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are adminis-
tered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging 
viruses or other pathogens. 
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis 
B virus (HBV), and hepatitis C virus (HCV), and for the non-enveloped hepatitis A virus (HAV). 
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infec-
tion may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoi-
esis (e.g., hemolytic anemia). 
It is strongly recommended that every time that ARTISS is administered to the patient, the name and batch number of the 
product are recorded in order to maintain a link between the patient and the batch of the product. 
4.5 Interaction with other medicinal products and other forms of interaction 
No formal interaction studies have been performed. 
Similar to comparable products or thrombin solutions, the product is denatured after exposure to solutions containing alco-
hol, iodine or heavy metals (e.g. antiseptic solutions). Such substances should be removed to the greatest possible extent 
before applying the product. 
See section 4,4 or 6.2 for substances that can interfere with the product's performance. 
4.6 Fertility, pregnancy and lactation 
The safety of fibrin sealants/haemostatics for use in human pregnancy or breastfeeding has not been established in con-
trolled clinical trials. Animal studies have also not been performed. 
Therefore, the product should be administered to pregnant and lactating women only if clearly needed. 
See section 4.4 for information on Parvovirus B19 infection. The effects of ARTISS on fertility have not been established. 
4.7 Effects on ability to drive and use machines 
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4.8 Undesirable effects 
Intravascular injection could lead to thromboembolic events and disseminated intravascular coagulation (DIC) and there is 
also a risk of anaphylactic reactions (see section 4.4). 
Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the application site, brady-
cardia, bronchospasm, chills, dyspnoea, flushing, generalized urticaria, headache, hives, hypotension, lethargy, nausea, 
pruritus, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) may occur in rare cases in patients 
treated with fibrin sealants/hemostatics. 
In isolated cases, these reactions have progressed to severe anaphylaxis. Such reactions may especially be seen if the 
preparation is applied repeatedly, or administered to patients known to be hypersensitive to aprotinin (see section 4.4) or 
any other constituents of the product. 
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Even if a first treatment with ARTISS was well tolerated, a subsequent administration of ARTISS or systemic administration 
of aprotinin may result in severe anaphylactic reactions. 
Antibodies against components of fibrin sealant may rarely occur. For safety with respect to transmissible agents, see 
section 4.4. 
Life threatening/fatal air or gas embolism when using devices with pressurized air or gas occurred; this event appears to 
be related to an inappropriate use of the spray device (e.g. at higher than recommended pressures and in close proximity 
of the tissue surface). 
Adverse reactions summarized in the table below were reported from clinical studies of ARTISS and from post-marketing 
experience with Baxter Fibrin Sealants (marked with a p in the adverse event table). Known frequencies of these adverse 
reactions are based on a controlled clinical study in 138 patients where skin grafts were fixed to excised burn wounds using 
ARTISS. None of the events observed in the clinical study were classified as serious. 
The ADRs and their frequencies are summarized below: 
Common (≥1/100 to <1/10) Uncommon (≥1/1000 to <1/100) 




System organ class (SOC) Preferred MedDRA Term Frequency 
Skin and subcutaneous tissue disorders Dermal cyst uncommon 
Pruritus common 
Injury, poisoning and procedural compli-
cations 
Skin graft failure common 
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Vascular disorders Air embolismp 
due to an inappropriate use 
of the spray device (see sec-
tion 4.4) 
not known 
p Adverse events observed in post-marketing experience with Baxter Fibrin Sealants. 
Class Reactions 
Other adverse reactions associated with products of the fibrin sealant/hemostatic class include: Hypersensitivity reactions 
which could manifest as application site irritation, chest discomfort, chills, headache, lethargy, restlessness and vomiting. 
Further class reactions are: Anaphylactic reaction, bradycardia, tachycardia, hypotension, haematoma, dyspnoea, nausea, 
urticaria, flushing, impaired healing, oedema, pyrexia and seroma. 
Reporting of suspected adverse reactions 
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued moni-
toring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected 
adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. 
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No case of overdose has been reported. 
5. Pharmacological properties 
5.1 Pharmacodynamic properties 
Pharmacotherapeutic group: local hemostatics, ATC code: B02BC; tissue adhesives, ATC code: V03A K 
ARTISS can replace sutures or staples when used for fixation of skin grafts to burned or otherwise injured wound areas. 
ARTISS can be used as an adjunct to sutures or staples to adhere and seal skin flaps in cases where sutures/staples are 
expected to yield unsatisfactory results with respect to postoperative hematoma or seroma formation. 
The fibrin adhesion system initiates the last phase of physiological blood coagulation. Conversion of fibrinogen into fibrin 
occurs by the splitting of fibrinogen into fibrin monomers and fibrinopeptides. The fibrin monomers aggregate and form a 
fibrin clot. Factor XIIIa, which is activated from factor XIII by thrombin, crosslinks fibrin. Calcium ions are required for the 
conversion of fibrinogen and the crosslinkage of fibrin. 
As wound healing progresses, increased fibrinolytic activity is induced by plasmin, and decomposition of fibrin to fibrin 
degradation products is initiated. Proteolytic degradation of fibrin is inhibited by anti-fibrinolytics. Aprotinin is present in 
ARTISS (frozen) as an antifibrinolytic to prevent premature degradation of the clot. 
For efficacy, in vivo studies in an animal model closely imitating the situation in patients were used. ARTISS (frozen and 
lyophilized presentations) demonstrated efficacy regarding sealing autologous split skin grafts and mesh grafts. 
ARTISS (frozen) was investigated for fixation of split thickness sheet skin grafts in burn patients in a prospective, random-
ised, controlled, multicenter clinical study. In each of the 138 patients, two comparable test sites were identified. In one test 
site the skin graft was fixed with ARTISS in the other test site the graft was fixed with staples (control). ARTISS proved to 
be non-inferior to staples with respect to the primary efficacy endpoint, complete wound closure at Day 28 was evaluated 
by a blinded evaluator panel from photographs. This was achieved in 55/127 patients (43.3%) treated with ARTISS (frozen) 
and 47/127 patients (37%) treated with staples. 
With respect to secondary endpoints, ARTISS showed a significantly lower incidence and size of hematoma/seroma on 
Day 1 (p < 0.0001 for incidence as well as size). Incidence and area of engraftment on Day 5 and wound closure on Day 
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14, as well as area of wound closure on Day 28 were not different. ARTISS was also superior to staples with respect to 
patient satisfaction (p < 0.0001) and patients experienced significantly less anxiety about pain with ARTISS than with sta-
ples (p < 0.0001). Moreover, ARTISS was significantly superior to staples with respect to the investigator's assessment of 
quality of graft adherence, preference of fixation method and satisfaction with graft fixation, overall quality of healing and 
overall rate of healing (p < 0.0001). 
Thirty-seven (37) pediatric patients aged 1.1 to 18 years were evaluated in this trial. Eighteen (18) of these patients were 
6 years old or younger. 
Dosage used in clinical trials was the same for pediatric and adult patients. 
5.2 Pharmacokinetic properties 
ARTISS is intended for epilesional use only. Intravascular administration is contraindicated. As a consequence, intravas-
cular pharmacokinetic studies were not performed in man. 
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Pharmacokinetic studies in different species of laboratory animals were not conducted. 
Fibrin sealants/hemostatics are metabolized in the same way as endogenous fibrin by fibrinolysis and phagocytosis. 
5.3 Preclinical safety data 
No preclinical safety data are available for ARTISS (thrombin 4 IU/ml). Toxicity studies were done with Fibrin Sealants 
containing thrombin 500 IU/ml, as representative for products containing thrombin 4 IU/ml. Single-dose toxicity studies in 
rats and rabbits indicated no acute toxicity of Fibrin Sealant VH S/D (500 IU/ml). Fibrin Sealant VH S/D (500 IU/ml) also 
proved well tolerated in wound healing models in rats and rabbits, and in in vitro human fibroblast cultures. 
6. Pharmaceutical particulars 
6.1 List of excipients 
Component 1: Sealer Protein Solution Human Albumin Solution 
L-Histidine Niacinamide 
Polysorbate 80 (Tween 80) Sodium Citrate Dihydrate Water for Injections 
Component 2: Thrombin Solution Human Albumin Solution 
Sodium Chloride Water for Injections 
6.2 Incompatibilities 
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Oxycellu-
lose-containing preparations may reduce the efficacy of ARTISS and should not be used as carrier materials. 
6.3 Shelf life 
2 years 
6.4 Special precautions for storage 
Store and transport frozen (at ≤ -20°C). 
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Keep the syringe in the outer carton in order to protect from light. 
Unopened pouches, thawed at room temperature, may be stored for up to 14 days at controlled room temperature (not 
exceeding +25°C). Do not refreeze or refrigerate after thawing. 
6.5 Nature and contents of container 
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1 ml, 2 ml, or 5 ml of sealer protein solution and 1, 2 or 5 ml of Thrombin Solution in a single- use double-chamber syringe 
(polypropylene) with a tip-cap in a bag , and one device set with one double syringe plunger, 2 joining pieces and 4 appli-
cation cannulae. 
Pack size of 1 (1 x 1 ml + 1 ml, 1 x 2 ml + 2 ml, 1 x 5 ml + 5 ml) 
Both Sealer Protein Solution and Thrombin Solution are contained in a single-use double- chamber syringe made of poly-
propylene. 
Not all pack sizes may be marketed. 
Other accessories for application of the product can be obtained from BAXTER. 
6.6 Special precautions for disposal and other handling General 
To prevent ARTISS from adhering to gloves and instruments, wet these with sodium chloride solution before contact. 
As a guideline for the gluing of surfaces, 1 pack of ARTISS 2 ml (i.e., 1 ml Sealer Protein Solution plus 1 ml Thrombin 
Solution) will be sufficient for an area of at least 10 cm2. 
The required dose of ARTISS depends on the size of the surface to be covered. 
Handling and Preparation 
The inner bag and its contents are sterile unless the integrity of the outside package is compromised. 
It is recommended to thaw and warm the two sealant components using a sterile water bath at a temperature of 33 – 37°C. 
The water bath must not exceed a temperature of 37°C. (In order to control the specified temperature range, the water 
temperature should be monitored using a thermometer and the water should be changed as necessary. When using a 
sterile water bath for thawing and warming, the pre-filled double chamber syringe assembly should be removed from the 
aluminum-coated plastic bags.) 
The protective syringe cap should not be removed until thawing is complete and the joining piece is ready to be attached. 
Do not use ARTISS unless it is completely thawed and warmed (liquid consistency). 
Thaw pre-filled syringes using one of the following options: 
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1. Room Temperature Thawing (not exceeding +25°C): 
The product can be thawed at room temperature. Times given in Table 1 are minimum times for thawing at room tempera-
ture. The maximum time the product can be kept (in both aluminum-coated plastic bags) at room temperature is 14 days. 
When thawing at room temperature, the product must be additionally warmed to 33°C – 37°C in an incubator just before 
use. Respective warming times in the incubator are also given in Table 1. 
Table 1: Thawing times at Room Temperature (= RT) followed by additional warming, prior to use, in an Incubator at 33°C 
to a maximum of 37°C 
 
Pack Size Thawing Times at Room Temperature 
(Product in aluminum-coated plastic 
bags) 
Warming Times at 33-37°C in Incubator after 
Thawing at RT (Product in aluminum-coated 
plastic bags) 
2 ml 60 minutes + 15 minutes 
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4 ml 110 minutes + 25 minutes 
10 ml 160 minutes + 35 minutes 
Once ARTISS has been warmed up to 33 – 37°C the product may be stored for up to 4 hours. 
2. Quick Thawing: 
Table 2: Thawing and Warming Times with Sterile Water Bath at 33°C to a maximum of 37°C 
Transfer plunger and the inner pouch to the sterile field, remove prefilled syringe from inner pouch and place directly into 
sterile water bath. Ensure the contents of the prefilled syringe are completely immersed in water. 
 
Pack Size Thawing and Warming Times 
(Product removed from aluminum-coated plastic bags) 
2 ml 5 minutes 
4 ml 5 minutes 
10 ml 12 minutes 
A third alternative is to thaw the product off the sterile field using a non-sterile water bath. 
Maintain the prefilled syringe in both pouches and place into a water bath off the sterile field for an appropriate time (see 
Table 3). Ensure the pouches remain submerged throughout thawing. Remove from the water bath after thawing, dry 
external pouch and transfer inner pouch with prefilled syringe and plunger to the sterile field. 
Table 3: Thawing and Warming times off the Sterile Field with Non-Sterile Water Bath at 33°C to a maximum of 37°C 
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Pack Size Thawing and Warming Times 
(Product in aluminum-coated plastic bags) 
2 ml 30 minutes 
4 ml 40 minutes 
10 ml 80 minutes 
Alternatively, the sealant components may be thawed and warmed in an incubator between 33°C and 37°C. The thawing 
and warming times in the incubator are indicated in Table 4 below. The times refer to product in the aluminum-coated 
plastic bags. 
Table 4: Thawing and Warming Times in Incubator at 33°C to a maximum of 37°C 
 
Pack Size Thawing and Warming Times in Incubator 
(Product in aluminum-coated plastic bags) 
2 ml 40 minutes 
4 ml 85 minutes 
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10 ml 105 minutes 
Note: Do not thaw by holding product in your hands. Do not 
microwave. 
After thawing do not refrigerate or refreeze. 
 
After Quick Thawing (i.e. thawing at a temperature of 33 – 37°C) ARTISS may be stored at 33 
– 37°C for a maximum of 4 hours. 
To facilitate optimal blending of the two solutions, the two sealant components must be warmed to 33 – 37°C immediately 
before use. (The temperature of 37°C must, however, not be exceeded!) 
The Sealer Protein and the Thrombin Solutions should be clear or slightly opalescent. Do not use solutions that are cloudy 
or have deposits. Thawed products should be inspected visually for particulate matter and discoloration prior to administra-
tion or any variation in physical appearance. In the event of either being observed, discard the solution. 
The thawed Sealer Protein Solution should be a slightly viscous liquid. If the solution has the consistency of a solidified gel, 
it must be assumed to have become denatured (e.g., due to an interruption of the cold storage chain or by overheating 
during warming). In this case, ARTISS must not be used. 
Unopened pouches, thawed at room temperature, may be stored for up to 14 days at controlled room temperature (not 
exceeding +25°C). If not used within 14 days after thawing, ARTISS has to be discarded. 
The protective syringe cap should not be removed until thawing is complete and the joining piece is ready to be attached. 
Do not use ARTISS unless it is completely thawed and warmed (liquid consistency). 
For further preparation instructions please refer to the responsible nurse or medical doctor. 
ADMINISTRATION 
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For application, the double-chamber syringe with the Sealer Protein Solution and the Thrombin Solution has to be con-
nected to a joining piece and an application cannula as provided in the accompanying set of devices. The common plunger 
of the double-chamber syringe ensures that equal volumes are fed through the joining piece before being mixed in the 
application cannula and ejected. 
Operating Instructions 
- Connect the nozzles of the double-chamber syringe to the joining piece ensuring that they are firmly fixed. 
Secure the joining piece by fastening the tether strap to the double-chamber syringe. If the tether strap tears, 
use the spare joining piece. If none is available, further use is still possible but tightness of the connection 
needs to be ensured to prevent any risk of leaking. 
- Fit an application cannula onto the joining piece. 
- Do not expel the air remaining inside the joining piece or application cannula until you start actual application 
as the aperture of the cannula may clog otherwise. 
- Immediately before application expel and discard the first several drops from the application cannula to en-
sure adequately mixed product 
- Apply the mixed Sealer Protein - Thrombin Solution onto the recipient surface or surfaces of the parts to be 
sealed. 
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If application of the fibrin sealant components is interrupted, clogging may occur in the cannula. Replace the application 
cannula with a new one only immediately before application is resumed. If the apertures of the joining piece are clogged, 
use the spare joining piece provided in the package. 
Application is also possible with other accessories supplied by BAXTER that are particularly suited for, e.g. minimally inva-
sive surgery, application to large or difficult-to-access areas. 
When using these application devices, strictly follow the Instructions for Use of the devices. 
Spray application 
When applying ARTISS using a spray device be sure to use a pressure and a distance from tissue within the ranges 
recommended by the manufacturer as follows: 
 
Recommended pressure, distance and devices for spray application of ARTISS 
 Spray set to be 
used 
Applicator tips 
to be used 
Pressure regu-










Tisseel / Artiss 
Spray Set 
n.a. EasySpray 10 – 15 cm 1.5-2.0 bar 
(21.5-28.5 psi) 
Tisseel / Artiss 
Spray Set 10 pack 
n.a. EasySpray 
When spraying the ARTISS, changes in blood pressure, pulse, oxygen saturation and end tidal CO2 should be 
monitored because of the possibility of occurrence of air or gas embolism (see sections 4.2 and 4.4). 
Disposal 
Any unused product or waste material should be disposed of in accordance with local requirements. 
7. Marketing authorisation holder 
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Baxter Healthcare Ltd Caxton Way 
Thetford Norfolk IP24 3SE 
United Kingdom 
8. Marketing authorisation number(s) 
PL00116/0634 
9. Date of first authorisation/renewal of the authorisation 
11/03/2009 
10. Date of revision of the text 
06/11/15 
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Company Contact Details Baxter Healthcare Ltd Address 
Caxton Way, Thetford, Norfolk, IP24 3SE, UK 
Fax 
+44 (0)1635 206071 
Medical Information e-mail medinfo_uki@baxter.com WWW 
http://www.baxterhealthcare.co.uk 
Medical Information Direct Line 
+44 (0)1635 206345 
Medical Information Fax 
+44 (0)1635 206071 
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A.3 Informed Consent Form (ICF) 
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A.4 GP Letter 
<<Insert senders name and address>> 
<<Insert recipient name and address>> 
<<Insert date>>  
Re: Patient inclusion in clinical trial – DEFeND: Determining the Effectiveness of 
Fibrin Sealants in Reducing Complications in Patients Undergoing Lateral Neck 
Dissection: A randomised external pilot trial  
 
Dear Dr <<insert GP name >>, 
Patient name: … <<Insert Patient Name >>……………………………… 
Date of Birth: … <<Insert Patient DOB>>………………………………… 
NHS Number: … <<Insert Patient NHS Number>>…………………… 
 
After giving written informed consent, the above patient has been entered into a clinical 
trial. Please find enclosed a copy of the Patient Information Sheet (PIS) for the study 
containing all the relevant information.  
DEFeND is a randomised multicentre pilot study to assess whether the application of 
Fibrin Sealant to the surgical wound reduces the rate of complications compared to 
‘standard of care’ surgery without Fibrin Sealant.   
Your patient will be randomised to have their neck dissection surgery either with Fibrin 
Sealant or without. This is a blinded trial which means your patient will not be told 
whether they received the Fibrin Sealant or not.  
You will be kept up to date with your patient’s progress but if you have any concerns 
or questions regarding this study please contact the responsible doctor: 
Dr __________________________________  at ________________________ (Hos-
pital) 
Tel: __________________________________ 
Yours sincerely,  
<<Insert PI Name and details>> 
Enc. Patient information sheet
 
 
A.5 Risk Assessment 
Liverpool Cancer Trials Unit: Risk Assessment Form 
SECTION 1 – Sponsorship and Research Governance Risk Assessment  
This section should be completed and reviewed by the Trial Research Team and Study Sponsors   
Project Acronym: 
DEFeND 
Full Name of Project Determining the Effectiveness of Fibrin Sealants in Re-
ducing Complications in Patients Undergoing Lateral 
Neck Dissection: A randomised external pilot trial 
 
Chief Investigator (CI): Andrew Schache Employer of CI: University of Liverpool 
Trial of IMP/intervention: Surgical Intervention: Neck dissection 
and Artiss Fibrin Sealant (non-CTIMP) 
Proposed Sponsor(s): University of Liverpool 
Date of Sponsorship and Research 




Risk/Hazard identified Likelihood (Low,Medium or High) Impact (Low, Medium or High) 
Concerns and Recommendations for miti-
gation and management 
Non-compliance with regulations L M The MHRA has deemed this study to be a non-
CTIMP trial. 
 
The sponsor, and delegated others, will need to 
assure compliance with the NHS Research Gov-
ernance Framework, putting the appropriate 
Quality Assurance (QA) measures in place. 
 
 
Sponsor audits will be performed in accordance 
with their standard operating procedures 
(SOPs). 
 
The Liverpool Cancer Trials Unit’s (LCTU) Quality 
System has been developed to facilitate compli-
ance with the regulations. This trial has been de-
veloped and will be managed by the LCTU Qual-
ity System and will be subject to the internal au-
dit programme 
 
Unclear accountability of organisa-
tions involved 
M L Sponsorship is confirmed by: 
University of Liverpool 
Research Support Office 
2nd Floor Block D 
Waterhouse Building 
3 Brownlow Street 
Liverpool 
L69 3GL 




A Clinical Trial Site Agreement (including a Ma-
terial Transfer Agreement) will be prepared and 
signed by each recruiting site, the Sponsor(s) 





Clear LCTU SOPs/plans describing trial proce-
dures must in place as part of the LCTU study 
green light checklist. 
 
Risk/Hazard identified Likelihood (Low,Medium or High) Impact (Low, Medium or High) 
Concerns and Recommendations for miti-
gation and management 
Inadequate/poorly documented dele-
gation to sites 
L M Recruiting sites: Principal Investigators at re-
cruiting sites will be take responsibility for the 
delegation of roles to the research team con-
firming each member ‘has been adequately 
trained on the current protocol for this trial’. 
 
GCP certificates and curriculum vitae of team 
members will be held on the site trial file and the 
delegation log will be signed by both the PI and 
the team member specifying the roles they are 
delegated to do.  
 
 
Poor quality control and quality assur-
ance 
L M LCTU: 
There will be regular internal audit of LCTU pro-




The PI and Research nurse will be GCP trained 
and familiar with the protocol thereby able to 
ensure SAEs and SUSARs are reported within the 




Risk/Hazard identified Likelihood (Low,Medium or High) Impact (Low, Medium or High) 
Concerns and Recommendations for miti-
gation and management 
Inadequate monitoring & auditing M M Monitoring by the LCTU will be undertaken ac-
cording to a monitoring plan based on the out-
come of the bespoke risk assessment. It is as-
sumed that on site monitoring will not be re-
quired. This will include GCP, Research Govern-
ance, and source data checks, as well as moni-
toring of laboratory handling of samples and 
data reliability. 
 
Poor archiving of study related 
information 
L L LCTU: 
LCTU staff will follow the current archiving SOP 
TM021 when required.  
 
Sites: 
Patient data will be managed in accordance with 
local practice, ICH GCP, the Caldecott Guardian 
/National Information Governance Board and 
the Data Protection Act. 
 
As part of the LCTU initiation & green light pro-
cess, sites will be informed about the archiving 
procedures required for the trial. 
 
Risk/Hazard identified Likelihood (Low,Medium or High) Impact (Low, Medium or High) 
Concerns and Recommendations for miti-
gation and management 
 
 
Inadequate patient safety monitoring  L M Sites: 
As DEFeND is a non-CTIMP trial, surgical compli-
cations and adverse reactions to ARTISS fibrin 
sealant will be the only events reported to as-
sess safety. Principal Investigators will report 
SAEs that are Clavien-Dindo grade IV or above in 
accordance with the protocol and regulatory re-
quirements.  This is delegated to site in the Re-
search Site Agreement which is signed prior to 
site opening. As ‘surgical complication’ is the pri-
mary outcome measure of the study, less seri-




As part of the study green light, necessary over-
sight committees must be in place prior to study 
opening. 
 
The Chief Investigator will be required to report 
all relevant safety information to the relevant 
committees as outlined in the study protocol. 
 
Study Design: inadequate study 
powered recruitment 
L M The LCTU has contributed to the design of the 
study.  The study has been adopted by the LCTU 
Trial Adoption Committee and reviewed by the 
NCRI Head & Neck CSG, surgery and localised 
therapies subgroup. Feasibility will be under-






Inadequate costing of the study M H The study is funded as a doctoral fellowship. The 
costing has been carried out by the LCTU and 
has been scrutinized by the funding body. The 
study is deemed to be low cost so a significant 
contingency allowance is not included. 
 
The Senior Management Team will regularly re-
view the finances throughout the study 
 
Withdrawal of study funding L H LCTU Senior management to monitor trial activ-
ity and funding and alert the Sponsor of any is-
sues. 
 
Insurance/indemnity L H The University of Liverpool will provide non-neg-
ligent indemnity. 
 
SECTION 1 Approvals 
Chief Investigator signature:  Date:  
Sponsor Signature:  Date:  
Trial Co-ordinator signature:  Date:  
 
 
SECTION 2: Intervention Risk Assessment and Safety Monitoring  
 
For safety monitoring, please refer to latest advice from the MRC/DH/MHRA Joint Project on Risk Adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Prod-
ucts. 
 
Intervention risk assessment based on SmPC/Investigator Brochure/protocol/relevant literature 
Study Title: DEFeND - Determining the Effectiveness of Fibrin Sealants in Reducing Complications in Patients Undergoing Lateral Neck Dissection: A random-
ised external pilot trial 
EudraCT Number: NA 
Sponsor(s): University of Liverpool 
Intervention Risk Assessment and Safety Monitoring Conducted by: Mandeep Bajwa 
Date of Assessment: 16/08/2018 
Risk Assessment Version: 1.0 
Risks associated with trial IMP(s)/intervention(s) for the IMP(s)/intervention(s) being 
investigated (single or in combination)  
 
 CTIMP Type A = Comparable to the risk of standard medical care 
 CTIMP Type B = Somewhat higher than the risk of standard medical care  
 CTIMP Type C = Markedly higher than the risk of standard medical care 
 Non-CTIMP 
 
Justification for type of trial indicated: 
The MHRA have deemed DEFeND to be a non-CTIMP. This study 
is an external pilot of a future phase III trial. Patients undergoing 
neck dissection will either have ARTISS fibrin sealant will be ap-
plied to the surgical wound or receive standard of care without 
ARTISS. Amongst other outcomes, the rate and severity of com-
plications will be compared. ARTISS fibrin sealant is a commer-
cially available FDA approved product with a CE mark. It will be 






Intervention CTCAE v5 Category Hazard Likelihood  
(L=low; M= Medium; 
H=High) 
Mitigation Comments 
ARTISS Fibrin Sealant Immune System Disorders Allergic reaction L Exclusion of patients who have a 
known allergy to Aprotinin 
Exclusion of patients who have been 
in contact with fibrin sealant in last 6 
months. 
Exclusion of patients who have al-
lergy to dairy products/bovine pro-
tein 
ARTISS is administered 
once during surgery. Any al-
lergic reactions will be 
noted and treated as a mat-
ter of urgency 
Skin and subcutaneous tissue 
disorders 
Pruritis L Nil This will be treated based 
on the patients symptoms 
Vascular Disorders Vascular disorders – other 
Air Embolism 
L Use of spray device in accordance 
with manufacturer’s advice i.e. pres-
sure set to maximum of 1.5 bars and 
device not held closer than 10cm to 
wound 
 
Injury, poisoning and proce-
dural complications  
Seroma L Nil This will be treated based 
on the patients symptoms 
 
Infections and infestations Viremia  L ARTISS fibrin sealant is derived from 
donated human blood. Standard pro-
cedures used to minimise the risk of 
transmission via blood transfusion 
are therefore inherent. This includes 
donor selection and screening of indi-
vidual donations for specific markers 
of infection. 
 
In addition to this steps have been 
taken during the manufacturing pro-
cess to inactivate or remove viruses. 
The manufacturer states that these 
measures are ineffective against par-
vovirus B19. This virus may be serious 
for pregnant women due to the risk 
viruses known to have been 
transmitted via blood prod-
ucts in the UK: 





Human T-Cell Lymphotropic 




of foetal infection. Pregnant women 
have therefore been excluded from 
the study. 
 





Any prion disease 
L ARTISS fibrin sealant is derived from 
donated human blood. Standard pro-
cedures used to minimise the risk of 
transmission via blood transfusion 
are therefore inherent. This includes 
donor selection and screening of indi-





Pharmacovigilance and processes that have been put in place to mitigate risks to participant safety (IDMC, inde-
pendent data review,...) 
The intervention is considered low risk and investigators will not be required to record AEs. PIs will be required to report SAEs that are classified as Clavien-Dindo grade IV 
or above to the sponsor (or delegated other). Reportable SAEs will require immediate reporting by PIs and will allow for monitoring. 
 
The study population are a group of adults who have head and neck cancer and suitable to undergo major surgery. They are likely to have multiple co-morbidities and may 
have already undergone extensive treatment including radiotherapy and/or chemotherapy.  
 
The process for reporting SAEs listed in the protocol to the sponsor via the LCTU will be defined in the protocol and research site agreement. The LCTU and sponsor will 
monitor the incidence of reportable SAEs – if this increases during the trial the sponsor (or delegated other) will report this as an unexpected and related SAE to the Re-
search Ethics Committee (REC) within the required timeline. If any SAEs are evaluated as being related to the trial intervention, they will be reported to the REC as an 
unexpected and related SAE. All SAEs will be reported in the SAE form and a summary provided for the sponsor and the Trial Steering Committee (TSC). 
 
As this is a pilot study, no formal IDMC is required. Instead independent members of the TSC will be responsible for reviewing safety and effectiveness and will provide 
advice to the TSC and TMG.   
 
SECTION 2 Approvals 





General Risk Identified Potential Risks Likelihood (Low, 
Medium or High) 
Mitigation or Adaption Monitoring methods to address  
Intervention is not standard man-
agement practice 
Intervention increases risk 
of known post-operative 
complications 
L Dose specified in protocol has 
been chosen according to the 
appropriate literature and has 
been peer reviewed by ex-
perts within the relevant field 
 
Case Report Forms will sys-
tematically collect data on pa-
tient status 
The LCTU will ensure a TSC has 
been formed for the study as part 
of the study green light process 
 
The LCTU will ensure an interim 




Sponsor Signature:  Date:  
Trial Co-ordinator:  Date:  
SECTION 3: Bespoke Trial Risk Assessment 
(participant safety relating to the IMP, study design, methods, safety and rights and reliability of results)  
 
Study Title: DEFeND - Determining the Effectiveness of Fibrin Sealants in Reducing Complications in Patients Undergoing Lateral Neck Dissection: A random-
ised external pilot trial 
EudraCT Number: NA 
Sponsor(s): University of Liverpool 
Bespoke Trial Risk Assessment Conducted by: Mandeep Bajwa 
Date of Assessment: 16/08/2018 
Risk Assessment Version: 1.0 
 
 
General Risk Identified Potential Risks Likelihood (Low, 
Medium or High) 
Mitigation or Adaption Monitoring methods to address  
 Intervention is given to in-
eligible patients 
L The eCRF does not allow ineli-
gible patients to be random-
ised. 
PI signs off eligibility criteria for all 
patients before randomisation is 
permitted. Central monitoring 
processes to ensure adherence to 
process. 
 Patient is given the wrong 
treatment 
L Allocation is revealed intra-op-
eratively at the specific time 
point when ARTISS administra-
tion would be required  
Theatre staff routinely record 
batch number of ARTISS adminis-
tered to the patient.  
 
Evidence: 
• Source data verification 
• Monitoring visit 
Availability or supply of ARTISS fi-
brin sealant 
Patients are given the 
wrong fibrin sealant 
L Baxter Healthcare LTD will en-
sure adequate supplies of 
their product within trial cen-
tres 
Theatre staff routinely record 
batch number of ARTISS adminis-
tered to the patient.  
 
Evidence: 
• Source data verification 
• Monitoring visit 
 Patients are not given the 
intervention 
L Allocation is revealed intra-op-
eratively at the specific time 
point when ARTISS administra-
tion would be required 
Theatre staff routinely record 
batch number of ARTISS adminis-
tered to the patient.  
 
Evidence: 
• Source data verification 
• Monitoring visit 
Storage ARTISS stored inappropri-
ately 
L Reference safety information 
is provided to site together 
No checks required on storage ar-
eas by on-site monitoring. 
 
 
General Risk Identified Potential Risks Likelihood (Low, 
Medium or High) 
Mitigation or Adaption Monitoring methods to address  
with the product information 
sheet prior to site activation 
 
Information regarding the lo-
cal facilities will be collected  
Baxter Healthcare LTD will en-







2. Subject safety, consent, rights and well being 
Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  




sent to the trials 
unit in error 
L Data protection and confidential-
ity will be covered in the site ini-
tiation.  
 
All staff in the LCTU complete 
data protection training to en-
sure awareness of the regula-
tions. All staff in the LCTU work 
to the LCTU Data Protection Pol-
icy Document. 
 
There is no reason for LCTU to 
receive confidential data as sites 
will enter anonymised data di-
rectly to the study database. The 
informed consent form contains 
patient data and copies will be 
uploaded to LCTU portal as part 
of monitoring. Consent for this 
will be requested from partici-
pants. Once the consent forms 
have been checked centrally by 
two authorised members of 
LCTU staff they will be perma-
nently deleted from the portal. 
After this point only the site will 
CVs, GCP training and delegation logs 
are reviewed by senior members of the 
LCTU as part of the site green light pro-
cess to ensure that site staff are trained 
in data protection which should be cov-
ered within their GCP training 
 
The receipt of any patient identifiable 
information from site will be recorded 
and reviewed as part of the central 
monitoring process. 
 
On receipt of any patient identifiers, 
site will be reminded not to send any 
unauthorised patient identifiers/re-
trained in accordance with LCTU policy. 
 
Evidence: 
• Monitoring plan 
• LCTU data protection policy 
• LCTU staff training records 
• Research site folders/investiga-
tor site files 
• Site initiation presentation 




Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
have the original signed consent 
form and there will be no other 
copies.   
 
Sites have the opportunity to 
have the trial paperwork/proce-
dures reviewed by their Caldicott 
Guardian prior to giving ap-
proval. 
 
Patient identifiers have been lim-
ited to initials, NHS number and 
date of birth. NHS numbers can 
only be used to gain personal in-
formation by NHS staff or people 
with access to the NHS database 
who will have been trained to 
follow NHS procedures. 
 
 
 Digital data does 
not have ade-
quate protection 
L MACRO is a web data entry sys-
tem and has the same security 
whether the trial is electronic re-
mote data capture or central 
data management. All data are 
stored in Microsoft SQL data-
bases on LCTU servers. These 




Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
University of Liverpool Compu-
ting Services Department. 
 
The MACRO system runs on a se-
cure web server which has an 
SSL security certificate. Data en-
tered on to the MACRO database 
is encrypted and transferred 
over a secure web address. 
 
Only authorised, trained users 
are provided with a password to 
enter data onto the database. 
Users are given role specific per-
missions to the correct site and 
trial. 






rect version of 




to participant  
 
L PI and RN to have ICH GCP and 
protocol training highlighting 
consent process 
 
Copy of signed consent form 
must be received at LCTU before 
randomisation process can begin 
 
LCTU staff to check at randomi-
sation that correct version of PIS 
TC to verify ALL trial participants have 
valid fully informed written consent. 
 
TC/DM to record any issue with con-
sent at randomisation into the random-
isation audit section of the MACRO da-





Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
has been provide to the partici-
pant.  
  
Only REC approved PIS/ICF to be 
used to consent a patient. If the 
wrong versions have been used 
then the correct versions will be 
provided and the patient re-con-
sented. 
 
If the PIS and/or ICF is updated 
after a patient has been con-
sented then REC will decide if 
the changes require re-consent. 
This must follow the study and 
GCP process for consent and the 
patient should be informed that 
they can withdraw if they wish.  
 
Re-consent (if required) rec-
orded and tracked through 
MACRO database. 
Sites must upload a copy of the 
new signed ICF to the LCTU por-
tal when patient is re-consented. 
 
Tracking on MACRO will include the 
versions of PIS and ICF given to patients 
so that it can be monitored centrally.  
 
Copies of the signed delegation log will 
be kept at the LCTU in the research site 
files. 
 
The electronic trial master file on the 
portal has an electronic receipt built in 




• Original consent forms 
• Randomisation plan 
• Electronic receipt of trial docu-
ments 
• Delegation list 
• CVs & GCP certificates 
 
 
Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
Current REC/HRA approved doc-
uments will be managed through 
the LCTU document manage-
ment system and made available 
to site staff via secure LCTU por-
tal. This will include the PIS/ICF. 
Only REC approved versions of 
the PIS and ICF will be made 
available on the PORTAL. The 
correct version of the protocol 
and PIS must be stored in the 
ISF. 
 
Copyholders of documents can 
be accessed via the DMS and can 
be informed automatically of 
new versions of documents. 
 
Site staff will receive protocol 
training (as part of SIV) highlight-
ing the consent process for the 
study. 
The person taking consent must 
be named on the site delegation 
log and be signed off by the PI as 




Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
Site staff should document that 
informed consent has been 
taken and that the patient has 
been entered into the trial in the 
case notes. 
 
The LCTU Document Controller 
will version control all docu-
ments on the PORTAL available 
to sites. 
Lack of a robust system 
for the review and ex-




ual sites.  
 
Paper SAEs re-
ceived by the trial 




viewed by the 
clinical co-ordina-
tor and reported 




Clear definitions of what consti-
tutes an SAE set out within the 
protocol along with details of ex-
pected events, which would not 
require reporting.  
 
PIs and research nurses made 
aware of the reporting guidelines 
and what to report during proto-
col training.  
 
LCTU staff have received phar-
macovigilance training and are 
fully aware of the reporting time-
lines.  
 
Monitoring and actioning of daily SAE 
email alerts.  
 
Ensuring adequate Clinical Co-ordinator 
cover for the assessment of SAEs.  
 
Senior SAE review rota to monitor the 
progress of all SAEs reported to the 
unit to ensure they are processed and 




• Protocol  
• Pharmacovigilance Plan  
• CC assessment rota  
• SAE status reports  
 
 
Subject safety, rights or 
wellbeing  
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
SAEs to be inputted onto the 
MACRO pharmacovigilance sys-
tem as soon as they are received 
into the unit regardless of 
whether all required information 
is present.  
 
MACRO pharmacovigilance sys-
tem set up to send email alerts 
of SAEs that are incomplete or 
that have not been assessed by 
the clinical co-ordinator.  
 
Development of a safety Plan for 
DEFeND will provide guidelines 













3. Trial Results 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
Slow recruitment - 






L Peer review of study design e.g. by 
NIHR CSG groups 
 
Collaboration with experienced col-
leagues  
 
Early statistical input into study de-
sign (LCTU adoption process) 
 
Trial Oversight Committees to re-
view and monitor recruitment 
 
Recruitment represents a key out-
come measure for this pilot/feasibil-
ity study. Flexibility to adapt trial de-
sign according to barriers 
 
Trial progress and recruitment re-
ported at monthly LCTU Business 
Meetings 
Patient Recruitment to be re-
viewed during Central Monitor-
ing against those rates forecast 
in the grant application and pro-
vided by sites on both the Re-
search Site Agreement (RSA) and 




• Central monitoring reports 
• CSG reports 
• LCTU Business Manage-





which can lead to: 
 
L Site and principle investigator will 
be selected on their expertise in the 
surgical management of head and 
Central monitoring to be con-
ducted on a monthly basis to iden-
tify any issues arising from miscom-
munication. This will include: 
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  










neck cancer as well as their interest 
and enthusiasm for the trial. 
 
All global and local approvals will be 
checked as being in place as part of 
the greenlight process prior to re-
cruiting any patients. 
 
All teams at sites will have nomi-
nated lead nurses to direct commu-
nications, support and advice to.  
 
 
• Protocol compliance 
• Randomisation compliance 
• Allocation reveal compli-
ance 
• Follow-up compliance 
• Data submission (timelines 
and quality) 
• SAE reporting 
• Recruitment including 
screening, enrolment and 
randomisations 
• Serious breaches 
 
100% source data verification will 
be conducted for the primary end-
point. Where applicable, central 
monitoring will be conducted at 




• Central monitoring reports 
• Trial site green light check-
list 
• Monitoring plan 
• Source data verification 
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
Complexity of trial re-
lated procedures 
Large number of 












vealed at correct 






Drain protocol not 
adhered to 
 
Assessment of trial 
outcomes not per-
formed by a blinded 
M Site initiation visit for training in 
study procedures. This will cover en-
rolment, randomisation, allocation 
reveal, drain protocol and blinding 
strategy 
 
Confirmation that the site has an 
appropriate serious breach proce-
dure in place 
 
If a serious breach is identified / re-
ported then LCTU’s SOP TM037 
should be followed 
 
Randomisation cannot occur until all 
important initial assessments are 
completed in the eCRF. Incomplete 
data will trigger a data query cen-
trally to prompt the research team 
as required 
 
Randomisation occurs prior to the 
patient undergoing surgery. Time, 
date and name of person perform-
ing randomisation is logged in the 
database 
Review of protocol deviations and 
serious breaches 
 
Protocol compliance to be re-
viewed monthly as part of the cen-
tral monitoring and source data 
verification report. This will include 
a review of all protocol deviations 
and serious breaches 
 
Evidence: 
• Central monitoring reports 
• Source data verification re-
ports 







Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
member of the re-
search team 
 
Time, date and name of person re-
vealing allocation is logged in the 
database 
 
Theatre teem to record batch num-
ber of ARTISS against the patient in 
their theatre logbook 
 
eCRF has protocol for drain removal 
in-built. Research team to simply 
enter drainage volume into CRF af-
ter which they will be told to either 
remove the drain, re-check volume 
later that day, or leave the drain in-
situ 
 
Names of surgical team in theatre 
during the allocation reveal will be 
recorded. The database will forbid 
these individuals from assessing 
&/or entering data thereafter.  
 
eCRF data  eCRF not fit for pur-
pose e.g. CRF does 
not collect tumour 
lesion at baseline 
 
M LCTU eCRFs are designed and vali-
dated in-house. The database used 
has password access, audit trail and 
back up. 
 
Central monitoring to be con-
ducted monthly which will include 
a review of the number and type of 
data queries raised across all sites 
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 






CRFs will be reviewed by the trial 
statistician, co-investigators in the 
relevant fields, the chief investi-
gator and some site research 
nurses prior to implementation.  
 
Data Query Process Plan to be 
implemented to ensure dis-
crepancies are queried in a 
standardised manor with easy 
to understand questions and 
comments.  
 
A data management plan will 
be put in place to ensure con-
sistency across data entry per-
sonal and clear guidelines on 
timelines for data entry. Early 
entry of data will allow prob-
lems with completion to be 
identified and addressed as 
early as possible preventing 
ongoing problems in future pa-
tients.  
 
MACRO will include validation 
rules to alert the user to incon-
sistent data that is inputted. All 
data are backed up every night 
and monitor and completeness 
rate across sites 
 
Central monitoring will allow spe-
cific problems with the CRF to be 
identified and addressed 
 
Independent members of the TSC 
will review the data completeness 
quality 6 monthly. 
Study will be subject to the LCTU 
data entry QC check process. 
 
Evidence: 
• Independent member TSC 
report 
• Data management plan 
• Data query process plan 
• ECRFs 
• Monitoring plan 
• Central monitoring reports 
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
in several secure locations.  
 
 
Lack of provisions for 






blinding by surgical 




fied analyses.  
M  It is unlikely that this trial will re-
quire unblinding as the ARTISS is ad-
ministered only once in the theatre 
environment. The surgeon applying 
the ARTISS will not be blinded. The 
patient, surgeons assessing out-
comes, ward nurses and research 
nurses will be blinded. The main 
clinical endpoints of interest (Cla-
vien-Dindo, removal of drain, fitness 
for discharge) require the assess-
ment of a surgeon. Therefore oper-
ating surgeons (who are unblinded) 
need to delegate these assessments 
to suitable blinded colleagues.  
 
A severe hypersensitivity reaction, 
air embolism or transmission of an 
infective agent constitute a serious 
adverse event and may be attributa-
ble to the administration of ARTISS. 
If they occur, severe hypersensitivity 
and air embolism would be antici-
pated to occur during or immedi-
ately after administration in the 
Independent members of the TSC 
to review unblinded safety and effi-
cacy data on a 6 monthly basis.  
 
All patients who have been un-
blinded will continue to be fol-
lowed up as per the schedule set 
out in the protocol to ensure pa-
tients are not being unblinded un-
necessarily. This data will be re-
viewed through central monitoring 
and by the independent members 
of the TSC.  
Evidence:  
• TSC report plan  
• Central Monitoring Reports  
• Statistical Analysis Plan  




Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
theatre setting. Staff caring for the 
patient at this time will not be 
blinded so there will not be a delay 
in diagnosis and emergency man-
agement. If they did happened, the 
patient, outcome assessors and 
nursing staff would be unblinded 
only if the information is required 
for the ongoing medical manage-
ment of the condition.  
 
In the event that the patient is diag-
nosed with an infectious disease 
that was not diagnosed pre-opera-
tively, they will be unblinded. Based 
on the ‘Serious Hazards of Transfu-
sion’ 2016 annual report, the follow-
ing infectious diseases are known to 
have been transmitted via blood 
products in the UK:  
1. Hepatitis A, B, C or E  
2. Human Immunodeficiency Virus 
(HIV)  
3. Parvovirus (B19)  
4. Cytomegalovirus (CMV)  
5. Human T-cell Lymphotropic Virus 
(HTLV) types I and II  
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
6. Malaria  
7. Variant Creutzfeldt-Jakob Disease 
(vCJD) or any other prion disease  
 
If the patient is newly diagnosed 
with any of the above infectious dis-
eases, they will be unblinded and 
immediately referred to the appro-
priate medical specialists for treat-
ment.  
 
The surgeon will be unblinded to 
the surgical procedure performed 
and is required by the protocol to 
maintain the blind. The surgeon 
must not state whether ARTISS was 
used in the patient’s notes or on the 
CRF. Surgeons are requested to 
state that the wound closure con-
ducted in accordance with the DE-
FeND trial randomisation in the pa-
tient’s notes as per protocol. 
 
A statistical analysis plan will be pro-
duced within 3 months of the study 
greenlight checklist being complete 
which will detail the formal 
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
procedures to be undertook when 
analysing the results of the trial. 
 




Follow-up is too in-
frequent to capture 
key data items 
 
Poorly design case 
report form 
 
No procedures in 
place to ensure a 
timely flow of data 
from sites 
 
Site non adherence 
to the protocol  
 
No database backup 
plan 
 
L CRF design undertaken with study 
chief investigator and trial statisti-
cian  
 
The issue of timely CRF com-
pletion and return to the LCTU 
will be addressed in the proto-
col training sessions along with 
the importance of  Data Query 
Process Plan to be imple-
mented to ensure discrepan-
cies are queried in a standard-
ised manor with easy to under-
stand questions and com-
ments.  
 
A data management plan will be 
put in place to ensure consistency 
across data entry personal and 
clear guidelines on timelines for 
data entry. Early entry of data will 
allow problems with completion 
to be identified and addressed as 
early as possible preventing ongo-
ing problems in future patients.  
Central monitoring to be con-
ducted on a monthly basis and 
will include a review of all proto-
col deviations, data queries and 
data retrieval rates across sites. 
Central review will allow specific 
problems with the CRF to be 
identified and addressed. This 
will be reviewed by the TMG pe-
riodically.  
 
Independent members of TSC to 
review of the data completeness 
quality and photograph compli-
ance at the end of the pilot 




• TSC Report Plan  
• Data management Plan  
• Data Query Process 
Plan  
• CRFs  
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
 
LCTU CRFs, the MACRO trial data-
base and associated systems are 
designed and validated in-house. 
All databases are access con-
trolled by the Information Sys-
tems department. All data are 
backed up every night in several 





• MACRO validation docu-
ments  
• Monitoring plan  
• Central monitoring re-
ports  
• TMG meeting minutes  
 
 
Poor quality data  Un-validated data-
base  
 
No audit trail 
 
Fraudulent data 
L MACRO database will undergo a 
full program of validation in ac-
cordance with LCTU standard 
operating procedures prior to go-
ing live for trial data.  
 
MACRO is designed specifically 
for clinical trials and has a full au-
dit trail and appropriate valida-
tions.  
 
Site personnel GCP trained and 
reminded during protocol training 
of the importance of accurate 
Monthly central monitoring re-
ports will look at key data 
metrics including: 
• Data query rates 
• Missing data  
 
Ongoing quality assurance 
checks on data entry including 
100% check of all primary end-
point data and 10% of every-
thing else.  
 
 
Trial Results  
General Risk Identified 
Potential Risks  Likelihood 
(Low, Medium 
or High) 
Mitigation or Adaption Monitoring methods to address  
CRF completion and maintaining 
accurate and well organised 
source documents.  
Inadequate medical 
record keeping 
(e.g. archiving)  
Unable to recon-
struct the trial.  
 
Missing docu-
ments at site 
closeout.  
L  Study archiving to be done in ac-
cordance with LCTU SOPs.  
 
Research Site Agreement to 
specify timelines for archiving 
data relating to the study.  
 
Site personnel alerted to new 
documentation as and when it 
becomes available throughout 
the course of the study and train-
ing will include use of the portal 
and the document repository.  
Study close out to be completed 
in accordance with LCTU SOP, 
including a check of all essential 
trial documents before sponsor 
permission to archive is given.  
 
 
4. Facilities, Equipment and Resources  
Facilities, equipment 
and recources 
General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
Insufficient Investiga-
tor facilities/resource  
Inability to perform 
the randomisation 
via the web based 
tool 
 
L Research Site Agreement must be 




• Greenlight checklist 





General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
No facilities to pro-




No facilities to 
store ARTISS fibrin 
sealant 
 
Site initiation visit to ensure site has 
a freezer that can store transla-
tional samples at -80C 
 
Baxter Healthcare LTD to review site 
facilities to ensure site has the ap-




than the PI and 
pharmacist have 
never been in-
volved in a clinical 
trial 
 




M LCTU to obtain current CVs and GCP 
training records to assess suitability 
of staff qualifications, training and 
experience prior to site opening 
 
LCTU provide a template delegation 
log for PI to formally authorise dele-
gation of tasks to appropriate site 
personnel 
 
Site research staff trained on the 
use of ARTISS and the trial proce-
dures at the site initiation visit 
 
Only PIs/sites with experience of 
head and neck surgery will be se-
lected to participate 
 
CVs, GCP training and delegation 
logs are reviewed by senior mem-
bers of the LCTU as part of the site 
green light process 
 
TC to carryout site research site 
specific training at initiation 
presentation 
 
Independent oversight of safety re-
porting by independent members 





General Risk Identified 
Potential Risks  Likelihood (Low, 
Medium or 
High) 
Mitigation or Adaption Monitoring methods to address  
Site staff delegation log with clearly 
defined delegation of responsibility 





5. Documentation, Governance and GCP Compliance  
Documentation, Gov-
ernance and GCP com-
pliance  
General Risk Identified 




Mitigation or Adaption Monitoring methods to address  
Trial Master File (TMF) Lack of documentation 
to reconstruct trial and 
confirm compliance with 
CT regulations, the protection 
of subject’s rights/well be-
ing/safety and the reliability of 
the trial results. 
L LCTU SOPs are in place to cover the 
maintenance of the trial master file and 
these must be followed by the LCTU 
trial team 
 
The research site agreements state that 
all site and patient documentation  
must be kept by the participating site  
 
An electronic TMF is maintained on the 
LCTU portal for access by Sponsor and 
participating sites  
 
The electronic TMF on the portal 
has an electronic receipt built in to 
record who has downloaded each 





ernance and GCP com-
pliance  
General Risk Identified 




Mitigation or Adaption Monitoring methods to address  
Inadequate Monitoring Non-compliance with regula-
tions  
 
Lack of source data  
 
Data reliability 
L Trial Oversight Committees must be in 
place and is checked as part of the LCTU 
study green light checklist 
 
 
LCTU monitoring plan template must be 
customised for the study and based on 
this risk assessment.  The monitoring 
plan must be in place prior to study 
opening and this is checked as part of 
the LCTU study green light checklist 
 
LCTU green light process; green 
light checklist must be signed by 





Overview of study 
LCTU are carrying out duties 
which are not formally dele-
gated such as SUSAR report-
ing/serious breaches/urgent 
safety measures  
 
 
Sponsor are unaware of proto-
col amendments 
L Responsibilities clearly documented in 
the appropriate agreements and in the 
Sponsor communication plan 
 
 
Provide Sponsor with access to LCTU 
portal (study documentation and safety 
data) 
 
All study amendments must be re-
viewed by the Sponsor  using the Spon-
sor Assessment Form in accordance 
with LCTU SOPs and Sponsor communi-
cation plan 
Internal audit of LCTU processes car-
ried out by the Quality Assurance 
team 
 
Regular reporting to the Joint Re-




ernance and GCP com-
pliance  
General Risk Identified 




Mitigation or Adaption Monitoring methods to address  
Lack of qualifications 
or training in research 
team to carry out as-
signed duties 
Data Manager has not re-
ceived training on MACRO da-
tabases before entering study 
data  
 
Research team member has 
not received ICH GCP, data 
protection training 
L LCTU induction training programme is 
arranged for new members of staff as 
required 
 
Regular ICH GCP training is arranged for 
LCTU staff 
 
Trial Co-ordinator to ensure training is 
documented on the LCTU web portal 
and the LCTU delegation log 
Internal audit of LCTU processes car-
ried out by the Quality Assurance 
team 
 
Long term absence or 
vacancy of research 
team member post 
Trial Co-ordinator absent on 
long-term sickness leave 
L Each tumour group has a designated tu-
mour group lead who has sufficient 
study knowledge to cover the Trial Co-
ordinator’s key duties 
Regular Trial Co-ordinator and busi-
ness management meetings to review 
resources 
Lack of adequate LCTU 
SOPs or plans 
No process documented for 
pharmacovigilance/randomi-
sation or registration proce-
dures 
 
Overall Trial Greenlight pro-
cess not followed 
L Clear LCTU SOPs/plans describing trial 
procedures must in place as part of the 
LCTU study green light checklist 
LCTU study green light checklist must 
be signed by LCTU senior manage-
ment prior to study opening 
 
Internal audit of LCTU processes car-
ried out by the Quality Assurance 
team 
 
Lack of QC and QA sys-
tems  implemented 
and maintained  
MACRO database not vali-
dated prior to entry of patient 
data  
 
L Database validations must be com-
pleted as part of the LCTU study green 
light in accordance with the timelines 
stated in the relevant SOPs 
LCTU study green light checklist must 
be reviewed by LCTU senior manage-
ment within the timelines specified in 




ernance and GCP com-
pliance  
General Risk Identified 




Mitigation or Adaption Monitoring methods to address  






Sponsor Signature:  Date:   
Trial Statistician:  Date:   
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A.6 Internal Delegation Plan 
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A.7 Data Management Plan 
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A.8 Monitoring Plan 
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A.9 Safety Plan 
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A.10 Randomisation Instructions 
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A.11 Unblinding Instructions 
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A.12 TSC Charter 
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Appendix B. ELECTRONIC CASE REPORT FORMS 
B.1 Screening Form 
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B.2 Eligibility Form 
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B.3 Baseline Data Form 
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B.4 Neck Dissection Impairment Index (NDII) Form 
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B.5 Neck Pain Scale Form 
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B.6 Randomisation Form 
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B.7 Day of Surgery Paper Case Report Form 
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B.8 Day of Surgery Electronic Case Report Form 
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B.9 Post-operative Complication Form 
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B.10 Drain Output Data Form 
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B.11 Hospital Discharge Form 
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B.13 Wound Healing Questionnaire (WHQ Form 
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B.14 Wound Healing Questionnaire (WHQ) Validation Form 
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B.15 Electronic Case Report Form Completion Guidelines 
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B.16 Data Query Process 
 

















































Appendix C. PREPARATION AND ADMINISTRATION PROTOCOLS 
C.1 Quick Thaw Protocol 
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C.2 EASYSPRAY Quick Reference Guide 
 
DEFeND Patient Information Sheet Version: 3.0 Date: Page 585 
 
 
C.3 Surgical Protocol 
 




Appendix D. CLAVIEN-DINDO CLASSIFICATION OF SURGICAL 
COMPLICATIONS ADAPTED TO COMMON HEAD & NECK 
COMPLICATIONS 
 
Post-operative Complication Description of Severity Clavien-Dindo Grade 
Neck Wound Infection 
Localised and superficial to 
platysma e.g. stitch ab-
scess   
I 
Spreading cellulitis or su-
perficial wound infection 
with no underlying collec-
tion treated with antibiotics 
II 
Collection deep to plat-
ysma requiring drainage 
(not under GA) 
IIIa 
Collection deep to plat-
ysma requiring drainage 
(under GA) 
IIIb 
Large collection with organ 
and/or life threatening se-
quelae (i.e. airway obstruc-
tion, severe sepsis, septic 
shock) 
IV  
(a or b depending on or-
gan dysfunction) 
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Other Surgical Site Infection 
Localised infection requir-




ment with antibiotics only 
II 
Collection  requiring drain-
age (not under GA) 
IIIa 
Collection requiring drain-
age (under GA) 
IIIb 
Large collection with organ 
and/or life threatening se-
quelae (i.e. airway obstruc-
tion, severe sepsis, septic 
shock) 
IV  
(a or b depending on or-
gan dysfunction 
Bleeding/Haematoma 
Haematoma not requiring 
drainage or suitable for 
simple aspiration with a 
needle (not radiologically 
guided) 
I 
Need for blood transfusion  II 
Requiring drainage (not 
under GA). Includes 
IIIa 





Requiring drainage or re-
turn to theatre for haemo-
stasis (under GA) 
IIIb 
Haematoma/haemorrhage 
sufficiently large to obstruct 
airway or cause 
hypovolaemic shock 
IV  
(a or b depending on or-
gan dysfunction) 
Chyle Leak 
Low output leak 
(<500ml/24hrs) suitable for 











Return to theatre for proce-
dure under GA 
IIIb 
Evidence of end organ 
dysfunction 
IV  
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(a or b depending on or-
gan dysfunction) 
Wound Breakdown 
Superficial skin dehiscence 
(platysma layer intact) 
managed with dressings  
I 
Small fistula managed by 
an enteral tube or paren-
teral nutrition only 
II 
Deep dehiscence (through 
platysma layer) or fistula 
managed with procedure 
not under GA 
IIIa 
Deep dehiscence (through 
platysma layer) or fistula 
managed with procedure 
under GA 
IIIb 
Evidence of end organ 
dysfunction 
IV  
(a or b depending on or-
gan dysfunction) 
Seroma/sialocele 
Small collection not requir-
ing drainage or suitable for 
aspiration with a needle 
(not radiologically guided) 
I 
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Requiring drainage (not 
















action treated with medica-
tion (e.g. antihistamine 
and/or steroid and/or 
adrenaline) 
II 
Anaphylactic shock  IV  
(a or b depending on or-
gan dysfunction) 




By definition clinically evi-






aged without a chest drain 
I 
Pneumothorax/Haemotho-
rax without respiratory fail-
ure requiring chest drain 
IIIa 
Evidence of respiratory fail-
ure or any other organ dys-
function 
IV 
(a or b depending on or-
gan dysfunction) 
Pulmonary Embolism 
Small PE without evidence 
of respiratory failure man-
aged with anticoagulation 
only 
II 
Evidence of respiratory fail-
ure or any other organ dys-
function 
IV 
(a or b depending on or-
gan dysfunction) 
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Need for endovascular in-
tervention including filters 
not under GA 
IIIa 
Need for endovascular in-
tervention or surgical 
thrombectomy under GA 
IIIb 
Lower Respiratory Tract Infec-




Managed with antibiotics II 
Evidence of respiratory fail-
ure or any other organ dys-
function 
IV 
(a or b depending on or-
gan dysfunction) 





Appendix E. CORRECTIVE & PREVENTIVE ACTIONS (CAPA) 
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E.1 CAPA number 1 
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E.2 CAPA number 2 
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